The following types of relationships may be deemed relevant include:

1 - Shareholder
2 - Grant/Research support
3 - Employee
4 - Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)
5 - Consulting Fees (e.g., advisory boards)
6 - Officer or Board Member
7 - Royalties
8 - Speaker/Honoraria includes speakers bureau, symposia, and expert witness
9 – Other

Mikkel Østergaard
ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Imaging
Disclosure:
2- AbbVie; Abbvie; Abbvie, Celgene, Centocor, Merck, and Novartis; Abbvie, Celgene, Centocor, Merck, Novartis; BMS; Boehringer-Ingelheim; Celgene; Centocor; Eli-Lilly; Hospira; Janssen; Merck; Novartis; Novo; Orion; Pfizer; Regeneron; Roche; Sandoz; Sanofi; UCB
5- Abbvie; Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB; Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; BMS; Boehringer-Ingelheim; Celgene; Eli Lilly and Company; Eli-Lilly; Hospira; Janssen; Merck; Novartis; Novo; Novo Nordisk; Orion; Pfizer; Regeneron; Roche; Sandoz; Sanofi; UCB
8- AbbVie; Abbvie; Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB; Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB; Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, UCB; Abbvie, BMS,

Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, and UCB; BMS; Boehringer-Ingelheim; Celgene; Eli Lilly and Company; Eli-Lilly; Hospira; Janssen; Merck; Novartis; Novo; Novo Nordisk; Orion; Pfizer; Regeneron; Roche; Sandoz; Sanofi; UCB

Daniel Aletaha
ACR Abstract: RA–Treatments V: Novel Therapy and Predicting Response
Disclosure:
2- AbbVie; AbbVie, Merck Sharp and Dohme, and Roche.; Merck Sharp and Dohme; Novartis; Roche
5- AbbVie; AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche; Amgen; Celgene; Janssen; Lilly; Medac; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme
8- AbbVie; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb, Celgene, Merck Sharp and Dohme, and UCB; Celgene; Lilly; Medac; Merck;
Merck Sharp and Dohme; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme; UCB

Allen Anandarajah
ACR Abstract: Healthcare Disparities in Rheumatology
Nothing to Disclose

Anca D Askanase
ACR Abstract: SLE–Clinical I: Clinical Trials I
Nothing to Disclose

Chiara Baldini
ACR Abstract: Sjögren’s Syndrome–Basic & Clinical Science I
Nothing to Disclose

Xenofon Baraliakos
ACR Abstract: Spondyloarthritis Incl PsA–Clinical VII: Miscellaneous Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB

Kamil E Barbour
ACR/ARP Abstract: Epidemiology & Pub Health I (1 moderator, 1 alternate)
Nothing to Disclose

Jennifer L Barnas
ACR Abstract: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Disclosure:
2- Rheumatology Research Foundation

Susan J. Bartlett
ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Patient Preferences, Beliefs, & Outcomes Disclosure:
2- Abbvie; Abbvie
5- Abbvie; Bayer; Janssen; Lilly; Merck; Novartis; Pfizer; UCB
6- International Society of QOL Research; PROMIS International
8- Janssen; Merck; Novartis; Pfizer Inc; UCB

Martin Bergman
ACR Abstract: RA–Treatments IV: Switching and Tapering RA Medications Disclosure:
1- JNJ (parent of Janssen); JNJ stock; Johnson & Johnson; Johnson and Johnson
4- Johnson & Johnson
5- Abbvie; AbbVie; AbbVie, BMS, Celgene Corporation, Genentech, Janssen, Merck, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech; Genentech/Roche; Genentech-Roche; Gilead; Horizon; Janssen; Merck; Novartis; Pfizer; Sandoz; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron
8- Abbvie; AbbVie; AbbVie, Celgene Corporation, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech/Roche; GlaxoSmithKline; GSK; Janssen; Merck; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron

Sasha Bernatsky
ACR Abstract: Epidemiology & Pub Health II: SLE Nothing to Disclose

Marcy Bolster
ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science Disclosure:
2- Abbvie; Pfizer
4- Johnson & Johnson; Johnson and Johnson
5- Gilead
9- Corbus ; Cumberland

Maya H. Buch
ACR Abstract: RA–DX, Manifestations, & Outcomes V: Outcomes
Disclosure:
2- Pfizer; Pfizer, Roche, and UCB; Roche; UCB
5- AbbVie; AbbVie, Eli Lilly, Sandoz, and Sanofi.; Eli Lilly; Sandoz; Sanofi

Christopher D. Buckley
ACR Abstract: RA–Etiology & Pathogenesis I
Disclosure:
2- Roche
8- GSK; Pfizer Inc
9- Roche (Research Grant with Roche £250k and £750k on fibroblast subsets)

Jonathan Burnham
ACR Abstract: Pediatric Rheum–Clinical I: Juvenile SLE & Dermatomyositis
Nothing to Disclose

Frank Buttgereit
ACR Abstract: RA–DX, Manifestations, & Outcomes III: Pulmonary & Other Comorbidities
Disclosure:
2- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme
5- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sandoz; Sanofi-Genzyme
8- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme

Scott Canna
ACR Abstract: Pediatric Rheumatology–Basic Science
Disclosure:
5- AB2 Bio Ltd; Novartis
8- AB2Bio, Ltd; Novartis

Eliza F. Chakravarty
ACR Abstract: Reproductive Issues in Rheumatic Disorders
Nothing to Disclose

Hector Chinoy
ACR Abstract: Muscle Biology, Myositis & Myopathies II
Nothing to Disclose

Cecilia P Chung
ACR Abstract: RA–DX, Manifestations, & Outcomes II: Cardiovascular Comorbidities
Disclosure:
2- NIH grant RC2GM092618 from NIGMS/OD; NIH grant U01HG004603 from NHGRI/NIGMS; NIH: R01GM126535 and R01 bridge award; Rheumatology Research Foundation K-supplement; Vanderbilt National Center for Advancing Translational Science grant 2UL1 TR000445-06 from NCATS/NIH

Ann E Clarke
ACR Abstract: SLE–Clinical VI: Emerging Knowledge of Current Treatments
Disclosure:
5- AstraZeneca/MedImmune; Bristol-Myers Squibb; Exagen Diagnostics

Andrew P Cope
ACR Abstract: Cytokines & Cell Trafficking
Nothing to Disclose

Maria I Danila
ACR Abstract: Measures of Healthcare Quality I
Disclosure:
2- Pfizer
5- Sanofi Regeneron

John M Davis
ACR Abstract: RA–DX, Manifestations, & Outcomes IV: Treatment
Disclosure:
2- Pfizer
5- Abbvie; Pfizer; Sanofi Genzyme

Kevin D Deane
ACR Abstract: RA–Etiology & Pathogenesis II
Disclosure:
2- Janssen; Janssen R&D; Pfizer
5- Bristol-Myers Squibb; Janssen; Microdrop
9- Inova

Fatma Dedeoglu
ACR Abstract: Pediatric Rheum–Clinical II: Systemic JIA
Nothing to Disclose

Cristina Drenkard
ACR Abstract: Healthcare Disparities in Rheumatology
Nothing to Disclose

Ali A Duarte Garcia
ACR Abstract: SLE–Clinical VI: Emerging Knowledge of Current Treatments
Nothing to Disclose

Bryant R England
ACR Abstract: Epidemiology & Pub Health I: RA
Nothing to Disclose

Ursula Fearon
ACR Abstract: RA–Etiology & Pathogenesis II
Nothing to Disclose

Candace H Feldman
ACR Abstract: Measures of Healthcare Quality I
Nothing to Disclose

Mary-Ann Fitzcharles
ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes
Nothing to Disclose

John FitzGerald
ACR Abstract: Metabolic & Crystal Arthropathies I
Nothing to Disclose

Paul R Fortin
ACR Abstract: SLE–Clinical III: Clinical Trials II
Nothing to Disclose

Tracy Frech
ACR Abstract: Systemic Sclerosis & Rel D/O I: Therapeutics & Outcomes
Nothing to Disclose

Mark Genovese
ACR Abstract: RA–Treatments II: Novel Treatments for RA
Disclosure: 4- UNITY

Michael D George
ACR Abstract: Epidemiology & Pub Health I: RA

Disclosure:
2- Bristol Myers Squibb; Bristol-Myers Squibb
5- AbbVie

Jon T Giles
ACR Abstract: RA–DX, Manifestations, & Outcomes III: Pulmonary & Other Comorbidities
Nothing to Disclose

Dafna Gladman
ACR Abstract: Spondyloarthritis Incl PsA–Clinical VII: Miscellaneous
Disclosure:
2- AbbVie; Amgen; Celgene; Eli Lilly; Novartis; Pfizer Inc; UCB
5- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; UCB

Rebecca Grainger
ACR Abstract: Epidemiology & Pub Health III: Risk Facts & Outcomes
Nothing to Disclose

Jennifer Grossman
ACR Abstract: SLE–Clinical I: Clinical Trials I
Nothing to Disclose

Monica Guma
ACR Abstract: RA–Animal Models
Nothing to Disclose

Jaime Guzman
ACR Abstract: Pediatric Rheum–Clinical III: JIA
Nothing to Disclose

Rula A Hajj-ali
ACR Abstract: Vasculitis–ANCA-Associated
Nothing to Disclose

Faye Hant
ACR Abstract: Systemic Sclerosis & Rel D/O II: Predictors of Outcome
Nothing to Disclose

Nigil Haroon
ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Axial Spondyloarthritis, Clinical Studies
Disclosure:
5- Abbvie, Amgen, Janssen, Eli Lilly, Novartis AG, UCB Pharma; Abbvie; Amgen; Eli Lilly; Janssen; Merck; Novartis; UCB Pharma
8- Abbvie, Amgen, Janssen, Eli Lilly, Novartis AG, UCB Pharma; Abbvie; Amgen; Eli Lilly; Janssen; Merck; Novartis; UCB Pharma

Evelyn Hsieh
ACR Abstract: Osteoporosis & Metabolic Bone Disease–Basic & Clinical Science
Nothing to Disclose

Peter Izmirly
ACR Abstract: SLE–Clinical III: Clinical Trials II
Disclosure:
5- GlaxoSmithKline

Eddie James
ACR Abstract: T Cell Biology & Targets in Autoimmune & Inflammatory Disease
Disclosure:
2- Janssen

Wael Jarjour
ACR Abstract: Muscle Biology, Myositis & Myopathies I
Nothing to Disclose

Meenakshi Jolly
ACR Abstract: SLE–Clinical II: Epidemiology
Disclosure:
7- LupusPRO

Meenakshi Jolly
ACR Abstract: SLE–Clinical IV: Lupus Nephritis
Disclosure:
7- LupusPRO

Kenneth C Kalunian
ACR Abstract: RA–DX, Manifestations, & Outcomes I: Diagnosis & Prognosis
Disclosure:
2- Ablynx; Bristol-Myers Squibb; Human Genome Sciences/GlaxoSmithKline; Kyowa Hakko Kirin; Pfizer; Takeda; UCB
5- Anthera; Bristol-Myers Squibb; Eli Lilly; Equillium; Exagen Diagnostics; Genentech

Diane L Kamen
ACR Abstract: SLE–Clinical IV: Lupus Nephritis
Nothing to Disclose

Patricia Katz
ACR/ARP Abstract: Health Services Research I
Nothing to Disclose

Susan Kim
ACR/ARP Abstract: Pediatric Rheum: Outcomes & Quality of Life (1 moderator, 1 alternate)
Nothing to Disclose

Margreet Kloppenburg
ACR Abstract: Osteoarthritis–Clinical II
Disclosure:
2- APPROACH-IMI; Dutch Arthritis Foundation; Dutch Arthritis Society; Pfizer
5- AbbVie; GSK; Levicept; Merck-Serono; Pfizer

Minna J Kohler
ACR Abstract: Imaging of Rheumatic Diseases I
Disclosure:
5- Horizon pharma
7- Springer

Sivia Lapidus
ACR Abstract: Pediatric Rheum–Clinical II: Systemic JIA
Nothing to Disclose

Ronald Laxer
ACR Abstract: Misc Rheumatic & Inflam DZ II
Nothing to Disclose

Yvonne C Lee
ACR Abstract: Pain Mechanisms–Basic & Clinical Science
Disclosure:
1- Cigna Corp
2- Eli Lilly; Eli Lilly and Company; Pfizer
4- Express Scripts
5- Eli Lilly

Linda C Li
ACR/ARP Abstract: Health Services Research II
Nothing to Disclose
Grace H Lo  
ACR Abstract: Osteoarthritis–Clinical I  
Nothing to Disclose

Christian Lood  
ACR Abstract: Innate Immunity  
Nothing to Disclose

Elena Losina  
ACR/ARP Abstract: Health Services Research I  
Disclosure:  
2- Flexion; Flexion Therapeutics; Pfizer; Pfizer Inc; Roche/Genentech; Samumed; TissueGene  
5- Regeneron; Regeneron Pharmaceuticals; Velocity; Velocity Pharmaceutical Development; Velocity Pharmaceutical Development

Ulf Müller-Ladner  
ACR Abstract: Imaging of Rheumatic Diseases II  
Nothing to Disclose

Tina Mahajan  
ACR Abstract: RA–Treatments I: Cardiovascular Disease and Readmissions  
Nothing to Disclose

Walter P. Maksymowycz  
ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Imaging  
Disclosure:  
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma  
3- CARE ARTHRITIS  
5- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma  
9- CARE ARTHRITIS

Lisa A Mandl  
ACR Abstract: Osteoarthritis–Clinical II  
Disclosure:  
3- Annals of Internal Medicine; Annals of Internal Medicine- Associate Editor  
7- UptoDate; Wolters Kluwer - Author at UptoDate; Wolters Kluwer - Author at UptoDate; Wolters Kluwer- Author at UptoDate

Maureen D Mayes  
ACR Abstract: Systemic Sclerosis & Rel D/O III: Cardiopulmonary  
Disclosure:  
5- Boehringer Ingelheim; Galapagos; Mitsubishi Tanabe Pharma; Mitsubishi-Tanabe  
8- Boehringer Ingelheim  
9- Boehringer Ingelheim ; Corbus ; Corbus Pharma ; Eicos ; Eicos Sciences ; Galapagos ; GlaxoSmithKline ; Reata Pharma ; Reata Pharmaceuticals ; Sanofi

John McBeth  
ACR Abstract: Pain Mechanisms–Basic & Clinical Science  
Nothing to Disclose

Maureen McMahon  
ACR Abstract: SLE–Clinical V: Flares & Morbidity of SLE  
Nothing to Disclose

Philip J. Mease  
ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Psoriatic Arthritis, Clinical Studies  
Disclosure:  
2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB  
5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; Sun; UCB; Boehringer Ingelheim
Vivek Mehta
ACR Abstract: Misc Rheumatic & Inflam DZ I
Nothing to Disclose

Vaishali R. Moulton
ACR Abstract: SLE–Animal Models
Nothing to Disclose

Louise B Murphy
ARP Abstract: [Title] III: New Approaches to Old Diseases
Nothing to Disclose

Preeya Nandkumar
ARP Abstract: [Title] II: Clinical Aspects & Outcomes Research
Nothing to Disclose

Victoria Navarro-Compán
ACR Abstract: Spondyloarthritis Incl PsA–Clinical II: Ax SpA, Treatment
Disclosure:
5- AbbVie; Eli Lilly and Company; Eli Lilly, Novartis, Abbvie, UCB, MSD; MSD; Novartis; Pfizer; UCB
8- AbbVie; Bristol; Bristol, Roche; Eli Lilly and Company; Eli Lilly, Novartis, Abbvie, UCB, MSD; MSD; Novartis; Roche; UCB

Amanda E Nelson
ACR Abstract: Imaging of Rheumatic Diseases I
Disclosure:
5- Flexion Therapeutics; GSK
7- Health Press, Ltd.
8- MedScape

Mandana Nikpour
ACR Abstract: Epidemiology & Pub Health II: SLE
Disclosure:
Janet Pope
ACR Abstract: Systemic Sclerosis & Rel D/O I: Therapeutics & Outcomes
Disclosure:
2- Amgen; AstraZeneca; Astra-Zeneca; Bayer; BMS; Merck; Pfizer; Roche; Seattle Genetics; UCB
5- AbbVie; Abbvie; BMS; Celgene; Eli Lilly and Company; Lilly; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; BMS; Celgene; Eli Lilly; Eli Lilly and Company; Lilly; MSD; Novartis; Pfizer; Roche; UCB

Chaim Putterman
ACR Abstract: SLE–Etiology & Pathogenesis II
Disclosure:
2- Equillium, Inc; Exagen
5- Equillium; Equillium, Inc

Homaira Rahimi
ACR Abstract: Pediatric Rheumatology–Basic Science
Nothing to Disclose

Homaira Rahimi
ACR Abstract: RA–Animal Models
Nothing to Disclose

Veena K Ranganath
ACR Abstract: RA–DX, Manifestations, & Outcomes V: Outcomes
Disclosure:
2- Genentech; bristol myer squibb; pfizer; mallinckrodt
5- bristol myer squibb

Deepak A Rao
ACR Abstract: Innate Immunity

Disclosure:
2- Merck
5- Janssen; Pfizer

Ann Reed
ACR Abstract: Muscle Biology, Myositis & Myopathies I
Nothing to Disclose

Soledad Retamozo
ACR Abstract: Sjögren’s Syndrome–Basic & Clinical Science I
Nothing to Disclose

John D Reveille
ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Axial Spondyloarthritis, Translational Research
Disclosure:
2- Abbvie; Eli Lilly; Janssen; Janssen Research & Development, LLC; Pfizer
5- CB; Eli Lilly; Novartis; Pfizer; UCB
8- Eli Lilly

Rennie L Rhee
ACR Abstract: Vasculitis–ANCA-Assocd II
Nothing to Disclose

Lisa G. Rider
ACR Abstract: Pediatric Rheum–Clinical III: JIA
Disclosure:
2- Bristol Myers Squibb; Cure JM Foundation; Hope Pharmaceuticals; NIEHS; NIEHS, NIH; NIH
9- . ; aTyr ; Cure JM Foundation ; Eli Lilly and Company ; Lilly-drug ; MedImmune / AstraZeneica ; MedImmune/AstraZeneica

Robert Roubey
ACR Abstract: Antiphospholipid Syndrome
Nothing to Disclose

Eric M Ruderman
ACR Abstract: Spondyloarthritis Incl PsA–Clinical V: Psoriatic Arthritis, Clinical Studies
Disclosure:
2- Pfizer

Carlo Salvarani
ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Large Vessel Vasculitis Treatment
Nothing to Disclose

Lisa Sammaritano
ACR Abstract: Reproductive Issues in Rheumatic Disorders
Nothing to Disclose

Gabriela Schmajuk
ACR Abstract: Measures of Healthcare Quality II
Nothing to Disclose

Hendrik Schulze-Koops
ACR Abstract: Cytokines & Cell Trafficking
Disclosure:
5- Eli Lilly and Company; AbbVie; Amgen; Biogen; Hexal-Sandoz
8- Eli Lilly and Company; AbbVie; Amgen; Biogen; Hexal-Sandoz

Joachim Sieper
ACR Abstract: Spondyloarthritis Incl PsA–Clinical VI: Axial Spondyloarthritis, Translational Research
Disclosure:
5- AbbVie; Eli Lilly and Company; Janssen; Lilly; Merck; Novartis
8- AbbVie; Eli Lilly and Company; Janssen; Lilly; Merck; Novartis

Julia Simard
ACR Abstract: Epidemiology & Pub Health III: Risk Factos & Outcomes
Nothing to Disclose

Nora G Singer
ACR Abstract: RA–Treatments II: Novel Treatments for RA
Nothing to Disclose

Josef S Smolen
ACR Abstract: RA–DX, Manifestations, & Outcomes IV: Treatment
Disclosure:
2- AbbVie, Eli Lilly, Janssen, MSD, Pfizer, Roche
8- AbbVie, Amgen, Astra-Zeneca, Astro, Celgene Corporation, Celtrion, Eli Lilly, Glaxo; ILTOO,

Janssen, Medimmune, MSD, Novartis, Pfizer, Roche, Samsung, Sanofi, UCB

Elizabeth B Solow
ACR Abstract: RA–Treatments I: Cardiovascular Disease and Readmissions Disclosure:
2- NIH

Lisa Stamp
ACR Abstract: Metabolic & Crystal Arthropathies II
Nothing to Disclose

Roland Staud
ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes
Nothing to Disclose

Virginia Steen
ACR Abstract: Systemic Sclerosis & Rel D/O III: Cardiopulmonary Disclosure:
2- CSL Behring
5- Boehringer Ingelheim; Corbus; CSL; CSL Behring; DSMB; Galapagos
9- Corbus ; CSL ; DSMB ; Galapagos

Joshua Stefanik
ACR Abstract: Osteoarthritis–Clinical I
Nothing to Disclose

Lisa Suter
ACR/ARP Abstract: Health Services Research II
Nothing to Disclose

Yoshiya Tanaka
ACR Abstract: RA–Treatments III: Safety and Outcomes Disclosure:
2- Asahi-kasei; Asahi-Kasei; Asahi-kasei, BMS, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Takeda, UCB; Astellas Pharma, Inc.; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Eisai; Mitsubishi-Tanabe; Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbott, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-
Toyama.; Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, Eisai; Ono; Sanofi; Takeda; UCB
3 - Astellas Pharma, Inc.
5 - AbbVie; Astellas Pharma, Inc.; BMS; Eli Lilly; Genzyme; Pfizer; Roche
8 - Abbvie; AbbVie; Astellas; Astellas Pharma, Inc.; Astellas, BMS, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe, Pfizer, Sanofi, UCB, YL Biologics; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers; Eisai; Eli Lilly; Eli Lilly and Company; Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi-kasei; Janssen; Mitsubishi-Tanabe; Novartis; Pfizer; Pfizer Inc; Takeda; Teijin; YL Biologics
9 - Astellas Pharma ; Astellas Pharma, Inc.

Betty P Tsao
ACR Abstract: Genetics, Genomics & Proteomics
Nothing to Disclose

Betty P Tsao
ACR Abstract: SLE–Etiology & Pathogenesis I
Nothing to Disclose

Sebastian H. Unizony
ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os II: Large Vessel Vasculitis Pathogenesis & Imaging
Nothing to Disclose

Ernest R Vina
ACR Abstract: Patient Outcomes, Preferences, & Attitudes I: Patient Preferences, Beliefs, & Outcomes
Nothing to Disclose

Michael M Ward
ACR Abstract: Spondyloarthritis Incl PsA–Clinical IV: Axial Spondyloarthritis, Clinical Studies
Nothing to Disclose

Kenneth J Warrington
ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os I: Large Vessel Vasculitis Treatment Disclosure:
2 - Eli Lilly; GlaxoSmithKline; roche; Roche
5 - Roche; Sanofi; sanofi
8 - roche; Roche

Yusuf Yazici
ACR Abstract: RA–Treatments V: Novel Therapy and Predicting Response
Disclosure:
5 - BMS, Celgene Corporation, Genentech, and Sanofi; BMS, Celgene Corporation, Genetech, Sanofi

Andrew S Aherrera
Emerging Best-in-Class IL2 Variant Highlights Utility of Treg-Directed Therapy for Autoimmune Disease
Nothing to Disclose

Sara K. Tedeschi
ACR Abstract: Metabolic & Crystal Arthropathies I
Nothing to Disclose

Ralf Thiele
ACR Abstract: Imaging of Rheumatic Diseases II
Nothing to Disclose

Louise Thoma
ACR/ARP Abstract: Orthopedics, Low Back Pain, & Rehabilitation
Nothing to Disclose

Karina D Torralba
ACR Abstract: Misc Rheumatic & Inflam DZ I
Nothing to Disclose

Karina D Torralba
ACR Abstract: Misc Rheumatic & Inflam DZ III
Nothing to Disclose

Zahi Touma
ACR Abstract: SLE–Clinical V: Flares & Morbidity of SLE
Disclosure:
2 - Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC
Sara Alehashemi
Preliminary Analysis of Hearing Loss in a Neonatal Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years Suggests That Early Treatment with Anakinra Maintains Normal Hearing
Nothing to Disclose

Gustavo J Almeida
Effect of Physical Activity on Cartilage Degradation and Inflammation in Lumbar Spinal Stenosis
Nothing to Disclose

Jérôme Avouac
P695663: Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis
Nothing to Disclose

Medeea O Badii
Regulation of Type 1 Interferon Signaling Pathway by Uric Acid Treatment in Primary Human Mononuclear Cells
Nothing to Disclose

Jea Hyun Baek
Dimethyl Itaconate Suppresses TLR-mediated Early Inflammatory Responses
Disclosure:
1- Biogen Inc.
3- Biogen Inc.

Sufia Bakshi
P698326: MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis
Nothing to Disclose

Juan M Bande
Duplicate - Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis
Nothing to Disclose

Maaman Z Bashir
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Nothing to Disclose

Edward Behrens
P696066: Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model
Nothing to Disclose

Sasha Bernatsky
Hematologic and Non-hematologic Cancer Risk in a Large Inception SLE Cohort
Nothing to Disclose

Sasha Bernatsky
Multiple Industrial Air Pollutants and Anti-Citrullinated Protein Antibody Positivity
Nothing to Disclose

Simon Bowman
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Disclosure:
5- AstraZeneca; Biogen; BMS; Celgene; Medimmune; MTPharma; Novartis; ONO; UCB; Xtlbio

Hermine I Brunner
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Disclosure:
2- BMS; MedImmune; Novartis; Pfizer Inc
3- CCMHC
5- AbbVie; Bayer; Biocon; BMS; Janssen; Novartis; Pfizer Inc; AstraZeneca-MedImmune; R-Pharm; Roche; Eli Lilly; Boehringer Ingelheim
8- Novartis; GSK; Roche

Ken Cai
P684963: The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders
Using Population-level Cardiovascular Risk Prediction Equations
Disclosure:
2- Arthritis Australia

Juan J Canoso
A Potential Critical Physiologic Role of the Infrapatellar (Hoffa) Fat Pad as Dynamic Protector of the Patellar Tendon
Nothing to Disclose

Nancy Carerton
Sjögren’s Foundation Clinical Practice Guidelines for the Management and Treatment of Pulmonary Manifestations of Sjögren’s Disclosure:
4- Gilead; Regeneron; Medtronic
9- BMS (DMC)

Pierre Charles
P686175: Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial
Nothing to Disclose

Sarah Chen
Patterns and Safety of Pegloticase Treatment Among Older Patients with Gout in US Medicare
Nothing to Disclose

Patrick CHERIN
Long-term Efficacy and Tolerance of Subcutaneous Immunoglobulins (Gammanorm®) in Inflammatory Myopathies: A 5-years Follow-up in 30 Patients
Nothing to Disclose

Ann Chodara
P697816: Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population
Nothing to Disclose

Meredith Christiansen
“I've Been to Physical Therapy Before for Other Reasons, for Other Problems but Not the Knees” Physical Therapy Utilization for Knee Osteoarthritis from the Patients’ Perspective
Nothing to Disclose

Alice Courties
P693462: Critical Role of the Cholinergic System Involvement in Osteoarthritis
Nothing to Disclose

Alice Courties
Transcutaneous Auricular Stimulation of the Vagus Nerve for Erosive Hand Osteoarthritis: An Open Label Pilot Study
Nothing to Disclose

Pierre Cunin
P699684: Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration
Nothing to Disclose

Fabrizio De Benedetti
Interferon-gamma (IFN-γ) Neutralization with Emapalumab and Time to Response in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (s-JIA) who failed High-Dose Glucocorticoids Disclosure:
2- AbbVie; BMS; Novartis; Novartis, Novimmune, Hoffmann- La Roche, SOBI, AbbVie, Pfizer; Novimmune; Pfizer; Roche; Sanofi; Sobi; Swedish Orphan Biovitrum; UCB

Adriana de Jesus
P700184: Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases
Nothing to Disclose

Atul Deodhar
P692639: Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
 Disclosure:
Atul Deodhar
P697955: Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Atul Deodhar
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Samuel Deshayes
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Nothing to Disclose

Umesh S Deshmukh
P698957: Activation of the STING Pathway Is a Shared Feature of Salivary Gland and Lung Inflammation in Sjogren's Syndrome
Nothing to Disclose
Martin Englund
P690113: Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial
Nothing to Disclose

Tariq E Farrah
The Endothelin System and Its Antagonism Link to Endothelial Dysfunction, Impaired Fibrinolysis and Arterial Stiffness in ANCA-Associated Vasculitis: A Randomized, Controlled Clinical Trial
Nothing to Disclose

Alice Fike
Measles Immune Status in a Rheumatology Clinic Serving Patients with Limited Access to Healthcare
Nothing to Disclose

Mary-Ann Fitzcharles
Cannabis Recreational Legalization Impacts Use by Rheumatology Patients: A Prospective Cross-Sectional Study of 1000 Patients
Nothing to Disclose

Roy Fleischmann
Discrepancy Between the Multi-Biomarker Disease Activity Score and Clinical Disease Activity Scores in the Open-label Period of a 2-Part, Multicenter Study of Repository Corticotropin Injection for Patients with Persistently Active Rheumatoid Arthritis
Disclosure:
2- AbbVie; Acea; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Centrexion; Eli Lilly; Eli Lilly and Company; EMD Merck-Serono; EMD Serono; EMD-Serono; Genentech; Genetech; GlaxoSmithKline; GSK; Janssen; Lilly; Merck; Nektar; Novartis; Pfizer; Pfizer Inc; Regeneron; Resolve; Roche; Sanofi Genzyme; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Genym

Richard A Furie
P693813: A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Disclosure:
2- AstraZeneca
5- AstraZeneca

Odile H Gabay
Rheumatoid Arthritis (RA) and Inflammatory Bowel Disease (IBD) Are Transmissible via Gut Microbiome
Nothing to Disclose

Shivani Garg
P697212: Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Nothing to Disclose

Mark Genovese
Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate - CREDO1 Study
Disclosure:
4- UNITY

Michael D George
P695251: Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Disclosure:
2- Bristol Myers Squibb; Bristol-Myers Squibb 5- AbbVie
Biswa Dip Ghosh
Alteration of Serum Biomarkers in Primary Knee OA
Nothing to Disclose

Biswa Dip Ghosh
Comparison of Methotrexate and Glucosamine in Primary Knee OA
Nothing to Disclose

Vera Golder
Lupus Low Disease Activity State (LLDAS) Is Associated with Improved Outcomes Independently of Remission
Nothing to Disclose

Eduardo Gomez Banuelos
Autoimmunity to Neutrophil Variants of Ro52/TRIM21 Is Linked to Interferon Dysregulation in Systemic Lupus Erythematosus
Nothing to Disclose

K Bates Gribbons
P697291: Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
Nothing to Disclose

Matthieu Groh
Idiopathic Eosinophilic Vasculitis (HES-related Vasculitis): An Additional Cause of Secondary Variable Vessel Non-granulomatous Vasculitis: A Comprehensive Analysis of 117 Cases in Asthma-free and ANCA-negative Patients
Disclosure:
5- AstraZeneca

Roberta Gualtierotti
Tocilizumab Effects on Coagulation Factor XIII in Patients with Rheumatoid Arthritis
Nothing to Disclose

Giacomo Maria Guidelli
Six-month Efficacy and Safety of Baricitinib in 376 Patients with Rheumatoid Arthritis: A Real-life Multicenter Study
Nothing to Disclose

Ambika Gupta
Prior Adherence to HMG Co-A Reductase Inhibitors Is a Predictor of Subsequent Adherence and Persistence to Oral, but Not Parenteral Osteoporosis Medications
Nothing to Disclose

Katherine Hammitt
Modifications to ICD-10 Code for Sjögren’s: SF and ACR Coordinate Successful Efforts to Change Diagnostic Coding
Nothing to Disclose

Man Han
Clinical Significance of Salivary Gland Ultrasonography in Chinese Patients with Primary Sjögren’s Syndrome
Nothing to Disclose

Richard Harris
NYX-2925 Impacts Functional and Chemical Neuroimaging Biomarkers and Patient-reported Outcomes of Pain in Patients with Fibromyalgia
Disclosure:
2- Pfizer; Aptinyx
5- Pfizer; Aptinyx

Andrew C Heisler
P695308: Association of Pain Centralization with DMARD Response in Active RA
Nothing to Disclose

Aase Hensvold
P699762: Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Nothing to Disclose

Rudy Hidayat
The Effect of Hydroxychloroquine on Endothelial Dysfunction in Patients with Rheumatoid Arthritis: A Double-Blind Randomized Clinical Trial
Nothing to Disclose

Marc C. Hochberg
P696290: Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study Disclosure:
3- Rheumcon, Inc
4- BriOri Biotech; Theralogix LLC
5- Bioiberica SA; Bone Therapeutics; Bristol Myers Squibb; Eli Lilly; EMD Serono; EMD Serono Research and Development Institute, Inc.; Galapagos; IBSA Biotechniq SA; Novartis Pharma AG; Pfizer; Pfizer Inc; Plexxikon; Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba; Samumed LLC; Theralogix LLC; TissueGene Inc
7- Elsevier; UpToDateTM
9- Galapagos, IQVIA and Hoffman LaRoche

Kaitlin H Hori
Mortality Rates and Outcomes of Patients with Hip Fractures at Hawaii Pacific Health
Nothing to Disclose

Benjamin Hsu
Safety, Tolerability, Pharmacokinetics, and Clinical Outcomes Following Single-Dose IA Administration of UBX0101, a Senolytic MDM2/p53 Interaction Inhibitor, in Patients with Knee OA Disclosure:
1- UNITY Biotechnology
3- UNITY Biotechnology
4- UNITY Biotechnology; Johnson & Johnson

Lingzhen Hu
Elevated Levels of Serum Slit2 Correlate with Skin and Renal Impairment in Systemic Lupus Erythematosus
Nothing to Disclose

David Isenberg
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial Disclosure:
5- Genentech, Inc.

David A Isenberg
This is a Test of the Submission Process
Nothing to Disclose

Peter Izmirly
P688664: The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block Disclosure:
5- GlaxoSmithKline

Sindhu R Johnson
Duplicate: Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease Disclosure:
2- Bayer; Boehringer Ingelheim; Corbus; Roche
5- Boehringer Ingelheim; Ikaria

Anna Helena Jonsson
P696797: An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium
Nothing to Disclose

Saumya Joshi
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
Nothing to Disclose

Stephen P Juraschek
A Randomized Trial of the Provision of DASH Patterned Groceries on Serum Urate in Gout Patients with Hyperuricemia Nothing to Disclose
2- Rheumatology Research Foundation; NIH/NHLBI

Sarah Kamounah
Detection of Salivary Anti-SSA and Anti-SSB Antibodies Utilizing the EFIRM-Platform
Nothing to Disclose

Barbara I Karp
NIH HEAL Initiative: Accelerating Discovery and Development of Non-addictive Pain Therapeutics- NINDS Preclinical and Clinical Programs
Nothing to Disclose

Seoyoung C. Kim
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study Disclosure:
2- AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; research grants to Brigham and Women's Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics; Roche; Roche/Genentech

Seoyoung C. Kim
P697111: Trajectories of Opioid Filling Patterns After Total Knee Replacement Disclosure:
2- AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; research grants to Brigham and Women's Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics; Roche; Roche/Genentech

Shaye Kivity
Anakinra for Refractory Familial Mediterranean Fever: A Cohort of 44 Patients Nothing to Disclose

Signe S Knudsen
P698282: Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study Nothing to Disclose

Benjamin D Korman
P697019: TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)

Nothing to Disclose

Féline Kroon
P698402: Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial Nothing to Disclose

Mukund Kumar
Causes and Predictors of 30-day and 90-day Readmission Rate for ANCA Associated Vasculitis: Insights from Nationwide Readmission Database Nothing to Disclose

Izumi Kurata
P691934: Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis Nothing to Disclose

Robert Lafyatis
Safety, Target Engagement, and Initial Efficacy of AVID200, a Potent and Isoform-Selective Inhibitor of TGF-beta 1 and 3, in Patients with Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase 1 Dose Escalation Study Disclosure:
2- PRISM Biolab; Regeneron; Elpidera; Kiniksa 5- MERCK; Bristol-Myers Squibb; Biocon; UCB; Formation; Sanofi; Genentech / Roche

Brian LaMoreaux
Amputation Procedures in Gout Patients: Large Dataset Analysis Disclosure:
3- Horizon 4- Horizon

David Leiman
Preliminary Results from a Phase 1b Double-blind Study to Assess the Safety, Tolerability and Efficacy of Intra-Articular Administration of Resiniferatoxin or Placebo for the Treatment of
Moderate to Severe Pain Due to Osteoarthritis of the Knee
Disclosure:
5- Heron; Acacia; Merck; Ingeneron; Durect; Innocoll; Adynxx; Regeneron
Khai Pang Leong
Exome Sequencing of Chinese Anti-CCP-positive Patients
Nothing to Disclose

Siri Lillegraven
Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial
Nothing to Disclose
2- AbbVie; MSD; Norwegian Research Council; Norwegian South-Eastern Health Region; Pfizer; Roche; UCB

S Sam Lim
P696173: The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
Nothing to Disclose

Chin-Hsiu Liu
HLA-B27-mediated Activation of TNAP Phosphatase Promotes Pathogenic Syndesmophyte Formation in Ankylosing Spondylitis
Nothing to Disclose

Merete Lund Hetland
A Multicenter Randomized Study in Early Rheumatoid Arthritis to Compare Active Conventional Therapy versus Three Biological Treatments: 24 Week Efficacy and Safety Results of the NORD-STAR Trial Disclosure:
2- Abbvie; AbbVie; Biogen; BMS; CellTrion; MSD; Novartis; Orion; Pfizer; Samsung; UCB 9- CellTrion
Andre Luquini

Effectiveness of the Making It Work™ Program at Improving Presenteeism in Workers with Inflammatory Arthritis – Results of a Randomized Controlled Trial
Nothing to Disclose

Anna Lynn-Palevsky
Inflammatory Markers, Foot Pain, and Foot Disorders: The Framingham Foot Study
Nothing to Disclose

haijun Ma
Mesenchymal Stem Cells Regulate the Activated Complement C5 by Clusterin in the Treatment of Lupus Nephritis
Nothing to Disclose

Michael Mahler
Clinical Associations of Anti-FHL1 Autoantibodies in Patients with Idiopathic Inflammatory Myopathies Disclosure:
3- Inova Diagnostics

Natalie McCormick
P692791: Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Nothing to Disclose

Philip J. Mease
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study Disclosure:
2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB 5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; Sun; UCB; Boehringer Ingelheim 8- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Genentech; Janssen; Novartis; Pfizer Inc; UCB
Richard Meehan
Comparison of Synovial Fluid Cytokines/Chemokines and Proteins from the Knees of Symptomatic RA and OA Patients to Levels in the Peripheral Blood and from Normal Symptomatic Knees
Nothing to Disclose

Joan T Merrill
Discrimination of Patients with Systemic Lupus (SLE) Who Exhibited Striking Response to Obexelimab (XmAb®5871) Based on Patterns of Immunological Markers
Disclosure: 2- Xencor

Dror Mevorach
Systemic Autoinflammatory Arthritis with Hyperactive Innate and Adaptive Immunity Due to Loss of TANK-Binding Kinase 1 (TBK1) Function
Disclosure: 4- Enlivex Ltd. 5- Enlivex Ltd. 6- Enlivex Ltd.

Paul Miller
P685241: Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Disclosure: 2- Amgen; Radius Pharma 5- Amgen; Radius Pharma; Alexion

Jorge Monserrat Sanz
Accumulation and Abnormal Behavior of CCR5+ and CCR6+ Tregs in Synovial Fluid from Recently Diagnosed DMARDs-naive Rheumatoid Arthritis Patients
Nothing to Disclose

Eric F Morand
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Disclosure: 2- AstraZeneca; Bristol Myers Squibb; Eli Lilly; Janssen; Merck Serono 5- AstraZeneca; Eli Lilly; Janssen; Merck Serono; UCB; GSK; CSL Inc; Neovacs; Wolf Biotherapeutics; AbbVie; Amgen

Peter Nash
Interactive Disease Visualization Encounter Tool to Navigate and Report the Efficacy Outcomes Across the Disease Manifestations in Secukinumab Treated Psoriatic Arthritis Patients
Disclosure: 2- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi; UCB 5- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi 8- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi

Peter Nash
Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
Disclosure: 2- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi; UCB 5- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi 8- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi

Renuka Nayak
P698382: Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Nothing to Disclose

Julie S Nusbaum
Knowledge and Beliefs Regarding Breastfeeding and Its Effect on Disease Activity Among Reproductive Age Women with SLE
Nothing to Disclose

OGBEBOR E OMOIKE
Systemic Response of Bone-turnover Biomarkers of Osteoporosis Differ Across Ethnicities from Tobacco Exposure. (poster presentation)
Nothing to Disclose

Liam O’Neil
A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis
Nothing to Disclose

Mert Oztas
Changing the Traditional p Value Significance Level to .005 Makes Less Impact on Observational Studies than on Randomized Controlled Trials
Nothing to Disclose

César Pacheco-Tena
Transcriptional and Histological Alterations of the Inflammatory Process and Joint Remodeling Influenced by Physical Exercise in Animal Models of Arthritis
Disclosure:
5- Pfizer; Sanofi; Roche; Eli Lilly; AbbVie; UCB; BMS
8- Pfizer; Sanofi; Roche; Eli Lilly; AbbVie; UCB; BMS

César Pacheco-Tena
Transcriptome Modifications Associated with Rheumatoid Arthritis at Very Early Stages of Complete Freund’s Adjuvant-Induced Arthritis
Disclosure:
5- Pfizer; Sanofi; Roche; Eli Lilly; AbbVie; UCB; BMS
8- Pfizer; Sanofi; Roche; Eli Lilly; AbbVie; UCB; BMS

John Page
Validation of a Deep Learning Based Algorithm to Diagnose Vertebral Compression Fractures
Disclosure:
1- Amgen Inc.
3- Amgen Inc.

Hilary Pang
Quality of Rheumatology Care for Patients with Fibromyalgia and Chronic Pain
Nothing to Disclose

Ginto Pottackal
P698977: Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
Nothing to Disclose

Xavier Puéchal for the French Vasculitis Study Group
P693221: Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry
Disclosure:
2- Pfizer
8- LFB; Pfizer; Roche

Amy Puenpatom
Treatment Persistence in Patients Cycling on Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors in Inflammatory Arthritis
Disclosure:
1- Merck & Co., Inc.
4- Merck & Co., Inc.

Luiz Eduardo Ramos da Silva
Plant Based Platforms for Immunobiologicals Production
Nothing to Disclose

Warren D Raymond
Mortality in IgA Vasculitis: A Longitudinal Population-based Data Linkage Study
Nothing to Disclose

Alicia Rodriguez-Pla
P684646: Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Nothing to Disclose

Christian Roux
P698534: Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
Nothing to Disclose

Ori Safran
Apoptotic Cells for Vanishing Bone Disease
Nothing to Disclose

Lara Sanchez-Bilbao
Long Term Follow-up and Successfully Optimization of Infliximab Therapy in Refractory Uveitis Due to Behçet’s Disease: Multicenter Study of 103 Caucasian Patients
Nothing to Disclose

Amit Saxena
P694010: Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Disclosure: 2- Exagen

Gabriela Schmajuk
P697460: Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Nothing to Disclose

Grant S Schultert
P698310: Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
Disclosure: 5- Novartis
8- Novartis

Morena Scotece
P699821: Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models
Nothing to Disclose

Swastina Shrestha
P698388: Five Year Structural Changes in Patients with Meniscal Tear and Osteoarthritis from an RCT of Arthroscopic Partial Meniscectomy vs. Physical Therapy
Disclosure: 2- Roche/Genentech

Genevieve S Silva
Nothing to Disclose

Jasvinder Singh
Association of Reduction of Serum Urate by Urate-lowering Therapy with Improved Physical and Mental Functional Outcomes in People with Gout
Nothing to Disclose

Sladjana Skopelja-Gardner
P699050: UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent
Nothing to Disclose

Rona M Smith
P695981: A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Disclosure: 2- Roche; Sanofi; Medimmune
8- Roche

Josef S Smolen
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Disclosure: 2- AbbVie; AstraZeneca; Eli Lilly and Company
Emily C Somers
Nothing to Disclose

John H Stone
P698498: Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
Disclosure:
2- Genentech; Roche; Xencor
5- Genentech; Roche; Xencor

Bryan Strouse
Momelotinib, a Dual Janus Kinase 1/2 and Activin Receptor 1 Inhibitor, Ameliorates Joint Inflammation, Systemic Th17 Differentiation and Arthritis-linked Anemia in Pre-clinical Autoimmune RA
Disclosure:
3- Sierra Oncology
4- Sierra Oncology

Mark Tatangelo
The Effect of Rheumatoid Arthritis on Health Care Costs Over Time from the Payers Perspective: A Matched Longitudinal Population Study
Nothing to Disclose

Peter C Taylor
Efficacy and Safety of the Prostaglandin EP4 Receptor Antagonist CR6086 Added to Methotrexate in DMARD-Naïve Early RA Patients: A Phase 2 Randomized Controlled Trial
Disclosure:
Palapun Waitayangkoon  
Lactobacillus Casei L39 as a Potential Disease-Modifying Treatment for Knee Osteoarthritis by Reducing Intraarticular Inflammation  
Disclosure:  
2- Faculty of Medicine Ratchadapiseksompot Grant  

Zachary Wallace  
P695852: Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study  
Disclosure:  
2- National Institute of Arthritis, Musculoskeletal, and Skin Diseases; Rheumatology Research Foundation  

Rene Westhovens  
Clinical Evaluation of the Immunogenicity to CT-P13 for Subcutaneous Use in Patients with Active Rheumatoid Arthritis: 1-Year Clinical Results from a Multicenter, Randomized Controlled Pivotal Trial  
Disclosure:  
2- Celltrion, Inc.; Galapagos/Gilead  
5- Celltrion; Celltrion, Inc.; Galapagos; Galapagos NV; Galapagos/Gilead; Gilead Sciences, Inc.  
8- Celltrion; Galapagos; Gilead Sciences, Inc.  
9- Celltrion ; Galapagos NV ; Gilead Sciences, Inc.  

Daniel Whittingslow  
Snap, Crackle, Pop: Joint Sounds as a Digital Biomarker of Juvenile Idiopathic Arthritis  
Nothing to Disclose  

Kathryn A Wierenga  
Preclinical Evidence of a Novel Blood Biomarker to Predict Efficacy of ω-3 Supplementation in Attenuating Lupus Flaring and Progression  
Nothing to Disclose  

Jessica Williams  
P698289: Racial Differences in Highly Effective Contraceptive Use Among Medicaid Beneficiaries with SLE  
Nothing to Disclose  

Frederick Wolfe  
A Comparison of the Modified American College of Rheumatology 2016 Diagnostic Criteria for Fibromyalgia and ACTTION-APS Pain Taxonomy Diagnostic Criteria in a Large Randomized Study of Fibromyalgia Prevalence in the General Population  
Nothing to Disclose  

Matthew Woodruff  
P699813: Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development  
Nothing to Disclose  

Thasia G Woodworth  
Rheumatoid Arthritis (RA) Patient Concerns About Adverse Effects (AEs): Results of Focus Groups Exploring Need for a Patient-oriented AE Reporting Instrument to Facilitate Adherence  
Nothing to Disclose  

Di Wu  
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study  
Nothing to Disclose  

Arisa Yaekura  
P693409: Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice  
Nothing to Disclose
Monica Yang
C1q/TNF-Related Protein 9 as a Novel Marker of Systemic Sclerosis-associated Interstitial Lung Disease
Nothing to Disclose

xiaolei yang
Pharmacokinetics and Safety of BAT1806 Injection vs Actemra® in Healthy Chinese Male Subjects
Disclosure:
3- Bio-thera Ltd.

Eric Yen
P699428: Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades
Nothing to Disclose

Ohoud AlAhmed
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Nothing to Disclose

Sara Alehashemi
Preliminary Analysis of Hearing Loss in a Neonatal-Onset Multisystem Inflammatory Disease (NOMID) Cohort Followed over a Mean of 10 Years: Normal Hearing at Baseline and Early Treatment with Anakinra Area Associated with Maintenance of Normal Hearing
Nothing to Disclose

Ekaterina Alexeeva
Long-Term Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Alessandra Alongi
Patients’ and Parents’ Perception of Disease and Its Impact on Life in Juvenile Idiopathic Arthritis: Results from Multinational Virtual Focus Groups by the OMERACT JIA Working Group
Nothing to Disclose

Hitha Amin
Is Early Standardized Rituximab Therapy Sufficient for Toddlers with NMDAR Encephalitis?
Nothing to Disclose

Sheila Angeles-Han
Systemic Therapy in Children with Juvenile Idiopathic Arthritis-Associated Uveitis Immediately Following Failure of Methotrexate, Adalimumab and Infliximab
Nothing to Disclose

Camilla Astley
Exercise Improves Arterial Inflammation in Childhood-onset Takayasu Arteritis: A Randomized Controlled Trial
Nothing to Disclose

Ugo Awa
Serum Sickness Following Rituximab Treatment of Childhood-Onset SLE: A Single Center Experience
Nothing to Disclose

Daniah Basodan
Utilization of Biologic Treatments in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis
Nothing to Disclose

Claudia Bracaglia
DNASE1L3 Variant in Hypocomplementemic Urticarial Vasculitis Syndrome Identifies a Different Clinical Phenotype
Nothing to Disclose

Claudia Bracaglia
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Monica Bray
Systemic Vascular Involvement in Kawasaki Disease: A Single Center Cohort
Nothing to Disclose

AnneMarie C Brescia
Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of TGFβ Signaling, to Delay Cell Differentiation and Maturation
Nothing to Disclose

Hermine I Brunner
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Disclosure:
2- Bristol-Myers Squibb; Genentech; Pfizer
5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB
8- Genentech; Novartis

Hermine I Brunner
Improvement in Patient-Reported Outcomes in Patients Aged 2–5 Years with Polyarticular-Course JIA Treated with Subcutaneous Abatacept: 2-Year Results from a Phase III International Study
Disclosure:
2- Bristol-Myers Squibb; Genentech; Pfizer
5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB
8- Genentech; Novartis

Hermine I Brunner
Tracking Whole-Brain Volumetric Trends in Childhood-onset Systemic Lupus Erythematosus Patients in the Clinical Setting by Magnetic Resonance Imaging
Disclosure:
2- Bristol-Myers Squibb; Genentech; Pfizer

5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB
8- Genentech; Novartis

Nathalie E Chalhoub
Clinical Variables Influencing Prednisone Dosing Towards the Development of Corticosteroid Treatment Algorithms in Pediatric Proliferative Lupus Nephritis
Nothing to Disclose

Audrea Chen
Practice Variations in Treatment of Pediatric Anti-neutrophil Cytoplasmic Antibody (ANCA)-associated Vasculitis (AAV) with Renal Disease
Nothing to Disclose

May Y Choi
Closing the Seronegative Gap in Pediatric Localized Scleroderma and Systemic Sclerosis
Nothing to Disclose

Adele Civino
Clinical Factors Distinguishing Between Pediatric Tumors with Arthritis at Onset and JIA: Preliminary Analysis of the ONCOREUM Study
Nothing to Disclose

Kathleen Collins
Injection Fear in Juvenile Idiopathic Arthritis Patients Using Injectable Medications
Nothing to Disclose

Ruth Costello
Incidence of Juvenile Idiopathic Arthritis in the United Kingdom: Estimates from a National Primary Care Dataset
Nothing to Disclose

Fabrizio De Benedetti
Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study Disclosure:
2- AbbVie; BMS; Novartis; Novartis, Novimmune, Hoffmann- La Roche, SOBI, AbbVie, Pfizer; Novimmune; Pfizer; Roche; Sanofi; Sobi; Swedish Orphan Biovitrum; UCB

Talia Diaz
Ethnicity and Neonatal Lupus Erythematosus Manifestations Risk in a Large Multi-Ethnic Cohort
Nothing to Disclose

Ivan Foeldvari
Is the Presentation and Severity Different of the Juvenile Diffuse and Limited Subtype Systemic Sclerosis? Results of Juvenile Scleroderma Inception Cohort
Disclosure:
5- Beyer; BMS; Glaxo; Inventa; Novartis

Ivan Foeldvari
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment According the Juvenile Spondyloarthritis Disease Activity Index
Disclosure:
5- Beyer; BMS; Glaxo; Inventa; Novartis

Ivan Foeldvari
Under Detection of Interstitial Lung Disease in Juvenile Systemic Sclerosis (jSSc) Utilizing Pulmonary Function Tests: Results from the Juvenile Scleroderma Inception Cohort
Disclosure:
5- Beyer; BMS; Glaxo; Inventa; Novartis

Charlene M Foley
Is down Syndrome Associated Arthritis (DA) a Distinct Disease from Juvenile Idiopathic Arthritis (JIA)?
Nothing to Disclose

Meghan D Foster
Improving Adolescent Health Care Transition: Piloting the Transition Readiness Assessment Questionnaire
Nothing to Disclose

Teresa Giani
Alagille Syndrome and Chronic Arthritis: An International Case Series
Nothing to Disclose

Mia Glerup
Complement Protein Levels Reflect Disease Activity in Juvenile Idiopathic Arthritis
Nothing to Disclose

Sabrina Gmuca
Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
Nothing to Disclose

Marla Guzman
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Nothing to Disclose

Sara Haro
Disease Activity and Health Care Utilization Among Young Adults with Childhood-onset Lupus Transitioning to Adult Care: Follow-Up Data from the Pediatric Lupus Outcomes Study
Nothing to Disclose

Jonathan S Hausmann
Health-related Social Media Use by Parents of Children with Rheumatic Diseases
Nothing to Disclose

Daniel B Horton
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Nothing to Disclose

Joyce Hui-Yuen
Differences in Chromatin Architecture in Treatment Naïve Pediatric Lupus Patients
Nothing to Disclose

Joyce Hui-Yuen
Validation of the 2017 Weighted Criteria in Pediatric Systemic Lupus Erythematosus (SLE)
Nothing to Disclose

Peter Hur
Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States
Disclosure:
3- Novartis; Novartis Pharmaceuticals Corporation; Novartis Pharmaceuticals Corporations

Ginger Janow
Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry
Nothing to Disclose

James N. Jarvis
The Juvenile Idiopathic Arthritis-Associated IL2RA Haplotype Contains an Intronic Enhancer Whose Function Is Diminished by JIA-Associated Genetic Variants
Nothing to Disclose

Jordan T Jones
The down Syndrome Arthropathy Cohort in the New Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics, Treatment and Outcomes
Nothing to Disclose

Amelie M Jule
Identical T Cell Clones Identified over Time in the Joints of Oligoarticular Juvenile Idiopathic Arthritis Patients
Nothing to Disclose

Ozgur Kasapcopur
Cognitive Impairment in Childhood-Onset Systemic Lupus Erythematosus: Early Detection with MRI Spectroscopy and Its Association with MOG Antibodies
Nothing to Disclose

Disclosure:
2- AbbVie

Ozgur Kasapcopur
Frequency of Juvenile Idiopathic Arthritis (JIA) Subgroups and JIA-associated Uveitis Among JIA Patients Admitted to Referral Pediatric Rheumatology Clinics In Turkey: A Retrospective Study, JUPITER
Disclosure:
2- AbbVie

Young Ho Kim
Cryopyrin-Associated Periodic Syndrome in Korea: 19 Years of Experience
Nothing to Disclose

Yukiko Kimura
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Patient Characteristics, Patient Reported Outcomes and Consensus Treatment Plan Choices
Disclosure:
5- Novartis; Sobi

Ovgu Kul Cinar
Can High ANA Titre Combined with Clinical Features Predict Developing Autoimmune Conditions in Children?
Nothing to Disclose

RAKESH KUMAR
Kawasaki Disease Shock Syndrome - More Common Than We Think: Our Experience at Chandigarh, North India
Nothing to Disclose

RAKESH KUMAR
Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention
Nothing to Disclose

Helen J Lachmann
Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial Disclosure:
5- Novartis, SOBI

Suzanne C Li
Persistent Disease Activity Is Associated with Avascular Necrosis Development in Juvenile Systemic Lupus Erythematosus Disclosure:
3- Merck & Co.

Lily SH Lim
Are Patterns of Early Disease Severity Predictive of Grade 12 Academic Achievement in Patients with Childhood-onset Chronic Rheumatic Diseases? Nothing to Disclose

S Sam Lim
Long-term Renal Survival of Pediatric Onset Lupus Patients in a Population-Based Cohort Nothing to Disclose

Mireia Lopez-corbeto
Application of the Autoinflammatory Disease Activity Index (ADDI) to a Cohort of Patients in a Tertiary Hospital Nothing to Disclose

Anastasia-vasiliki Madenidou
Low Bone Mineral Density Was Associated with Lupus Nephritis Irrespective of Duration on Steroid Treatment in a Large Observational Study of Juvenile Systemic Lupus Erythematosus Patients Nothing to Disclose

Susan M Maillard
Review of Effectiveness of an Intensive Rehabilitation Programme in Managing Strength, Pain and Function in 123 Young People with Rheumatological Conditions Nothing to Disclose

Melissa Mannion
Investigation of Inactive Disease Activity States Among JIA Patients in the CARRA Registry Nothing to Disclose

edoardo marrani
A Systematic Literature Review of Efficacy and Safety of Biologic Agents for the Treatment of Juvenile Dermatomyositis Nothing to Disclose

Anne McHugh
Profiling Behavioral and Psychological Symptoms in Children with Spondyloarthritis and Polyarthritis Nothing to Disclose

Jacob Mitchell
Interferon Response Gene Expression Differs in Whole Blood, Peripheral Blood Mononuclear Cells, Monocytes, Dendritic Cells, Neutrophils, and Skin Tissue in Patients with the Autoinflammatory Interferonopathies, CANDLE and SAVI Nothing to Disclose

Gina A Montealegre Sanchez
Development of Large Vessel Vasculitis Including Aortitis in a Patient with Deficiency of the IL-1 Receptor Antagonist (DIRA) Points to Converging Roles of IL-1 and TNF in Vascular Pathogenesis Recapitulating Findings from a Murine Model Nothing to Disclose

Agna Neto
Association of Body Mass Index with Juvenile Idiopathic Arthritis Disease Activity: A Portuguese and Brazilian Collaborative Analysis with Data from Reuma.pt Registry Nothing to Disclose
Kate M Neufeld
Depression and Anxiety Symptoms in Childhood-Onset Systemic Lupus Erythematosus
Nothing to Disclose

Rebecca Nicolai
Type I Interferon Score and Interferon Induced Mediators CXCL10 and Neopterin Are Correlated with Disease Activity in Juvenile Dermatomyositis
Nothing to Disclose

Ekemini A Ogbaru
Impact of Preceding and Co-existing Autoimmune Cytopenias on Severity of Childhood-onset Systemic Lupus Erythematosus: A Single-Center Retrospective Cohort Study
Nothing to Disclose
2- National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378 and TL1TR002382

Rebecca S Overbury
Implementation of an Evidence-based Transition Clinic in a Pediatric Rheumatology Academic Institution
Nothing to Disclose

Rebecca S Overbury
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Nothing to Disclose

Manuela Pardeo
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Sara T Patrizi
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Nothing to Disclose

Rosemary G Peterson
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Rachel L Randell
Pediatric Sjögren Syndrome: A Single-Center Experience
Nothing to Disclose

Daniel Reiff
Characteristics of Coexisting Localized Scleroderma and Juvenile Idiopathic Arthritis
Nothing to Disclose

Jackeline Rodriguez-Smith
Distinguishing S100 Proteins and Cytokine Levels Between Active and Inactive Uveitis in Children with Juvenile Idiopathic Arthritis
Nothing to Disclose

Dax G Rumsey
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis Disclosure:
9- Childhood Arthritis and Rheumatology Research Alliance (CARRA) (Financial support in the form of statistical support and publication support for this study.)

Rebecca E Sadun
Predictors of Health Care Transition Practices Among North American Pediatric Rheumatology Providers
Nothing to Disclose

Erdal Sag
Oligoarticular Juvenile Idiopathic Arthritis Displayed Increased Expression of Co-Inhibitory Receptors Without Signs of T-Cell Exhaustion
Nothing to Disclose

Sujata Sawhney
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Nothing to Disclose

Sujata Sawhney
Kawasaki Disease: Is Intravenous Immunoglobulin Alone Adequate for the Child with Kawasaki Disease and Coronary Artery Lesions? A Retrospective Study of 65 Children with Kawasaki Disease from a Single North Indian Centre
Nothing to Disclose

Christina Schutt
Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma
Nothing to Disclose

Cristina Segu-Verges
Application of Systems Biology-Based In Silico Tools for Optimal Treatment Strategy Identification in Still’s Disease
Nothing to Disclose

Jessica Shantha
Baseline Characteristics and Quality of Life Metrics in Non-Infectious Uveitis
Nothing to Disclose

Natalie Shiff
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry Disclosure: 9- CARRA (Registry Associate with salary support)

Muhammad R Shipa
Predictors of Response to Tumour Necrosis Factor - α Inhibitors (TNFi) in Juvenile Idiopathic Arthritis (JIA): A Single-center Experience
Nothing to Disclose

Gabriele Simonini
Adalimumab Alone Is Superior to Adalimumab Plus Methotrexate in Juvenile Idiopathic Arthritis Associated Uveitis: Data from the ORCHIDEA Registry
Nothing to Disclose

Elizabeth E Sloan
Identifying Additional Risk Factors for Arterial and Venous Thrombosis Among Pediatric Antiphospholipid Antibodies Carriers
Nothing to Disclose

Emily A Smitherman
Disease Activity in Childhood-Onset Systemic Lupus Erythematosus: Initial Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
Nothing to Disclose

Alexander Solyom
Farber Disease (Acid Ceramidase Deficiency): The First Natural History Study of This Rare Disease Involving Symptoms Which Can Mimic JIA Disclosure: 3- Enzyvant 4- Enzyvant

Brandi Stevens
Disease Manifestations and Impact on Quality of Life in Subjects with Pre-Pubertal Onset Systemic Lupus Erythematosus
Nothing to Disclose

Catherine Strahle
Evaluating the New 2018 ACR/EULAR SLE Classification in Pediatric Patients
Nothing to Disclose

Kiana Taba
A Retrospective Study Comparing Refractoriness to Biologic Disease Modifying Anti-Rheumatic Drugs in Adults with Juvenile Idiopathic Arthritis as Compared to Those with Rheumatoid Arthritis
Nothing to Disclose

Divya Takellapti
Changes in MiR-17-92 Cluster Expression Link Systemic Juvenile Idiopathic Arthritis, Monocyte-to-Macrophage Differentiation, and Interferon Regulation
Nothing to Disclose

Jose Luis Tandaipan
STING-associated Vasculopathy with Onset in Infancy (SAVI Syndrome) Can Mimic Juvenile Idiopathic Arthritis
Nothing to Disclose

Sofia Torreggiani
Multiple Genetic Diagnoses in a Cohort of Patients with Cryopyrin Associated Periodic Syndrome (CAPS)
Nothing to Disclose

Shoko Tsuji
The Study of the Novel G87V Mutation in the TNFRSF1A Gene Identified in a Family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Disclosure:
2- Chugai Pharmaceutical Co., Ltd.; Glaxo Smith Kline K.K.

Jessica L Turnier
Cutaneous Gene Expression Signatures in Juvenile Myositis Reveal a Prominent IFN Signature in Lesional Skin
Nothing to Disclose

Natalia Vasquez-Canizares
Von Willebrand Factor Is Localized in the Extravascular Tissue of Patients with Juvenile Scleroderma
Nothing to Disclose

Devy Zisman
Long-term Outcome of Juvenile-onset Psoriatic Arthritis
Disclosure:
5- Pfizer
8- Pfizer

Francesco Zulian
Mycophenolate Mofetil for the Treatment of Severe or Methotrexate-refractory Juvenile Localized Scleroderma
Nothing to Disclose

Francesco Zulian
Rituximab for Rapidly Progressive Juvenile Systemic Sclerosis: A Proof-of-concept Study in Four Patients
Nothing to Disclose

Francesco Zulian
Speckle Tracking Echocardiography, a Sensitive Tool to Detect Early Cardiac Dysfunctions in Juvenile Systemic Sclerosis
Nothing to Disclose

Ken Cai
The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Disclosure:
2- Arthritis Australia

Atul Deodhar
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis Who Were Biologic-Naïve or Prior TNFα Inhibitor-Treated: Week 24 Results of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Atul Deodhar
Ixekizumab in Non-Radiographic Axial Spondyloarthritis: Primary Results from a Phase 3 Trial
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Bhargavi Duvvuri
Mitochondrial Contribution to Juvenile Dermatomyositis Pathogenesis
Nothing to Disclose

Richard A Furie
A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Disclosure:
2- AstraZeneca
5- AstraZeneca

Shivani Garg
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Nothing to Disclose

Aase Hensvold
Development of Ultrasound Detectable Arthritis Among ACPA Positive Subjects with Musculoskeletal Symptoms: The Risk RA Prospective Study
Nothing to Disclose

Peter Izmirly
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Disclosure:
5- GlaxoSmithKline

Benjamin D Korman
TNF-α Drives Progressive Obliterative Pulmonary Vascular Disease and Represents a Novel Model of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension (CTD-PAH)

Nothing to Disclose

Féline Kroon
Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial
Nothing to Disclose

Natalie McCormick
Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Nothing to Disclose

Paul Miller
Efficacy and Safety of Romosozumab vs Placebo Among Patients with Mild-to-Moderate Chronic Kidney Disease
Disclosure:
2- Amgen; Radius Pharma
5- Amgen; Radius Pharma; Alexion

Christian Roux
Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
Nothing to Disclose

Sladjana Skopelja-Gardner
UV Light Induces Acute Type I Interferon Production in the Skin and Blood Which Is cGAS Dependent
Nothing to Disclose

Rona M Smith
A Randomized, Controlled Trial of Rituximab versus Azathioprine After Induction of Remission with Rituximab for Patients with ANCA-associated Vasculitis and Relapsing Disease
Disclosure:
2- Roche; Sanofi; Medimmune
8- Roche
John H Stone
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
Disclosure:
2- Genentech; Roche; Xencor
5- Genentech; Roche; Xencor

Désirée van der Heijde
Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical Study of Patients with Active Ankylosing Spondylitis
Disclosure:
4- Rheumatology bv
5- AbbVie; AbbVie, Amgen, Astellas, AstraZeneca, BMS; Amgen; Astellas; Astellas Pharma; AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim, Celgene, Daichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB; Boehringer-Ingelheim; Bristol-Myers Squibb; Celgene; Daichi; Daichi Sankyo; Eli Lilly; Eli Lilly and Company; Eli-Lilly; Galapagos; Gilead; Gilead Sciences, Inc.; GlaxoSmithKline; Glaxo-Smith-Kline; GSK; Janssen; Janssen Pharmaceutica; Merck; Novartis; Pfizer; Pfizer Inc; Regeneron; Roche; Sanofi; Takeda; Takeda Pharmaceutical Company; UCB; UCB Pharma
6- Director of Imaging Rheumatology
8- GSK; Janssen; Merck; Novartis; Pfizer; Regeneron; Roche; Sanofi; Takeda; UCB
9- Astellas ; Daichi ; Director of Imaging Rheumatology bv ; Imaging Rheumatology bv ; Imaging Rheumatology bv .; Rheumatology bv

Lykke Midtbøll Ørnbjerg
Patient Reported Outcomes over Time in 25,988 Axial Spondyloarthritis Patients Initiating Treatment with 1st, 2nd or 3rd TNF Inhibitor in Clinical Practice – Is PRO Remission Achieved? Results from the EuroSpA Collaboration
Disclosure:
2- Novartis

Lykke Midtbøll Ørnbjerg
Predicting ASDAS Inactive Disease After 6 Months of TNFi Treatment in Bio-Naive Axial Spondyloarthritis Patients Treated in Clinical Practice – Results from the EuroSpA Collaboration
Disclosure:
2- Novartis

Ufuk İlgen
Tuberculin Skin Test and Quantiferon®-TB Gold In- Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Nothing to Disclose

Polona Žigon
Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Nothing to Disclose

Waleed Abdellatif
CT Mapping of Spinal & Vascular Abdominal Urate Deposition with Correlation to Uric Acid Level
Nothing to Disclose

Nobuya Abe
Resting-State Functional Connectivity of Pain Processing Brain Region Associated with Therapeutic Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis
Nothing to Disclose

Saori Abe
Detection and Clinical Significance of Circulating M3 Muscarinic Acetylcholine Receptor Reactive Th17 Cells in Patients with Primary Sjögren’s Syndrome
Nothing to Disclose

Ilana Abeles
Measurement of Type I IFNα Production at the mRNA Level and Its Potential Use as a Biomarker in Systemic Lupus Erythematosus
Nothing to Disclose

Grigor Abelian
The Relationship Between Abatacept Exposure and CD86 Receptor Occupancy in Rheumatoid Arthritis Patients Following Subcutaneous Administration and Its Association to Patient Outcomes
Disclosure:
3- Bristol-Myers Squibb

Fatima Abji
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Nothing to Disclose

Aos Aboabat
Application of the Systemic Lupus Erythematosus (SLE) Quality Indicators in Patients Attending a Young Adult Transition Program
Nothing to Disclose

Ahmed Abogamal
Tendons Involvement at Early Onset of Gouty Arthritis, Ultrasonographic Study
Nothing to Disclose

Saurav Acharya

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases
Nothing to Disclose

Maria Elisa Acosta
IL-6 and TNF-α Influence on Clinical Manifestations, Activity and Comorbidity in Psoriatic Arthritis Patients
Nothing to Disclose

Giovanni Adami
Methods to Efficiently Recruit Minority Patients with Gout for Clinic-Based Registries
Nothing to Disclose

Sana Afroz
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Nothing to Disclose

Cecilia V Agapito Tito
Structural Abnormalities of the Optic Nerve and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis
Nothing to Disclose

Natalia Aguilera
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Nothing to Disclose

Sergio Aguilera
Tofacitinib Inhibits Increased Inflammatory Marker Expression in a Human Salivary Cell Line Deficient in Autophagy: A Model of Sjögren’s Syndrome
Nothing to Disclose

Sarah Ahmed
Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Nothing to Disclose

Lorien Ahn
Osteoporosis Management Outcomes in a Southern California County Health System
Nothing to Disclose

Se Han Ahn
Predictor of Placebo Response in Hand Osteoarthritis: A Post Hoc Analysis of Two Randomized Controlled Trials
Nothing to Disclose

Rizi Ai
Novel Somatic Mutations Identified by Whole Genome Sequencing of Rheumatoid Arthritis (RA) Fibroblast-Like Synoviocytes (FLS)
Nothing to Disclose

Yoshimi Aizaki
Aberration of Histone Lysine Methylation in Adult-Onset Still’s Disease Are Novel Biomarker Candidates Associated with the Disease Activity
Nothing to Disclose

Servet Akar
Evaluation of Influenza and Pneumococcal Vaccination Rate in Patients with Rheumatoid Arthritis and Spondyloarthritis, and the Attitudes of Rheumatologists About Vaccination Disclosure:
2- Abbvie; Amgen; MSD; Novartis; Pfizer; Roche; UCB
5- Abbvie; Amgen; MSD; Novartis; Pfizer; Roche; UCB
8- Pfizer

Kengo Akashi
The Comparative Efficacy of Pneumocystis Pneumonia Prophylactic Regimens in Patients with Connective Tissue Diseases Receiving Prolonged High-dose Glucocorticoids
Nothing to Disclose

Abdalhamid Al Harash
Efficacy and Outcomes of Telephone-Based Management Program in Patients with Gout
Nothing to Disclose

Muhsen Al-ani
Interstitial Lung Disease in Patients with Systemic Lupus Erythematosus: Who Should We Screen?
Nothing to Disclose

John A. Albert
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice Disclosure:
8- Horizon

Cleandro Albuquerque
High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthritis
Nothing to Disclose

Daniel Aletaha
Enthesitis Frequency and Treatment Patterns in Patients with Psoriatic Arthritis in Europe and Japan Disclosure:
2- AbbVie; AbbVie, Merck Sharp and Dohme, and Roche.; Merck Sharp and Dohme; Novartis; Roche
5- AbbVie; AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche; Amgen; Celgene; Janssen; Lilly; Medac; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme
8- AbbVie; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb, Celgene, Merck Sharp and Dohme, and UCB; Celgene; Lilly; Medac; Merck; Merck Sharp and Dohme; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme; UCB

Daniel Aletaha
Systematic Literature Review and Meta-Analysis of DAS28 Clinical Response Rates Among Advanced Therapies in Biologic-Naïve Patients with Rheumatoid Arthritis Disclosure:
2- AbbVie; AbbVie, Merck Sharp and Dohme, and Roche.; Merck Sharp and Dohme; Novartis; Roche
5- AbbVie; AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche; Amgen; Celgene; Janssen;
Daniel Aletaha
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Disclosure: 2- AbbVie; AbbVie, Merck Sharp and Dohme, and Roche.; Merck Sharp and Dohme; Novartis; Roche.
5- AbbVie; AbbVie, Janssen, Lilly, Novartis, Pfizer, and Roche; Amgen; Celgene; Janssen; Lilly; Medac; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme
8- AbbVie; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb, Celgene, Merck Sharp and Dohme, and UCB; Celgene; Lilly; Medac; Merck; Merck Sharp and Dohme; Novartis; Pfizer; Roche; Sandoz; Sanofi/Genzyme; UCB

Sofia Alfred
Cognitive Impairments in SLE Negatively Related to Participation and Quality of Life: A Systematic Review
Nothing to Disclose

Ramadan A Ali
Potent Anti-neutrophil Properties of the Natural Compound 6-Gingerol in Models of Lupus and Antiphospholipid Syndrome
Nothing to Disclose

Fatma Alibaz-Oner
Efficacy of TNF α Inhibitors for Refractory Vascular Behcet’s Disease: A Multicenter Observational Study of 27 Patients
Nothing to Disclose

Fatma Alibaz-Oner
Vascular Damage Is Less Present in an Early Inception Cohort in Takayasu’s Arteritis
Nothing to Disclose

Jihad Aljabban
Multi-Organ System Meta-Analytic Approach to Investigating Sarcoidosis
Nothing to Disclose

Jihad Aljabban
Tripartite Motif (TRIM) Gene Family Expression in Dermatomyositis
Nothing to Disclose

Najla Aljaberi
The Performance of a Renal Activity Index in Lupus Nephritis in Induction Therapy
Nothing to Disclose

Yannick Allanore
Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
Disclosure: 2- Actelion; Alpine; Bayer; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech Roche; Inventiva; Italfarmaco; Sanofi; Servier
5- Actelion; Alpine; Bayer; BMS; Boehringer Ingelheim; Bristol Myers Squibb; Bristol-Myers Squibb; Genentech Roche; Inventiva; Italfarmaco; Sanofi; Servier

Yannick Allanore
Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Disclosure:
2- Actelion; Alpine; Bayer; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech Roche; Inventiva; Italfarmaco; Sanofi; Servier
5- Actelion; Alpine; Bayer; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Genentech Roche; Inventiva; Italfarmaco; Sanofi; Servier
Squibb; Genentech Roche; Inventiva; Italfarmaco; Sanofi; Servier

Gelsomina Alle
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Nothing to Disclose

Michael Allen
Clinical, Serologic and Morphologic Features of Interstitial Pneumonia with Autoimmune Features (IPAF): A Single Center Experience
Nothing to Disclose

Peter C Allen
Genome-Wide DNA Methylation Signatures in Classical Monocytes from African Ancestry Patients with Systemic Sclerosis
Nothing to Disclose

Saja Almaaitah
Long Term Outcome of Hydralazine-Associated Vasculitis
Nothing to Disclose

Salem Almaani
Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis
Nothing to Disclose

Nickolas Almodovar
Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)
Nothing to Disclose

Jinan Al-Naqeeb
Association of Gout with Vitamin D: A Population-Based Study
Nothing to Disclose

Valerie Aloush
Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients
Nothing to Disclose

Abdulrahman Alrashid
Proton Pump Inhibitor Induced Subacute Cutaneous Lupus Erythematosus: Clinical Characteristics and Outcomes – Case Control Study
Nothing to Disclose

Abdulrahman Alrashid
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Nothing to Disclose

Rieke Alten
Real World Switching Patterns of Etanercept Original and Biosimilar in Germany Disclosure:
2- Galapagos; Galapagos NV; Gilead; Gilead Sciences, Inc.; Novartis; Pfizer
8- Pfizer

Alessia Alunno
Heterogeneity of Strategies and Methods for Assessment of Competences in Rheumatology Training: Results of a Systematic Literature Review to Inform EULAR Points to Consider
Nothing to Disclose

Rodolfo N Alvarado
Risk of Heart Valve Disease in Systemic Sclerosis
Nothing to Disclose

Abhimanyu Amarnani
DNA Methylation of the Dual Specificity Phosphatase 22 (DUSP22) Gene Promoter in Plasma and Medication Use in Rheumatoid Arthritis (RA)
Nothing to Disclose

Abhimanyu Amarnani
Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function
Nothing to Disclose

M A Amin
Citrullination of Interleukin 6 Augments Its Pro-Inflammatory Capacity and Signaling Potency
Through Interleukin-6 Receptor in Rheumatoid Arthritis
Nothing to Disclose

Shreyasee Amin
Attenuated Association Between Proton Pump Inhibitor Use and Fracture Risk After Consideration of Chronic Comorbidities
Nothing to Disclose

Howard AMITAL
Impact of Tocilizumab on Anxiety and Depression in Patients with Rheumatoid Arthritis
Nothing to Disclose

Sogol S Amjadi
Use of Serum Lung Injury Biomarkers for Predicting the Severity of Interstitial Lung Disease in Patients with Connective Tissue Disease Associated Interstitial Lung Disease and Interstitial Pneumonia with Autoimmune Features
Nothing to Disclose

Jonathan Amos
Efficacy of Mycophenolate Mofetil in the Treatment of Rheumatoid Arthritis Associated Interstitial Lung Disease
Nothing to Disclose

Jie An
Mitochondrial DNA: A Potential Trigger of Cyclic GMP-AMP Synthase Activation in Systemic Lupus Erythematosus
Nothing to Disclose

Allen Anandarajah
Poverty and Systemic Lupus International Collaborating Clinics Damage Index (SDI) Are Significant Risk Factors for Hospitalization in SLE Patients
Nothing to Disclose

Vidyanand Anaparti
Circulating 25(OH)D, LL-37 and Antimicrobial Protein and Peptide (APP) Levels Are Altered Prior to Onset of Rheumatoid Arthritis
Nothing to Disclose

Christine Anastasiou
Opioid Overdose Hospitalizations in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nothing to Disclose

Kathleen M Andersen
Duration of Oral Corticosteroid Therapy Does Not Change with the Addition of a Parenteral Injection: Results from a Real-World Canadian Early RA Cohort
Disclosure:
2- National Heart, Lung and Blood Institute (NHLBI) Pharmacoepidemiology T32 Training Program (T32HL139426-01); National Heart, Lung and Blood Institute Pharmacoepidemiology T32 Training Program (T32HL139426-01).

Kathleen M Andersen
No Evidence of an Increased Risk of Serious Infections Among 3 Classes of Biologics for Psoriasis or Psoriatic Arthritis: A Retrospective Real-World Cohort Study
Disclosure:
2- National Heart, Lung and Blood Institute (NHLBI) Pharmacoepidemiology T32 Training Program (T32HL139426-01); National Heart, Lung and Blood Institute Pharmacoepidemiology T32 Training Program (T32HL139426-01).

Nicole J Andersen
Major Stressors in the Year Prior to Diagnosis Affects RA Characteristics at Presentation and 1 Year
Nothing to Disclose

Caleb Anderson
Naming Is Everything! the Cost of Inappropriate “Lupus Panel” Testing
Nothing to Disclose

Caleb Anderson
The Combat Rheumatologist: Long Term Professional Outcomes of Graduates from a Tri-
Service Military Rheumatology Fellowship Program  
Nothing to Disclose

Erik Anderson  
The Impact of Disease Activity and Related Factors on Cognitive Dysfunction in SLE  
Nothing to Disclose

Takayasu Ando  
The Effectiveness of anti-IL-6 Therapy to Elderly-onset Rheumatoid Arthritis  
Nothing to Disclose

Brian J Andonian  
High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles  
Nothing to Disclose

Reema Andrade  
Opioid Treatment Pattern in a Community Based Rheumatology Clinic  
Nothing to Disclose

Rikke A Andreasen  
The Impact of Sex and Disease Classification on Patient-reported Outcome Measures in Axial Spondyloarthritis: A Descriptive Prospective Cross-sectional Study  
Nothing to Disclose

Kristofer M Andreasson  
Self-reported Anxiety, Depression and Levels of Physical Activity in Patients with Adult Idiopathic Inflammatory Myopathies  
Nothing to Disclose

James Andrews  
Sarcopenia and the Likelihood of Incident Knee Osteoarthritis and Knee Pain Among Older Adults in the Health ABC Study  
Nothing to Disclose

Sheila Angeles-Han  
Epidemiology of JIA-Associated Uveitis: Environmental Factors and Disease Characteristics of a JIA-Associated Uveitis Cohort  
Nothing to Disclose

Meghan Angley  
Risk of Preterm Birth by Timing of Lupus Diagnosis Among Women in the Georgia Lupus Registry  
Nothing to Disclose

Judith Aniekwena  
Influenza Vaccination Rates Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis on Immunosuppressive Therapy: Findings from a Large Public Hospital  
Nothing to Disclose

Richard Antbring  
Lupus Teledematology: A Pilot Project to Evaluate the Plausibility of a Rapid Access Dermatology Service for Lupus Patients  
Nothing to Disclose

Anna Antony  
The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis  
Nothing to Disclose

Benny Antony  
A Randomised Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-Synovitis of Knee Osteoarthritis  
Nothing to Disclose

Benny Antony  
Clinical Significance of Magnetic Resonance Imaging Derived Femur Bone Shape in Young Adults  
Nothing to Disclose

Akiko Aoki  
Predictors of Long-term Therapy with Glucocorticoid in Polymyalgia Rheumatica  
Nothing to Disclose
Diane Apostolopoulos
Factors Associated with Damage Accrual in SLE Patients with No Clinical or Serological Disease Activity
Nothing to Disclose

Yasuto Araki
Histone Lysine Methyltransferase MLL1 Regulates the Expression of Cytokines and Chemokines in Rheumatoid Arthritis Synovial Fibroblasts
Nothing to Disclose

Kaveh Ardalan
Comparison of PROMIS Computerized Adaptive Testing-Administered Item Banks versus Fixed Short Forms in Juvenile Myositis
Nothing to Disclose

Kaveh Ardalan
Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Nothing to Disclose

Ana B Arevalo
Cardiovascular Impact of Hyperuricemia in Patients with Psoriatic Arthritis
Nothing to Disclose

Ana B Arevalo
Lumbar Spinal Stenosis in Patients with Wild-type Transthyretin Cardiac Amyloidosis
Nothing to Disclose

Ivan Arias de la Rosa
Complement Component 3 as Biomarker of Cardiometabolic Risk in Rheumatic Diseases: Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis and Systemic Lupus Erythematosus
Nothing to Disclose

Ivan Arias de la Rosa
Liver Dysfunction Associated with Rheumatoid Arthritis: Impact of Obesity and Effects of DMARDs in Hepatic Alterations
Nothing to Disclose

Ivan Arias de la Rosa
PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease
Nothing to Disclose

Martin Aringer
Performance of the EULAR/ACR 2019 Classification Criteria for Systemic Lupus Erythematosus in Men, Diverse Ethnicities, and Early Disease
Disclosure:
5- Abbvie; AbbVie; AstraZeneca; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai; Hexal; HEXAL; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis
8- Abbvie; AbbVie; AstraZeneca; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai; Hexal; HEXAL; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis; UCB

Martin Aringer
Rituximab Rescue Therapy in Patients with Systemic Sclerosis or Other Connective Tissue Diseases and Refractory Interstitial Lung Disease
Disclosure:
5- Abbvie; AbbVie; AstraZeneca; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai; Hexal; HEXAL; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis
8- Abbvie; AbbVie; AstraZeneca; BMS; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai; Hexal; HEXAL; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis; UCB

Elizabeth V Arkema
Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Nothing to Disclose

Cristina Arriens
Differing Opinions on Clinical Research Between Healthcare Providers and Lupus Patients
Mariangelí Arroyo-Ávila
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at <3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Nothing to Disclose

Bahar Artim-Esen
Association of Serum and Urine Levels of TWEAK, MCP-1 and NGAL with Disease Activity in Systemic Lupus Erythematosus
Nothing to Disclose

Sheila Arvikar
Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
Nothing to Disclose

Shuji Asai
Disclosure:
8- AbbVie; Abbvie; Astellas; Bristol-Myers Squibb; Chugai; Chugai Pharmaceutical CO., LTD.; Daiichi-Sankyo; Eisai; Janssen; Janssen Pharmaceutical; Pfizer; Takeda; Tanabe Mitsubishi Pharma; UCB Japan

Dalit Ashany
Patients with Axial Spondyloarthritis Have Abnormal Microarchitecture Despite Normal Areal Bone Mineral Density and Trabecular Bone Score by DXA
Nothing to Disclose

Anca D Askanase
Belatacept in Systemic Lupus Erythematosus (SLE) Kidney Transplant Patients
Nothing to Disclose

Anca Askanase
Clinician’s Simple Opinion of SLE Disease Progress: Used in a Clinical Trial
Disclosure:
5- GSK; AstraZeneca; Janssen; Eli Lilly; AbbVie; Bristol-Myers Squibb

Anca D Askanase
New Imaging Modality to Evaluate Arthritis in Lupus Based on Frequency-domain Optical Transmission
Nothing to Disclose

Anca D Askanase
Safety Results of 50% Enrollment from a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate-dose Corticoster
Nothing to Disclose

Florence Assan
New 2019 SLE EULAR/ACR Classification Criteria for SLE Are Valuable for Distinguishing Patients with SLE from Patients with pSS in Daily Practice
Nothing to Disclose

Emma Astrike-Davis
Associations of Clinical Biomarkers with Radiographic Progression of Rheumatoid Arthritis (RA) in African Americans with Early Disease
Nothing to Disclose

Şebnem Ataman
Evaluation of the Early Cervical Structural Changes in Patients with Non-Radiographic Axial Spondyloarthropathy
Nothing to Disclose

Belén Atienza-Mateo
Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behçet’s Disease: National Multicenter Study of 51 Cases
Nothing to Disclose

Mohammad Atiquzzaman
Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variab

Laura Attipoe
Imaging Neoangiogenesis in Rheumatoid Arthritis (INIRA): Whole-Body Synovial Uptake of a 99mTc-Labelled RGD Peptide Is Highly Correlated with Power Doppler Ultrasound

Fabiola Atzeni
Patients with Fibromyalgia Associated with Rheumatoid Arthritis and Patients with Primary Fibromyalgia Differ in Depression, Anxiety, Stress-related Disorders and Events: A Cross-sectional Study

Jérôme Avouac
One Size Fits All : Replacing ESR by yGT in DAS28 Calculation Permits a Dual Evaluation of Joint Activity Together with Cardiovascular Risk

Jerome Avouac
Activation of the Desacetylase Sirtuin-1 Counteracts the Activated and Proangiogenic Profile of Endothelial Cells in Rheumatoid Arthritis and Alleviates Experimental Arthritis

Jerome Avouac
Effects of Successive Switches to Different Biosimilars Infliximab on Immunogenicity in Chronic Inflammatory Diseases in Daily Clinical Practice

Gizem Ayan
Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA

Sibel Zehra Aydin
Current Smoking Status Increases the Risk of Axial Psoriatic Arthritis: An Explanation to Smoking Paradox

Rehan Azeem
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Enables Sustained Reduction of Acute Gout Flares in Symptomatic Gout Patients

Rehan Azeem
Phase 2 Dose-ranging Study of SEL-212 in Symptomatic Gout Patients: Selection of Doses for Further Clinical Development

Ana Belén Azuaga-Piñango
Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis

Naoto Azuma
Evaluation of Changes in Oral Health-Related Quality of Life over Time in Patients with Sjögren’s Syndrome

Hakan Babaoglu
Homocysteinemia Predicts Renal Insufficiency in Systemic Lupus Erythematosus
Hakan Babaoglu
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Nothing to Disclose

Hakan Babaoglu
Time to Lupus Low Disease Activity State: Role of African-American Ethnicity
Nothing to Disclose

Hamayon Babary
Improving the Rate of Tuberculosis Screening Among High Risk Rheumatoid Arthritis Patients on Biologic Agents Using a Proposed Questionnaire
Nothing to Disclose

Winifred Badaiki
Predicting Risk of Developing Psoriatic Arthritis (PsA) in Siblings of Patients with Psoriatic Arthritis
Nothing to Disclose

Sang-Cheol Bae
Results of the Open-label, Non-randomized 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment with Belimumab in Patients with SLE
Nothing to Disclose

Sangmee Bae
Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies
Nothing to Disclose

Lisa Baganz
Comparing Real-world Retention Rates in a Matched Cohort of Rheumatoid Arthritis Patients Who Either Remained on the Etanercept Originator or Switched to a Biosimilar
Nothing to Disclose

Joshua F Baker
Defining Minimal Clinically Important Changes for the Patient Activity Scale-II
Disclosure:

2- Myriad RBM
5- Bristol-Myers Squib; Burns-White LLC

Joshua F Baker
Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Disclosure:
2- Myriad RBM
5- Bristol-Myers Squib; Burns-White LLC

Matthew Baker
Novel Approach to the Treatment of Cardiac Sarcoidosis with TNF-alpha Inhibition
Disclosure:
5- Vorso Inc

Chiara Baldini
Comparison of Ultra High-resolution Ultrasound (UHFUS) of Labial Salivary Glands and Conventional Salivary Gland Ultrasonography in Primary Sjögren’s Syndrome Assessment
Nothing to Disclose

Chiara Baldini
Extracellular Vesicles in Primary Sjögren’s Syndrome: A Promising Source for Novel Proteomic Biomarkers
Nothing to Disclose

Elena Baldissera
Efficacy and Safety of Tocilizumab in Giant Cell Arteritis: A Monocentric Real-life Experience
Disclosure:
5- Sanofi
8- Sobi; Roche; Pfizer; Novartis; Abbvie; Alfa-sigma

Elena Baldissera
Extravascular Inflammatory Manifestations of Takayasu Arteritis in a Monocentric Cohort
Disclosure:
5- Sanofi
8- Sobi; Roche; Pfizer; Novartis; Abbvie; Alfa-sigma

Stephen Balevic
Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus
Disclosure:
2- Rheumatology Research Foundation; Thrasher Research Foundation; NIH
5- UCB

Juan M Bande
Knowledge of Cardiovascular Disease Risk Among Patients with Rheumatoid Arthritis
Nothing to Disclose

So-Young Bang
A Genome-Wide Association Study of Copy Number Variations Identifies the Deletion Associated with Efficacy of TNF-Alpha Blocker Therapy in Korean Patients with Rheumatoid Arthritis
Nothing to Disclose

So-Young Bang
Higher Genetic Risk Load in Patients with More Diverse Manifestations in a Korean Systemic Lupus Erythematosus Cohort
Nothing to Disclose
3- Hanyang University

Milad Baniaamam
Increased Prevalence of Cardiac Disorders in Dutch Ankylosing Spondylitis Patients: The CARDAS Study
Nothing to Disclose

Raveendhara R Bannuru
A Positive Response to Nonpharmacological Therapies in Patients with Fibromyalgia
Nothing to Disclose

Julian E Barahona-Correa

Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis
Nothing to Disclose

Xenofon Baraliakos
Early Recognition of Patients with Axial Spondyloarthritis by Using a Practical Referral System – Evaluation of the Recently Proposed 2-step Strategy
Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB

Xenofon Baraliakos
Identification of Factors Associated with Magnetic Resonance Images Changes Suggestive of Axial Spondyloarthritis in the Axial Skeleton of Individuals < 45 Years - Evaluation of Data from a Large Community Study
Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB
Xenofon Baraliakos
Localization and Morphology of Magnetic Resonance Imaging Features of Pathologic Changes in the Sacroiliac Joints Suggestive of Axial Spondyloarthritis – a Systematic Comparison of Patients and Controls with Chronic Back Pain
Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB

Xenofon Baraliakos
Long-Term Certolizumab Pegol Treatment of Axial Spondyloarthritis Is Associated with Rapid and Sustained Reduction of Active Inflammation and Minimal Structural Changes in the Spine: 4-Year MRI Results
Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Bristol-Myers Squibb; Celgene; Chugai; Eli Lilly; Galapagos; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; UCB
9- AbbVie; Biocad; Bristol-Myers Squibb

Claire Barber
Are We Meeting Benchmarks for Wait Times to Pediatric Rheumatology Care for Juvenile Idiopathic Arthritis (JIA)?
Nothing to Disclose

Claire Barber
Testing Rheumatoid Arthritis Performance Measures to Optimize Treat to Target Strategies
Nothing to Disclose

Gabrielle Barbera
EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis
Nothing to Disclose

Medha Barbhaiya
Development of New International Classification Criteria for Antiphospholipid Syndrome: Phase II Results
Nothing to Disclose

Tatiana Barbich
Performance of CQR5 vs CQR19 in the Evaluation of Adherence to Tofacitinib in Daily Clinical Practice
Nothing to Disclose

Thomas Bardin
Risk Factors for Cutaneous Reactions to Allopurinol in Kinh Vietnamese: Results of a Prospective Study in Ho Chi Minh City
Nothing to Disclose

Andrea M Barker
VA Musculoskeletal “Master Educator” Faculty Development Program for Health Professions Educators: Follow-Up on Changes in Educational Duties and Perceptions of Program Content
Nothing to Disclose

Jessica Barlow
Is There an Association of Serum LDL, HDL and Total Cholesterol with the Development of Knee Osteoarthritis?
Nothing to Disclose

Jennifer L Barnas
Interferon Lambda Promotes Age-Associated B Cells
Disclosure:
2- Rheumatology Research Foundation

Joana Barroso
Risk Factors for Pain After Total Joint Replacement in Osteoarthritis: Different Pain Measures, Distinct Predictors?
Nothing to Disclose

Christie Bartels
Examining Five Year Lupus Retention in Care in an Academic Cohort

Disclosure:
2- Pfizer; Pfizer Independent Grants for Learning and Change

Susan J. Bartlett
Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis
Disclosure:
2- Abbvie; Abbvie
5- Abbvie; Bayer; Janssen; Lilly; Merck; Novartis; Pfizer; UCB
6- International Society of QOL Research; PROMIS International
8- Janssen; Merck; Novartis; Pfizer Inc; UCB

Susan J. Bartlett
When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA
Disclosure:
2- Abbvie; Abbvie
5- Abbvie; Bayer; Janssen; Lilly; Merck; Novartis; Pfizer; UCB
6- International Society of QOL Research; PROMIS International
8- Janssen; Merck; Novartis; Pfizer Inc; UCB

Elena Bartoloni
Neurological Involvement in a Cohort of Primary Sjogren’s Syndrome Patients: Results of a Multicenter Italian Study
Nothing to Disclose

Anne R Bass
Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival
Nothing to Disclose

Michael J Battistone
A Shared Mental Model for Teaching and Assessing Examination of the Hand, Wrist, and Elbow in the “Training Rheum” Continuing Professional Development Program
Nothing to Disclose

Michael J Battistone
Use of a Systematic Consensus Process to Inform Development of the Veterans Health Affairs Simulation Learning, Education and Research Network (SimLEARN) Musculoskeletal Clinician Course
Nothing to Disclose

Pauline Baudart
Individual Socio-economic Status and Symptomatic Hip and Knee Osteoarthritis: A Longitudinal Study, Results from the KHOALA Cohort
Nothing to Disclose

Sarah D Bayefsky
The Association of Body Weight Fluctuation and All-Cause Mortality in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Anne C Bay-Jensen
A Low Cartilage Formation & Repair Endotype Predicts Radiographic Progression in Symptomatic Knee Osteoarthritis Patients and Identifies Optimal Responders to a Potential OA Treatment
Disclosure:
1- Nordic Bioscience
2- Nordic Bioscience
3- Nordic Bioscience

Alison Bays
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Nothing to Disclose

Katie Bechman
Is Background Methotrexate Still Advantageous in Extending TNF Drug Survival in the Elderly: An Analysis of the British Society for Rheumatology Biologics Register – Rheumatoid Arthritis
Nothing to Disclose

Arthur Beck
Does Fibromyalgia Change the Evaluation of Spondyloarthritis Activity? A Meta-analysis of Observational Studies
Nothing to Disclose

Yann Becker
Antibodies Targeting Mitochondrial Antigens Are Associated with Reduced Thrombotic Events in APS
Nothing to Disclose

Shazia Beg
Diet as a Risk Factor for Rheumatoid Arthritis
Nothing to Disclose

Frank Behrens
Achilles Tendon Enthesitis and Disease Burden in Psoriatic Arthritis and Axial Spondyloarthritis: Baseline Results from a Randomized Controlled Trial
Disclosure:
2- Pfizer Inc
5- Pfizer Inc
8- Pfizer Inc

Frank Behrens
Improvement of Mental Health and Quality of Life During Therapy with Tocilizumab
Disclosure:
2- Pfizer; BMS; Janssen; Lilly; Celgene; Abbvie; Roche; Chugai; Novartis
5- BMS; Janssen; Lilly; Celgene; Abbvie; Roche; Chugai; Novartis; MSD; Biotest; Genzyme; Boehringer; Sandoz; UCB
8- Pfizer; BMS; Janssen; Lilly; Celgene

Marisel Vanesa V Bejarano
Post Traumatic Stress Disorder in Patients with Rheumatoid Arthritis
Nothing to Disclose

Delamo I Bekele
Clinical Manifestations and Management of US Patients with SAPHO (Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis) Syndrome, a Retrospective Study
Nothing to Disclose

Jennifer Belasco
Normalization of Inflammatory Gene Expression and Cellular Markers by Abatacept in the Skin
Lesions of Psoriatic Arthritis Patients: A Biopsy Substudy of a Phase III Study
Nothing to Disclose

Christopher F Bell
24-Month Outcomes Associated with Belimumab in Black/African-American Patients with Systemic Lupus Erythematosus in a Clinical Practice Setting in the United States
Disclosure:
1- GlaxoSmithKline
3- GlaxoSmithKline
4- GlaxoSmithKline

Christopher F Bell
Within-Trial Cost Analysis of Flares from a Phase 3 Clinical Trial Evaluating Subcutaneous Belimumab for the Treatment of Systemic Lupus Erythematosus
Disclosure:
1- GlaxoSmithKline
3- GlaxoSmithKline
4- GlaxoSmithKline

Richard D Bell
Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare
Nothing to Disclose

Michael Belsky
Neuromyelitis Optica Overlaps Frequently with Systemic Rheumatic Diseases in African-Americans: Experience at a Large US Academic Medical Center
Nothing to Disclose

Whitney Bembry
Should Lupus Podocytopathy Be a Subclass in Class I and Class II Lupus Nephritis?
Nothing to Disclose

Jihad Ben Gabr
Infrequent Screening but High Prevalence of Antinuclear Antibodies in Patients with Neuropsychiatric Disorders
Nothing to Disclose

Diego Benavent
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Nothing to Disclose

Diego Benavent
Differences and Similarities According to Gender in Patients with Psoriatic Arthritis Initiating Biological Therapy
Nothing to Disclose

Diego Benavent
Gender Influence on Treatment Effectiveness in Psoriatic Arthritis
Nothing to Disclose

Francis Berenbaum
Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies
Disclosure:
2- 4P Pharma

Martin Bergman
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Disclosure:
1- JNJ (parent of Janssen); JNJ stock; Johnson & Johnson; Johnson and Johnson
4- Johnson & Johnson
5- Abbvie; AbbVie; AbbVie, BMS, Celgene Corporation, Genentech, Janssen, Merck, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech; Genentech/Roche; Genentech-Roche; Gilead; Horizon; Janssen; Merck; Novartis; Pfizer; Sandoz; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron
8- Abbvie; AbbVie; AbbVie, Celgene Corporation, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech/Roche; GlaxoSmithKline; GSK; Janssen; Merck; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron
Martin Bergman
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-B
Disclosure:
1- JNJ (parent of Janssen); JNJ stock; Johnson & Johnson; Johnson and Johnson
4- Johnson & Johnson
5- Abbvie; AbbVie; AbbVie, BMS, Celgene Corporation, Genentech, Janssen, Merck, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech; Genentech/Roche; Genentech-Roche; Gilead; Horizon; Janssen; Merck; Novartis; Pfizer; Sandoz; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron
8- Abbvie; AbbVie; AbbVie, Celgene Corporation, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech/Roche; GlaxoSmithKline; GSK; Janssen; Merck; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron

Martin Bergman
Upadacitinib Treatment and the Routine Assessment of Patient Index Data 3 (RAPID3) Among Patients with Rheumatoid Arthritis
Disclosure:
1- JNJ (parent of Janssen); JNJ stock; Johnson & Johnson; Johnson and Johnson
4- Johnson & Johnson
5- Abbvie; AbbVie; AbbVie, BMS, Celgene Corporation, Genentech, Janssen, Merck, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech; Genentech/Roche; Genentech-Roche; Gilead; Horizon; Janssen; Merck; Novartis; Pfizer; Sandoz; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron
8- Abbvie; AbbVie; AbbVie, Celgene Corporation, Novartis, Pfizer, Sanofi; Amgen; BMS; Celgene; Genentech/Roche; GlaxoSmithKline; GSK; Janssen; Merck; Novartis; Pfizer; Sanofi; Sanofi/Regeneron; Sanofi-Regeneron

Sasha Bernatsky
Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
Nothing to Disclose

Sasha Bernatsky
Recent Use, Missed Doses and Discontinuation of Infliximab in a Population-Based Cohort: Comparisons of Biosimilar and Originator Exposures
Nothing to Disclose

Sasha Bernatsky
Risk Factors Associated with Serious Infections Among Users of Biosimilar and Originator Infliximab Therapies
Nothing to Disclose

Alvise Berti
Circulating PR3-Specific B Cells in Patients with Active ANCA-Associated Vasculitis
Nothing to Disclose

Isabela M Bertoglio
Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Nothing to Disclose

Louis Bessette
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Disclosure:
2- AbbVie; Abbvie; Amgen; Amgen, BMS, Janssen, Roche, UCB Pharma, AbbVie Inc, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, and Novartis.; BMS; Bristol-Myers Squibb; Bristol-Myers-Squibb; Celgene; Eli Lilly; Eli Lilly and Company; Janssen; Lilly; Merck; Novartis; Pfizer; Pfizer Inc; Roche; Sanofi; UCB; UCB Pharma
5- AbbVie; Abbvie; Amgen; Amgen, BMS, Janssen, Roche, UCB Pharma, AbbVie Inc, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, and Novartis.; BMS; Bristol-Myers Squibb; Bristol-Myers-Squibb; Celgene; Eli Lilly; Eli Lilly and Company;
Janssen; Lilly; Merck; Novartis; Pfizer; Pfizer Inc; Roche; Sanofi; UCB; UCB Pharma
8- AbbVie; Abbvie; Amgen; Amgen, BMS, Janssen, Roche, UCB Pharma, AbbVie Inc, Pfizer, Merck, Celgene, Sanofi, Eli Lilly, and Novartis.; BMS; Bristol-Myers Squibb; Bristol-Myers-Squibb; Celgene; Eli Lilly; Eli Lilly and Company; Janssen; Lilly; Merck; Novartis; Pfizer; Roche; Sanofi; UCB

Natacha Bessis
Polymorphonuclear Neutrophils and Regulatory T Lymphocytes (Treg) Cooperate to Sustain Treg Activity but This Interaction Is Altered in Rheumatoid Arthritis Patients
Nothing to Disclose

Jennie Best
Comparison of Real-World Persistence of Subcutaneously Administered Biologic Disease-Modifying Antirheumatic Drug Therapies Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Disclosure:
1- Genentech; Genentech, Inc.
3- Genentech; Genentech, Inc.

Jennie Best
Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study
Disclosure:
1- Genentech; Genentech, Inc.
3- Genentech; Genentech, Inc.

Jennie Best
Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a US-based Electronic Health Records Database
Disclosure:
1- Genentech; Genentech, Inc.
3- Genentech; Genentech, Inc.

Rhea Bhargava
Bioinformatics Analysis of Transcriptomics Data Reveals That SRSF1 Is a Novel Molecular Brake for the T Cell Activation Program and Controls Key Cytokine Signaling Genes Implicated in Systemic Lupus Erythematosus
Nothing to Disclose

Jawad Bilal
Risk of Thromboembolism with Janus Kinase Inhibitors: A Systematic Review and Meta-Analysis of Randomized Placebo Controlled Trials
Nothing to Disclose

Clifton O Bingham
Construct Validation of PROMIS Short Form and Profile-29 T-Scores with SF-36 in Rheumatoid Arthritis Patients Treated for 1 Year: Results from a Real World Evidence-Based Study in the United States
Disclosure:
2- BMS; Bristol Meyer Squibb; Bristol Myers-Squibb; Bristol-Myers Squibb; Janssen Research & Development, LLC
5- Abbvie; AbbVie; BMS; Bristol Meyer Squibb; Bristol Myers-Squibb; Eli Lilly; Eli/Lilly; Genentech/Roche; Janssen; Pfizer Inc; Regeneron/Sanofi; Sanofi/Regeneron

Paul Bird
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Disclosure:
5- Pfizer; AbbVie; Novartis; Janssen; Celgene; Eli Lilly

Mehret M Birru Talabi
Perspectives About Contraception Among Reproductive-Aged Women with Rheumatic Diseases
Nothing to Disclose

Nicole Bitencourt
Interventions to Improve Time to Appointment and Outcome Variables in the Pediatric to Adult Transition of Care in Rheumatology
Nothing to Disclose

Lilian Bizzocchi
Bone Health: An Independent Predictor of Coronary Artery Disease
Nothing to Disclose

Joseph Patrick Michele M Blair
Identification of Heterogenous Treatment Response Trajectories to anti-IL6 Receptor Treatment in Rheumatoid Arthritis
Nothing to Disclose

Caitlin Blaney
Improved Anxiety, Depression, and Emotional Distress for Rheumatoid Arthritis Patients Following the Completion of an Online Mental Health Intervention
Nothing to Disclose

Annelies B Blanken
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Nothing to Disclose

Ashley Blaske
Higher Than Expected Rates of Adverse Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus from Three Tertiary Care Centers
Nothing to Disclose

Andrew Blauvelt
Long-term Safety of Tildrakizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Incidence of Severe Infections Through 3 Years (148 Weeks) from 2 Phase 3 Trials
Disclosure:
2- AbbVie; Aclaris; Akros; Allergan; Almirall; Amgen; Arena; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Dermavant; Dermira Inc.; Dermira, Inc; Dermira, Inc.; Eli Lilly and Co; Eli Lilly and Company; Galderma; Genentech/Roche; GlaxoSmithKline; Janssen; Leo; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Purdue Pharma; Regeneron; Revance; Sandoz; Sanofi Genzyme; Sienna Pharmaceuticals; Sun Pharma; Sun Pharmaceutical Industries, Inc; UCB Pharma; Valeant; Vidac
5- AbbVie; Aclaris; Akros; Allergan; Almirall; Amgen; Arena; Boehringer Ingelheim; Bristol-

MYERS Squibb; Celgene; Dermavant; Dermira Inc.; Dermira, Inc; Dermira, Inc.; Eli Lilly and Company; Galderma; Genentech/Roche; GlaxoSmithKline; Janssen; Leo; Meiji; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Purdue Pharma; Regeneron; Revance; Sandoz; Sanofi Genzyme; Sienna Pharmaceuticals; Sun Pharma; Sun Pharmaceutical Industries, Inc; UCB Pharma; Valeant; Vidac

Ashira Blazer
A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries
Nothing to Disclose

Ashira Blazer
Apolipoprotein L1 Variant-Carrying Monocytes Exhibit Mitochondrial Respiration Defects
Nothing to Disclose

Joel A. Block
BMI Has Minimal Effect on Reduction of Symptoms in Patients with Osteoarthritis of the Knee Treated with Diclofenac 1% Gel
Disclosure:
2- Abbvie; Janssen; Novartis; Pfizer; TissueGene
5- GlaxoSmithKline Consumer Healthcare; Medivir; Zynerba Pharma
6- ACR
7- Agios; Daiichi-Sankyo; Omeros

Anne Boel
Are the Modified New York and ASAS Criteria Interchangeable in the Classification of Patients with Spondyloarthritis with Radiographic Sacroiliitis?
Nothing to Disclose
Luigi Boiardi
Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period: No Correlation with Demographical, Clinical, Laboratory and Imaging Data
Nothing to Disclose

Maria I Bokarewa
Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin
Nothing to Disclose

Gonçalo Boleto
Mixed Cryoglobulinaemia Since the Advent of New Direct-acting Antivirals for Hepatitis C Infection: Clinical Characteristics, Etiologies and Biological Features in 679 Patients
Nothing to Disclose

Fernando Bomfim
Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers
Nothing to Disclose

Michael Bonelli
Histone deacetylase 1 (HDAC1): A Key Mediator of T Cells for the Pathogenesis of Rheumatoid Arthritis
Nothing to Disclose

Karina R Bonfiglioli
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Nothing to Disclose

JB Boone
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
Nothing to Disclose

Nicola Booth
Assessing the Humanistic and Economic Burden of Enthesitis Among Patients with Peripheral and Axial Spondyloarthritis: Results from a Multi-National Real World Survey Database
Nothing to Disclose

Carina Borst
Predictors of Structural Progression in Psoriatic Arthritis: Clinical versus Systemic Inflammation
Nothing to Disclose

Vasiliki Kalliopi Bournia
CXCL4-L1 Levels Are Elevated in Systemic Sclerosis Patients and Correlate with Pulmonary Arterial Hypertension and Capillaroscopic Indices of Vascular Damage
Nothing to Disclose

Emily Bowers
A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Michael Bowes
Machine Learning Defines the Relationship Between Structural Knee Osteoarthritis and Patient-Important Outcomes: An 8-year Study of 47,858 Knee MRIs from the Osteoarthritis Initiative (OAI)
Disclosure:
3- Imorphics (Stryker)
9- OrthoTrophix

Latifa Boyce
Development and Usability Testing of Take Charge: An Email Series to Increase Knowledge of Self-Management Skills in People with Lupus
Disclosure:
3- Lupus Foundation of America

Rogely Boyce
The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis, Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection
Disclosure:
5- Flexion Therapeutics
Cecilie Heegaard Brahe
Does Drug Effectiveness of 2nd and 3rd TNF Inhibitors in Patients with Psoriatic Arthritis Depend on the Reason for Withdrawal from the Previous Treatment? – Results from the EuroSpA Research Collaboration
Disclosure:
2- Novartis

Cecilie Heegaard Brahe
Does Retention and Remission Rates to 2nd and 3rd TNF Inhibitors in Patients with Axial Spondyloarthritis Depend on the Reason from Withdrawal to the Previous Treatment? – Real World Data from 12 European Countries in the EuroSpA Research Collaboration
Disclosure:
2- Novartis

Anahy Brandy-Garcia
Mediators of Bone Metabolism (DKK1, OPG, Sclerostin and RANKL) in a Cohort of Patients with Elderly-onset Arthritis
Nothing to Disclose

Alan Brett
Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study
Disclosure:
3- Imorphics, Manchester, UK

Gabriel S Breuer
ANCA Testing: Final Diagnoses in Cases with Positive Immunofluorescence and Negative ELISA
Nothing to Disclose

Gabriel S Breuer
Uric Acid Level as a Predictor of Long Term Mortality in Advanced Age Population
Nothing to Disclose

Ian N Bruce
Disease Activity and Cognitive Function in Systemic Lupus Erythematosus

Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb
2- Genzyme Sanofi; GlaxoSmithKline; GSK; Sanofi Genzyme; UCB
5- AstraZeneca; Eli Lilly; GlaxoSmithKline; Ilttoo; MedImmune; Merck Serono; Roche; UCB
8- GlaxoSmithKline; MedImmune; Roche; UCB
3- Bristol-Myers Squibb
5- AstraZeneca; Eli Lilly; GlaxoSmithKline; Ilttoo; MedImmune; Merck Serono; Roche; UCB
8- GlaxoSmithKline; MedImmune; Roche; UCB
5- Advicenne
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb

Cosimo Bruni
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Disclosure:
5- Eli Lilly
8- Eli Lilly; Actelion

Gary L Bryant
Estimate of Prevalence of Secondary Distal Renal Tubular Acidosis Among Patients with Sjogren’s Syndrome and Systemic Lupus Erythematosus in a US Population with Employer-Sponsored Health Insurance
Disclosure:
5- Advicenne

Joshua Bryson
Association Between Baseline Anti-CCP2 Antibody Concentration and Clinical Response After 6 Months of Treatment with Abatacept or a TNF Inhibitor in Biologic-Experienced Patients with RA: Results from a US National Observational Study
Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb
4- Bristol-Myers Squibb

Maya H. Buch
A Comparative Analysis of Upadacitinib Monotherapy and Upadacitinib Combination Therapy for the Treatment of Rheumatoid Arthritis from Two Phase 3 Trials
Disclosure:
2- Pfizer; Pfizer, Roche, and UCB; Roche; UCB
5- AbbVie; AbbVie, Eli Lilly, Sandoz, and Sanofi; Eli Lilly; Sandoz; Sanofi

Christopher D. Buckley
Exploratory Analysis of a Phase 2b Study Confirms Substantial Pain Improvement with Anti-GM-CSF Monoclonal Antibody Otilimab (GSK3196165) in Patients (Pts) with Active RA
Disclosure:
2- Roche
8- GSK; Pfizer Inc
9- Roche (Research Grant with Roche £250k and £750k on fibroblast subsets)

Jane Buckner
The Effect of HLA-DRB1 Risk Alleles (Shared Epitope) on Changes in Immune Cell Subsets and Disease Activity Following Treatment with Abatacept versus Adalimumab in Seropositive Biologic-Naïve Patients with Early, Moderate-to-Severe RA: Data from a Head-to-Head Trial
Disclosure:
2- Bristol-Myers Squibb; Janssen; Novo Nordisk; Pfizer
5- Bristol-Myers Squibb; Eli Lilly

Ralph Budd
Treatment of Lupus-prone MRL-lpr Mice with the Mitochondrial Antioxidant MitoQ
Nothing to Disclose

Anne Bull Haaversen
Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis
Nothing to Disclose

Bruna Giusto Bunjes
Evaluation of Illness Perception in Systemic Sclerosis Patients with Pulmonary Involvement
Nothing to Disclose

Blaž Burja
The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts
Disclosure:
2- FOREUM; Swiss-European Mobility Programme (SEMP)

Gerd R Burmester
A Randomized Double-Blind Study Comparing Pharmacokinetics (PK) and Pharmacodynamics (PD) of ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Disclosure:
2- Pfizer; Roche; Union Chimique Belge
5- AbbVie; AbbVie, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma.; AbbVie Inc.; BMS; Eli Lilly; Eli Lilly and Company; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; Merck; Merck Shar & Dohme; MSD; Pfizer; Roche; Roche, Sanofi-Genzyme; Sanofi; UCB; Union Chimique Belge
8- AbbVie; AbbVie, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma.; AbbVie Inc.; BMS; Eli Lilly; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; Merck; Merck Shar & Dohme; MSD; Pfizer; Roche; Roche, Sanofi-Genzyme; Sanofi; UCB; Union Chimique Belge

Gerd R Burmester
Efficacy and Safety Results from a Randomized Double-Blind Study That Compared the Proposed Biosimilar ABP 798 with Rituximab in Subjects with Moderate to Severe RA
Disclosure:
2- Pfizer; Roche; Union Chimique Belge
Gerd R Burmester
Long-Term Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to CsDMARDs: Results at 60 Weeks
Disclosure:
2- Pfizer; Roche; Union Chimique Belge
5- AbbVie; Abbvie; AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma.; AbbVie Inc.; BMS; Eli Lilly; Eli Lilly and Company; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; Merck; Merck Shar & Dohme; MSD; Pfizer; Roche; Roche, Sanofi-Genzyme; Sanofi; UCB; Union Chimique Belge
8- AbbVie; Abbvie; AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma.; AbbVie Inc.; BMS; Eli Lilly; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; Merck; Merck Shar & Dohme; MSD; Pfizer; Roche; Roche, Sanofi-Genzyme; Sanofi; UCB; Union Chimique Belge
Frank Buttgereit
Glucocorticoid Tapering in Monthly 1-mg Decrements Does Not Result in Clinically Manifest Adrenal Insufficiency in Patients with Rheumatoid Arthritis: Learnings from a Phase 3/4 Study
Disclosure:
2- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme
5- Medac; Pfizer; Roche; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme

Vivian P Bykerk
Impact of Sarilumab on Unacceptable Pain and Inflammation Control in Moderately-to-Severely Active Rheumatoid Arthritis (RA) Patients in 3 Phase 3 Studies
Disclosure:
1- Amgen; Brainstorm Therapeutics; Pfizer; Sanofi-Genzyme/Regeneron; Scipher; UCB
2- Amgen; Brainstorm Therapeutics; NIH; Pfizer; Sanofi-Genzyme/Regeneron; Scipher; UCB
3- Amgen; Brainstorm Therapeutics; Pfizer; Sanofi-Genzyme/Regeneron; Scipher; UCB
5- AbbVie; Amgen; Brainstorm Therapeutics; Bristol-Myers Squibb; Genentech; Gilead; Pfizer; Regeneron; Regeneron Pharmaceuticals, Inc; Sanofi; Sanofi/Genzyme-Regeneron; Sanofi-Genzyme/Regeneron; Scipher; UCB; UCB Pharma
8- Amgen; Brainstorm Therapeutics; Pfizer; Sanofi-Genzyme/Regeneron; Scipher; UCB
9- The Cedar Hill Foundation

Keld-Erik Byg
Neurofilament Light Chain Levels in Cerebrospinal Fluid and Plasma in Neurosarcoidosis
Disclosure:
9- Eli Lilly (Congress participation)

Vivian P Bykerk
Body Mass Index and Systemic Corticosteroid Use as Indicators of Disease Burden and Their Influence on the Safety Profile of Certolizumab Pegol Across Indications
Disclosure:
Genzyme/Regeneron; Scipher; UCB; UCB Pharma
8- Amgen; Brainstorm Therapeutics; Pfizer; Sanofi-Genzyme/Regeneron; Scipher; UCB
9- The Cedar Hill Foundation

Vivian P. Bykerk
Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores Disclosure:
5- Amgen; Pfizer Pharmaceuticals; Sanofi-Genzyme/Regeneron; Schiper; UCB

Aleksandra Bylinska
Alterations of Memory and Naive B Cell Subsets Associate with Reduced IFNa and TNFRII in ANA+ Healthy Individuals Nothing to Disclose

Fabio Cacciapaglia
Cardiovascular Risk Evaluation in Systemic Lupus Erythematosus and Rheumatoid Arthritis: Preliminary Results from the “Cardiovascular Obesity and Rheumatic DiSease (CORDIS)” Study Group of the Italian Society of Rheumatology Nothing to Disclose

Patrice Cacoub
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis Disclosure:
5- Abbvie; AstraZeneca; Bristol meyer squibb; Gilead; Glaxo Smith Kline; Janssen; Merck Sharp Dohme; Roche; Servier; Vifor

Irene Calabuig
Carotid Atherosclerosis and Sonographic Signs of Urate Crystal Deposits in Patients with Gout: An Association Study Disclosure:
2- Fundación Valenciana de Reumatología (FVR); Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)

Mónica Calderón-Goercke
Efficacy of Tocilizumab in Giant Cell Arteritis, Independent of the Time of Disease Evolution Nothing to Disclose

Mónica Calderón-Goercke
Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients Nothing to Disclose

Mónica Calderón-Goercke
Response to Tocilizumab in Patients with Giant Cell Arteritis, According to Ischemic vs Systemic Symptoms Nothing to Disclose

Mónica Calderón-Goercke
Tocilizumab in Aortitis: A Multicenter Study of 79 Patients Nothing to Disclose

Mónica Calderón-Goercke
Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous Nothing to Disclose

Mónica Calderón-Goercke
Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone Nothing to Disclose

Irene Calderon
Genes Associated with Nucleotide Oligomerization Domain-Like Receptor Signaling Pathway Are Upregulated in Discoid Lupus Erythematosus Nothing to Disclose

Noel Agustin Callahuara Goiburú
Clinical Characteristics of Primary Sjögren’s Syndrome in Adult Patients Diagnosed at Age Less Than or Equal to 35 Years versus Those over 35 Years of Age Nothing to Disclose

Jaime Calvo-Alen
Real Life Serious Infections in Patients with Chronic Inflammatory Arthritis on Treatment with TNF Inhibitors
Nothing to Disclose

enrique Calvo-Aranda
Treating Gout to Target Entails Renoprotective Effect in Patients with Moderate Chronic Kidney Disease
Nothing to Disclose

Itziar Calvo-Zorrilla
Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center
Nothing to Disclose

María Camacho-Encina
Two Biomarkers with Predictive Capacity to Diagnosis Pre-Radiographic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Nothing to Disclose

Ana Campar
Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy
Nothing to Disclose

Ana Campar
Performance of EULAR/ACR Classification Criteria for Idiopathic Inflammatory Myopathies in a Real-life Cohort of Adult Patients
Nothing to Disclose

T Mark Campbell
A Flexion Contracture Is a Risk Factor for Radiographic Progression and Earlier Need for Arthroplasty in Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Nothing to Disclose

Corrado Campochiaro
Drug Retention and Discontinuation Reasons Between Seven Biologics in Patients with Takayasu Arteritis
Disclosure:

5- GSK, SOBI, Pfizer; SOBI
8- GSK; GSK, SOBI, Pfizer; Pfizer

Corrado Campochiaro
Efficacy of Canakinumab Treatment in Adult-onset Still’s Disease
Disclosure:
5- GSK, SOBI, Pfizer; SOBI
8- GSK; GSK, SOBI, Pfizer; Pfizer

Grant W Cannon
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Disclosure:
2- Amgen

Ye Cao
Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Nothing to Disclose

Dafne Capelusnik
Treatment Preferences in Patients with Axial Spondyloarthritis
Nothing to Disclose

Roberto Caporali
Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry
Nothing to Disclose

Philip M Carlucci
Association Between Neutrophil to Lymphocyte, Monocyte to Lymphocyte, and Platelet to Lymphocyte Ratios and Lupus Disease Activity and Lupus Nephritis
Nothing to Disclose

Joel Carmichael
Multimodal Edema Management After Total Knee Arthroplasty: A Pilot Study
Nothing to Disclose
Daniel Carranza Leon
Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Nothing to Disclose

Emily Carroll
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Nothing to Disclose

Ivette Casafont-Solé
Adult-Onset Still's Disease Prognosis Score: Clinical Patterns, Complications and Biologic Treatment
Nothing to Disclose

Maria casal-Dominguez
Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies
Nothing to Disclose

Siobhan Case
Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study
Disclosure:
3- Foundation Medicine
4- Foundation Medicine

Raul Castellanos-Moreira
Anti-TNF-α Exposure During Pregnancy: Impact on the Neonate's Immune System
Nothing to Disclose

Raul Castellanos-Moreira
Interstitial Lung Disease Is Associated with Distinct Fine Specificities of Anti-Carbamylated Peptide/Protein Antibodies in Rheumatoid Arthritis
Nothing to Disclose

Francine Castillo
Improving Safe Prescribing of Hydroxychloroquine in a Safety Net Hospital Rheumatology Clinic
Nothing to Disclose

Mireia Castillo-Vilella
Pelvic Congestion Syndrome, an Uncommon Cause of Osteoarticular Pain
Nothing to Disclose

Isabel Castrejon
Hispanic Patients with Rheumatoid Arthritis Have Greater Discordance Between Patient and Physician Global Estimates Than Other Ethnic Groups, Explained Largely by Fibromyalgia (FM) According to a FM Assessment Screening Tool 3 (FAST3)
Nothing to Disclose

Cristina M Castro
Adenosine A2A Receptor (A2AR) Stimulation Mitigates Mitochondrial Inflammaging, Enhances Mitochondrial Metabolism and Reduces Reactive Oxygen Species-Mediated Mitochondrial Injury In Vitro and In Vivo in Osteoarthritis
Nothing to Disclose

Vanessa Castro Coello
Serum Albumin as a Long-term Predictor of Renal Evolution in Lupus Nephritis
Nothing to Disclose

Rocío Castro-Viñuelas
Establishing an in Vitro Model of Hand Osteoarthritis by Generating Induced Pluripotent Stem Cells (iPSC) That Carry Single Nucleotide Polymorphisms Associated with Hand Osteoarthritis Risk
Nothing to Disclose

Michelle D Catalina
Ancestry Influences the Gene Expression Profile in Systemic Lupus Erythematosus and Contributes to Transcriptomic Heterogeneity in Lupus Patients
Nothing to Disclose

Giulio Cavalli
Role of Trained Immunity in the Pathogenesis of Erdheim-Chester Disease
Irene Cecchi
Type I Interferon Signature Activation in Antiphospholipid Syndrome: Gene Expression Heterogeneity Among Disease Subsets
Nothing to Disclose

francesca cedola
Choline Metabolite Is Associated with Inflammation in Arthritis in the Elderly
Nothing to Disclose

Bruno Cenni
LOU064: A Highly Selective and Potent Covalent Oral BTK Inhibitor with Promising Pharmacodynamic Efficacy on B Cells for Sjogren’s Syndrome
Disclosure:
1- Novartis Pharma AG, Switzerland
3- Novartis Pharma AG, Switzerland

Simran Chahal
A Qualitative Study Evaluating Near-Patient Tools Including a Mobile Application for Earlier RA Referral; Potential to Reduce Chronic Disease Burden
Disclosure:
3- Augurex Life Sciences Corp

Benjamin Chaigne
Proteomic and Transcriptomic Analysis of Human Eosinophilic Fasciitis Fibroblasts
Nothing to Disclose

Srita Chakka
Assessing Meaningful Changes in Disease Activity as Clinical Trial Efficacy Measures for Cutaneous Lupus Erythematosus
Nothing to Disclose

Madhavi Latha S Chalasani
CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis
Nothing to Disclose

Samantha Chalmers
Amelioration of Immune Complex-Mediated Glomerulonephritis by CD6 Modulation
Disclosure:
2- Equillium, Inc

Christina D Chambers
Incidence of Non-serious Infections Among Live Born Infants Born to Mothers Who Used Biologic Medications During Pregnancy for the Treatment of Autoimmune Diseases
Disclosure:
2- AbbVie; Amgen Inc.; Apotex; Barr Laboratories, Inc.; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Pharmaceuticals; Kali Laboratories, Inc.; Pfizer, Inc.; Hoffman La Roche-Genentech; Sandoz Pharmaceuticals; Genzyme Sanofi-Aventis; Takeda Pharmaceutical Company Limited; UCB, USA; Gerber Foundation; Teva Pharmaceutical Industries Ltd.

Eugenio Chamizo Carmona
Influence of the Clinical Characteristics and Different Genetic Polymorphisms Related to MTX, on the Efficacy and Safety in Patients with RA Treated with MTX in Monotherapy
Emilie Chan
New-onset ANCA-associated Vasculitis Is Associated with Significant Phenotypic B Cell Dysfunction
Nothing to Disclose

Kelvin Chan
Lupus Auto-antibodies Act as Positive Allosteric Modulators at GluN2A-containing NMDA Receptors to Induce Excitotoxicity and Spatial Memory Deficits
Nothing to Disclose

Vinod Chandran
Serum Metabolomic Analysis of Psoriatic Arthritis Using Solid Phase Microextraction – Liquid Chromatography – High-Resolution Mass Spectrometry Identifies Putative Disease Activity Markers
Nothing to Disclose

Anita C Chandrasekaran
Computer Vision Applied to Dual Energy Computed Tomography Images for Precise Calcinosi Cutis Quantification in Patients with Systemic Sclerosis
Nothing to Disclose

Alison H Chang
Impact of Eliminating the Bouted Minutes Requirement in the New 2018 Physical Activity Guidelines for Americans on Gender Disparity in Guideline Attainment for Persons with or at High Risk of Knee Osteoarthritis
Nothing to Disclose

Margaret Chang
Persistent Synovial Resident Memory T Cells Mediate Arthritis Flares
Nothing to Disclose

Pierre Charles
Comparison Between Long-Term and Conventional Rituximab-Maintenance Treatments: Results of a Placebo-Controlled Randomized Trial
Nothing to Disclose

Pierre Charles
Reducing the Number of Rituximab Infusions at Onset of Maintenance Therapy for ANCA-associated Vasculitides: Results of a Post Hoc Analysis from a Randomized–controlled Trial
Nothing to Disclose

Christina Charles-Schoeman
Elevated Pro-inflammatory Lipid Mediators Associate with Low Paraoxonase 1 Activity in Patients with Rheumatoid Arthritis and Arthritic K/BxN Mice
Disclosure:
2- Abbvie; AbbVie; BMS; Bristol Myers Squibb; Octapharma; Pfizer
5- Amgen; Gilead; Octapharma; Pfizer; Regeneron; Regeneron/Sanofi; Sanofi

Christina Charles-Schoeman
Treatment with Upadacitinib Is Associated with Improvements in Reverse Cholesterol Transport in Patients with Rheumatoid Arthritis: Correlation with Changes in Inflammation and HDL Levels
Disclosure:
2- Abbvie; AbbVie; BMS; Bristol Myers Squibb; Octapharma; Pfizer
5- Amgen; Gilead; Octapharma; Pfizer; Regeneron; Regeneron/Sanofi; Sanofi

Loukas Chatzis
Comparison of Clinical Phenotype, Serological Characteristics and Histologic Features Between Males and Females Patients with Primary Sjögren’s Syndrome (pSS)
Nothing to Disclose

Loukas Chatzis
Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Nothing to Disclose
Jonathan T Cheah
MRI-based Textural Analysis of Trabecular Bone: A Novel Method for the Opportunistic Screening of Bone Quality
Nothing to Disclose

Shashank Cheemalavagu
Antiphospholipid Syndrome-Associated Preeclampsia Is Defined by a Distinct Clinical Phenotype
Nothing to Disclose

Gamal Chehab
Patient-reported Outcome Measures in Systemic Lupus Erythematosus: Use in Clinical Practice - Preliminary Results from the Integrate Project
Nothing to Disclose

Antonia Chen
A Prospective, Multi-center, Randomized, Clinical Trial Comparing the Effectiveness and Safety of Cooled Radiofrequency Ablation versus a Single Injection of Hyaluronic Acid in the Management of OA Knee Pain
Disclosure:
2- Avanos Medical
5- Avanos Medical
8- Avanos Medical

Ming-Han Chen
NLRP12 Regulates Interferon-α Expression and Is a Biomarker for Disease Activity of Systemic Lupus Erythematosus
Nothing to Disclose

Sarah Chen
Risk of Diabetes Treatment Switching or Intensification Associated with Use of Abatacept versus Other Biologic Drugs in Patients with Rheumatoid Arthritis and Diabetes Mellitus
Nothing to Disclose

Weirong Chen
Characterization of Antibody Secreting Cells in Patients with Active Systemic Lupus Erythematos
Nothing to Disclose

Ye Chen
CD126 Negative CD4+Foxp3+ Cell Represents a Superior Treg Subset in Treating Autoimmune Diseases
Nothing to Disclose

Ye Chen
Targeting ITK Signaling Ameliorates Collagen-Induced Arthritis via Shifting the Balance Between Th17 and Regulatory Th17 Cells
Nothing to Disclose

Zhu Chen
Alterations in Cholesterol Homeostasis Regulate Autoimmunity/Age-associated B Cells
Nothing to Disclose

Chieh-Yu Cheng
Serum Myositis Specific/associate Autoantibodies Help Identify Early Connective Tissue Diseases Relevant Interstitial Lung Diseases: A Medical Center Experience
Nothing to Disclose

Isaac T. Cheng
Relationship Between Serum Calprotectin Level and Presence of Subclinical Atherosclerosis and Arterial Stiffness in Patient with Psoriatic Arthritis
Nothing to Disclose

Ting Cheng
Clinical Study of Peripheral Blood Lymphocyte Subsets in Patients with Rheumatoid Arthritis Complicated with Osteoporosis
Nothing to Disclose

Yun-Hong Cheon
Myopenia Is an Independent Risk Factor for Rotator Cuff Tear and Shoulder Dysfunction in Elderly People: Data from NAMGARAM Cohort
Nothing to Disclose
Soo-Kyung Cho  
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis  
Nothing to Disclose

Soo-Kyung Cho  
Validation of Claims-based Algorithms to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis  
Nothing to Disclose

Sung Kweon Cho  
Contribution of MOCS on Xanthinuria Type III and Its Clinical Significance for Screening  
Nothing to Disclose

Yu Pei Chock  
Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009-2016  
Nothing to Disclose

Chan-Bum Choi  
Vitamin D Is Not Associated with Treatment Responses in Patients with Newly Diagnosed Rheumatoid Arthritis  
Nothing to Disclose

Hyon K. Choi  
Population Impact Attributable to Modifiable Risk Factors for Hyperuricemia and the Fallacy of the Variance Explained  
Disclosure: 2- AstraZeneca 5- GSK; Horizon; Selecta; Takeda

May Y Choi  
A Meta-Analysis of Anti-Ribosomal P Autoantibodies in Systemic Lupus Erythematosus: A Misunderstood Autoantibody  
Nothing to Disclose

May Y Choi  
Is ANA-status at Disease Inception Associated with Long-term Damage Accrual and Direct and Indirect Health Care Costs in the Systemic Lupus

International Collaborating Clinics (SLICC) Inception Cohort?  
Nothing to Disclose

Se Rim Choi  
High Initial Methotrexate Dose Is Not Associated with an Increased Risk of Liver Toxicity in Korean Patients with Rheumatoid Arthritis  
Nothing to Disclose

Seong-Eun Choi  
Association of Co-positivity for Anti-dsDNA, -Nucleosome, and -Histone Antibodies and Disease Activity in Patients with Lupus Nephritis: Results from the KORNET Registry  
Nothing to Disclose

Su Jin Choi  
Angiographic Patterns and Changes in Arterial Lesions in Patients with Behcet’s Disease  
Nothing to Disclose

Denis Choquette  
Profile of Renal Function in Patient Suffering from Rheumatoid Arthritis  
Disclosure: 5- AbbVie; AbbVie Canada; Amgen; Amgen Canada; BMS; BMS Canada; Celgene; Celgene Canada; Eli Lilly Canada; Eli-Lilly; Merck; Merck Canada; Novartis; Novartis Canada; Pfizer; Pfizer Canada; Sandoz Canada; Sanofi-Genzyme; Sanofi-Genzyme

Evelyn H Chow
Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis

Nothing to Disclose

Lisa Christopher-Stine
Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Disclosure:
2- Corbus Pharmaceuticals; CSL Behring; Kezar; Novartis; Pfizer
5- AstraZeneca (Medimmune) Kezar; Mallinckrodt Pharmaceuticals; OptionCare
7- Inova Diagnostics

Jun Chu
Improving a SLE-Quality Indicator Tool in an Outpatient Tertiary Care Setting
Nothing to Disclose

Raymond Chu
A Ten-Year Retrospective Review of Temporal Artery Biopsy Lengths in Alberta
Nothing to Disclose

Raymond Chu
Management of Idiopathic Inflammatory Myopathies Using Intravenous Immunoglobulin Therapy: A Retrospective Cohort Study
Nothing to Disclose

Raymond Chu
Temporal Artery Biopsy Lengths in Alberta: Which Surgical Subspecialty Achieves Optimal Biopsy Lengths?
Nothing to Disclose

Su H. Chu
Integrating Genetic Risk Scores and Pre-Diagnostic Metabolomics to Infer Dysregulated Mechanisms in Rheumatoid Arthritis in Women
Nothing to Disclose

Government Subsidization of Biologic Therapy for Inflammatory Arthritis in a Co-Funded Healthcare Model: A Singapore Experience
Nothing to Disclose

Cecilia P Chung
Combining Clinical and Candidate Gene Data into a Risk Score for Azathioprine-Associated Leukopenia in Routine Clinical Practice
Disclosure:
2- NIH grant RC2GM092618 from NIGMS/OD; NIH grant U01HG004603 from NHGRI/NIGMS; NIH: R01GM126535 and R01 bridge award; Rheumatology Research Foundation K-supplement; Vanderbilt National Center for Advancing Translational Science grant 2UL1 TR000445-06 from NCATS/NIH

Cecilia P Chung
Therapy of Lupus Nephritis with Mycophenolate Mofetil in Routine Clinical Practice: Response Rates and Role of Ethnicity
Disclosure:
2- NIH grant RC2GM092618 from NIGMS/OD; NIH grant U01HG004603 from NHGRI/NIGMS; NIH: R01GM126535 and R01 bridge award; Rheumatology Research Foundation K-supplement; Vanderbilt National Center for Advancing Translational Science grant 2UL1 TR000445-06 from NCATS/NIH

Sang Wan Chung
Distinctive Clinical Features and Biomarkers of Connective Tissue Disease Associated Interstitial Lung Disease
Nothing to Disclose

Sarah H Chung
Clinical Impact of a Rheumatology Musculoskeletal Ultrasound Clinic at a U.S. Academic Center
Nothing to Disclose

Sarah H Chung
The Veterans Health Administration (VHA) National Database Cohort: Incident Ophthalmic Complications in Giant Cell Arteritis (GCA)
Patients with a Negative Temporal Artery Biopsy
Nothing to Disclose

Jacopo Ciaffi
Evolution of Systemic Sclerosis-Related Interstitial Lung Disease After Autologous Hematopoietic Stem Cell Transplantation
Nothing to Disclose

Maria C. Cid
GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Nothing to Disclose
9- Roche (Participated as regional PI in the Giacta trial, sponsored by Roche.)

Gustavo Citera
Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies
Disclosure:
2- Abbvie; Gema Biotech
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Eli Lilly; Gema Biotech; Genzyme; Janssen; Novartis; Pfizer; Roche; Sanofi Genzyme
8- AbbVie; Abbvie; BRISTOL MYERS SQUIBB ARGENTINA; Bristol-Myers Squibb; Gema Biotech; Janssen; Novartis; Pfizer; Roche; Sanofi Genzyme

Gustavo Citera
Tofacitinib in Patients with Rheumatoid Arthritis and Indicative of Depression And/or Anxiety: A Post Hoc Analysis of Phase 3 and Phase 3b/4 Clinical Trials
Disclosure:
2- Abbvie; Gema Biotech
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Eli Lilly; Gema Biotech; Genzyme; Janssen; Novartis; Pfizer; Roche; Sanofi Genzyme
8- AbbVie; Abbvie; BRISTOL MYERS SQUIBB ARGENTINA; Bristol-Myers Squibb; Gema Biotech; Janssen; Novartis; Pfizer; Roche; Sanofi Genzyme

Giorgia Citriniti
Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients
Nothing to Disclose

Alfred Cividino
Clinical Presentation and Treatment of Oligoarticular Psoriatic Arthritis in Canada: High Frequency of Smaller Joint Involvement Disclosure:
2- AbbVie, BMS, Celgene Corporation, Pfizer
5- AbbVie, BMS, Celgene Corporation, Pfizer

Robert Clancy
The Oral Microbiome as a Risk Factor for Benign or Pathologic Autoimmunity Associated with Anti-SSA/Ro Positivity and Mimicry for Von Willebrand Factor Type a Domain Protein (vWFA) of L. Mirabilis
Disclosure:
2- Exagen Diagnostics
5- Bristol Myers Squibb

Kristina E Clark
Analysis of Serum Markers Across the Scleroderma Spectrum Shows Subset and Stage Specific Profiles of Fibrogenesis
Nothing to Disclose

Kristina E Clark
Parallel Analysis of Systemic Sclerosis and Keloidal Morphea Skin Biopsies Delineates the Hallmark Profibrotic Gene Expression Profile for Scleroderma in Vivo
Nothing to Disclose

Kristina E Clark
The PPAR Agonist Lanifibranor Protects Against Right Ventricular Hypertrophy in a Mouse Model of Systemic Sclerosis Associated Pulmonary Hypertension
Nothing to Disclose

Megan E Clowse
Biologic Differences Between Type 1 and 2 Lupus
Disclosure:
Laura C Coates
A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Laura C Coates
Achievement of Very Low Disease Activity and Remission Treatment Targets Is Associated with Reduced Radiographic Progression in Patients with Psoriatic Arthritis Treated with Certolizumab Pegol
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Laura C Coates
Long-term Safety of Filgotinib in Patients with Psoriatic Arthritis, Week 52 Safety Data from a Phase 2 Open-Label Extension Study
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Laura C Coates
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc

Laura C Coates
The Performance Characteristics of Composite Measures Used in a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Laura C Coates
What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Laura C Coates
Withdrawal of Ixekizumab Results in Loss of Efficacy in Multiple Clinical Domains in Patients with Psoriatic Arthritis Who Had Achieved Minimal Disease Activity: Results from the SPIRIT-P3 Study
Disclosure:
2- AbbVie; Celgene; Eli Lilly; Novartis; Pfizer Inc
5- AbbVie; Amgen; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc
8- AbbVie; Amgen; Eli Lilly; Novartis; Pfizer Inc; UCB

Caitrin M Coffey
Hospitalization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1980-2016)
Nothing to Disclose
Caitrin M Coffey
Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)
Nothing to Disclose

Caitrin M Coffey
The Impact of Gender on Time to Rheumatoid Arthritis Classification
Nothing to Disclose

Stanley B Cohen
Efficacy and Safety of Tofacitinib Modified-Release 11 Mg Once Daily + MTX in RA Patients with an Inadequate Response to MTX: Open-Label Phase Results from a Global Phase 3b/4 MTX Withdrawal Study
Disclosure:
2- AbbVie; Eli Lilly; Genentech; Gilead; Pfizer Inc
5- AbbVie; Eli Lilly; Genentech; Gilead; Pfizer Inc

Stanley B Cohen
Safety Profile of Upadacitinib in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Disclosure:
2- AbbVie; Eli Lilly; Genentech; Gilead; Pfizer Inc
5- AbbVie; Eli Lilly; Genentech; Gilead; Pfizer Inc

Keith Colaco
Comparison of Carotid Ultrasound and Coronary Artery Calcium Score in Cardiovascular Risk Stratification of Patients with Inflammatory Rheumatic Diseases
Nothing to Disclose

Keith Colaco
Validity of Patient-reported Cardiovascular Events in a Large Longitudinal Cohort of Patients with Psoriatic Arthritis and Psoriasis
Nothing to Disclose

Ines Colmegna
Causes of Influenza Vaccine Hesitancy in Rheumatoid Arthritis and Adults with Juvenile Idiopathic Arthritis
Nothing to Disclose

Ines Colmegna
The High Dose Influenza Vaccine Increases Immune Protection in Both Adults and Elderly Seropositive RA Patients
Nothing to Disclose

Bernard G Combe
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: FINCH1 Primary Outcome Results
Disclosure:
2- MSD; Pfizer; Roche
5- AbbVie; BMS; Chugai; Eli Lilly; Eli Lilly and Company; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Roche-Chugai; Sanofi; UCB; USD
8- BMS; Chugai; Eli Lilly and Company; Gilead; Gilead Sciences, Inc.; Lilly; MSD; Pfizer; Roche; Roche-Chugai

Alice Combier
Risk of Immunization to Rituximab in Systemic Autoimmune Diseases and Rheumatoid Arthritis: Frequency and Risk Factors. Analysis of the Efficacy of an Alternative Treatment by Ofatumumab
Nothing to Disclose

Philip G Conaghan
Concordance of Baseline Pain Measures (Across Two Reporting Instruments) Influences Treatment Effect: Post Hoc Analysis of a Phase 3 Randomized Controlled Trial of Triamcinolone Acetonide Extended-Release in Patients with Knee Osteoarthritis
Disclosure:
5- Abbvie; AbbVie; AstraZeneca; BMS; Bristol Myers Squibb; EMD; EMD Serono; EMD Serono Research and Development Institute, Inc.; Flexion; Flexion Therapeutics; Galapagos; Glaxo Smith Kline; GlaxoSmithKline; Medivir; Novartis; Pfizer; Roche; Samumed; Serono; Stryker
8- Abbvie; AbbVie; AstraZeneca; BMS; Bristol Myers Squibb; Eli Lilly; EMD Serono Research and Development Institute, Inc.; Flexion; Flexion Therapeutics; Galapagos; GlaxoSmithKline; Lilly;
Medivir; Novartis; Pfizer; Roche; Samumed; Stryker

Francisco M Conesa-Buendia
First-line Antiretroviral Therapy with Tenofovir Produces Deleterious Effects on Bone and an Increase in Proinflammatory Cytokines Expression After 12 Months of Treatment in Naïve HIV Patients
Nothing to Disclose

Caoilfhionn Connolly
Patient Reported Outcomes and Factors Predicting Clinical Activity in Patients with Immune-Checkpoint Inhibitor Inflammatory Arthritis
Nothing to Disclose

Gustavo Contreras
Impact of Day of Admission and Time to Diagnostic Arthrocentesis on Mortality and Other Outcomes in Septic Arthritis: A Nationwide Analysis
Nothing to Disclose

Ian Cooley
The Association of Lupus Nephritis Histopathologic Classification with Venous Thromboembolism Is Modified by Age at Biopsy
Nothing to Disclose

Roxana Coras
Inhibition of Choline Kinase Alpha Improves Synovitis and Cartilage Damage in Animal Models of Osteoarthritis
Nothing to Disclose

Tatiana Costa Pires
Prevalence and Outcome of Thrombocytopenia in Systemic Lupus Erythematosus – Single Centre Cohort Analysis
Nothing to Disclose

Nathalie Costedoat-Chalumeau
Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Nothing to Disclose

Gary Craig
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Disclosure:
4- Arthritis NW, PLLC; Discus Analytics
5- Premera Blue Cross
8- Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Celgene; AbbVie; Novartis; Sandoz

Gemma Cramarossa
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Nothing to Disclose

Randy Q Cron
Characterization of DOCK8 as a Novel Gene Associated with Macrophage Activation Syndrome
Disclosure:
2- SOBI
5- Novartis
9- Pfizer

Caitlin Cruz
An Analysis of Inpatient Rheumatology Consults at an Academic Military Medical Center over 16 Years: Do Consults Requests Accurately Reflect the Curriculum and Prepare Fellows for Board Certification and Future Practice?
Nothing to Disclose

Karla Paola Cuellar-Calderon
Cardiovascular Risk Awareness in Patients with Rheumatic Diseases: A Case-Control Study
Nothing to Disclose

Karla Paola Cuellar-Calderon
Depression: A Common Comorbidity in Rheumatic Diseases. a Case-Control Study
Nothing to Disclose

Karla Paola Cuellar-Calderon
Levels of Proinflammatory Cytokines in Rheumatoid Arthritis Patients with Carotid Plaque: A Case-Control Study
Nothing to Disclose

Jing Cui
Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk
Nothing to Disclose

Xiaomeng Cui
Treatment Efficacy Evaluation of Leflunomide by Regulating Macrophages in Takayasu Arteritis
Nothing to Disclose

Jeffrey R Curtis
Comparing the Generalizability of Cardiovascular Risk in Different Rheumatoid Arthritis Cohorts
Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Institute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Roche/Genentech; UCB
9- Radius Health, Inc.

Jeffrey R Curtis
Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis
Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Institute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Roche/Genentech; UCB
9- Radius Health, Inc.

Jeffrey R Curtis
Comparison of Medication New User Definitions in Multi-Specialty EMR Data
Disclosure:
Component and Cluster Analysis of the BRASS Registry

Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Insitute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; AbbVie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janseen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB
9- Radius Health, Inc.

Jeffrey R Curtis
Low Probability of Clinical Worsening Following Switching Biologic DMARD in Patients with RA and Partia Response to Adalimumab

Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Insitute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; AbbVie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janseen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB
9- Radius Health, Inc.

Jeffrey R Curtis
Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis

Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Insitute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; AbbVie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janseen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB
9- Radius Health, Inc.

Jeffrey R Curtis
Withdrawal of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Sarilumab Open-Label EXTEND Study: Efficacy and Safety Analysis

Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Insitute (PCORI); Pfizer; Regeneron; Roche; UCB
3- Roche
5- AbbVie; AbbVie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janseen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB
9- Radius Health, Inc.
Maurizio Cutolo
An Engineered Glove for the Computerised Quantification of Hand Disability in Rheumatoid Arthritis
Disclosure:
2- Boehringer, Actelion, Celgene, Bristol-Mayer Squibb

Maurizio Cutolo
Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities
Disclosure:
2- Boehringer, Actelion, Celgene, Bristol-Mayer Squibb

Maurizio Cutolo
Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients
Disclosure:
2- Boehringer, Actelion, Celgene, Bristol-Mayer Squibb

Maurizio Cutolo
Trabecular Bone Score and Malnutrition in a Cohort of Systemic Sclerosis Patients
Disclosure:
2- Boehringer, Actelion, Celgene, Bristol-Mayer Squibb

Deborah Da Costa
Sleep Quality in Women with Rheumatoid Arthritis Is Associated with Disease Activity and Depressive Symptoms
Nothing to Disclose

Thomas Dörner
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Disclosure:
2- GSK; Janssen; Novartis; Sanofi; UCB Pharma

Alemnew F Dagnew
Efficacy and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Pre-existing Potential Immune Mediated Diseases: A Pooled Post-hoc Analysis on Two Parallel Randomized Trials
Disclosure:
3- GSK group of companies

Marilia Dagostin
Mortality Predictors in ANCA-associated Vasculitis: Experience of a Brazilian Monocentric Cohort of a Rheumatology Center
Nothing to Disclose

Lie Dai
Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study
Nothing to Disclose

Lie Dai
Excessive Alcohol Intake Is Associated with Tophi Formation in Gout Patients
Nothing to Disclose

Lie Dai
Myopenia in Elderly Female Patients with Rheumatoid Arthritis Is Associated with Severe Joint Damage: A Cross-sectional Study
Nothing to Disclose

Daniel Dairaghi
Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay
Disclosure:
1- Eli Lilly and Company
3- Eli Lilly and Company
Yousra Dakkak
How Accurate Is Physical Joint Inflammation of the MTP-joints and What Can We Learn from Additional MRI on Forefoot Involvement in Early Arthritis?
Nothing to Disclose

Yousra Dakkak
Tenosynovitis at the Metatarsophalangeal Joints, a Novel Feature of RA: Results from an Anatomical and Large Magnetic Resonance Imaging Study of Tendon Sheaths of the Forefoot
Nothing to Disclose

Deepan S Dalal
Facility-Level Variation in Biologic Disease Modifying Agents for Medicare Enrollees with Rheumatoid Arthritis
Nothing to Disclose

Deepan S Dalal
Medicaid Spending (2013-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Nothing to Disclose

Deepan S Dalal
Medicare Spending (2012-2017) on Disease Modifying Agents Commonly Used in Rheumatoid Arthritis
Nothing to Disclose

Nicola Dalbeth
The Effects of Message Framing on Patients’ Perceptions and Willingness to Switch to a Biosimilar
Disclosure:
2- Amgen; AMGEN; AstraZeneca
5- Abbvie; AstraZeneca; Dyve; Dyve BioSciences; Hengrui; Horiaon; Horizon; Janssen; Kowa; Pfizer
8- Abbvie; AstraZeneca; Dyve; Hengrui; Horiaon; Horizon; Janssen; Kowa; Pfizer
9- Abbvie; AstraZeneca; Dyve; Hengrui; Horizon; Janssen; Kowa; Pfizer

Andrea Dalmao-Fernández
Metabolic Regulation in Cybrids Obtained from Healthy and Osteoarthritic (OA) Patients: Impaired Metabolic Flexibility in OA Process
Nothing to Disclose

Lanh Dang
Prevalence of Corticosteroid Use in Incidental Vertebral or Hip Fractures
Nothing to Disclose

Lucas O Dantas
Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials
Nothing to Disclose

Julie D’Aoust
Autoantibody Profiles Delineate Three Distinct Subsets of Scleromyositis
Nothing to Disclose
The following types of relationships may be deemed relevant include:

1. Shareholder
2. Grant/Research support
3. Employee
4. Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)
5. Consulting Fees (e.g., advisory boards)
6. Officer or Board Member
7. Royalties
8. Speaker/Honoraria includes speakers bureau, symposia, and expert witness
9. Other

John M Davis
Multimorbidity May Worsen Fatigue in Patients with Rheumatoid Arthritis
Disclosure:
2. Pfizer
5. Abbvie; Pfizer; Sanofi Genzyme

Helene de Cagny
Incidence of Antimalarials-Induced Retinopathy in Inflammatory Rheumatic Diseases, Using OCT and Visual Field Test: A Systematic Review and Meta-analysis
Nothing to Disclose

Diederik De Cock
The Burden of Comorbidity in Patients with RA, PSA or SPA in a General Practice Registry
Nothing to Disclose

Ann-Sophie De Craemer
Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients
Nothing to Disclose

Ann-Sophie De Craemer
Restricted Work Participation Relates to High Disease Activity in Spondyloarthritis Patients
Nothing to Disclose

Manouk de Hooge
Diagnostic Utility of Individual Inflammatory Back Pain Parameters in Patients with Axial Spondyloarthritis
Nothing to Disclose

Manouk de Hooge
Erosions Are the Most Often Reported Structural Lesion on MRI of the Sacroiliac Joints in axSpA Patients with IBP
Nothing to Disclose

María L de la Torre
Are Hematologic Indexes Helpful in the Diagnosis and Prognosis of Polymyalgia Rheumatica?
Nothing to Disclose

María L de la Torre
Validation and Transcultural Adaptation of the Spanish Version of Brief Index of Lupus Damage (BILD) Questionnaire
Nothing to Disclose

Maria de la Vega
Predictors of Response to Etanercept-Methotrexate Treatment: Post-hoc Analysis of a Randomized, Open-label Study in Latin American Patients with Rheumatoid Arthritis
Disclosure:
5. Pfizer; Raffo; Sanofi
8. AbbVie; BMS; Janssen; Lilly; Pfizer; Raffo; Sanofi
9. Roche

Giacomo De Luca
Systemic Sclerosis Myocarditis Has Unique Clinical, Histological and Prognostic Features:
Comparative Analysis Between Patients with Endomyocardial Biopsy-proven Myocarditis
Disclosure:
2- SOBI
5- Celgene; Pfizer
8- Celgene; SOBI; Pfizer

Eugenio de Miguel
Large Vessel Vasculitis: Diagnosis Is Very Frequent with Ultrasound Examination and Shows Responsiveness to Treatment
Disclosure:
2- AbbVie; Novartis; Pfizer
5- AbbVie; Novartis; Pfizer
8- AbbVie; BMS; BMS, MSD, UCB, Roche; MSD; Novartis; Pfizer; Roche; UCB

Emma C de Moel
Increased Sodium Accumulation Detected by 23Na-Magnetic Resonance Imaging in Inflamed Knees of Patients with Autoimmune Joint Disease
Nothing to Disclose

Alexandre Wagner de Souza
HLA-B*51 and Its Subtypes in Brazilian Patients with Behçet’s Disease
Nothing to Disclose

Alexandre Wagner de Souza
Cyclophosphamide Therapy for the Neurologic Involvement of Behçet’s Disease – Is It Superior to Azathioprine in Preventing Relapses?
Nothing to Disclose

Salvatore De Vita
The Salivary Glands as the Key Site of Inflammation and Lymphoproliferation Leading to Lymphoma in Primary Sjögren’s Syndrome: Relevance for Dedicated Scoring, Biomarker Development and Lymphoma Prevention
Nothing to Disclose

Kevin D Deane
Clinical and Biomarker Factor Associations with Symptoms and Future Development of RA: TIP-RA Collective
Disclosure:
2- Janssen; Janssen R&D; Pfizer
5- Bristol-Myers Squibb; Janssen; Microdrop
9- Inova

Kendra DeBusk
Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Disclosure:
1- Roche; Bristol-Myers Squibb; Seattle Genetics
3- Roche; Bristol-Myers Squibb; Seattle Genetics
4- Roche; Bristol-Myers Squibb; Seattle Genetics

Melissa DeFoe
Documenting Bone Health for Veterans with Rheumatoid Arthritis in an Outpatient Academic Clinic: A Multiphase Quality Improvement Project
Nothing to Disclose

Wesley DeHaan
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Disclosure:
1- Selecta Biosciences
3- Selecta Biosciences

Mats Dehlin
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis - A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Nothing to Disclose

Eric Dein
Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
Nothing to Disclose

Nicoletta Del Papa
NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison
with Both the Composite EScSG and EUSTAR Indices for This Disease Status.
Nothing to Disclose.

Javier Del Pino-Montes
The p.R321C Mutation in P62 Associated with Paget’s Disease of Bone Leads to a Change of Localization of the Protein in Human Osteoclasts.
Nothing to Disclose.

Helena F DeLiia
Arterial Elasticity by 2 Dimensional Circumferential Strain and Beta Stiffness Index in Patients with Ankylosing Spondylitis.
Nothing to Disclose.

David W Dempster
Modeling-Based Bone Formation Persists in the Femoral Neck Despite Remodeling Inhibition in Subjects Treated with Denosumab.
Disclosure:
2- Amgen Inc.
5- Amgen Inc.
8- Amgen Inc.

Atul Deodhar
Certolizumab Pegol Improves Work and Household Productivity and Social Participation over 1 Year of Treatment in Patients with Non-Radiographic Axial Spondyloarthritis.
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Atul Deodhar
Ixekizumab Improves Fatigue, Pain, and Sleep up to 52 Weeks in Patients with Radiographic Axial Spondyloarthritis.
Disclosure:
5- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma
8- Abbvie, Amgen, Boehringer Ingelheim, BMS, Eli Lilly, GlaxoSmithKline, Janssen, Novartis AG, Pfizer, and UCB Pharma

Kimberly DeQuattro
Affordability Concerns Prevalent Among Patients with Systemic Lupus Erythematosus (SLE).
Nothing to Disclose.

Thierry Dervieux
Disclosure:
1- Exagen
3- Exagen
4- Exagen
6- Exagen

Thierry Dervieux
Enhanced Methotrexate Polyglutamation in Japanese as Compared to Caucasian.
Rheumatoid Arthritis Patients Starting Methotrexate
Disclosure:
1- Exagen
3- Exagen
4- Exagen
6- Exagen

Nancy Desai
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nothing to Disclose

Nancy Desai
Ultrasound Evaluation of the Achilles Enthesis in Inflammatory and Non-inflammatory Processes: A Systematic Review
Nothing to Disclose

Nancy Desai
Visceral Fat Deposition Associated with Pain in Osteoarthritis
Nothing to Disclose

Anne C Desbois
A Role for Microbiota in the Pathophysiology of Takayasu Arteritis (TAK) and Giant Cell Arteritis (GCA)
Nothing to Disclose

Umesh S Deshmukh
Autoantibody Mediated Salivary Gland Hypofunction in Sjögren’s Syndrome Involves Activation of Innate Immunity and Endothelial Cells
Nothing to Disclose

Umesh S Deshmukh
Salivary Gland Hypofunction in a Mouse Model for Sjögren’s Syndrome Is Strongly Associated with Hyperglycemia
Nothing to Disclose

Luke Desilet
Post-Traumatic Stress Disorder, Depression, Anxiety and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis
Nothing to Disclose

Valérie Devauchelle Pensec
Development of an Algorithm to Identify Sjögren’s Syndrome Patients in the French National Healthcare Claims Database
Disclosure:
2- Bristol_myers Squibb; CHUGAI; Roche
8- Chugai Pharma France

J. Patricia Dhar
Lack of Uptake of Prophylactic Human Papilloma Virus (HPV) Vaccination Among Women with Systemic Lupus Erythematosus (SLE) in the Detroit, MI Area, a High Risk Population
Nothing to Disclose

Surjeet Dheer
Treat-to-Target Approach in the Management of Elderly Rheumatoid Arthritis Patients
Nothing to Disclose

Varun Dhir
Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients
Nothing to Disclose

Rashmi Dhital
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US-results from a National Inpatient Database
Nothing to Disclose

Rashmi Dhital
Effect of Obesity and Surgical Weight Loss on Joint Surgery Hospitalizations in Psoriatic Arthritis: Data from National Inpatient Sample
Nothing to Disclose

Rashmi Dhital
Perioperative Glucocorticoid Management in Patients with Rheumatologic Diseases Undergoing Elective Joint Surgeries
Nothing to Disclose

Andrea Di Matteo
Third Generation Anti-cyclic Citrullinated Peptide Antibodies Improve Prediction of Clinical Arthritis in Second Generation Anti-cyclic Citrullinated Peptide Positive Subjects at Risk of Rheumatoid Arthritis
Nothing to Disclose

Julie A Di Paolo
Evaluation of Potential Mechanisms Underlying the Safety Observations of Filgotinib in Clinical Studies in RA
Disclosure:
1- Gilead Sciences, Inc.
3- Gilead Sciences; Gilead Sciences, Inc.

Francis DiDonato
Zipcode-Binding Protein 1 (ZBP1) Facilitates Ro60 Surface Translocation, Cellular Growth and Autoimmune Sequelae
Nothing to Disclose

Henriette Didriksen
The Lymphangiogenetic Factor VEGF-C and Its Receptor VEGFR-3 Are Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Disclosure:
8- Actelion
9- Actelion (Travel bursary); GSK (Travel bursary)

Stacey R Dillon
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Associated with Sjögren’s Syndrome
Disclosure:
1- Alpine Immune Sciences
3- Alpine Immune Sciences
4- Alpine Immune Sciences

Jodi Dingle
Comparison of Debate vs. Lecture to Teach Medical Students Pediatric Rheumatology
Nothing to Disclose

Dana DiRenzo
Emotional and Social Determinants of Health Increase Office Communication for Patients with Rheumatoid Arthritis
Nothing to Disclose

Dana DiRenzo
Health-Related Quality of Life in Primary Sjogren’s Syndrome: Insights from Using PROMIS and Comparison to ESSPRI
Nothing to Disclose

Haner Direskeneli
Is the Risk of Tuberculosis Increased in Behçet’s Disease Compared to Other Rheumatological Disorders After Anti-TNF-α Treatment?
Nothing to Disclose

Haner Direskeneli
Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group
Nothing to Disclose

Erdal Diri
The Efficacy of Low Dose Prednisone for Remission Induction in Newly Diagnosed Rheumatoid Arthritis Patients
Nothing to Disclose

Ebru Dirikgil
A Dutch Consensus Statement on the Diagnosis and Treatment of ANCA Associated Vasculitis
Nothing to Disclose

Oliver Distler
Pain Chronification and the Important Role of Non-disease Specific Symptoms in Patients with Systemic Sclerosis
Disclosure:
2- Actelion; Actelion Pharmaceuticals; AnaMar; Bayer; Biogen Idec; Boehringer Ingelheim; ChemomAb; espeRare Foundation; Genentech/Roche; GSK; Inventiva; Italfarmaco; Lilly; Medac; MedImmune; Mitsubishi Tanabe; Mitsubishi Tanabe Pharma; Novartis; Pfizer; Pharmacyclics; Sanofi; Sinoxa; UCB; UCB in the area of potential treatments of scleroderma and its complications
Improving Adherence to Pregnancy Screening in Patients on Teratogenic Medications Using an Electronic Medical Record Alert System: A Quality Improvement Initiative

Nothing to Disclose

Lingli Dong
Clinical Characteristics and the Level Disease Activity of Behcet’s Disease in China: A Study Based on Smart System of Disease Management (SSDM)

Nothing to Disclose

Lingli Dong
The Increased Ratio of Blood CD56bright to CD56dim NK Cells Is a Distinguishing Feature of Primary Sjögren’s Syndrome

Nothing to Disclose

sha dong
Positive Rate of Small Intestinal Bacterial Overgrowth Test (SIBO) Was Significant Correlations to Disease Activity of Primary Sjogren's Syndrome (pSS)

Nothing to Disclose

Robin Dore
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry

Disclosure:

2- AbbVie; Abbvie, Inc.; Amgen; Biogen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB
5- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis
8- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Lilly; Pfizer; Radius; Regeneron; Sanofi; UCB; VCB
9- AbbVie, Inc.; Amgen; Biogen; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB

Robin Dore
Real-World Evidence: Clinical and Economic Burden of Anemia, Venous Thromboembolism, and Malignancy Among Rheumatoid Arthritis Patients Switching from First Biologic DMARD to Another Treatment in the US
Disclosure:
2- AbbVie; Abbvie, Inc.; Amgen; Biogen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB
5- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis
8- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Lilly; Pfizer; Radius; Regeneron; Sanofi; UCB; VCB
9- AbbVie, Inc.; Amgen; Biogen; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB

Switching from First Biologic DMARD to Another Treatment in the US
Disclosure:
2- AbbVie; Abbvie, Inc.; Amgen; Biogen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB
5- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis
8- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Lilly; Pfizer; Radius; Regeneron; Sanofi; UCB; VCB
9- AbbVie, Inc.; Amgen; Biogen; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB

Robin Dore
Real-World Evidence: Infections Among RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Disclosure:
5- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis
8- AbbVie; AbbVie, Inc.; Abbvie, Inc.; Amgen; Lilly; Pfizer; Radius; Regeneron; Sanofi; UCB; VCB
9- AbbVie, Inc.; Amgen; Biogen; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB

Robin Dore
Comparison of Patient Self-reported Data to Physician-driven Cohorts in Patients with Eosinophilic Granulomatosis with Polyangiitis
Nothing to Disclose

Irena Doubelt
The Cumulative Burden of Damage for Patients with Eosinophilic Granulomatosis with Polyangiitis
Nothing to Disclose

Maxime Dougados
Ixekizumab: 52-Week Efficacy and Safety in Radiographic Axial Spondyloarthritis Patients with Prior Inadequate Response/Intolerance to Tumor Necrosis Factor Inhibitors
Disclosure:
2- Pfizer; Abbvie; Eli Lilly and Company; UCB; Novartis
5- Pfizer; Abbvie; Eli Lilly and Company; UCB; Novartis
8- Pfizer; Abbvie; Eli Lilly and Company; UCB; Novartis

Maxime Dougados
The Effect of Tofacitinib on Residual Pain in Patients with Psoriatic Arthritis
Disclosure:
2- AbbVie; BMS; Eli Lilly; Gilead; Janssen; Merck; Merck Inc; Novartis; Pfizer; Pfizer Inc; Roche; UCB
Kendall Downer
Associations Between Antibodies to the Angiotensin II Type 1 Receptor and Endothelin-1 Type a Receptor and the Incidence of Vascular Complications in Early Diffuse Systemic Sclerosis
Nothing to Disclose

Matthew Dragovich
SLAMF6 Clustering Is Required to Augment Autoimmune T Cell Activation
Nothing to Disclose

Kyle Drehmel
Applying Systemic Lupus International Collaborating Clinics (SLICC) and Provisional ACR/EULAR Systemic Lupus Erythematosus Classification Criteria in a Cohort of Patients with Undifferentiated Connective Tissue Disease
Nothing to Disclose

Barbara Dreo
Negative Immune Checkpoint Molecules on T Regulator Cells Distinguish RA, SLE and Healthy Controls
Nothing to Disclose

Jeffrey Driban
A Novel Composite Score Reflecting Disease Activity Predicts Future Knee Replacements: Data from the Osteoarthritis Initiative Disclosure: 8- Pfizer, Inc.

Patryk J Drobinski
Connective Tissue Remodeling Is Differently Modulated by Tocilizumab versus Methotrexate Monotherapy in Patients with Early RA: The AMBITION Study
Nothing to Disclose

Katie L Druce
Alcohol Consumption Is Not an Independent Predictor of Fatigue Severity over Time
Nothing to Disclose

Kristin M D'Silva
Rituximab Therapy for Interstitial Pneumonia with Autoimmune Features (IPAF): A Case Series of Nineteen Patients
Nothing to Disclose

Lihua Duan
CCN3 Regulates Macrophage Function in MSU-induced Inflammation
Nothing to Disclose

Catia C Duarte
Inflammation but Also Pain and Function, and Psychological Impact Is Related to Non-Acceptable Status in Patients with Rheumatoid Arthritis: A Factorial Analysis in 643 Patients
Nothing to Disclose

Ali A Duarte Garcia
Effect of Omega-3 Fatty Acids on Systemic Lupus Erythematosus Disease Activity: A Systematic Review and Meta-Analysis
Nothing to Disclose

Bright Dube
What Is the Relationship Between the 3 Knee Bones in Osteoarthritis? Baseline and Longitudinal Associations Using a Latent Growth Modelling Approach on 37,583 MR Images from the Osteoarthritis Initiative
Nothing to Disclose

Shirish Dubey
Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry
Nothing to Disclose

Christina Duesing
Potentially Reversible Associations with Fatigue in SLE Patients - Results from a Single-centre Study
Nothing to Disclose

Anastasia Dupré
Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome
Nothing to Disclose

Laurence M Duquenne
In CCP Positive "At Risk of Rheumatoid Arthritis" Individuals, the Presence of Sub-clinical Synovitis in 4-10 joints Universally Results in Clinical Synovitis
Nothing to Disclose

Laurence M Duquenne
Validation of Risk Scores for Predicting Progression in Individuals “At Risk of Rheumatoid Arthritis”
Nothing to Disclose

Sergio Duran-Barragan
Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Nothing to Disclose

Alejandro Duran-Sotuela
Mitochondrial DNA Sub-haplogroup H1 Influences the Risk of Rapidly Progressive Osteoarthritis of the Knee: Data from the Osteoarthritis Initiative
Nothing to Disclose

Teodor Duro
Learner Practice Gaps in Osteoporosis: Piloting a Metabolic Bone Disease Curriculum Within a Fracture Liaison Service Framework
Nothing to Disclose

Mehmet Tuncay Duruoz
A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis Disclosure:
2- Abvie
8- İbrahim etem; Abdi İbrahim; Abdi İbrahim; Abvie; AMGEN; AMGEN, Novartis, ILKO, ONKO, İbrahim Ethem, Abdi İbrahim; İbrahim Ethem; ILKO; Novartis; ONKO

Mehmet Tuncay Duruoz
The Relationship Between Fatigue and Disease Activity as Determined by Different Indices in Patients with Psoriatic Arthritis (PsA) Disclosure:
2- Abvie
8- İbrahim etem; Abdi İbrahim; Abdi İbrahim; Abvie; AMGEN; AMGEN, Novartis, ILKO, ONKO, İbrahim Ethem, Abdi İbrahim; İbrahim Ethem; ILKO; Novartis; ONKO

Michael J Duryee
Increased Antibody and T-cell Responses Following Treatment of Collagen-Induced Arthritis in C57Bl/6 Mice with Organic Dust Inhalants
Nothing to Disclose

Bhargavi Duvvuri
Circulating Mitochondrial Danger-Associated Molecular Patterns as Novel Biomarkers of Disease Activity and Inflammation in Rheumatoid Arthritis
Nothing to Disclose

Sarah Dyball
Disentangling Connective Tissue Diseases: Overlaps and Disparities in Clinical Diagnosis, Classification Criteria and Autoantibodies – Results from the Lupus Extended Autoimmune Phenotype Study
Nothing to Disclose

Konrad Dziamski
Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays
Nothing to Disclose

Hang Korng Ea
Monosodium Urate and Calcium Pyrophosphatecrystal-induced Interleukin 1 Production Depends on Glucose Uptake Through Glut1 Transporter
Nothing to Disclose

Charles B Eaton
Cross-sectional Associations of Multiple Joint Osteoarthritis in the Osteoarthritis Initiative
Nothing to Disclose

Ariadne V Ebel
Associations of Self-Reported Inhalant Exposures with Autoantibodies and Disease Severity in U.S. Veterans with Rheumatoid Arthritis
Nothing to Disclose

Yonatan Edel
The Safety of Pulse Therapy- Systematic Review and Meta-analysis
Nothing to Disclose

Cuoghi Edens
Workforce Survey: Career Trends of Combined Adult and Pediatric Rheumatology Fellowship Graduates
Nothing to Disclose

Lihi Eder
Blockage of TNFα and IL-12/23 Improves Depressive Symptoms in Patients with Psoriatic Arthritis – Analysis of Clinical Trial Data
Disclosure:
2- Abbvie; Lily; Novartis; Pfizer; UCB
5- Abbvie; Celgene; Janssen; Lily; Novartis
8- Abbvie; Pfizer

Lihi Eder
The Performance of a Multi-marker Genetic Test to Identify Patients with Psoriatic Arthritis Among Psoriasis Patients
Disclosure:
2- Abbvie; Lily; Novartis; Pfizer; UCB
5- Abbvie; Celgene; Janssen; Lily; Novartis
8- Abbvie; Pfizer

Colin C Edgerton
Outpatient Costs and Evaluation and Management (E&M) Expenditure Trends in Rheumatoid Arthritis (RA) Patients Treated with Biologic Therapies in US Community Practices
Nothing to Disclose

N. Lawrence Edwards

Gout Management in the Medical Community: A Claims-Based Analysis
Disclosure:
5- Astra Zeneca; Horizon; Ironwood Pharmaceuticals; Selecta

Bugra Han Egeli
The Impact of Aging on Familial Mediterranean Fever Patients
Nothing to Disclose

Lisa Ehlers
AMP Deaminase 2 Surface Expression Counteracting CD73-Driven Generation of Anti-Inflammatory Extracellular Adenosine
Nothing to Disclose

Debbie Ehrmann Feldman
Chronic Musculoskeletal Pain and Its Initial Management in Children, Adolescents and Young Adults in the United States
Nothing to Disclose

Lara El Khoury
Angiotensin Receptor Blockers Prevent Loss of Dendritic Complexity in a Lupus Mouse Model of Cognitive Impairment
Nothing to Disclose

Hayam EIAggan
Peripheral Blood Toll Like Receptor 7 Expression and Serum Interferon Lambda 1 Levels in Systemic Lupus Erythematosus and Their Relation to Disease Activity and Lupus Nephritis
Nothing to Disclose

Ofir Elalouf
High Body Mass Index Shortens Retention of Tumor Necrosis Factor-α Blocker Treatment in Rheumatoid Arthritis
Nothing to Disclose

David Eldeiry
Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus
Nothing to Disclose
Mamoun B Elnagar  
Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution  
Nothing to Disclose

Paul Emery  
Baseline Characteristics Associated with Sustained SDAI Remission Following Treatment with Abatacept in Combination with MTX Compared with Abatacept Placebo in Combination with MTX in ACPA Positive Patients with Early RA  
Disclosure:  
2- AbbVie; BMS; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Samsung Bioepis Co., Ltd.; Sandoz; UCB  
5- AbbVie; BMS; Bristol-Myers Squibb; Gilead; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Sandoz; UCB  
9- AbbVie; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Sandoz; UCB

Paul Emery  
Patient-Reported Outcomes of Abatacept in Combination with MTX in Early, MTX-Naïve, ACPA Positive Patients with RA: 1-Year Results from a Phase IIIb Study  
Disclosure:  
2- AbbVie; BMS; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Samsung Bioepis Co., Ltd.; Sandoz; UCB  
9- AbbVie; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Sandoz; UCB

Paul Emery  
Reduction in CD4 TEMRA Cells and Its Association with DAS28 (CRP) < 2.6 Treatment Response with Abatacept in Patients with Early, ACPA+, DMARD-Naïve RA  
Disclosure:  
2- AbbVie; BMS; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Samsung Bioepis Co., Ltd.; Sandoz; UCB  
5- AbbVie; BMS; Bristol-Myers Squibb; Gilead; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Sandoz; UCB  
9- AbbVie; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche; Samsung; Sandoz; UCB

Hakan Emmungil  
Different Colchicine Preparations for Familial Mediterranean Fever: Are They the Same?  
Nothing to Disclose

Yushiro Endo  
Efficacy and Safety of Tocilizumab Treatment for Anti–human T Lymphotropic Virus Type I Antibody–positive Rheumatoid Arthritis  
Nothing to Disclose

Yushiro Endo  
Positivity of Anti-Ro/SSA Antibody Confer Poor Response and Persistence with Abatacept Therapy  
Nothing to Disclose

Bryant R England  
Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis  
Nothing to Disclose
Jessica English
Hair Chemicals and Systemic Lupus Erythematosus: A Case-Control Study
Nothing to Disclose

Didem Erdem
Reliability and Validity of the Self-Administered Comorbidity Questionnaire in Psoriatic Arthritis
Nothing to Disclose

Mustafa Erdogan
Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis
Nothing to Disclose

Sinem Nihal Esatoglu
Disease Course of Behçet’s Syndrome Patients Not Fulfilling International Study Group Criteria at Presentation
Nothing to Disclose

Sinem Nihal Esatoglu
Evidence-Based Recommendations for the Management of Enteropathic Arthritis: A Rheumatology – Gastroenterology Collaborative Initiative
Nothing to Disclose

Nouran Eshak
Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis
Nothing to Disclose

Monica Espinoza
The Diversity and Community Metrics of the Esophageal Microbiome of SSc Patients
Nothing to Disclose

Suzan Esslinger
Pregnancy Outcomes in Women Exposed to Golimumab
Disclosure:
3- Johnson & Johnson
4- Johnson & Johnson

Shannon Estadt
Interferon Alpha Promotes Caspase-Dependent Apoptosis Independently of Reactive Oxygen Species in Ultraviolet B-Exposed Keratinocytes
Nothing to Disclose

Amanda M Eudy
Longitudinal Changes in Manifestations of SLE Disclosure:
2- GSK

Elena Eusterwiemann
‘If You Don’t Use It, You Lose It’: Rehabilitation of Finger Dexterity and Ability to Perform Activities of Daily Living in Systemic Sclerosis
Nothing to Disclose

Lawrence S Evans
ALPN-101, a First-in-Class Dual ICOS/CD28 Antagonist, Suppresses Key Effector Mechanisms Underlying Rheumatoid and Psoriatic Arthritis Disclosure:
1- Alpine Immune Sciences
3- Alpine Immune Sciences
4- Alpine Immune Sciences

Nnenna Ezeh
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Nothing to Disclose

Robert Fairchild
Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis
Nothing to Disclose

Robert Fairchild
Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Nothing to Disclose

Jessica Fairley
Clinical Characteristics and Survival in Systemic Sclerosis-mixed Connective Tissue Disease and Systemic Sclerosis-overlap Syndrome
Nothing to Disclose
Jessica Fairley
Management of Cutaneous Manifestations of Lupus Erythematosus: A Systematic Review
Nothing to Disclose

Trevor D Faith
Expanding Access to Research Using TeleHealth: Lupus and Informatics Feasibility Study
Nothing to Disclose

Tamas Faludi
Flux Analysis Reveals Influence of Rab4 Expression on Mitochondrial and Pentose Phosphate Pathway Metabolism of Lupus T Cells
Nothing to Disclose

R Andrea Fan
Profiling of Gene Expression, Immune Cell Subtypes, and Circulating Protein Biomarkers in Systemic Lupus Erythematosus Patients Treated with the Selective Immunoproteasome Inhibitor, KZR-616
Disclosure: 3- Kezar Life Sciences 4- Kezar Life Sciences

Christie Fanton
Selective Induction of Functional Regulatory T-Cells in Healthy Volunteers by NKTR-358, a Novel IL-2 Conjugate Treg Stimulator, in Development for the Treatment of Autoimmune Diseases
Disclosure: 1- Nektar Therapeutics 3- Nektar Therapeutics 4- Nektar Therapeutics

Alejandra de Lourdes Farias-Sierra
Histological Characteristics in SICCA Syndrome - Clinical and Serological Association
Nothing to Disclose

Bayram Farisoğulları
Temporal Relationship Between Enteropathic Spondylitis Symptoms/diagnosis and Inflammatory Bowel Diseases Diagnosis: HUR-BIO Real Life Results
Nothing to Disclose

Sohail Farshad
Evaluation of Subclinical Coronary Atherosclerosis in ANCA-associated Small Vessel Vasculitides (AAVs) Compared to Matched Controls Through Visual Assessment of Coronary Arterial Calcium (CAC) Score Using Non-Gated Chest Computed Tomography (CT)
Nothing to Disclose

Sohail Farshad
Utility of Coronary Calcium Scoring (CCS) in the Spectrum of Connective Tissue Disorders (CTDs) for the Evaluation of Subclinical Coronary Atherosclerosis – a Systematic Review
Nothing to Disclose

Serena Fasano
Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus
Nothing to Disclose

Angelo Fassio
Acute Effects of IL-6 Blockade, TNFα Inhibitor or Glucocorticoids on Bone Turnover Markers and Wnt Inhibitors in Early Rheumatoid Arthritis
Nothing to Disclose

Tahzeeb Fatima
The Association Between Urate and CSF Markers of Alzheimer’s Disease in a Population-Based Sample of 70-Year-Olds
Nothing to Disclose

Marine Fauny
Relationship Between Structural Spine Involvement and the Scanographic Bone Attenuation Coefficient of L1 in a Population of 73 Patients with Ankylosing Spondylitis
Nothing to Disclose

Marine Fauny
Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of
the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls
Nothing to Disclose

Marine Fauny
What Are the Consequences of Spinal Ankylosis on the Bone Trabecular Fragility Assessed on CT-scan in Patients with Ankylosing Spondylitis?
Nothing to Disclose

Bruno Fautrel
PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naïve and Transitioned Patients Receiving Infliximab Biosimilar SB2; An Interim Analysis Disclosure:
2- AbbVie; Eli Lilly and Company; MSD; Pfizer
5- AbbVie; Biogen; BMS; Celgene; Eli Lilly and Company; Janssen; Medac; MSD; NORDIC Pharma; Novartis; Pfizer; Roche; Sanofi-Aventis; SOBI; UCB
8- AbbVie; Biogen; BMS; Boehringer Ingelheim; Celgene; Janssen; Lilly; Medac; MSD; NORDIC Pharma; Novartis; Pfizer; Roche; SOBI; UCB

Andrea Fava
Renal Single Cell Genomics Links Type II Interferon and Lupus Nephritis in African-Americans
Nothing to Disclose

Francoise Fayet
Adherence to Subcutaneous Anti-tnf Therapies in Chronic Inflammatory Rheumatism and Therapeutic Education
Nothing to Disclose

Lynne Feehan
24-hour Activity Profiling in People Living with Arthritis: Habits Matter
Nothing to Disclose

aurore FELCE
Effects of Deep Haptic Massage in Fibromyalgia (pilot Study)
Nothing to Disclose

Candace H Feldman
Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis
Nothing to Disclose

Min Feng
Increased Apoptosis and Compromised Suppressive Capacity of Regulatory T Cells in Primary Sjögren’s Syndrome
Nothing to Disclose

Lyn D Ferguson
Effect of Phosphodiesterase 4 Inhibition with Apremilast on Cardiometabolic Outcomes in Psoriatic Arthritis – Initial Results from the Immune Metabolic Associations in Psoriatic Arthritis (IMAPA) Study
Nothing to Disclose

Elisa Fernández
False Positives in the Ultrasound Diagnosis of Giant Cell Arteritis: Some Diseases Can Also Have Halo Sign
Nothing to Disclose

C. Fernández-Diaz
Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients Disclosure:
8- Bristol Meyer

Giovana Fernandes
A Functional Exercise Program Improves Pain and Health Related Quality of Life in Patients with Fibromyalgia: A Randomized Controlled Trial
Nothing to Disclose

Virginia Fernandes Moça Trevisani
Effects of Resistive Exercise on Fatigue and Disease Activity in Women with Primary Sjogren’s Syndrome
Nothing to Disclose
Mercedes Fernandez-Moreno  
Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy  
Nothing to Disclose

Marcela Ferrada  
Clinical Phenotypes in Relapsing Polychondritis in a Prospective Cohort  
Nothing to Disclose

stéphanie Ferrero  
Impact of ACL Injury Management on the Development of Knee Osteoarthritis: A Meta-analysis  
Nothing to Disclose

Leticia Ferri  
Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors and the Role of Auto-antibodies  
Disclosure: 1- Bristol-Myers Squibb; Bristol-Myers Squibb Company  
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company  
4- Bristol-Myers Squibb

Leticia Ferri  
Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review  
Disclosure: 1- Bristol-Myers Squibb; Bristol-Myers Squibb Company  
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company  
4- Bristol-Myers Squibb

Francesco Ferro  
Ultrasonography of Major Salivary Glands in Primary Sjögren’s Syndrome: Identification of Distinct Evolving Patterns in the Long-Term Follow-up  
Nothing to Disclose

Antonio Figliomeni  
Disease Activity and Quality of Life in Behçet’s Syndrome: The Role of Patient Reported Outcome  
Nothing to Disclose

Nothing to Disclose

Camille P Figueiredo  
Cortical Bone Erosion in the 2nd Metacarpal Bone Head: Association with Its Bone Mineral Density by HR-pQCT in Rheumatoid Arthritis Patients  
Nothing to Disclose

Gabriel Figueroa-Parra  
Results of the Implementation of a Bone Health Program in Patients with Rheumatoid Arthritis to Improve the Evaluation of Osteoporosis  
Nothing to Disclose

Alice Fike  
Double Trouble: Utility of Serial TB Screening in a Rheumatology Clinic Serving a Foreign-Born Population  
Nothing to Disclose

Samuel R Finlay  
Presence of the MerTK Receptor on Human Synovial Tissue Macrophages Lowers Inflammatory Cytokine Production and Activation of the MerTK+CD206+ Subpopulation Limits the Inflammatory Response of Synovial Fibroblasts  
Nothing to Disclose

Aryeh Fischer  
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom  
Disclosure: 5- Boehringer Ingelheim; Bristol Myers Squibb; Bristol-Myers Squibb Company; Hoffmann-La Roche; Roche

John Fitzgerald  
Limits of Detection of Monosodium Urate Crystals in Synovial Fluid by Ultrasound  
Nothing to Disclose

Timothy Fitzgerald  
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an
Infliximab Biosimilar or Remaining on Originator
Infliximab (REMICADE)
Disclosure:
1- Johnson & Johnson
3- Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC; Johnson & Johnson
4- Johnson & Johnson

Chelsie L Fleischer
Preferences and Insights for Rheumatoid Arthritis Clinical Prevention Trial Participation
Nothing to Disclose

Roy Fleischmann
Assessment of Bone and Cartilage Turnover Markers Following Treatment with Repository Corticotropin Injection in Patients with Persistently Active Rheumatoid Arthritis
Disclosure:
2- AbbVie; Acea; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Eli Lilly and Company; EMD Merck-Serono; EMD Serono; EMD-Serano; EMD-Serono; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Merck; Nektar; Novartis; Pfizer; Pfizer Inc; Regeneron; Resolve; Roche; Sanofi Genzyme; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Genzyme; Selecta; UCB; Boehringer Ingelheim; Gilead; Aventis; Samumed
5- AbbVie; Acea; Akros; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Eli Lilly and Company; EMD Merck-Serono; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Novartis; Pfizer; Pfizer Inc; Samsung; Sandoz; Sanofi-Aventis; Sanofi-Aventis; Tahio; Taiho; UCB; Galvani

Roy Fleischmann
Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Disclosure:
2- AbbVie; Acea; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Eli Lilly and Company; EMD Merck-Serono; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Merck; Nektar; Novartis; Pfizer; Pfizer Inc; Regeneron; Resolve; Roche; Sanofi Genzyme; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Genzyme; Selecta; UCB; Boehringer Ingelheim; Gilead; Aventis; Samumed
5- AbbVie; Acea; Akros; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Eli Lilly and Company; EMD Merck-Serono; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Novartis; Pfizer; Pfizer Inc; Samsung; Sandoz; Sanofi-Aventis; Sanofi-Aventis; Tahio; Taiho; UCB; Galvani
Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 48 Weeks

Disclosure:

Silvia Grazietta Foddai
Antiphospholipid Antibodies Prevalence in Women with Late Pregnancy Complication and Low-Risk for Chromosomal Abnormalities
Nothing to Disclose

Olivier Fogel
Effects of Anti-TNF on MiR Expression in Monocytes and CD4+ T-lymphocytes in Spondyloarthritis
Nothing to Disclose

Carmen Fonseca
Minocycline for Refractory Calcinosiss in Systemic Sclerosis: A Single-Centre Observational Cohort Study
Nothing to Disclose

Julia A Ford
Asthma, Chronic Obstructive Pulmonary Disease, and Subsequent Risk for Incident Rheumatoid Arthritis Among Women: A Prospective Cohort Study
Nothing to Disclose

Kerri Ford
Cost-per-Responder Analysis of Sarilumab for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis (RA)
Disclosure:

1- Sanofi
3- Sanofi
4- Sanofi

David A Fox
Effects of Abatacept on T Regulatory Cells in Early Diffuse Systemic Sclerosis
Nothing to Disclose

David A Fox
Lymphocyte Subset Abnormalities in Early Diffuse Cutaneous Systemic Sclerosis
Nothing to Disclose

David A Fox
Targeting CD6 Expression Attenuates T Cell Activity in Murine Collagen Induced Arthritis
Nothing to Disclose

René-Marc Flipo
Real-Life Golimumab Persistence in Patients with Chronic Inflammatory Rheumatic Disease: Results of the GO PRACTICE Study

Disclosure:

3- Sanofi

Achilleas Floudas
Increased T Cell Polyreactivity with Marked Accumulation of TNF-α DP (CD4+CD8+) in the Synovial Tissue of pre-RA, Arthralgia Subjects
Nothing to Disclose

Victoria A Flower
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Nothing to Disclose

Victoria A Flower
Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis
Nothing to Disclose
Megan Francis-Sedlak
Renal Transplant Complications in Patients with and Without Gout
Disclosure: 3- Horizon; Horizon Therapeutics
4- Horizon; Horizon Therapeutics

Eloi Franco-Trepat
A Drug Repurposing Story: New Therapeutic Tools Ready to Block Innate Immune Responses in Osteoarthritis
Nothing to Disclose

Mojca Frank-Bertoncelj
Joint-specific Responses to Tofacitinib and Methotrexate in Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Start
Disclosure: 2- Kurt und Senta Herrmann Foundation; Promedica Foundation

Brittany Frankel
Inconsistency in Uric Acid Reference Ranges Among 20 Top United States Hospitals: What Is "Normal"?
Nothing to Disclose

Tracy Frech
Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers
Nothing to Disclose

Tracy Frech
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
Nothing to Disclose

Lauren Freid
Prescribing Exercise: Facilitators and Barriers to the Successful Implementation of Physical Activity Guidelines in Inflammatory Arthritis
Nothing to Disclose

Dalifer Freites Nuñez
Evolution of Health-Related Quality of Life in Psoriatic Arthritis Patients
Nothing to Disclose

Dalifer Freites Nuñez
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Nothing to Disclose

Sarah French
A Medical Assistant Driven Quality Improvement Intervention Increases Rates of DEXA Screening Among RA Patients
Nothing to Disclose

Håvard Fretheim
Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions
Disclosure: 9- GSK (Travel bursaries); Actelion (Travel bursaries)

Benjamin Friedman
Adenosine A2A Receptor Signals Through AMPK and SIRT1 to Increase Chondrocyte Homeostasis
Nothing to Disclose

William Fung
Nothing to Disclose

Victoria Furer
Evidence of Subclinical Joint Inflammation of Hands by Magnetic Resonance Imaging in Patients with Psoriatic Arthritis in Minimal Disease Activity – Interim Analysis
Nothing to Disclose

Richard A Furie
Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results
from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial
Disclosure:
2- GlaxoSmithKline; UCB Pharma
5- Biogen; GlaxoSmithKline; UCB Pharma; Genentech, Inc.

Daniel E Furst
Improved Patient-Reported Outcomes in Patients with Persistently Active Rheumatoid Arthritis Following Treatment with Repository Corticotropin Injection
Disclosure:
2- Actelion; Actelion Pharmaceuticals; Amgen; BMS; Corbus; Galapagos; GlaxoSmithKline; GSK; NIH; Novartis; Pfizer; Roche/Genentech; Sanofi; Abbvie
5- Actelion; Actelion Pharmaceuticals; Amgen; BMS; CME; Corbus; Galapagos; Galapagos Novartis; GSK; Novartis; Pfizer; Roche/Genentech; Sanofi; Abbvie; Cytori
8- CME; CMC Connect

Sayaka Furukawa
Effectiveness of Screening by Nurse with Predetermined Questionnaire on Infections Before Administration of Intravenous Biologics in Patients with Rheumatoid Arthritis
Nothing to Disclose

Tetsuya Furukawa
Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis
Nothing to Disclose

Jose A Gómez-Puerta
Prognostic Value of Urinary Biomarkers for the Developing of End Stage Renal Disease in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Jose A Gómez-Puerta
Relationship Between Recurrent Thrombosis and the Antiphospholipid Antibodies Profile in a Cohort of Patients with Antiphospholipid Syndrome
Nothing to Disclose

Angelo L Gaffo
Depressive Symptoms Influence Success of Allopurinol in Reducing Serum Urate
Disclosure:
2- Amgen

Angelo L Gaffo
Effect of Serum Urate Lowering with Allopurinol on Blood Pressure in Young Adults
Disclosure:
2- Amgen

Elena Galli
Comparison Between Transmural and Isolated Periadventitial And/or Adventitial Inflammation at Temporal Artery Biopsy: A Single Center Cohort of Biopsy-Positive GCA with Long Term Follow-up
Nothing to Disclose

Rocio-V. Gamboa-Cárdenas
Not Achieving Clinical Remission Predicts a Poor Health-Related Quality of Life in Rheumatoid Arthritis Patients: Results of a Latin American Real World Database
Nothing to Disclose

Yash Gandhi
Evaluation of Pharmacokinetics and Immunogenicity Following Subcutaneous Administration of Abatacept in Primary Sjogren’s Syndrome (pSS) and RA Patients
Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb; CSL Behring
4- Bristol-Myers Squibb; CSL Behring

Saviana Gandolfo
Fatigue in Primary Sjögren’s Syndrome as a Manifestation of Heavier Disease Activity of Mucosa-Associated Lymphoid Tissue (MALT)
Nothing to Disclose

Saviana Gandolfo
Thymic Stromal Lymphopoietin (TSLP) as a Biomarker of Primary Sjögren’s Syndrome (pSS)
and Related Lymphoma: Results in Independent Cohorts
Nothing to Disclose

Liliya Gandrabur
Implementation of Cardiovascular Screening in Hispanic Patient Population with RA, SLE and PsA
Nothing to Disclose

Sujata Ganguly
NMR Spectroscopy Reveals Alterations of Urinary Acetate and Citrate Levels Following Cyclophosphamide Therapy in Patients with Lupus Nephritis
Nothing to Disclose

Sujata Ganguly
Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Nothing to Disclose

Xuan Gao
The Impact of Body Mass Index Variability in Systemic Lupus Erythematosus
Nothing to Disclose

Maria Garbarino
Minor Salivary Gland Biopsy and Dry Ocular Tests to Detect Occult Sjögren Syndrome in Patients with Interstitial Pneumonia with Autoimmune Features
Nothing to Disclose

Diego Felipe Garcia
Hand Digital Thermography Findings in Patients with Primary Fibromyalgia
Nothing to Disclose

Lucila Garcia
Adjusted GAPSS in Systemic Lupus Erythematosus Patients in Argentina
Nothing to Disclose

Samuel Garcia
Sema3B Expression Is Reduced in Rheumatoid Arthritis Patients and Has a Protective Role in a Murine Model of Arthritis
Nothing to Disclose

Gabriela Garcia-Guevara
Factors Associated with Peripheral Neuropathies in Patients with Systemic Lupus Erythematosus: A Single Center Experience
Nothing to Disclose

Maria de la luz Garcia-Hernandez
Stromal Cell-derived DCSTAMP Coordinates Cell Migration and Osteoclast Activation in TNF-driven Murine Arthritis
Nothing to Disclose

Agnes Gardet
Comprehensive Characterization of the Immune Infiltrate of Skin Biopsies from Cutaneous Lupus Erythematosus Patients Using Single Cell RNAseq Disclosure: 1- Biogen 3- Biogen

Shivani Garg
Meta-Analysis Examining the Clinical Significance of Monitoring of Hydroxychloroquine Levels in SLE
Nothing to Disclose

Shivani Garg
Renal Arteriosclerosis Predicts Cardiovascular Disease in Lupus Nephritis
Nothing to Disclose

Marco Garrido-Cumbregra
Are There Really Differences Between Non-radiographic and Radiographic Axial Spondyloarthritis? Data from the Spanish Atlas
Nothing to Disclose

Yevgeniya Gartshteyn
Platelet Bound Complement Split Product (PC4d) May Be a Marker of Platelet Activation and Cardiovascular Events in Systemic Lupus Erythematosus
Nothing to Disclose

Thomas Garvey
Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Nothing to Disclose

Estefania Gauto-Mariotti
Acute Gout Attacks Among Patients Admitted Due to Heart Failure: Analysis of NIS Database
Nothing to Disclose

Kelly Gavigan
Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease
Disclosure: 3- Global Healthy Living Foundation

Tal Gazitt
Implementation of Recommendations for Prevention of Glucocorticosteroid-Induced Osteoporosis in Hospitalized Patients
Nothing to Disclose

Jessica Gehin
Intensive CBT Is Effective in the Treatment of Significant Functional Impairment and Psychological Distress Found in Fibromyalgia: But Can We Improve Depressive Symptoms?
Nothing to Disclose

Christian Geier
In Rheumatoid Arthritis (RA) Decreases in Conventional Dendritic Cell Lineages Are Associated with Adverse Measures of Myocardial Function and Expansions of Anomalous HLA-DR+ Myeloid Subsets
Nothing to Disclose

Segolene Gendreau
Poor-Prognosis Factors of Systemic Vasculitides with Gastrointestinal Involvement: Data from a Large Retrospective Study
Nothing to Disclose

Mark Genovese
A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs
Disclosure: 4- UNITY

Mark Genovese
Efficacy and Safety Results from a Phase 3 Study of Biosimilar Candidate ABP 710 in Subjects with Moderate to Severe RA
Disclosure: 4- UNITY

Mark Genovese
Efficacy of Biosimilar Candidate ABP 710 in a Phase 3 Study in Subjects with Moderate to Severe RA: Additional Analysis Focusing on the ACR Individual Components
Disclosure: 4- UNITY

Mark Genovese
Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Disclosure: 4- UNITY

Mark Genovese
Safety Profile of Ixekizumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Integrated Analysis of 18 Clinical Trials
Disclosure: 4- UNITY

Mark Genovese
Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 Weeks
Disclosure: 4- UNITY

Fernanda Genre
Vaspin rs35262691 Is Associated with Atherosclerotic Disease in Axial Spondyloarthritis Patients
Nothing to Disclose

Thieroff George
Neurosarcoidosis: An Evaluation Based on the Neurosarcoidosis Consortium Consensus Group
Nothing to Disclose

Sofia Georgopoulou
Physician-Patient Interaction and Medication Adherence in Lupus Nephritis
Nothing to Disclose

Maria Chiara Gerardi
Disease Flares of Rheumatoid Arthritis During Pregnancy: What Is the Impact of Stopping bDMARDs at the Beginning of Pregnancy?
Nothing to Disclose

Onay Gercik
Factors Associated with Overall and First-Year Mortality in Turkish Patients with ANCA-Associated Vasculitides: Retrospective, Multicentre Trial
Nothing to Disclose

Onay Gercik
Performance of Berden’s Classification and ANCA Renal Risk Score for the Prediction of End-Stage Renal Disease in ANCA-associated Vasculitis
Nothing to Disclose

Elisabeth Gervais
Real Life 12 Year Retention Rate of Subcutaneous Anti-TNF in Spondyloarthritis. Results from a Multicenter Cohort of 1170 Patients
Nothing to Disclose

Jeroen Geurts
Preclinical Evaluation of Targeting TGF-beta Signaling and Senescence in ex Vivo Models of Human Knee and Spine Osteoarthritis
Nothing to Disclose

Halise Hande Gezer
Evaluation of Clinical and Functional Parameters by Joint Involvement and Remission in Psoriatic Arthritis
Nothing to Disclose

Mehrnaz Gharaee-Kermani
Interferon Kappa Promotes the Development of Psoriasis
Nothing to Disclose

Thibault Ghesquière
Mucosal Associated Invariant T Cells in Giant Cell Arteritis
Nothing to Disclose

Milena Gianfrancesco
A Pragmatic Randomized Trial to Improve Safe Dosing of Hydroxychloroquine
Nothing to Disclose

Teresa Giani
Prevalence of Subclinical Sacroiliitis in Young Patients with Inflammatory Bowel Disease Revealed by Entero-MRI
Nothing to Disclose

Allan Gibofsky
US Rheumatologists’ Beliefs and Knowledge About Biosimilars – an Ongoing Survey
Disclosure:
1- Merck
4- Abbvie; Amgen; Pfizer; Regeneron; Johnson & Johnson
5- Abbvie; Pfizer; Boehringer Ingelheim; Merck; Celgene; Novartis
8- Abbvie; Pfizer; Celgene; Novartis

Kathryn A Gibson
Performance of the Patient Reported Outcomes Measurement Information System 29-item Profile in Comparison to the Clinical Disease Activity Index (CDAI) and Routine Assessment of Patient Index Data 3 (RAPID3) in an Australian Rheumatoid Arthritis Cohort
Disclosure:
2- Novartis
8- Janssen; UCB
Kathryn A Gibson
Performance of the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Item Profile in a Cohort of Australians with RA, OA and Other Inflammatory Arthritic Conditions
Disclosure:
2- Novartis
8- Janssen; UCB
9- UCB

Abigail Gilbert
What Is an Important Difference in Gait Speed in Adults with Knee Osteoarthritis?
Nothing to Disclose

Emily L Gilbert
Clinical Utility of DECT in the Diagnosis of Gout at Mayo Clinic in Florida
Nothing to Disclose

Jon T Giles
Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population
Disclosure:
2- Pfizer Inc
5- Eli Lilly & Company

Geoffrey O Gillard
Administration of a CD45 Antibody Drug Conjugate as a Novel, Targeted Approach to Achieve Immune System Reset: A Single Dose of CD45-targeted ADC Safely Conditions for Autologous Transplant and Ameliorates Disease in Multiple Models of Autoimmune Disease
Disclosure:
1- Magenta Therapeutics
3- Magenta Therapeutics
4- Magenta Therapeutics

Christos Gkamaloutsos
Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
Disclosure:
3- Janssen Cilag Pharmaceutical SACI (Greece)

Elena Gkrouzman
Presence of Antiphospholipid Antibodies in Patients with SLE and Venous Thromboembolic Events of African American and Caucasian Race
Nothing to Disclose

Dafna Gladman
Oligoarticular Psoriatic Arthritis
Disclosure:
2- AbbVie; Amgen; Celgene; Eli Lilly; Novartis; Pfizer Inc; UCB
5- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; UCB

Dafna Gladman
Time to Response for Clinical and Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Tofacitinib, Adalimumab, or Placebo
Disclosure:
2- AbbVie; AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB; Amgen; Celgene; Eli Lilly; Novartis; Pfizer Inc; UCB
5- AbbVie; AbbVie, Amgen, BMS, Celgene Corporation, Janssen, Novartis, Pfizer, UCB; Amgen; BMS; Celgene; Eli Lilly; Galapagos; Gilead; GlaxoSmithKline; Janssen; Novartis; Pfizer Inc; UCB
8- GlaxoSmithKline

Kelsey Gockman
Beta-2 Glycoprotein I as a DNA- and NET-binding Protein
Nothing to Disclose

Niti Goel
Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome
Disclosure:
3- Kezar Life Sciences
4- Kezar Life Sciences
6- Kezar Life Sciences
Dieter Goette
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients - A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Disclosure:
3- Vifor Pharma
4- Vifor Pharma

Dieter Goette
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Disclosure:
3- Vifor Pharma
4- Vifor Pharma

John C Goetzinger
CCP Autoantibody Positive SLE Patients Show Unique Enrichments in SLE Criteria and Autoantibody Biomarkers That Vary by Race
Nothing to Disclose

Jon Golenbiewski
Hospital Admissions and Mortality in Patients with ANCA-associated Vasculitis
Nothing to Disclose

Jon Golenbiewski
The Vasculitis Pregnancy Registry (V-PREG): Information from the First 3 Years
Nothing to Disclose

Yvonne M Golightly
Association of Traumatic Knee Injury with Knee Function, Symptoms, and Radiographic Osteoarthritis in Military Officers
Nothing to Disclose

Luis Gomez-Lechon
Comparison of Comorbidity in Spondyloarthritis: Influence on Inflammatory Activity in Patients with Psoriatic Arthritis
Nothing to Disclose

rafaela Gonçalves
MDA Versus DAPSA: Applicability in a Real World
Nothing to Disclose

Xavier González-Giménez
Hip Fracture Incidence in a Teaching Hospital: Intervention for the Prevention of Second Hip Fracture
Nothing to Disclose

Lucía González-Rodríguez
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Nothing to Disclose

Luis Gonzalez
Are Immunosuppressants a Risk Factor Associated with Mycobacterium Tuberculosis Infection in Colombian Patients with Systemic Lupus Erythematosus? A Case-control Study
Nothing to Disclose

Iñigo Gonzalez-Mazon
Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients
Nothing to Disclose

Iñigo Gonzalez-Mazon
Epidemiology, Clinical Features and Relationship to Biological Therapy of Uveitis in Axial Spondyloarthritis: Single Center University Study
Nothing to Disclose

Iñigo Gonzalez-Mazon
Long-Term Follow-Up of Anti-IL6-Receptor Tocilizumab in Refractory Uveitis in Patients with Behçet Disease: Multicenter Study of 14 Patients in Clinical Practice
Nothing to Disclose

Iñigo Gonzalez-Mazon
Uveitis in 320 Patients with Psoriatic Arthritis. Epidemiology, Clinical Features and Biological Treatment: Study from a Single University Center
Adam P Goode
Transitions in Lumbar Spine Osteoarthritis: The Johnston County Osteoarthritis Project
Nothing to Disclose

Susan M Goodman
Clinical Features of Prosthetic Joint Infections in Patients with Rheumatic Diseases vs Osteoarthritis
Disclosure:
2- Horizon; horizon; Novartis; Pfizer; Roche
3- NYU College of Medicine; NYU Langone College of Medicine
4- Regenosine
5- BMC Rheumatology; Calgene; Celgene; Current Rheumatology reports; Horizon; Novartis; Pfizer; UCB
6- BMC Rheumatology; Current Rheumatology Reports
9- Regenosine

Carl S Goodyear
Apremilast Inhibits Immune Cells Support of Inflammatory Osteoclastogenesis
Disclosure:
2- Celgene; AstraZeneca; MedAnnex; UCB; Jannsen
5- AstraZeneca; MedAnnex

Susan M Goodman
Risk Factors for Transfusion and Use of Tranexemic Acid in Patients with Rheumatoid Arthritis Undergoing Total Hip Arthroplasty and Total Knee Arthroplasty
Disclosure:
2- Horizon; horizon; Novartis; Pfizer; Roche
3- NYU College of Medicine; NYU Langone College of Medicine
4- Regenosine
5- BMC Rheumatology; Calgene; Celgene; Current Rheumatology reports; Horizon; Novartis; Pfizer; UCB
6- BMC Rheumatology; Current Rheumatology Reports
9- Regenosine

Peter Gorevic
Mixed Cryoglobulin Immune Complex Proteomics: Analysis by Mass Spectroscopy
Nothing to Disclose

Laure Gossec
Are There Country Differences in Disease Activity and Life Impact of Psoriatic Arthritis? An Analysis of 436 Patients from 14 Countries
Disclosure:
2- BMS; Celgene Corporation; Lilly; Pfizer
5- Abbvie; AbbVie; Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, SANofi-Aventis, UCB; Amgen; Biogen; BMS; Celgene; Jannsen; Lilly; MSD; Nordic Pharma; Novartis; Pfizer; Sanofi; Sanofi-Aventis; UCB

Laure Gossec
Differences in Clinical Characteristics, Quality of Life, Disability, and Work Productivity in Psoriatic Arthritis Patients by Gender: Findings from a Cross-sectional Survey in the US and Europe
Disclosure:
2- BMS; Celgene Corporation; Lilly; Pfizer
5- Abbvie; AbbVie; Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB; Amgen; Biogen; BMS; Celgene; Janssen; Lilly; MSD; Nordic Pharma; Novartis; Pfizer; Sanofi; Sanofi-Aventis; UCB

Laure Gossec
Health Professionals Agreed with Recommendations to Evaluate and Optimize Adherence to Disease-modifying Treatments, but Perceived Feasibility Was Lower: A Study of 357 Physicians and Health Professionals in France
Disclosure:
2- BMS; Celgene Corporation; Lilly; Pfizer
5- Abbvie; AbbVie; Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB; Amgen; Biogen; BMS; Celgene; Janssen; Lilly; MSD; Nordic Pharma; Novartis; Pfizer; Sanofi; Sanofi-Aventis; UCB

Ustekinumab and TNF Inhibitors Similarly Improve Patient-perceived Impact of Psoriatic Arthritis but Differentially Affect the Scale Subdomains: Results from a European Observational Cohort Study
Disclosure:
2- BMS; Celgene Corporation; Lilly; Pfizer
5- Abbvie; AbbVie; Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB; Amgen; Biogen; BMS; Celgene; Janssen; Lilly; MSD; Nordic Pharma; Novartis; Pfizer; Sanofi; Sanofi-Aventis; UCB

Helen Gosselt
Replication of a Prognostic Multivariable Prediction Model for Insufficient Clinical Response to Methotrexate in Early Rheumatoid Arthritis
Nothing to Disclose

Carmen E Gota
How Well Do Visual Analogue Scales Used in the Fibromyalgia Impact Questionnaire (FIQ) Correlate with Other Measures of Pain, Fatigue, Sleep, Sleep Disturbance, Anxiety and Depression in Patients with Fibromyalgia
Nothing to Disclose

Carmen E Gota
Relationship Between a History of Abuse and Fibromyalgia Symptoms and Severity: Data from the Cleveland Clinic Fibromyalgia Registry
Nothing to Disclose

Stephanie Gottheil
Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project
Nothing to Disclose

Philippe Goupille
Golimumab Persistence in Biologic Naive and Non-Naive Patients with Axial Spondyloarthritis: Results of the GO PRACTICE Study
Disclosure:
5- AbbVie; Amgen; Biogaran; BMS; Celgene; Eli Lilly; Hospira; Janssen-Cilag; MSD; Pfizer; Sanofi-Genzyme; UCB

Pravitt Gourh
Aggregation of Functional Variants in NOTCH4 Gene Increases SSc Risk
Nothing to Disclose

Caroline Grönwall
Autoreactivity to Acetylated Histones Defines a Subset of RA Patients and Is Associated with Acetyl - Citrulline Anti-Modified Protein Autoantibody (AMPA) Cross-Reactivity
Nothing to Disclose

Elizabeth Graef
Clinical Characteristics of Lymphadenopathy in Systemic Lupus Erythematosus: A Case Control Study from a Tertiary Care Center
Lee D Graham
Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
Nothing to Disclose

Rebecca Grainger
Self-Joint Counts by People with Rheumatoid Arthritis: Does a Video Increase Accuracy and Does It Matter?
Nothing to Disclose

Amelia Granel
Myositis Specific Antibodies and Clinical Features in Patients from Argentina
Nothing to Disclose

Michael A Grant
The Opioid Epidemic: The Rheumatology Response to Management of Chronic Pain
Nothing to Disclose

Elena Grau García
Frequency of Polyautoimmunity in a Tertiary Hospital
Nothing to Disclose

Martín Greco
Antisynthetase Syndromes: Correlation of Indirect Immunofluorescence Patterns with Diagnosis Criteria Fulfillment
Nothing to Disclose

Jacob Greenmyer
DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis
Nothing to Disclose

K Bates Gribbons
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
Nothing to Disclose

Ricardo Grieshaber-Bouyer
Divergent Mononuclear Cell Participation and Cytokine Release Profiles Define Hip and Knee Osteoarthritis
Nothing to Disclose

Madison Grinnell
Factors Influencing Discontinuation in Long-term RA Treatment
Nothing to Disclose

Madison Grinnell
Probiotic Use and Psoriatic Arthritis Disease Activity
Nothing to Disclose

Julien Grosse
ACPA-positive versus ACPA-negative Rheumatoid Arthritis: Two Distinct Erosive Disease Entities on Radiography and Ultrasonography
Nothing to Disclose

Danica Grujic
Enteral Administration of ALLN-346, a Recombinant Urate-degrading Enzyme, Decreases Serum Urate in a Pig Model of Hyperuricemia
Nothing to Disclose

Jieyu Gu
‘Non-criteria’ Antiphospholipid Antibodies Add Value to Antiphospholipid Syndrome Diagnoses in a Large Chinese Cohort
Nothing to Disclose

Guillermo Guaracha-Basañez
Invasive Aspergillosis in Rheumatologic Patients in Tertiary Care Hospital in Mexico
Nothing to Disclose

Tania Gudu
Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound
Nothing to Disclose
Hans Guehring
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of the Anti-ADAMTS-5 Nanobody®, M6495, in Healthy Male Subjects: A Phase I, Placebo-Controlled, First-in-Human Study
Disclosure: 3- Merck KGaA, Darmstadt, Germany

Dana Guglielmo
Exercise Is Medicine® in Primary Care Practice: Provider Characteristics and Physical Activity Counseling for Patients with Arthritis, DocStyles, 2018
Nothing to Disclose

Francisco Guiñazú
Metabolic Syndrome and Early Arthritis: Frequency, Association with Antibodies Profile and Disease Activity
Nothing to Disclose

Ahmet Gul
AGBL3 as a Novel Gene Associated with Hereditary Hypocomplementemic Urticarial Vasculitis and Favorable Response to Rituximab
Nothing to Disclose

Tina Gunderson
Prevalent and Incident Multimorbidity in Rheumatoid Arthritis: A Population-Based Cohort Study
Nothing to Disclose

Angela Gupta
Red Cell Distribution Width Positively Correlates with Atherosclerotic Cardiovascular Disease Risk Score in Psoriatic Arthritis and Decreases with BDMARD Therapy
Nothing to Disclose

Ranjan Gupta
Urinary MRP8/14, an Endogenous Toll-Like Receptor 4 Ligand, Reflects Renal Disease Activity in Lupus Nephritis: A Cross-Sectional and Longitudinal Assessment
Nothing to Disclose

Sarthak Gupta
Role of Aerobic Exercise in Modulating Fatigue in Women with Systemic Lupus Erythematosus
Nothing to Disclose

Margaret Guthrie
Validation of a Claims Algorithm to Identify Interstitial Lung Disease in Patients with Rheumatoid Arthritis
Nothing to Disclose

You-Jung Ha
Nothing to Disclose

You-Jung Ha
Pyruvate Kinase M2 May Contribute to the Inflammation and Joint Destruction in Rheumatoid Arthritis
Nothing to Disclose

Isabell Haase
Pregnancy in Rheumatoid Arthritis: Continue, Reduce or Stop TNF Inhibitors? A Prospective Observational Study
Nothing to Disclose

Rebecca Haberman
Assessing Risk of PsA Progression: Results from a Combined Psoriasis-PsA Center Cohort
Nothing to Disclose

Rebecca Haberman
The Paradoxical Effect of Depression on Psoriatic Arthritis Outcomes in a Combined Psoriasis-Psoriatic Arthritis Center
Nothing to Disclose

Mirette Habib
 Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease
Analysis from the University of Michigan
Scleroderma Cohort
Nothing to Disclose

Mahmood Y Hachim
Estimating the Infiltration of Immune Cells in Synovium of Rheumatoid Arthritis Compared to Osteoarthritis and Healthy Control Using Transcriptomic Profiling
Nothing to Disclose

Melanie Hagen
Prediction of Disease Relapses by Multi-biomarker Disease Activity Score and Autoantibody Status in RA Patients Tapering DMARD Treatment in Stable Remission
Nothing to Disclose

Stephen Hall
Characterization of Remission in Patients with Rheumatoid Arthritis Treated with Upadacitinib or Comparators
Disclosure:
2- AbbVie; BMS; Eli Lilly; Janssen; Lilly; Novartis; Pfizer; UCB; UCB Pharma
5- AbbVie; BMS; Eli Lilly; Janssen; Lilly; Novartis; Pfizer; UCB; UCB Pharma

Yasuhito Hamaguchi
Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course
Nothing to Disclose

mohammad hammad saied
Rheumatic Fever in a Tertiary Medical Center - 25 Years of Follow Up
Nothing to Disclose

Nevin Hammam
Development of Machine Learning Models (Artificial Neural Networks) for Prediction of Vision Threatening Behçet’s Disease
Nothing to Disclose

Hilde B Hammer
Fatigue Levels Are Not Associated with Inflammatory Activity, but with Subjective Outcomes: Results from a Longitudinal Study of Patients with Rheumatoid Arthritis Initiating bDMARD Therapy
Nothing to Disclose

Hilde B Hammer
Intermetatarsal Bursitis Is Prevalent in Patients with Established Rheumatoid Arthritis and Is Associated with Anti-CCP and RF
Nothing to Disclose

Angie Hammond
IRAK4 Inhibition Suppresses TLR7, TLR9, and SLE Serum-Induced IFNA Production in Primary Human Plasmacytoid Dendritic Cells Disclosure:
1- Gilead Sciences, Inc.
3- Gilead Sciences, Inc.
4- Gilead Sciences, Inc.

Bobby Kwanghoon Han
Neutrophil Lymphocyte Ratio as a Marker for Immune Complex-Driven Inflammation in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Xue Han
ACPA Testing and Resultant Treatment Patterns in Patients with Rheumatoid Arthritis: Findings from US Community Rheumatology Practices Disclosure:
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company

Xue Han
Epidemiology, Risk/Prognostic Factors, and Treatment Landscape in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Systematic Literature Review Disclosure:
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company

Xue Han
Evaluation of Real-World Early-Line Abatacept versus Tumor Necrosis Factor Inhibitors
Persistence in Rheumatoid Arthritis Patients with Anti-Citrullinated Protein Antibody or Rheumatoid Factor Positivity
Disclosure:
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company

Xue Han
Real-World Distribution of Anti-Cyclic Citrullinated Peptide Concentrations and Impact on Treatment Patterns of Patients with Rheumatoid Arthritis
Disclosure:
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company

Xue Han
The Association Between Treatment of Abatacept or Other Target Disease-Modifying Anti-rheumatic Drugs and Type 2 Diabetes Mellitus (T2DM)-Related Healthcare Resource Utilization and Costs in Commercially Insured Rheumatoid Arthritis Patients with T2DM
Disclosure:
3- Bristol-Myers Squibb; Bristol-Myers Squibb Company

Xue Han
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Disclosure:
3- Bristol-Myers Squibb Company

Beatriz Hanaoka
Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis
Nothing to Disclose

Hironari Hanaoka
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Disclosure:
2- Mitsubishi Tanabe Pharma Corporation Sohyaku

John G Hanly
Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results from an International, Inception Cohort Study
Nothing to Disclose

Renata Hansen
Development of Comorbidity in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Renata Hansen
Impact of Diabetes on Risk of End Stage Renal Disease in Danish Nationwide Cohort of Newly Diagnosed Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Mahamudul Haque
Regulation of Interleukin-1β (IL-1β)-induced COX-2 Expression and IL-6 and MMP-1 Production in Human OA Synovial Fibroblasts by Guanylate Binding Protein 5
Nothing to Disclose

Masayoshi Harigai
Expression of Peptidyl-arginine Deiminases in Peripheral Blood Neutrophils and Its Association with Single Nucleotide Variants in Patients with Rheumatoid Arthritis
Disclosure:
5- Bristol Meyers Squib; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly
8- AbBvie Japan GK; Bristol Meyers Squib; Bristol-Myers Squibb Co. Ltd; Chugai

Sohyaku
Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly; Teijin Pharma Ltd.; Teijin Pharma, Ltd.

Masayoshi Harigai
Genome-wide Association Study in a Japanese Population Revealed Novel Candidate Genes for Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Disclosure:
5- Bristol Meyers Squib; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly
8- AbbVie Japan GK; Bristol Meyers Squib; Bristol-Myers Squibb Co. Ltd; Chugai Pharmaceutical Co. Ltd.; Chugai Pharmaceutical Co., Ltd.; Eli Lilly; Teijin Pharma Ltd.; Teijin Pharma, Ltd.

Josna Haritha
Contraception Documentation Rates in Women with Rheumatic Diseases on Teratogenic Medications in an Academic Rheumatology Clinic
Nothing to Disclose

Matthew Harkey
Changes in Novel Composite Scores of Disease Activity and Cumulative Damage Are Prognostic of Accelerated Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Nothing to Disclose

Matthew Harkey
Patient-Specific Reference Values for Objective Physical Function Tests: Cross-Sectional Analysis Using Data from the Osteoarthritis Initiative
Nothing to Disclose

Tyler Harkness
A Novel Patient-Reported Outcome Measure in IgG4-Related Disease: The Symptom Severity Index
Nothing to Disclose

Tyler Harkness
Serum IgG4 Concentrations Differ According to Race and Sex
Nothing to Disclose

James Harnett
Impact of TNF Inhibitor Cycling with Adalimumab and Etanercept vs Switching to Tofacitinib
Disclosure:
1- Pfizer Inc
3- Pfizer Inc

Frances Harris
Analysis of Discoid Lupus Erythematosus (DLE) Gene Expression Reveals Dysregulation of Pathogenic Pathways Associated with Infiltrating Immune/Inflammatory Cells
Nothing to Disclose

Nathaniel Harris
The PROMIS-29 as a Measure of Type 1 and 2 SLE Activity
Nothing to Disclose

Leslie R Harrold
Association Between Baseline Anti-citrullinated Protein Antibody Status and Response to Abatacept or Non-TNF Inhibitor Therapy in Patients with RA: Results from a US National Observational Study
Disclosure:
1- Corrona
2- Pfizer
3- Pfizer
5- AbbVie; Bristol-Myers Squibb; Genentech

Onengiya Harry
Electronic Monitoring of Medication Adherence in Young Adults with Childhood-Onset Systemic Lupus Erythematosus over 12 Weeks
Nothing to Disclose

Bohdan Harvey
Therapeutic Anti-TNF Biologic Agents Exhibit Functional Differences in Blocking TNF-induced Effects on Human Monocytes In VitroDisclosure:
3- AbbVie, Inc.
4- AbbVie, Inc.

Judith Haschka
Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement
Nothing to Disclose

Tepppei Hashimoto
Circulating Cell Free DNA Released from Eosinophils Is a Practical Biomarker in Patients with Eosinophilic Granulomatosis with Polyangiitis
Nothing to Disclose

Gulen Hatemi
Pentoxifylline Gel for Oral Ulcers in Patients with Behçet’s Syndrome
Disclosure:
2- BMS, Celgene Corporation, Silk Road Therapeutics; Silk Road Therapeutics
8- Abbvie, Mustafa Nevzet, UCB

Shakaib Hayat
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Nothing to Disclose

Joshua Hedrick
Using PROMIS Data to Assess Activity of Inflammatory Eye Disease
Nothing to Disclose

Philip S Helliwell

Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies Disclosure:
2- AbbVie; Janssen; Janssen Research & Development, LLC; Novartis
8- AbbVie; Amgen; Celgene; Celgene; Galapagos; Pfizer; Pfizer Inc; UCB

Joerg Henes
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Nothing to Disclose

Mette Herly
Are Vitamin D Metabolite Levels at Time of Diagnosis Associated with Long-term Severe Cardiovascular Events in Early Diagnosed Rheumatoid Arthritis Patients, Aggressively Treated During 10 Year Follow Up? Post-hoc Analyses of Observational Data from the C Disclosure:
2- Pfizer

isabel Hernandez Rodriguez
Management of Patients with Incident Rheumatoid Arthritis in Rheumatology Clinical Practice
Nothing to Disclose

Cristina Hidalgo
Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease
Nothing to Disclose

Kazuhiko Higashioka
Identification of IFN-γ-producing Effector B Cells in Humans: Their Relevance to the Pathogenesis of Systemic Lupus Erythematosus
Nothing to Disclose
Kristin B Highland
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Disclosure:
2- Actelion Pharmaceuticals; Boehringer Ingelheim; Eiger Pharmaceuticals; Genentech; Reata Pharmaceuticals; United Therapeutics
5- Boehringer Ingelheim
8- Actelion Pharmaceuticals; Bayer; Bayer Healthcare; Boehringer Ingelheim; Genentech; Gilead Sciences; United Therapeutics
9- Actelion Pharmaceuticals; Boehringer Ingelheim

Shinya Hirahara
Association of Work Productivity Assessed by Absenteeism and Presenteeism with Disease Activity, Damage and Health-related Quality of Life in Patients with ANCA-associated Vasculitis
Nothing to Disclose

Kazuoto Hiramoto
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Disclosure:
2- Mitsubishi Tanabe Pharma Corporation

Aiko Hirano
Efficacy and Safety of Dose Adjustment Based on Patients’ Body Size in Low Dose Intravenous CYC Treatment for Rheumatic Diseases
Nothing to Disclose

Shintaro Hirata
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Disclosure:
2- AbbVie; Eli Lilly; UCB
5- Bristol-Myers Squibb; UCB
8- AbbVie; Astellas; Eisai; Eli Lilly; Jansen; Kissei; Pfizer; Sanofi; Takeda; Tanabe-Mitsubishi; UCB

Kei Hirose
A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis Nothing to Disclose

Alojzija Hocevar
Assessing the Vascularization of Salivary Glands in Patients with Sjögren's Syndrome - An OMERACT Ultrasound Group Reliability Exercise
Nothing to Disclose

Alojzija Hocevar
Predictors of Gastrointestinal and Renal Involvement in Adult IgA Vasculitis
Nothing to Disclose

Alojzija Hocevar
Ultrasonography in the Diagnosis of Giant Cell Arteritis
Nothing to Disclose

Marc C. Hochberg
Clinically Relevant Improvements in Knee Osteoarthritis Pain with Diclofenac Sodium Gel 1%
Disclosure:
3- Rheumcon, Inc
4- BriOri Biotech; Theralogix LLC
5- Bioiberica SA; Bone Therapeutics; Bristol Myers Squibb; Eli Lilly; EMD Serono; EMD Serono Research and Development Institute, Inc.; Galapagos; IBSA Biotechniq SA; Novartis Pharma AG; Pfizer; Pfizer Inc; Plexxikon; Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba; Samumed LLC; Theralogix LLC; TissueGene Inc
7- Elsevier; UpToDateTM
9- Galapagos, IQVIA and Hoffman LaRoche
Marc C. Hochberg
Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
Disclosure:
3- Rheumcon, Inc
4- BriOri Biotech; Theralogix LLC
5- Bioiberica SA; Bone Therapeutics; Bristol Myers Squibb; Eli Lilly; EMD Serono; EMD Serono Research and Development Institute, Inc.; Galapagos; IBSA Biotechniq SA; Novartis Pharma AG; Pfizer; Pfizer Inc; Plexxikon; Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerva; Samumed LLC; Theralogix LLC; TissueGene Inc
7- Elsevier; UpToDateTM
9- Galapagos, IQVIA and Hoffman LaRoche

Anna Maria Hoffmann-Vold
Changes in Fecal Microbiota Composition After Fecal Microbiota Transplantation in Systemic Sclerosis
Disclosure:
2- Boehringer Ingelheim
5- Actelion; Boehringer Ingelheim; GSK
8- Actelion; Boehringer Ingelheim; GSK

Anna-Maria Hoffmann-Vold
Course of Progressive Lung Fibrosis in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) in the EUSTAR Database
Disclosure:
2- Actelion; Boehringer Ingelheim; GSK
5- Actelion; Boehringer Ingelheim; GSK

Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
Disclosure:
2- Actelion; Boehringer Ingelheim; GSK
5- Actelion; Boehringer Ingelheim; GSK

Alberta Hoi
Prevalence and Predictors of Fibrosis in Rheumatological Patients on Therapy and Risk Factors for Chronic Liver Disease
Nothing to Disclose

Melissa G Holdren
Maximal Improvement in Fatigue Lags Behind Achievement of Sustained Remission in Early Rheumatoid Arthritis
Nothing to Disclose

Elizabeth A Holdsworth
Real World Effectiveness of Secukinumab in Patients with Ankylosing Spondylitis: Findings from a Recent Cross Sectional Survey of Rheumatologists and Patients in Europe
Nothing to Disclose

Signe Holm Nielsen
A Biomarker of Type VI Collagen Degradation (C6M) Is Associated with Changes in ASDAS MRI Measures of Inflammation in Patients with Axial Spondyloarthritis During TNF Inhibitor Therapy
Disclosure:
3- Nordic Bioscience

Sarah Homann
Tumor Necrosis Factor Alpha Inhibitor (TNF-α Inhibitor) Exposure and Risk of Hip Fracture in Veterans with Rheumatoid Arthritis: A Nested Case Control Study
Nothing to Disclose

Suguru Honda
Lymphoproliferative Disorders in Patients with Rheumatoid Arthritis: Results from Japanese Multi-institutional Study Using Research Electronic Data Capture
Nothing to Disclose

Huixian Hong
Intestinal Microbiota Alters Th1/Th17 Balance but Is Dispensable for the Development of Systemic Autoimmune Disease in BXD2 Mice
Nothing to Disclose

Nadine Honke
β-adrenergic Receptor Activation: A Way to Enhance CD4 T Cell Suppression by Improving Regulatory B Cell Function
Nothing to Disclose

Bradley A Hooker
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Disclosure:
3- AbbVie

Paul Hoover
The Single-cell Transcriptomic Landscape of NZB/W Murine Lupus at Early and Late Stages of Disease
Nothing to Disclose

Audrey Hopkins
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Nothing to Disclose

Hideyuki Horikoshi
Effectiveness of Platelet-derived Microparticles for the Diagnosis and Clinical Evaluation of Rheumatoid Arthritis
Nothing to Disclose

Diane Horowitz
Histologic and Clinical Correlates of Ultrasound Measures of Joint Inflammation: Analysis of RA Tissue Obtained by Ultrasound Guided Biopsy in Phase 2 of the Accelerating Medicines Partnership RA Network
Nothing to Disclose

Yoshihiko Hoshida
Multi-center Analyses on 518 Cases with Rheumatoid Arthritis Developing Lymphoproliferative Disorders (RA-LPD): The Prognostic Factors and the Influence of Antirheumatic Drugs on LPD Development
Nothing to Disclose

Benjamin Hsu
Senescent Synoviocytes in Knee Osteoarthritis Correlate with Disease Biomarkers, Synovitis, and Knee Pain
Disclosure:
1- UNITY Biotechnology
3- UNITY Biotechnology
4- UNITY Biotechnology; Johnson & Johnson

Vivien Hsu
Reduced Circulating Levels of Inorganic Pyrophosphate Are Associated with Ectopic Calcification in Scleroderma Spectrum Disorders
Nothing to Disclose

Fang Yuan Hu
The Study of Peripheral Blood Lymphocyte Subsets and CD4+T Subsets in Recurrent Polychondritis
Nothing to Disclose

Feng Huang
Development of Smart-phone Spondyloarthritis Management System and Real-world Study of Chinese Patients with Ankylosing Spondylitis
Nothing to Disclose

Feng Huang
Work Productivity Is Associated with Disease Activity and Functional Ability in Chinese Patients with Axial Spondyloarthritis Using a Smart-Phone Management System: A Prospective Cohort Study
Nothing to Disclose

Irvin Huang
Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares
Nothing to Disclose

Jianlin Huang
Influential Factors in Promoting Treat-to-Target for Systemic Lupus Erythematosus via Empowering Patients: A Cohort Study from China by Smart System of Disease Management (SSDM)
Nothing to Disclose
Michelle W Huang
Anti-IFNAR Treatment Does Not Reverse Neuropsychiatric Disease in MRL/lpr Lupus Mice
Nothing to Disclose

Nick Huang
Rab4A Controls mTOR Pathway Activation, Pro-inflammatory Lineage Development, and Disease Pathogenesis in Lupus-prone Mice
Nothing to Disclose

Qi Q Huang
The Role of Flip in Differentiation and Survival of Synovial Tissue Resident Macrophages
Nothing to Disclose

Runyue Huang
Efficacy and Safety of Chinese Herbal Medicine Biqi Capsule Combined with Methotrexate in Patients with Rheumatoid Arthritis: A Pilot Study
Nothing to Disclose

Sicong Huang
Association of Rheumatoid Arthritis-related Autoantibodies with Pulmonary Function Test Abnormalities in a Prospective Rheumatoid Arthritis Registry
Nothing to Disclose

Sicong Huang
Factors Associated with Differing Types of Heart Failure in Patients with Rheumatoid Arthritis
Nothing to Disclose

Erika Hubbard
Analysis of Gene Expression from Systemic Lupus Erythematosus Synovium Reveals Unique Pathogenic Mechanisms
Nothing to Disclose

Jamie L Huizinga
Direct Medical and Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Nothing to Disclose

Thomas W.J. Huizinga
Effect of ACPA IgM Serostatus on Efficacy Outcomes Following Treatment with Abatacept or Adalimumab: A Post Hoc Analysis of a Phase III Head-to-Head Trial
Disclosure:
2- Abblynx; Abbott; Biotest AG; Boehringer Ingelheim; Boeringher Ingelheim; Bristol-Myers Squibb; Crescendo Bioscience; Eli Lilly; Epirus; Galapagos; Janssen; Merck; Novartis; Nycomed; Pfizer; Roche; Sanofi; Sanofi-Aventis; Takeda; UCB; Zydus
5- Abblynx; Abbott; Biotest AG; Boehringer Ingelheim; Boeringher Ingelheim; Bristol-Myers Squibb; Crescendo Bioscience; Eli Lilly; Epirus; Galapagos; Janssen; Merck; Novartis; Nycomed; Pfizer; Roche; Sanofi; Sanofi-Aventis; Takeda; UCB; Zydus
8- Abblynx; Abbott; Biotest AG; Boehringer Ingelheim; Boeringher Ingelheim; Bristol-Myers Squibb; Crescendo Bioscience; Eli Lilly; Epirus; Galapagos; Janssen; Merck; Novartis; Nycomed; Pfizer; Roche; Sanofi-Aventis; Takeda; UCB; Zydus

Theresa Hunter
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States: Findings from a US Survey Disclosure:
1- Eli Lilly; Eli Lilly and Company
3- Eli Lilly; Eli Lilly and Company

Theresa Hunter
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey Disclosure:
1- Eli Lilly; Eli Lilly and Company
3- Eli Lilly; Eli Lilly and Company

Peter Hur
A Retrospective Medical Chart Review of Patients with Periodic Fever Syndromes Initiating Canakinumab in the United States Disclosure:
M. Elaine Husni

Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial

Disclosure:
2- Janssen Research & Development, LLC
3- Janssen Research & Development, LLC
5- Abbvie; AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB; Abbvie, Amgen, Janssen, Novartis, Lilly, Regeneron, Pfizer and UCB; Bristol-Myers Squibb; Eli Lilly; Genentech; Janssen; Novartis; Pfizer; Sanofi-Genzyme; UCB
7- PASE questionnaires

M. Elaine Husni

Ixekizumab Demonstrates Improvement Comparable to Adalimumab Across ACR Components in Biologic-Naïve Patients with Psoriatic Arthritis

Disclosure:
2- Janssen Research & Development, LLC
3- Janssen Research & Development, LLC
5- Abbvie; AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB; Abbvie, Amgen, Janssen, Novartis, Lilly, Regeneron, Pfizer and UCB; Bristol-Myers Squibb; Eli Lilly; Genentech; Janssen; Novartis; Pfizer; Sanofi-Genzyme; UCB
7- PASE questionnaires

M. Elaine Husni

Psychometric Properities of the Patient Related Outcome Measure FACIT-Fatigue in Rheumatic Arthritis and Psoriatic Arthritis: A Literature Review

Disclosure:
2- Janssen Research & Development, LLC
3- Janssen Research & Development, LLC
5- Abbvie; AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, UCB; Abbvie, Amgen, Janssen, Novartis, Lilly, Regeneron, Pfizer and UCB; Bristol-Myers Squibb; Eli Lilly; Genentech; Janssen; Novartis; Pfizer; Sanofi-Genzyme; UCB
7- PASE questionnaires

Yasmin Hussein

Impact of IL34, IFN-α and IFN-λ1 on Disease Activity of SLE Patients in Egypt
Nothing to Disclose

Jiwon Hwang

Risk of Lymphoma and Thyroid Cancer in Primary Sjögren’s Syndrome Measured Using the Korean Health Insurance Claims Database
Nothing to Disclose

Jiwon Hwang

The Association of Serum Uric Acid Levels and the Risk of Lower Urinary Tract Symptoms in Korean Healthy Adults
Nothing to Disclose

Yong Gil Hwang

Comparison Between Fibromyalgia and Neuropathic Pain in Patients with Established Rheumatoid Arthritis
Nothing to Disclose

Sebastian Ibanez

Axial Spondyloarthritis Patients Report Important Impairments in Daily Life and Work Ability – a Web Survey in 472 Patients
Nothing to Disclose

Sebastian Ibanez

Results at 6 Months of Abatacept vs TNF-α Blockers in Patients with Severe, Long-standing, DMARDs Resistant Rheumatoid Arthritis
Nothing to Disclose

Claudia Ickinger

Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis
Nothing to Disclose

Takashi Igawa
Expression of SLAMF6 and Its Functional Significance in Podocytes of Lupus Nephritis: Report with Consideration Based on the Results of Microarray Analysis in Podocytes of MRL/lpr Mice
Nothing to Disclose

Juliana Imgenberg-Kreuz
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Nothing to Disclose

Jun Inamo
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Nothing to Disclose

Nevsun Inanc
Periodontal Pockets as a Potential Source of Circulating TREM-1 and Its Ligand PGLYRP1 in Patients with Rheumatoid Arthritis
Nothing to Disclose

Francesca Ingegnoli
The Impact of Air Pollution on Extracellular Vesicles as a Potential Pro-inflammatory Stimulus in Rheumatoid Arthritis
Nothing to Disclose

Francesca Ingegnoli
The Influence of Mediterranean Diet in Rheumatoid Arthritis: A Monocenter Cross-sectional Study
Nothing to Disclose

Patil Injean
Role of Alternative Immunosuppressant Therapy in Management of Cardiac Sarcoidosis
Nothing to Disclose

Rabia Iqbal
Do Myocardial Inflammation and Microvascular Dysfunction in RA Lead to Adverse Changes in Left Ventricular Structure and Function over Time? A Longitudinal Analysis of Participants from Rheumatoid Arthritis: Study of the Myocardium
Nothing to Disclose

Shumaila M Iqbal
Effect of Body Mass Index on the Disease Activity of Patients with Rheumatoid Arthritis in a Gender Specific Manner and Association of Respective Serum C - Reactive Protein Levels with the Body’s Inflammatory Status
Nothing to Disclose

Taeko Ishii
Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports
Disclosure:
1- Eli Lilly Japan KK
3- Eli Lilly Japan KK

Yuki Ishikawa
Cigarette Smoking Has Different Impacts on ACPA and RF Production Depending on Shared Epitope Allele Status in Japanese RA Patients; A Study with the Two Independent Japanese Cohorts (IORRA and KURAMA)
Nothing to Disclose

Mohamed Ismail
Exposure-Response Analyses for Upadacitinib Efficacy and Safety in Ankylosing Spondylitis – Analyses of the SELECT-AXIS I Study
Disclosure:
3- AbbVie Inc.

Michele Iudici
Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Registry
Nothing to Disclose

Maura D. Iversen
Reporting of Adverse Events in Randomized Controlled Trials of Therapeutic Exercise for Knee Osteoarthritis: A Systematic Review
Nothing to Disclose
2- Pfizer; Swedish Rheumatism; Norrebacca Eugenia Foundation

Shigeru Iwata
mTORC1-phosphorylated CXCR3+memory B Cells and Their Potential as a New Mode of Action of TNF Inhibitors in RA
Nothing to Disclose

Radhika Iyer
Antibody Repertoire Sequencing, Antigen Array Analysis, and Cytokine Profiling of Blood from Individuals at High-risk for RA Reveals Candidate Immunoglobulin V Genes, ACPA, and Cytokines That May Promote the Transition to Arthritis
Nothing to Disclose

Zara Izadi
The ACR’s Rheumatology Informatics System for Effectiveness (RISE) Demonstrates Improvements in Many Measures of Quality of Care Between 2015 and 2017
Nothing to Disclose

Sara Jaafar
Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis
Nothing to Disclose

Fatemeh Jafari Farshami
Quality Improvement in Diagnostic and Therapeutic Arthrocentesis in the Flexed Knee Using Pneumatic Compression of the Suprapatellar Bursa
Nothing to Disclose

Jason Jakiela
Activity in Work and Life: The Association Between Physical Activity and Employment
Nothing to Disclose

Status with Future Slow Walking in Knee Osteoarthritis
Nothing to Disclose

Jason Jakiela
Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis
Nothing to Disclose

Levi H Jales Neto
Identification and Validation of Transcriptional Genes Associated with Osteoporotic Vertebral Fractures by Microarray Study, in Community Elderly Women
Nothing to Disclose

Tim L Jansen
Impact of Apremilast on PsA Impact of Disease Core Components in Patients with a Limited Number of Active Joints: Results from a Real-World Study Disclosure:
2- Olatec, Grunenthal
5- AbbVie, Celgene Corporation
8- Grunenthal, Sobi

James N. Jarvis
Transcriptomic Responses in CD4+ T Cells During Successful Therapy for Juvenile Idiopathic Arthritis
Nothing to Disclose

Shraddha Jatwani
Impact of Rheumatoid Arthritis on Outcomes of Atrial Fibrillation: Results for National Inpatient Sample
Nothing to Disclose

Shraddha Jatwani
National Trends in Hospitalizations and Mortality for Acute Myocardial Infarction in Patients with Rheumatoid Arthritis: Data from National Inpatient Sample 2010-2014
Nothing to Disclose

Shraddha Jatwani
Nothing to Disclose

Shraddha Jatwani
Rheumatoid Arthritis Associated with Longer Hospital Stays in Patients Admitted with Venous Thromboembolism: A Nationwide Analysis 2010-2014
Nothing to Disclose

Damini Jawaher
The Pre-pregnancy Rheumatoid Arthritis Gene Expression Signature Correlates with Improvement or Worsening of Disease Activity During Pregnancy: A Pilot Study
Nothing to Disclose

Arundathi Jayatilleke
Evaluation of ACGME Competencies in a Rheumatology Observed Structured Clinical Examination
Nothing to Disclose

Arif Jetha
Casting a Wide Net: Comparing Strategies for Recruiting 18-35-year-olds with Rheumatic Disease as Study Participants
Nothing to Disclose

Arif Jetha
It Starts at Work: The Relationship Between Workplace Supports and Presenteeism Among Young Adults with Rheumatic Disease
Nothing to Disclose

Gabriel Jeyasingham
Assessing Perceptions, Barriers, and Preferences to Exercise in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Beulah Ji
Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus
Nothing to Disclose

Disclosure:
1- GlaxoSmithKline
3- GlaxoSmithKline
4- GlaxoSmithKline

Zongfei Ji
IL-6 Promotes IgG4-related Disease by Inducing Fibroblast-dependent Tfh Cell and B Cell Differentiation Factors
Nothing to Disclose

Miao Jiang
Comorbidities, Health Care Utilization, and Cost of Care in Systemic Lupus Erythematosus Increase with Disease Severity During 1 Year Before and After Diagnosis: A Real-World Cohort Study in the United States, 2004–2015
Disclosure:
3- AstraZeneca

Wei Jiang
Progesterone Decreases Gut Permeability Through Upregulating Occludin Expression in Primary Human Gut Tissues and Caco-2 Cells
Nothing to Disclose

Shangyi Jin
Bone Mineral Density and Microarchitecture Among Chinese Patients with Rheumatoid Arthritis
Nothing to Disclose

Sadao Jinno
Are There Differences in Efficacy and Safety of Biological Disease-modifying Antirheumatic Drugs Between Elderly-onset and Young-onset Rheumatoid Arthritis?
Nothing to Disclose

Sungsin Jo
1,25D3 Promotes Mineralization of Osteoblasts by Activating C/EBPβ-DKK1 Axis
Nothing to Disclose

Sungsin Jo
Effect of Testosterone on Spinal Ankylosis in Ankylosing Spondylitis: in Vivo and in Vitro
Nothing to Disclose
Neelakshi R. Jog
Dysregulation of Granulopoiesis in Systemic Lupus Erythematosus
Nothing to Disclose

Neelakshi R. Jog
Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Nothing to Disclose

Fredrik D Johansson
Predicting Remission in Rheumatoid Arthritis: External Validation for Tocilizumab
Monotherapy Using Corrona Real World Data
Disclosure:
2- Genentech

Hanna Johnsson
Tendon T-cell Interactions as Drivers of Chronicity in Spondyloarthritis
Nothing to Disclose

Britney Jones
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Nothing to Disclose

Dina L Jones
Participation in the Stanford University Chronic Pain Self-Management Program in a Population with a High Prevalence of Arthritis
Nothing to Disclose

Gareth T Jones
Predicting Response to Biologic Therapy in Patients with Axial Spondyloarthritis (axSpA)
Disclosure:
2- Celgene

Angela R Jones-Leone
Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

Disclosure:
1- GlaxoSmithKline
3- GlaxoSmithKline

April Jorge
Contemporary Prescription Opioid Use and Predictors Among Patients with Systemic Lupus Erythematosus
Nothing to Disclose

April Jorge
Opioid Prescription Use Among Patients with Rheumatic Disease: A Population Based Cohort Study
Nothing to Disclose

Antonio Julià
Cross-sectional Study and Mendelian Randomization Analysis of Diet in Six Prevalent Autoimmune Diseases
Nothing to Disclose

Antonio Julià
Identification of Immunological Processes Associated with the Response to Abatacept in Rheumatoid Arthritis Using Longitudinal Blood RNA-seq Analysis
Nothing to Disclose

Jae-Bum Jun
ASDAS Is More Important Than BASDAI in Advanced Ankylosing Spondylitis
Nothing to Disclose

Mats Junek
Rationalizing the Use of MRI of the Scalp Arteries in the Diagnosis of Giant Cell Arteritis Through Multivariable Predictive Modelling
Nothing to Disclose

Kyong-Hee Jung
Associations of Serum Uric Acid with Cardiovascular Disease Risk: Data from the Korea National Health and Nutrition Examination Survey
Nothing to Disclose

Sangyoun Jung
Autophagy Protein Microtubule-associated Protein 1 Light chain-3B (LC3B) Regulates Joint Inflammation and Destruction in Rheumatoid Arthritis
Nothing to Disclose

Aydan Köken Avşar
Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease
Nothing to Disclose

Aline Kühl Torricelli
Antiphospholipid Syndrome Damage Index (DIAPS): Distinct Long-term Kinetic in Primary Antiphospholipid Syndrome and APS Related to SLE
Nothing to Disclose

Naureen Kabani
Comparative Analysis of Clinical, Laboratory and Therapeutic Strategies Among Blacks with Rhupus, SLE and RA
Nothing to Disclose

Bashar Kahaleh
Epigenetic Regulation-Mediated Reduction in the Expression of Prostacycllin Receptor and Prostacyclin Synthase in Scleroderma Skin, Vascular Smooth Muscle Cells, and Microvascular Endothelial Cells
Nothing to Disclose

J Michelle Kahlenberg
Ultraviolet Light Induces Increased T Cell Activation in Lupus-Prone Mice via Type I Interferon-Dependent Inhibition of T Regulatory Cells
Disclosure:
5- AstraZeneca; Bristol Myers Squibb; Eli Lilly

Shinjiro Kaieda
Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody
Nothing to Disclose

Hiroshi Kajiyama
Association of Cumulative Urinary Podocyte Number and Urinary Podocalyxin with Long-term Renal Prognosis in Lupus Nephritis
Nothing to Disclose

Romy Kallas
Association of African-American Ethnicity and Smoking Status and Total and Individual Damage Index in Systemic Lupus Erythematosus
Nothing to Disclose

Romy Kallas
Risk Factors for Avascular Necrosis in SLE: A Multivariate Model
Nothing to Disclose

Kenneth Kalunian
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis Disclosure:
2- BMS; Exagen; Idosia; Kirin; Pfizer; Resolve; Takeda; UCB
5- Abbvie; Amgen; AstraZeneca; Biogen; Chemocentryx; Eli Lilly; Equillium; Genentech/Roche; GSK; Janssen; MedImmune; Nektar
9- AbbVie ; Biogen ; BMS ; Eli Lilly ; Gilead ; Gilead Sciences, Inc. ; Roche

Umut Kalyoncu
Can Fecal Calprotectin Predict Future Development of Inflammatory Bowel Disease in Axial Spondyloarthritis Patients? - TReasure Real-Life Preliminary Data
Nothing to Disclose

Umut Kalyoncu
Can Patient-Reported Outcomes and Disease Activity Scores Predict Patient Acceptable Symptom State in Adult-Onset Still's Disease?
Nothing to Disclose

Umut Kalyoncu
Retention Rates and Response of Anti-TNF Treatments in the Enteropathic Spondylitis: HUR-BIO Real Life Results
Nothing to Disclose

Kazuro Kamada
Gadolinium-Enhanced Magnetic Resonance Imaging in Shoulders Contributes Accurate Diagnosis and Predicting Recurrence to Patients with Polymyalgia Rheumatica
Nothing to Disclose

Soumyasri Kambhatla
Emergency Department Utilization for Fibromyalgia Patients
Nothing to Disclose

Soumyasri Kambhatla
Hospitalization Trends for Bacterial Septic Arthritis in the United States from 1997 to 2014
Nothing to Disclose

Soumyasri Kambhatla
Outcomes and Risk Factors in Septic Arthritis with Underlying Rheumatic Conditions
Nothing to Disclose

Soumyasri Kambhatla
Younger Age at Presentation Is a Risk Factor for Failure to Achieve Remission in Adult Dermatomyositis
Nothing to Disclose

Mari Kamiya
Inhibition of Necroptosis Suppresses Muscle Cell Death and Inflammatory Infiltrate, and Improves Muscle Strength in Experimental Polymyositis
Nothing to Disclose

Eun Ha Kang
Helicobacter Pylori Infection Among Korean Patients with Rheumatoid Arthritis and Its Interaction with Shared Epitope
Nothing to Disclose

Ji-Hyoun Kang
Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Ji-Hyoun Kang
LDL-cholesterol as a Risk Factor of Progression to ESRD in Patients with Lupus Nephritis
Nothing to Disclose

Juyeon Kang
Radiographic Association of Hip and SI Joints in Ankylosing Spondylitis Patients
Nothing to Disclose

Sun Ah Kang
Lysosome Defects in SLE Promote the Accumulation of Nuclear Antigens on the Surface of Hematopoietic Cells
Nothing to Disclose

Meliha C Kapetanovic
Efficacy and Safety of Upadacitinib Monotherapy in MTX-naïve Patients with Early Active RA Receiving Treatment Within 3 Months of Diagnosis: A Post-hoc Analysis of the SELECT- EARLY Disclosure:
2- Pfizer
5- Abbvie

Murat Karabacak
Childhood-Onset Takayasu’s Arteritis (TAK) Is Clinically More Active, However Has Similar Cumulative Damage Compared to Adult-Onset TAK
Nothing to Disclose

Omer Karadag
Amyloidosis in Behcet’s Disease: Experience of a Vasculitis Centre at Silk Road
Nothing to Disclose

Omer Karadag
Are There Phenotypic Overlaps Between Giant Cell Arteritis Subgroups?
Nothing to Disclose

Omer Karadag
Periaortitis and Coronary Arteritis in IgG4-Related Disease: Eastern Mediterranean Experience
Nothing to Disclose

Omer Karadag
Target Organ Associations in Polyarteritis Nodosa (PAN): Results of a Worldwide Collaboration Study
Nothing to Disclose

Paras Karmacharya
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Nothing to Disclose

Marissa Karpoff
Palliative Care Curriculum in Rheumatology: Teaching Serious Illness Conversations
Nothing to Disclose

George A Karpouzas
Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
Disclosure:
2- Pfizer; pfizer
5- Sanofi
8- Bristol Meyer Squibb; bristol Meyer Squibb; Bristol-Meyer-Squibb; Sanofi
9- Pfizer

Anita Kass
Efficacy and Safety of Gonadotropin-Releasing Hormone Antagonism in Severe Biologic Refractory Rheumatoid Arthritis
Disclosure:
1- Kaass Discovery

Mamatha Katikaneni
BK Polyomavirus Viremia and Viruria in Patients with Autoimmune Connective Tissue Diseases: Impact of Immunosuppressants
Nothing to Disclose

Hiroshi Kato
IL-21-mediated Suppression of STAT5 Phosphorylation Underlies Treg Depletion and Dysfunction in SLE
Nothing to Disclose

Takayuki Katsuyama
Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
Nothing to Disclose

Takayuki Katsuyama
Serine Arginine-Rich Splicing Factor 1 (SRSF1) Restrains IFN-γ and IL-17 Inflammatory Cytokine Production and Its Selective Deficiency in T Cells Exacerbates Experimental Autoimmune Encephalomyelitis (EAE) and Nephrotoxic Nephritis (NTN)
Nothing to Disclose

Alexis Katz
Frequency of Concomitant Non-aminoacyltransfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome
Nothing to Disclose

Patricia Katz
Self-Reported Sleep Disturbances in Rheumatoid Arthritis (RA)
Nothing to Disclose

Robert Katz
Comparing Patients with Fibromyalgia Syndrome with Non-Fibromyalgia Rheumatic Disease Patients Regarding Exercise
Nothing to Disclose

Robert Katz
Concomitant Fibromyalgia in Patients with Other Rheumatic Diseases and Response to Treatment
Nothing to Disclose

Robert Katz
The Effectiveness of Medications for Fibromyalgia Based on Patient Experiences
Nothing to Disclose

Robert Katz
The SELENA SLEDAI Is an Imperfect Measure of Lupus Disease Activity in Patients with Concomitant Fibromyalgia
Nothing to Disclose

Robert Katz
Whom Do Patients with Fibromyalgia Turn to for Emotional Support?
Nothing to Disclose

Warren A Katz
Osteoarthritis: What’s in a Name?
Nothing to Disclose

Alexandra Katz Small
Determination of Muscle Pressure in Patients with Fibromyalgia by Two Examiners; The Examiners Get Similar Results
Nothing to Disclose

Alexandra Katz Small
Muscle Pressure as Measured by a Manometer Correlates with Dolorimetry in Patients with Fibromyalgia
Nothing to Disclose

Alexandra Katz Small
Muscle Pressure Correlates with Pain Levels in Fibromyalgia Patients and Muscle Tension May Be the Cause of Their Pain
Nothing to Disclose

Alexandra Katz Small
Repeat Muscle Pressures Measured in Fibromyalgia Patients and Compared with Pain Scores
Nothing to Disclose

Arthur Kavanaugh
Resolution of Enthesitis and Dactylitis Is Maintained over Two Years of Ixekizumab Treatment in Patients with Psoriatic Arthritis
Disclosure:
2- Abbott; Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB; Amgen; Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen; Janssen Research & Development, LLC; Novartis; Pfizer; Pfizer Inc; Roche; UCB Pharma
5- Eli Lilly; Eli Lilly and Company; Novartis

Arthur Kavanaugh
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Disclosure:
2- Abbott; Abbott, Amgen, AstraZeneca, BMS, Celgene Corporation, Centocor-Janssen, Pfizer, Roche, UCB; Amgen; Bristol-Myers Squibb; Gilead Sciences, Inc.; Janssen; Janssen Research & Development, LLC; Novartis; Pfizer; Pfizer Inc; Roche; UCB Pharma
5- Eli Lilly; Eli Lilly and Company; Novartis

Satoshi Kawaai
Comparison of Mizoribine with Azathioprine in Efficacy and Safety for ANCA-Associated Vasculitis
Nothing to Disclose

Kyoko Kawahara
The Role of Adopter Protein SH3BP2 in a Murine Systemic Lupus Erythematosus Model
Disclosure:
2- Chugai Pharmaceutical Co., Ltd.; Glaxo Smith Kline K.K.

Vivian Kawai
Pleiotropy of Genetic Predisposition to Rheumatoid Arthritis Increases the Risk for Autoimmune Disease
Nothing to Disclose

Vivian Kawai
Pleiotropy of Systemic Lupus Erythematosus (SLE) Risk Alleles: Association with Increased Risk for Type 1 Diabetes (T1D) Complications Through a PTPN22 Polymorphism
Nothing to Disclose

Shotaro Kawano
Tumor Necrosis Factor Receptor 2 Signaling Potentiates Proliferation and Suppressive Activities of Follicular Regulatory T Cells
Nothing to Disclose

Aya Kawasaki
Association of TERT and DSP Polymorphisms with Susceptibility to Myeloperoxidase-ANCA-Associated Vasculitis
Nothing to Disclose

Aya Kawasaki
Association of Functional (GA)n Microsatellite Polymorphism in the FLI1 Gene with Susceptibility to Human Systemic Sclerosis
Nothing to Disclose

Aniket A Kawatkar
Evaluation of Rheumatoid Arthritis Patients’ Preferences Using Discrete Choice Experiment Disclosure:
2- Medac Pharma, Inc.; Bristol-Myers Squibb; Shire; Novartis

Sema Kaymaz-Tahra
Damage in Takayasu’s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up
Nothing to Disclose

Sema Kaymaz-Tahra
Involvement of Iliofemoral and Axillary Arteries in PET-CT May Be Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis
Nothing to Disclose

Joanna Kedra
The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations
Nothing to Disclose

Melinda Kedves
Epidemiology and Mortality of SLE (Systemic Lupus Erythematosus) in Hungary Based on a Nationwide Retrospective Claims Database Study
Nothing to Disclose

Marcel Keller
In Vitro Characterization of the Effect of Cenerimod, a Potent and Selective Sphingosine 1-Phosphate Receptor 1 (S1P1) Modulator, on S1P1 Receptor Expression, Receptor Internalization, and Migration of Primary Human T Cells in the Presence or Absence of G Disclosure:
1- Idorsia Pharmaceuticals Ltd
3- Idorsia Pharmaceuticals Ltd
4- Idorsia Pharmaceuticals Ltd

Herbert L Kellner
In the Real World Clinical Setting Etanercept Biosimilar SB4(BENEPAIL®) Demonstrates Equivalent Safety and Effectiveness in Biological Naïve as Well as with ENBREL® Pretreated RA,SPA, and PSA Patients Disclosure:
5- Roche

H. Mark Kenney
Lineage Tracing of Murine Lymphatic Smooth Muscle Cells to Determine the Role of the Lymphatic System in Inflammatory Arthritis
Nothing to Disclose

Tanaz A Kermani
Accuracy of Self-Reported Diagnosis of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Nothing to Disclose

Andreas Kerschbaumer
Efficacy and Safety of Disease-Modifying Drugs in Psoriatic Arthritis (PsA): A Systematic Literature Review
Disclosure: 8- BMS; Pfizer; Celgene; MSD
Andreas Kerschbaumer
Efficacy of Pharmacological Treatment in Rheumatoid Arthritis: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Disclosure: 8- BMS; Pfizer; Celgene; MSD

Sandra Keyes
A Randomised Controlled Clinical Trial Comparing the Effectiveness of 6 and 12 Weeks of a Shoulder Specific Exercise Programme for Patients with Rotator Cuff Related Shoulder Pain
Nothing to Disclose
Edward Keystone
A Pilot Phase 1, Randomized, Double-blind, Two-arm, Parallel Group, Single-dose Study to Evaluate the Safety and Pharmacokinetics of CT-P17 and Humira in Healthy Male Subjects
Disclosure: 2- Abbvie; Amgen; Gilead Sciences; Lilly Pharmaceuticals; Merck; Pfizer Pharmaceuticals; PuraPharm; Sanofi; AstraZeneca Pharma
5- Abbvie; Amgen; Gilead Sciences; Lilly Pharmaceuticals; Merck; Pfizer Pharmaceuticals; Sanofi; Bristol-Myers Squibb Company; Celltrion; Crescendo Bioscience; F. Hoffmann-La Roche Inc; Genentech Inc; Janssen Inc; Sandoz; Samsung Bioepis
8- Abbvie; Amgen; Merck; Pfizer Pharmaceuticals; Sanofi; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Inc; Janssen Inc; UCB

Edward C Keystone
Disease Activity Measures at Baseline and 3 Months as Predictors of Rapid Radiographic Progression in Methotrexate Naive Patients with Early Rheumatoid Arthritis
Disclosure:
2- Abbvie; Amgen; BMS; F. Hoffmann-La Roche Inc; Gilead; Janssen; Lilly; Pfizer; Pfizer Pharmaceuticals; Roche; Sanofi; Sanofi-Aventis
5- Abbvie; Amgen; AstraZeneca; Astra-Zeneca; Biotest; BMS; Celltrion; Crescendo; Crescendo Bioscience; F. Hoffmann-La Roche Inc; Genentech; Genentech Inc.; Genzyme; Gilead; Gilead Sciences, Inc.; Janssen; Lilly; Merck; Pfizer; Pfizer Pharmaceuticals; Roche; Sandoz; Sanofi; UCB
8- Abbvie; Amgen; BMS; F. Hoffmann-La Roche Inc; Janssen; Lilly; Merck; Pfizer; Pfizer Pharmaceuticals; Roche; Sanofi; Sanofi-Aventis; UCB

Dinesh Khanna
Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial
Disclosure:
1- Eicos Sciences, Inc/ CiviBioPharma, Inc; Eicos Sciences, Inc/ CiviBioPharma, Inc.
2- Bayer; BMS; Bristol Myers Squibb; Bristol-Myers Squibb; Horizon; NIH K24 and R01; NIH / NIAMS K24 AR-063120; NIH/NIAMS R01& K24; Pfizer
3- CiviBioPharma, Inc.
4- Eicos; Eicos Sciences; Eicos Sciences, Inc; Eicos Sciences, Inc/ CiviBioPharma, Inc; Eicos, Inc; Eicos, INC.
5- Acceleron; Acceleron Pharma; Actelion; Actelion Pharmaceuticals; Astra Zeneca; Bayer; Behring; Blade; Blade Therapeutics; Blade therapeutics; BMS; Boehhringer Ingelham; Boehhringer Ingelheim; Boehhringer-Ingehelm; Bristol Myers Squibb; Bristol-Myers Squibb; Celgene; Celgene; ChemomAB; ChemomAb; Corbus; Corobus; Corpus; CSL Behring; Curizon; Curzion; Cytori; Eicos, Inc.; Galapagos; Genentech; Genentech/Roche; GlaxoSmithKline; GSK; Horizon; Mitsubishi Tanabe Pharma; Mitsubishi Tanabe Pharma Dev America; Mitsubishi Tanabe Pharma Development America; Mitsubishi Tanabe;
Pfizer; Sanofi; Sanofi Aventis; Sanofi-Aventis; Sanofi-Aventis/Genzyme; UCB; UCB Pharma; Acceleron; Actelion; Bayer; Blade Therapeutics; BMS; Boehringer Ingelheim; Celgene; CSL Behring; Cytori; Eicos, Inc.; Sanofi-Aventis

So Young Ki
Identification of CJ-15314, a Novel Highly Selective JAK1 Inhibitor, for the Treatment of Rheumatoid Arthritis
Nothing to Disclose

Genki Kidoguchi
Prevalence of Thyroid Dysfunction with Therapeutic Indication in Patients with Rheumatological Diseases
Nothing to Disclose

Patrick D Kiely
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Nothing to Disclose

Hirotoshi Kikuchi
The Long-term Outcome of Patients with Arthritis of Behçet’s Disease
Nothing to Disclose

Jun Kikuchi
Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Disclosure: 2- Mitsubishi Tanabe Pharma Corporation
Sohyaku

Erkan Kilic
Regional Difference in Disease Burden Among Patients with Psoriatic Arthritis: A Multi-Center Study
Nothing to Disclose

Uta Kiltz
Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)
Disclosure: 2- AbbVie; ABBVIE, NOVARTIS, PFIZER, BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY, BIOCAD, GRUNENTHAL, UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB

Uta Kiltz
Development of a Set of ASAS Quality Standards for Adults with Axial Spondyloarthritis
Disclosure: 2- AbbVie; ABBVIE, NOVARTIS, PFIZER, BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY, BIOCAD, GRUNENTHAL, UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB

Uta Kiltz
Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort
Disclosure: 2- AbbVie; ABBVIE, NOVARTIS, PFIZER, BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY, BIOCAD, GRUNENTHAL, UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB
Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Disclosure:
2- AbbVie; ABBVIE, NOVARTIS, PFIZER,BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Jasnsssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Jasnsssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB

Uta Kiltz
Non-medical Switching from Reference to Biosimilar Etanercept - No Evidence for Nocebo Effect – a Retrospective Analysis of Real-life Data Disclosure:
2- AbbVie; ABBVIE, NOVARTIS, PFIZER,BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Jasnsssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Jasnsssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB

Alfred H Kim
Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus Disclosure:
2- GlaxoSmithKline; Kypha, Inc; Kypha, Inc. 5- Exagen Diagnostics, Inc.; Exagen Diagnostics, Inc.; GlaxoSmithKline 8- Exagen Diagnostics, Inc.; Exagen Diagnostics, Inc.; GlaxoSmithKline

Gunwoo Kim
Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome Nothing to Disclose

Hanna Kim
Preliminary Response to Janus Kinase (JAK) Inhibition with Baricitinib in Refractory Juvenile Dermatomyositis Disclosure:
2- Cure JM Foundation

Hyun Kim
Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review Nothing to Disclose

Hyoun-Ah Kim
Drug Survival and Safety of Biosimilar CT-P13 versus Reference Infliximab in Patients with Ankylosing Spondylitis: Data from the Korean College of Rheumatology Biologics Registry Nothing to Disclose

Jeong Yeon Kim
Mitochondrial Transplantation Suppressed Muscle Inflammation and Improved the Mitochondrial Dysfunction in C Protein-induced Myositis Model Nothing to Disclose

Ji-Soong Kim
Clinical and Genetic Factors Associated with Thrombosis or Pregnancy Morbidity of Antiphospholipid Antibody-Positive Systemic Lupus Erythematosus Patients Nothing to Disclose

Ji-Won Kim
Angiogenic Factors for Assessing Rheumatoid Arthritis in the Era of Sonographic Diagnosis and Biologic Therapy Nothing to Disclose

Ji-Won Kim
Circulating CCR7loPD-1hi Follicular Helper T Cells Indicate Disease Activity and Glandular
Inflammation in Patients with Primary Sjögren’s Syndrome
Nothing to Disclose

Mimi Kim
Identifying Subgroups of SLE Patients with Differential Responses to a BLYs Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Disclosure: 5- Celgene

Min Jung Kim
Clinical Biomarkers at Renal Flare Are Associated with Histologic Changes in Repeat Renal Biopsy in Patients with Biopsy-proven Lupus Nephritis
Nothing to Disclose

Min Jung Kim
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Nothing to Disclose

Ra Ham Kim
Bromodomain Inhibitor, I-BET762 Inhibits Production of Pro-inflammatory in Rheumatoid Arthritis Fibroblast-like Synoviocytes and Differentiation of Osteoclast
Nothing to Disclose

Sang T Kim
Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy
Nothing to Disclose

Seon Uk Kim
Anti-inflammatory Effect of Novel Spleen Tyrosine Kinase Inhibitor, SKI-O-592, on Fibroblast-like Synoviocyte in Rheumatoid Arthritis and THP-1 Cell
Nothing to Disclose

Seoyoung C. Kim

No Increased Risk of Incidence Diabetes in Patients with Rheumatoid Arthritis Compared to Patients Without RA
 Disclosure:
2- AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics; Roche; Roche/Genentech

TAE-JONG KIM
Memory ex-Th17 Cells Contribute to Synovial Inflammation in Spondyloarthritis
Nothing to Disclose

Andrew J Kinloch
A Novel Image Analysis Program, “CytoSkaler”, Demonstrates That Anti-Vimentin Antibody Affinity Maturation in Lupus Tubulointerstitial Nephritis Also Results in More Selective Antigen Targeting
Nothing to Disclose

Thomas Kirchgesner
Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis
Nothing to Disclose

Bruce Kirkham
Effect of Baricitinib on Functional Impairment in RA Patients with Moderate Disease Activity and an Inadequate Response to Conventional DMARDs
Disclosure:
2- AbbVie; Eli Lilly and Company; Novartis
8- AbbVie; Eli Lilly and Company; Gilead; Janssen; Novartis; Pfizer

Daiga Kishimoto
MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27
Nothing to Disclose

Yogan Kisten
Fluorescence Optical Imaging in the Diagnosis of Individuals Suspected of Arthritis Development – a Probabilistic Approach
Nothing to Disclose

Alan J Kivitz
Efficacy of Secukinumab in a US Patient Population with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies
Disclosure:
4- Amgen; Gilead; Pfizer Inc; Sanofi; GSK
5- AbbVie; Boehringer Ingelheim; Genzyme; Janssen; Pfizer Inc; Regeneron; Sanofi; Sun Pharma; UCB
8- AbbVie; Celgene; Flexion; Genzyme; Horizon; Merck; Novartis; Pfizer Inc; Regeneron; Sanofi

Juliette Kleinman
A Pilot Study of the Psychosocial Impact of Undifferentiated Connective Tissue Disease
Nothing to Disclose

Viola Kluck
Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Nothing to Disclose

Rachel Kneeland
Fragility Fractures in a Community Setting: Clinical Characteristics, Care Gaps, and Outcomes
Nothing to Disclose

Rachel Kneeland
Pachymeningitis in Rheumatic Disease
Nothing to Disclose

Johannes Knitza
Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS)
Nothing to Disclose

Johannes Knitza
The Urge for Mobile Apps in Rheumatology – a German Patient Perspective
Nothing to Disclose

Kyung Min Ko
Contribution of Personality Traits, Psychological Factors and Health Related Quality of Life on Medication Adherence in Patients with RA
Nothing to Disclose

Daisuke Kobayashi
Joint Overuse in Patients with Rheumatoid Arthritis
Nothing to Disclose

Daisuke Kobayashi
Risk Factors for Cytomegalovirus Infection in Patients with Autoimmune Diseases
Nothing to Disclose

Hitomi Kobayashi
Prediction of Myocardial Fibrosis in Rheumatoid Arthritis Assessed by Cardiac Magnetic Resonance Imaging Using Artificial Neural Networks Models
Nothing to Disclose

Masanari Kodera
The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy
Nothing to Disclose

Michaela Koehm
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment Disclosure:
2- Pfizer; Janssen; BMS
8- Pfizer; Celgene

Taylor Koenig
RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets
Nothing to Disclose

Tomohiro Koga
Inhibition of Calcium/calmodulin-dependent Protein Kinase IV in Rheumatoid Arthritis: Dual Effect on Th17 Cell Activation and Osteoclastogenesis

Nothing to Disclose

Toshihisa Kojima
Discontinuation of Concomitant Methotrexate in Japanese Patients with Rheumatoid Arthritis Treated with Tocilizumab: An Interventional Study
Disclosure:
2- AbbVie; Astellas; Bristol-Myers Squibb; Chugai; Chugai Pharmaceutical CO., LTD.; Daiichi-Sankyo; Eli Lilly; Janssen; Lilly; Mitsubishi Tanabe; Novartis; Pfizer; Takeda
8- AbbVie; Abbvie; Astellas; Bristol-Myers Squibb; Chugai; Chugai Pharmaceutical; Chugai Pharmaceutical CO., LTD.; Daiichi-Sankyo; Eli Lilly; Janssen; Janssen Pharmaceutical; Lilly; Mitsubishi Tanabe; Novartis; Pfizer; Takeda; Tanabe Mitsubishi Pharma

Toshihisa Kojima
Improving Depression by Joint Surgery in Established Rheumatoid Arthritis; Results from Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Patient’s Reported Outcome
Disclosure:
2- AbbVie; Astellas; Bristol-Myers Squibb; Chugai; Chugai Pharmaceutical; Chugai Pharmaceutical CO., LTD.; Daiichi-Sankyo; Eli Lilly; Janssen; Lilly; Mitsubishi Tanabe; Novartis; Pfizer; Takeda
8- AbbVie; Abbvie; Astellas; Bristol-Myers Squibb; Chugai; Chugai Pharmaceutical; Chugai Pharmaceutical CO., LTD.; Daiichi-Sankyo; Eli Lilly; Janssen; Janssen Pharmaceutical; Lilly; Mitsubishi Tanabe; Novartis; Pfizer; Takeda; Tanabe Mitsubishi Pharma

Weiping Kong
Identification of Potential Risk Factors for Spinal Structural Damage in Chinese Patients with Ankylosing Spondylitis
Nothing to Disclose

Xiufang Kong
Dynamic Distribution and Phenotype Shift from M1 to M2 of Macrophages in Vascular Lesions of Naive and Treated Patients with Takayasu Arteritis
Nothing to Disclose

Bon San Koo
Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
Nothing to Disclose

Jacek A Kopec
Impact of Hypothetical Changes in the Use of Analgesics on the Burden of Osteoarthritis: A Population-based Microsimulation Study
Nothing to Disclose

Jacek A Kopec
Trends in Prescribing of NSAIDs and Opioids Among Osteoarthritis Patients in British Columbia, Canada, 1998-2014
Nothing to Disclose

Sahil Koppikar
Incidence and Predictors of Heart Failure in Patients with Psoriatic Disease – a Cohort Study
Nothing to Disclose

Benjamin D Korman
Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis
Nothing to Disclose

Ruriko Koto
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Disclosure:
3- Teijin Pharma Limited

Yoshinobu Koyama
Skin Lesions as a Side Effect of anti-IL6 Therapy: Transcriptome Analysis of Peripheral Blood Shows a Risk of Paradoxical Neutrophil Activation and Exacerbation of Skin Ulcer Disclosure:
8- Ayumi; BMS; Chugai; Asahi-Kasei; Lilly; Tanabe-Mitsubishi

Klaus Krüger
‘BENEFIT’ Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story Disclosure:
5- AbbVie; Biogen; BMS; Celgene; Hexal; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis; UCB
8- AbbVie; Biogen; BMS; Celgene; Celgene; Hexal; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; UCB

Klaus Krüger
Golimumab Improves Work Productivity and Activity and Quality of Life in Patients with Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA): Final Results from a Non-Interventional Study in Germany (GO-ART) Disclosure:
5- AbbVie; Biogen; BMS; Celgene; Hexal; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; Sanofi-Aventis; UCB
8- AbbVie; Biogen; BMS; Celgene; Celgene; Hexal; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi; UCB

Megan L Krause
Pattern of Arthropathy in Patients with Cystic Fibrosis Nothing to Disclose

Joel M Kremer
A Comparison of Upadacitinib Plus Methotrexate and Upadacitinib Plus Other CsDMARDs in Patients with Rheumatoid Arthritis: An Analysis of Two Phase 3 Studies Disclosure:
1- Corrona
2- AbbVie; Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
5- AbbVie; Amgen; Bristol-Myers Squibb; Genentech; Gilead; Lilly; Pfizer; Regeneron; Sanofi

Joel M Kremer
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five-Year Results from a US-based Rheumatoid Arthritis Registry Disclosure:
1- Corrona
2- AbbVie; Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
5- AbbVie; Amgen; Bristol-Myers Squibb; Genentech; Gilead; Lilly; Pfizer; Regeneron; Sanofi

Akilan Krishnamurthy
Anti-citrullinated Protein Antibodies Induce Subclinical Inflammation, Bone Loss and Pain in Mice Nothing to Disclose

Monika Krošel
Individual Functions of Histone-acetyltransferases CBP and p300 in Regulating Autophagy and Proteasomal Degradation in Synovial Fibroblasts Nothing to Disclose

Olga Kubassova
Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis Disclosure:
1- Image Analysis Group
3- Image Analysis Group
4- Image Analysis Group
Katerina Kubinova  
Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study  
Nothing to Disclose  

Jasmin B. Kuemmerle-Deschner  
Tocilizumab - An Effective Rescue Therapy for Refractory Unclassified Autoinflammatory Diseases in Children  
Disclosure:  
2- Novartis; SOBI  
5- Novartis; SOBI  
8- Novartis; SOBI  

Taiga Kuga  
Prevalence of Malignancy in Myositis Patients with Anti-aminocyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review  
Nothing to Disclose  

Kensuke Kume  —  
TNF Inhibitors Improves Arterial Stiffness with Cs DMARDs-resistant Active Psoriatic Arthritis: A Cohort Extended Study  
Nothing to Disclose  

Yosuke Kunishita  
Dysfunction of TRIM21 Promotes Aberrant Plasmablast Differentiation in Systemic Lupus Erythematosus Due to the Reduction of TRIM21-mediated Ubiquitylation of IRF5  
Nothing to Disclose  

Masataka Kuwana  
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial  
Disclosure:  
2- Abbvie; Actelion; Actelion Pharmaceuticals; Astellas; Chugai; Eisai; Eli Lilly; Ono; Pfizer; Tanabe-Mitsubishi  
5- Bayer; Boehringer Ingelheim; Boehringer-Ingelheim; Chugai; Corbus; CSL Behring; CSL Berling; Reata  

7- MBL  
8- Abbvie; Actelion; Actelion Pharmaceuticals; Astellas; Chugai; Eisai; Janssen; Japan Blood Products Organization; MBL; Ono; Tanabe-Mitsubishi  

Ai Kuzumi  
Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody  
Nothing to Disclose  

C. Kent Kwoh  
MRI-detected Abnormalities in Prediction Models of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up  
Disclosure:  
5- Express Scripts; GSK; Kolon Tissue Gene; MerckSerono; Regeneron; Regulus; Taiwan Liposome Company; Thusane  

C. Kent Kwoh  
Rates of Incident Radiographic Knee Osteoarthritis and Knee Replacement by Sex and Race, Across Three Large, Diverse Cohorts  
Disclosure:  
5- Express Scripts; GSK; Kolon Tissue Gene; MerckSerono; Regeneron; Regulus; Taiwan Liposome Company; Thusane  

Timothy S Kwok  
Bone Mineral Density in Psoriatic Arthritis: Results from a Longitudinal Study  
Nothing to Disclose  

Sooyeon Kwon  
Patient Perception of Benefit and Risks Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus (SLE)  
Nothing to Disclose  

Brian B Løgstrup  
Is Cardiovascular Risk and Mortality in Rheumatoid Arthritis Compared to Diabetes Mellitus and the General Population Overestimated?  
Nothing to Disclose
Clementina López-Medina
Baseline Characteristics and Natural History of Radiographic versus Non-radiographic Axial Spondyloarthritis: 5 Years Follow-up of the Desir Cohort
Nothing to Disclose

Linda Laaouad
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Nothing to Disclose

Adam Labonte
Analysis of Lupus Nephritis Gene Expression Reveals Dysregulation of Pathogenic Pathways Activated Within Infiltrating Cells
Nothing to Disclose

María Lourdes Ladehesa-Pineda
Association Between Radiographic Progression and Cardiovascular Risk in Spondyloarthritis: Data from CoSpaR REGISTRY
Nothing to Disclose

Chien-Chih Lai
Bronchoalveolar Lavage Fluid Analysis and Mortality Risk in Systemic Lupus Erythematosus Patients with Pneumonia and Respiratory Failure
Nothing to Disclose

Lindsay S Lally
Cell-free Mitochondrial DNA Levels in Granulomatosis with Polyangiitis
Nothing to Disclose

Wietse Lambers
Myxovirus Resistance Protein a Is a Useful Additional Histological Marker for Cutaneous Lupus Erythematosus
Nothing to Disclose

Brian LaMoreaux
Incident Gout After Renal Transplantation in Gout-naive Patients: Large Database Analysis Disclosure:
3- Horizon
4- Horizon

Ana Lamuedra
Disorganization of Chondrocyte Columns in the Growth Plate During Experimental Osteoarthritis in Mice
Nothing to Disclose

Ana Lamuedra
What Is the Pathogenic Meaning of Chondrocyte Hypertrophy in Osteoarthritis? Effect of Evc Deletion Through Hedgehog Signaling
Nothing to Disclose

Océane Landon-Cardinal
Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy
Nothing to Disclose

Océane Landon-Cardinal
JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis
Nothing to Disclose

Océane Landon-Cardinal
Single-specificity Anti-SMN Autoantibodies Are Associated with a Novel Scleromyositis Overlap Syndrome
Nothing to Disclose

Nancy E Lane
Abaloparatide Followed by Alendronate on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis Disclosure:
5- Amgen Inc.; GSK
8- Amgen Inc.; Radius Health, Inc.

Teresina Laragione
Fecal Transfer from Mice on High or Low Magnesium Diets Confers Arthritis Protection
Teresina Laragione
Validation of New Genes Identified in a Molecular Bayesian Network of Rheumatoid Arthritis Synovitis
Nothing to Disclose

Ane Larrañaga-Vera
Alendronate-CGS21680 Conjugates Prevent Bone Erosion in a Murine Osteolysis Model but Not in A2A KO Mice
Nothing to Disclose

Ane Larrañaga-Vera
Pannexin-1 KO Mice Are Unresponsive to Tenofovir Induced Bone Loss
Nothing to Disclose

Marissa Lassere
Australian Rheumatoid Arthritis (RA) Biologic Treatment Pathways: An Australian Rheumatology Association Database (ARAD) Analysis
Nothing to Disclose

ChiChi Lau
Thyroperoxidase Antibodies in Patients with Positive ANA
Nothing to Disclose

Kim Lauper
Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
Disclosure:
2- AbbVie
8- AbbVie
9- Pfizer

Able Lawrence
Major Histocompatibility Antigen HLA-DQB1*0601 Is Associated with Rheumatoid Arthritis Among Indians in a Replication Study: Evidence of Gene-Environment Interaction with LPG Stove Use

Benoit Le Goff
Factors Associated with the Disappearance of Calcifications Following Ultrasound Guided Percutaneous Lavage of Rotator Cuff Calcific Tendinopathy: A Post Hoc Analysis of a Randomized Controlled Trial
Nothing to Disclose

Nicholas Lebedoff
Enhancing Medicine Trainees’ Exposure to Gout Diagnosis and Management Through an Interprofessional Approach in the Primary Care Setting
Nothing to Disclose

Nicholas Lebedoff
Impact of Hospital Admissions on Adherence to Allopurinol Therapy After Discharge
Nothing to Disclose

Chan Mi Lee
Identifying Patterns of Histopathologic Presentation in CNS Vasculitis
Nothing to Disclose

Dylan Lee
Elevated Serum Levels of Tie-1 in Patients with Rheumatoid Arthritis
Nothing to Disclose

Eunyoung E Lee
Cancer Risk in Patients with Ankylosing Spondylitis: A Nationwide Population-based Dynamic Cohort Study from Korea
Nothing to Disclose

Eunyoung E Lee
Performance of the Proposed American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Lupus Erythematosus in Korean Patients
Nothing to Disclose

Ha-Reum Lee
NADPH Oxidase 4 Regulates the Migration and Invasion of Synoviocytes in Rheumatoid
Arthritis Through Pro-angiogenic Factor Secretion
Nothing to Disclose

Iris Lee
SLE Disease Activity May Be Associated with Choroidal Thickness
Nothing to Disclose

Jeong Seok Lee
Allograft Inflammatory factor-1 Drives Th17 Like Pathologic Signature and Predict Poor Response to TNF Inhibitor in Ankylosing Spondylitis
Nothing to Disclose

Jeong Seok Lee
Association of Serum KL-6 Level and Change of Pulmonary Function in Interstitial Lung Disease of Rheumatoid Arthritis - Data from Prospective KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) Study
Nothing to Disclose

Jimin Lee
Evaluating an Illustrated Storybook for Children with Juvenile Idiopathic Arthritis
Nothing to Disclose

Jisoo Lee
Burden of Systemic Lupus Erythematosus Among Korean Women in Childbearing Years Based on the National Health Insurance Service Data
Nothing to Disclose

Julie Lee
Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy
Disclosure:
1- Pfizer Inc
3- Pfizer Inc

Sang-il Lee
RKIP, as an Upstream Regulator of Intracellular Signaling, Exerts Anti-arthritic Effect in Fibroblast-like Synoviocyte and Collagen-induced Arthritis
Nothing to Disclose

Seulkee Lee
Association Between Anemia and Hyperuricemia: Korean National Health and Nutrition Survey 2016-2017
Nothing to Disclose

So-Yun Lee
The Correlation of Bone Bridge and Low Bone Mineral Density Measured by Quantitative Computed Tomography in Patients with Ankylosing Spondylitis
Nothing to Disclose

Wen Shi Lee
Autophagy Receptor Optineurin in Synovial Fibroblasts Plays a Protective Role Against Joint Destruction in Rheumatoid Arthritis
Nothing to Disclose

Yvonne Lee
Cardiac Sarcoidosis Awareness: Are We Underdiagnosing?
Nothing to Disclose

Adam Lefferts
Expansion of Peripheral Cytotoxic T Cells in Co-morbid Inflammatory Bowel Disease and Spondyloarthritis
Nothing to Disclose

Micah Lefton
Ankylosing Spondylitis-associated Killer Immunoglobulin-like Receptors Are Strongly Expressed on γδ T Cells
Nothing to Disclose

Alexandra Legge
Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index
Nothing to Disclose

Mara Lennard Richard
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Nothing to Disclose

Jean-Guillaume Letarouilly
Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients
Nothing to Disclose

David Leverenz
A Quality Improvement Project to Increase Documentation Efficiency in an Academic Rheumatology Practice
Nothing to Disclose

David Leverenz
The Impact of Spaced Education and Reciprocal Peer Teaching on Rheumatology Fellows’ Long-term Recall from Core Curriculum
Nothing to Disclose

Dana Levit
Evaluating Fibromyalgia Symptoms in Transgender Patients
Nothing to Disclose

Laura B Lewandowski
Determining a Polygenic Risk Score in Pediatric Systemic Lupus Erythematosus
Nothing to Disclose

Chen Li
Quality of Life in Patients with SAPHO Syndrome: A Single-center Survey of 588 Patients
Nothing to Disclose

Edward Li
Long-term Financial Impact of Switching from Reference to Biosimilar Etanercept When Considering Short-term Formulary Management Costs in the US Disclosure:
3- Sandoz

Fen Li

Protein Biomarkers Predicting the Response to IFX+MTX+LEF Treatment in Patients with Rheumatoid Arthritis
Nothing to Disclose

Jessica Li
Frequency and Early Prediction of Hydroxychloroquine Induced Retinopathy in SLE
Nothing to Disclose

Jing Li
Association Between Acute-phase Reactants, interleukin-6(IL6), Tumor Necrosis Factor-alpha(TNFa) and Disease Activity in Takayasu’s Arteritis During Follow-up with Repeated Evaluation of Vascular Imaging Manifestations
Nothing to Disclose

Justin W Li
Assessing the Relationship Between Gout and Return to Hemodialysis Among U.S. Renal Transplant Patients Disclosure:
2- Horizon Pharma

Linda C Li
Efficacy of a Counselling Program to Promote Physical Activity in People with Inflammatory Arthritis
Nothing to Disclose

Lingyi Li
Trends in NSAIDs and Opioids Among Patients with SLE: A Population-based Study
Nothing to Disclose

xiaodi li
A New Risk Factor for Predicting the Long-term Outcome of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Pulmonary Artery Size Measured by Chest Computed Tomography
Nothing to Disclose

Xiaojuan Li
Multi-vendor Multi-site T1ρ and T2 Quantification of Knee Cartilage
Nothing to Disclose
Yi Li
Identification of IL-17+ and IL-10+ TCRαβ+ CD4-CD8- Double Negative (DN) T Cell Subsets in Lupus-prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Nothing to Disclose

Yueting Li
Mandibular Involvement in SAPHO Syndrome: A Single-center Retrospective Study of 26 Patients
Nothing to Disclose

Kimberly P Liang
Toward Cardiovascular Risk Stratification in Rheumatoid Arthritis: Use of Regression Tree Analyses to Evaluate Impact of Serum Biomarkers and Cardiovascular Risk Factors on Carotid Intima Media Thickness
Nothing to Disclose

Katherine Liao
The Association Between Disease Activity with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Nothing to Disclose

Sarah B Lieber
Frailty and Sarcopenia in Women with Systemic Lupus Erythematosus
Nothing to Disclose

Sarah B Lieber
Frailty in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis: Data from a National Claims Database
Nothing to Disclose

Sarah B Lieber
Frailty in Systemic Rheumatic Diseases: A Systematic Review
Nothing to Disclose

David F Liew
Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers
Nothing to Disclose

David F Liew
Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline
Nothing to Disclose

Jean W Liew
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Nothing to Disclose

Doo-Ho Lim
Serum Uric Acid Level and Subclinical Coronary Atherosclerosis in Asymptomatic Individuals: An Observational Cohort Study
Nothing to Disclose

Khin Lim
Correlation of Ultrasound Guided Synovial Biopsies and Surgical Synovial Biopsies in Patients with Inflammatory Arthritis
Nothing to Disclose

Khin Lim
Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis
Nothing to Disclose

Lily SH Lim
Longitudinal Work Transitions in Early Inflammatory Arthritis Patients: Are There Targets for Intervention to Improve Employment?
Nothing to Disclose

Tricia Lim
Profibrotic Macrophage Activation in Systemic Sclerosis Is Dependent on the Mechanosensing MRTF-A Pathway
Nothing to Disclose
Kaitlin Lima
Factors Associated with Participation in Rheumatic Disease-Related Research Among Underrepresented Populations: A Systematic Review
Nothing to Disclose

Yanwei Lin
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-Ranging Study to Evaluate Efficacy and Tolerability of SHR4640 in Patients with Hyperuricemia
Nothing to Disclose

Lisa Lindsay
Serious Infection in Patients with Systemic Lupus Erythematosus, Lupus Nephritis and Rheumatoid Arthritis Compared to the General Population: Incidence Rates Using Real-World Claims Data
Disclosure:
3- Genentech, Inc.
4- Genentech, Inc.

Ross Lindsay
CD123+ Plasmacytoid Dendritic Cells from Systemic Sclerosis Patients Are Susceptible to the Cytotoxic Activity of Tagraxofusp, a CD123-Targeted Therapy
Disclosure:
1- Stemline Therapeutics
3- Stemline Therapeutics

Prasanth Lingamaneni
Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis
Nothing to Disclose

Matthew D Linnik
Clinical Evidence Supporting Therapeutic Potential of Activating the Immune Checkpoint Receptor BTLA in SLE
Disclosure:
1- Eli Lilly and Company
3- Eli Lilly and Company
4- Eli Lilly and Company

Eric Liu
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Nothing to Disclose

Hang Liu
Disease Severity Is Linked to an Increase in Autoantibody Diversity in IgG4-related Disease
Nothing to Disclose

Jiannong Liu
Who Prescribed Which Osteoporosis Medication to Whom
Nothing to Disclose

Tingting Liu
Anti-β2GPI Domain 1 Antibodies Stratify High Risk of Thrombosis and Pregnancy Morbidity in a Large Cohort of Chinese Patients with Antiphospholipid Syndrome
Nothing to Disclose

Wei Liu
Identification of Differentially Expressed Genes and Signaling Pathways in Systemic Lupus Erythematosus by Integrated Bioinformatics Analysis
Nothing to Disclose

Yue Liu
Increased Levels of IL-2 and IL-4 Promote Th17/Treg Immune Imbalance in Patients with Behcet's Disease
Nothing to Disclose

Luciano Fernando Lo Giudice
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Nothing to Disclose

Jesús Loarce-Martos
Clinical Manifestations and Comparison of Subtypes of Juvenile Idiopathic Inflammatory Myopathies: Data from the REMICAM Registry
Nothing to Disclose

Marieke Loef
Reference Curves for the Knee Injury and Osteoarthritis Outcome Score in the Middle-aged Dutch Population
Disclosure: 2- Innovative Medicines Initiative Joint Undertaking

Marieke Loef
The Association of Plasma Fatty Acids Levels with Hand and Knee Osteoarthritis
Disclosure: 2- Innovative Medicines Initiative Joint Undertaking

Jennifer Lofland
Real-World Evidence Associated with the Treatment of Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Disclosure: 3- Janssen Scientific Affairs, LLC

Jennifer Lofland
Systemic Lupus Erythematosus Registries: Are the Measures Captured in the Real World Similar to Those in Clinical Trials?
Disclosure: 3- Janssen Scientific Affairs, LLC

Jennifer Lofland
The Direct and Indirect Costs of Illness Associated with Systemic Lupus Erythematosus in the USA, UK, France, and Germany: A Structured Review
Disclosure: 3- Janssen Scientific Affairs, LLC

Isis Lopez
Adherence to Guideline Directed Management of Gout Among VA Providers
Nothing to Disclose

Christian Lood
A Neutrophil Signature Is Strongly Associated with Cardiovascular Risk in Gout
Nothing to Disclose

Christian Lood
A Novel Method to Analyze Circulating Immune Complexes Predicts Disease Activity and Severity in Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nothing to Disclose

Christian Lood
Complement Deposition C4d on Platelets Is Associated with Vascular Events in Systemic Lupus Erythematosus
Nothing to Disclose

Christian Lood
Neutrophil Activation Identifies Patients with Active Polyarticular Gout – a Role for Neutrophil Biomarkers in Monitoring Gout Disease Activity and Severity
Nothing to Disclose

Maria A Lopez-Olivo
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Nothing to Disclose

Maria A Lopez-Olivo
Physical Challenges in RA: A Qualitative Study of an Online Patient Support Group
Nothing to Disclose

Maria A Lopez-Olivo
Treatment Sequences, Effectiveness, and Costs of Tumor Necrosis Factor Inhibitor Cycling Compared with Swapping to a Novel Disease-
modifying Anti-rheumatic Drug in Rheumatoid Arthritis Patients
Nothing to Disclose

Chary Lopez-Pedrera
Anti-phosphatidylserine/prothrombin Antibodies Confer a Distinctive Molecular Profile in Primary Antiphospholipid Syndrome Patients
Nothing to Disclose

Chary Lopez-Pedrera
Biomarkers Identified by Serum Inflammatory Profile Analysis to Predict Biologic Treatment Response in Rheumatoid Arthritis Patients
Nothing to Disclose

Chary Lopez-Pedrera
Phenotype-based Clustering Along with Analysis of Molecular Profile Might Help to Define Precise CV-risk Profiles in RA Patients
Nothing to Disclose

Irene Lorenzo-Gomez
HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis
Nothing to Disclose

Valentina Lorenzoni
Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project
Nothing to Disclose

Elena Losina
Opioids Use Among Medicare Beneficiaries with Knee Osteoarthritis: Prevalence and Correlates of Chronic Use
Disclosure:
2- Flexion; Flexion Therapeutics; Pfizer; Pfizer Inc; Roche/Genentech; Samumed; TissueGene
5- Regeneron; Regeneron Pharmaceuticals; Velocity; Velocity Pharmaceutical Development; Velocity Pharmaceutical Development

marion louvois

Parkinson's Disease and Risk of Fractures: A Meta Analysis of Cohort Studies
Nothing to Disclose

Michael Lovy
Factors Contributing to Fracture in Pernicious Anemia Patients Presenting with Symptomatic Subacute Vertebral Compression Fractures
Nothing to Disclose

Candice Low
Comparison of Clinical Features, Synovial Histology and Immunohistochemistry in Seropositive Arthralgia, Rheumatoid Arthritis, and Osteoarthritis
Nothing to Disclose

Candice Low
Evolution of Seropositive Arthralgia over Time: Predictors of Evolution to Rheumatoid Arthritis
Nothing to Disclose

Mariana Luís
Early Retirement Attributed to Rheumatoid Arthritis and Its Predictors in Portugal
Nothing to Disclose

Charlotte Lucas
Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis
Nothing to Disclose

Rachel Lu-Do
Utilization of a Multispecialty Team for the Diagnosis of Giant Cell Arteritis Reduces Patient Morbidity
Nothing to Disclose

Geyanne Lui
Health Services Utilization as Recommended by the American Diabetes Association Among Middle-Aged Patients Disabled with Rheumatoid Arthritis and Diabetes Mellitus
Nothing to Disclose

Aurelia Luissi
Effect of Tofacitinib on the Qualitative Profile of High Density Lipoproteins Molecules in Patients with Rheumatoid Arthritis
Nothing to Disclose

Gisele Alejandra Luna
Adherence to Treatment with Intravenous Biological Agents in Patients with Rheumatoid Arthritis
Nothing to Disclose

Merete Lund Hetland
Does a Mandatory Non-medical Switch from Originator to Biosimilar Etanercept Lead to Increase in Healthcare Use and Costs? A Danish Register-based Study of 1620 Patients with Inflammatory Arthritis
Disclosure:
2- Abbvie; AbbVie; Biogen; BMS; CellTrion; MSD; Novartis; Orion; Pfizer; Samsung; UCB 9- CellTrion

Merete Lund Hetland
Hepatobiliary Events in >5000 Patients with Inflammatory Arthritis Treated with Biosimilar or Originator Etanercept in Routine Care, Results from the Danish Nationwide DANBIO Registry
Disclosure:
2- Abbvie; AbbVie; Biogen; BMS; CellTrion; MSD; Novartis; Orion; Pfizer; Samsung; UCB 9- CellTrion

Katie Lundon
Measuring Advanced/Extended Practice Roles in Arthritis and Musculoskeletal Care in Canada: Stand up and Be Counted Too (2)!
Nothing to Disclose

Lovisa Lyngfelt
Expression of Uncoupling Protein-1 in Subcutaneous Fat Is Increased by Tocilizumab
Nothing to Disclose

Jasmin Ma
Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Nothing to Disclose

Lili Ma
CYR61/TGF-β Axis Promotes Adventitial Fibrosis of Takayasu Arteritis in the IL-17 Mediated Inflammatory Microenvironment
Nothing to Disclose

Signe Møller-Bisgaard
Magnetic Resonance Imaging in Patients in Clinical Remission: Tenosynovitis and Osteitis Are Independent Predictors of Radiographic and MRI Damage Progression
Nothing to Disclose

Tjardo Maarseveen
A Validated Text-mining Algorithm to Extract Rheumatoid Arthritis Medication Contained in Format-free Fields of Electronic Medical Records
Nothing to Disclose

Tjardo Maarseveen
Automated Diagnosis Extraction from Electronic Medical Records with Machine Learning Classifiers
Nothing to Disclose

Johanna M Maassen
Clinical Presentation and Disease Course Evaluation of Mono- and Bilateral Knee Arthritis: Results from the Leiden Early Arthritis Clinic Cohort
Nothing to Disclose

Johanna M Maassen
Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort
Nothing to Disclose

Rohan Machhar
Single Cell RNA Sequencing of Patients with Psoriatic Disease
Nothing to Disclose
Bhanupriya Madarampalli
Platelet Derived Growth Factor Receptor Alpha (PDGFRα) Blockade Inhibits Arthritis in Mice
Nothing to Disclose

Laurence Magder
How Often Should SLE Patients Be Tested for Lupus Anticoagulant?
Nothing to Disclose

Laurence Magder
Longitudinal Trends for Estimated Glomerular Filtration Rate and Predictors of Change in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Marina N Magrey
Infections in Patients with Active Radiographic Axial Spondyloarthritis Treated with Ixekizumab in 2 Phase 3 Clinical Trials
Disclosure:
2- AbbVie; Abbvie, UCB and Amgen; Amgen; UCB; UCB Pharma
5- Amgen; Eli Lilly; Eli Lilly and Company; Eli Lily, Novartis; Novartis
9- Novartis

Marina N Magrey
Recognition of Inflammatory Back Pain by US Healthcare Providers and Barriers to Specialist Referral
Disclosure:
2- AbbVie; Abbvie, UCB and Amgen; Amgen; UCB; UCB Pharma
5- Amgen; Eli Lilly; Eli Lilly and Company; Eli Lily, Novartis; Novartis
9- Novartis

Sinead Maguire
Worse Outcomes for Female Patients with Axial Spondyloarthropathy
Disclosure:
9- AbbVie (Financial support for educational activities)

Mithu Maheswaranathan
Investigating Health Literacy and Numeracy in an Academic Center Lupus Cohort
Nothing to Disclose

Michael Mahler
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Disclosure:
3- Inova Diagnostics

Salman B Mahmood
The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study
Nothing to Disclose

Alfred Mahr
Presentation and Management of Giant Cell Arteritis in a Real-World Setting (Artemis Study)
Disclosure:
8- Celgene; Chugai Pharma France; Roche; Roche, Chugai

Alice Mai
B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Nothing to Disclose

Anselm Mak
Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus - Meta-analyses of Observational Studies Published Between 1979 and 2018
Nothing to Disclose

Jean-Paul Makhzoum
Color Doppler Ultrasound for the Diagnosis of Giant Cell Arteritis in Montreal: A Canadian Single Center Experience
Nothing to Disclose

Hadijat M Makinde
A Common Transcriptional Signature Is Present in Circulating Classical Monocytes and Skin Macrophages in Systemic Sclerosis
Nothing to Disclose

Hadijat M Makinde
Effect of Ifnα and Costimulatory Blockade on Brain Infiltration in a Model of 'Neuropsychiatric Symptoms of Systemic Lupus Erythematosus'
Nothing to Disclose

Hadijat M Makinde
Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Nothing to Disclose

Ayako Makiyama
Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus
Nothing to Disclose

Ervant Maksabedian
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Disclosure:
1- Amgen
3- Amgen
4- Amgen

Walter P. Maksymowych
Description and Prevalence of Spondyloarthritis in Unselected Patients with Psoriasis, Acute Anterior Uveitis, and Inflammatory Bowel Disease Presenting with Undiagnosed Back Pain
Disclosure:
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
3- CARE ARTHRITIS
5- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
6- Canadian Research and Education Arthritis;
CARE ARTHRITIS
8- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
9- CARE ARTHRITIS

Walter P. Maksymowych
Enhanced Performance of the ASAS Classification Criteria by Deletion of Non-Discriminatory Clinical Items: Data from the Screening in Axial Spondyloarthritis in Psoriasis, Iritis, and Colitis Cohort
Disclosure:
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
3- CARE ARTHRITIS
5- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
6- Canadian Research and Education Arthritis;
CARE ARTHRITIS
8- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma J; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
9- CARE ARTHRITIS

Walter P. Maksymowych
Ixekizumab Is Effective in the Treatment of Radiographic Axial Spondyloarthritis Regardless of the Level of C-Reactive Protein or Magnetic Resonance Imaging Scores
Walter P. Maksymowych
Longitudinal Assessment of MRI of the Sacroiliac Joints in the ASAS Classification Cohort: Evolution of Diagnostic Features and Predictive Utility for Axial Spondyloarthritis
Disclosure:
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
9- CARE ARTHRITIS

Walter P. Maksymowych
Replacement of Radiographic Sacroilitis by MRI Structural Lesions: What Is the Impact on Classification of Axial Spondyloarthritis in the ASAS Classification Cohort?
Disclosure:
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Eli Lilly; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
3- CARE ARTHRITIS
Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
6- Canadian Research and Education Arthritis; CARE ARTHRITIS
8- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
9- CARE ARTHRITIS

Walter P. Maksymowych
What Is the Impact of MRI on the Performance of the ASAS Classification Criteria in Patients Presenting with Undiagnosed Back Pain?
Disclosure:
2- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
3- CARE ARTHRITIS
5- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
6- Canadian Research and Education Arthritis; CARE ARTHRITIS
8- Abbvie; AbbVie; AbbVie Inc.; Abbvie, Amgen, Eli Lilly, Janssen, Merck, Pfizer, Synarc, Sanofi, and UCB Pharma ]; Amgen; Boehringer; Boehringer-Ingelheim; Celgene; Eli Lilly; Galapagos; Janssen; Lilly; Merck; Novartis; Pfizer; Sanofi; Synarc; UCB; UCB Pharma
9- CARE ARTHRITIS

Olivier Malaise
Systematic Osteoporosis Screening in Chronic Obstructive Pulmonary Disease (Study of Correlation Between Pulmonary Functions Tests and Bone Parameters): Emphysematous Status Is Linked to Low Bone Density and Osteoporosis
Nothing to Disclose

Navita L Malallieu
Pharmacokinetics and Pharmacodynamics of Tocilizumab in Combination with Prednisone Tapering in Patients with Giant Cell Arteritis: 3-Year Results from a Randomized Controlled Phase 3 Trial
Disclosure:
1- Roche
3- Roche

Margaux MALAURIE
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thromboembolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Nothing to Disclose
Genessis Maldonado
LARS Study: Latin American Rheumatologist Survey
Nothing to Disclose

Genessis Maldonado
The Status of Latin-American Women in Rheumatology
Nothing to Disclose

Yasmin R Maldonado
Factors Associated with Complete Spinal Fusion in Patients with Ankylosing Spondylitis
Nothing to Disclose

Nancy Maltez
Cyclophosphamid for the Treatment of Skin Fibrosis in Systemic Sclerosis: A Systematic Review
Nothing to Disclose

Nancy Maltez
Longitudinal Changes in Health-related Quality of Life in Systemic Sclerosis Treated with Autologous Hematopoietic Stem Cell Transplant Compared to Standard of Care
Nothing to Disclose

Matthew Malus
Hepatitis C Affects More Than Just the Liver: A Retrospective Chart Review on the Prevalence of Connective Tissue Diseases and Autoantibodies in Hepatitis C Virus Infections in an Academic Rheumatology Clinic
Nothing to Disclose

Ana Malvar
Histologic Findings from Paired Renal Biopsies and Clinical Outcomes: Results from a Single Site in the Phase III Study of Abatacept in Patients with Proliferative LN
Nothing to Disclose

Gulnara Mamyrova
Seasonal and Temporal Analyses of Disease Onset and Diagnosis in Myositis Autoantibody Phenotypes in Juvenile Dermatomyositis (JDM)
Disclosure:
2- Cure JM Foundation

Julia Manasson
Beyond Genes—a Multi-omic Analysis of Monozygotic Twins Discordant for Rheumatoid Arthritis
Nothing to Disclose

Lisa A Mandl
Frail Patients Have Less Pain After Total Hip Replacement
Disclosure:
3- Annals of Internal Medicine; Annals of Internal Medicine- Associate Editor
7- UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer- Author at UpToDate

Lisa A Mandl
Frail Patients Have Worse Function After Total Knee Replacement
Disclosure:
3- Annals of Internal Medicine; Annals of Internal Medicine- Associate Editor
7- UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer- Author at UpToDate

Lisa A Mandl
Risk Factors for Poor Outcomes After Hip Fracture Patients in the Robust Elderly: Are Patient Reported Outcomes Important?
Disclosure:
3- Annals of Internal Medicine; Annals of Internal Medicine- Associate Editor
7- UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer - Author at UpToDate; Wolters Kluwer- Author at UpToDate

Kieran P Manion
Dynamic Changes During SLE Flare Implicate Age-Associated B Cells and Altered T Follicular and Peripheral Helper Cell Responses in Disease Activity
Herman Mann
The Effect of Co-medication with Methotrexate and Other Conventional Synthetic Disease Modifying Anti-rheumatic Drugs on First Tumor Necrosis Inhibitor Drug Survival in Patients with Rheumatoid Arthritis: Results From a Nationwide Registry
Nothing to Disclose

Sally Mannix
Assessment of Fatigue in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE): A Qualitative Study to Explore What Patients Feel Should Be Measured in Clinical Trials
Nothing to Disclose

Sarah Manske
The Relationship Between Subclinical Inflammation and Bone Damage in Patients with Rheumatoid Arthritis Using Multimodality Imaging
Nothing to Disclose

Joseph Maranville
Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease Disclosure: 3- Celgene Corporation

Nathalie Marchand
A Healthy Plant-Rich Diet and the Risk of Rheumatoid Arthritis in Women
Nothing to Disclose

Joanna Marco
Anti-TNF Therapy in Patients with HIV Infection
Nothing to Disclose

Carla Marco-Pascual
Applicability of FRAX in Clinical Practice: 10-year Results
Nothing to Disclose

Xavier Mariette

A Phase 2a Study of MEDI5872 (AMG557), a Fully Human Anti-ICOS Ligand Monoclonal Antibody in Patients with Primary Sjögren’s Syndrome
Nothing to Disclose

Kathryne E Marks
RA Presents in Disease Patterns Impacting Treatment Response
Nothing to Disclose

José Marona
Drug Concentrations and Anti-drug Antibodies Influence in Response to Adalimumab: Results from the BioEfficacySpA Clinical Trial
Nothing to Disclose

Claudia Marques
Oncostatin M Receptor (OSMR) Underexpression in Patients with Ankylosing Spondylitis
Nothing to Disclose

Diane Marsman
Polymyalgia Rheumatica Patients with and Without Elevated Baseline Acute Phase Reactants: Distinct Subgroups of Polymyalgia Rheumatica?
Nothing to Disclose

Diane Marsman
Polymyalgia Rheumatica: Winter Is Coming
Nothing to Disclose

Diane Marsman
Prescribing Methotrexate in Polymyalgia Rheumatica: A Missed Opportunity?
Nothing to Disclose

Laura Aline Martínez-Martínez
Correlation Between Heart Rate Variability Parameters and Circulating Neuropeptides in Fibromyalgia
Nothing to Disclose

Johanne Martel-Pelletier
Developing a Comprehensive Patient-Specific Disease Progression Prediction Model for Knee Osteoarthritis Using Machine/Deep Learning Methods
Disclosure:
1- ArthroLab Inc.
5- TRB Chemedica

Carolina Marlene Martinez-Flores
Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Nothing to Disclose

Laura Martinez-Prat
Anti-Protein-Arginine Deiminase (PAD) 4 IgA Are Present in the Sera of Rheumatoid Arthritis Patients and Are Associated with Joint Erosion and Biological Treatment Use
Disclosure:
3- Inova Diagnostics

Marianne M Martinic
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Disclosure:
3- Idorsia Pharmaceuticals Ltd.
4- Idorsia Pharmaceuticals Ltd.

Eduardo Martin-Nares
Chemokine and Cytokine Tear Profile of Patients with IgG4-Related Disease
Nothing to Disclose

Eduardo Martin-Nares
Distinctive Imaging Features Between IgG4-Related Ophthalmic Disease and Graves’ Orbitopathy: A Comparative Study
Nothing to Disclose

Eduardo Martin-Nares
Juvenile-Onset IgG4-Related Disease: A Systematic Review
Nothing to Disclose
The following types of relationships may be deemed relevant include:

1. Shareholder
2. Grant/Research support
3. Employee
4. Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds)
5. Consulting Fees (e.g., advisory boards)
6. Officer or Board Member
7. Royalties
8. Speaker/Honoraria includes speakers bureau, symposia, and expert witness
9. Other

Anoka S Martis
Effect of Biologics on the Hemoglobin A1c in a Population of Rheumatoid Arthritis Patients
Nothing to Disclose

Helena Marzo-Ortega
Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
Disclosure:
2. Janssen; Janssen and Novartis; Janssen, Novartis; Novartis
5. AbbVie; AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB; Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer, Ucb; Celgene; Eli Lilly and Company; Janssen; Novartis; Pfizer; UCB
8. AbbVie; Abbvie, Celgene, Janssen, Lilly, Novartis, Pfizer, Ucb; AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB; Celgene; Eli Lilly and Company; Janssen; Novartis; Pfizer; UCB

Barbara Mascialino
Should There Be Hierarchical Scoring Applied to Serologic Testing in the 2010 ACR/EULAR Classification Criteria?
Disclosure:
3. Thermo Fisher Scientific

Barbara Mascialino
The Generation of Anti-CCP Tests Affects Diagnostic Accuracy in Rheumatoid Arthritis: A Systematic Literature Review and Meta-Analysis
Disclosure:
3. Thermo Fisher Scientific

Scott Matson
Findings of Pulmonary Abnormalities on High Resolution Computed Tomography in a Cohort of Rheumatoid Arthritis Patients Without Known Lung Disease
Nothing to Disclose

Mayumi Matsuda
Efficacy, Safety and Continuation Rate of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis: The Comparative Observational Study
Nothing to Disclose

Takashi Matsushita
Elevated Serum BAFF Levels in Patients with Dermatomyositis: Association with Interstitial Lung Disease
Nothing to Disclose

Eric Matteson
The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases
Disclosure:
2. Pfizer; Sun Pharmaceuticals
5. Boehringer Ingelheim

Jessica Maxwell
Relation of MRI-detected Structural Damage in the Patellofemoral Joint to Pain and Performance Based Function: The MOST Study
Nothing to Disclose

Adam Mayer
Comparison of Aortitis and Non-Inflammatory Thoracic Aortic Aneurysms Undergoing Open Surgical Repair
Nothing to Disclose

Maureen D Mayes
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
Disclosure:
5- Boehringer Ingelheim; Galapagos; Mitsubishi Tanabe Pharma; Mitsubishi-Tanabe
8- Boehringer Ingelheim
9- Boehringer Ingelheim ; Corbus ; Corbus Pharma ; Eicos ; Eicos Sciences ; Galapagos ; GlaxoSmithKline ; Reata Pharma ; Reata Pharmaceuticals ; Sanofi

Nadine Mbuyi
Emergency Department Length of Stay in Patients with Acute Gout
Nothing to Disclose

Kathryn E McCall
Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction
Nothing to Disclose

Sara McCoy
Sjögren’s Syndrome Foundation National Survey: The Impact and Burden of Oral Symptoms
Nothing to Disclose

Sara McCoy
The Effect of Estrogen and Interferon γ on the Immunobiology of Minor Salivary Gland Mesenchymal Stromal Cells
Nothing to Disclose

Courtney J McCray
Vasculitis in HIV-Infected Individuals: Making the Case for an Antigen Driven Process
Nothing to Disclose

Stephen C McDonald
Rituximab Treatment Is Not Associated with Increased Risk of Infection or Mortality in Refractory SLE Patients: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR)
Nothing to Disclose

Matthew McElwee
Identification of Citrullinated Peptide Specific T-cells in Humanized Mice Immunized with Citrullinated Peptides
Nothing to Disclose

Dennis McGonagle
Insights into Osteoarthritis Progression by Gene Expression and miRNA Profiling of Mesenchymal Stromal Cells from Medial and Lateral Femoral Condyles
Disclosure:
2- Abbvie; Celgene; Janssen; Lilly; Novartis; Pfizer
8- Abbvie; Celgene; Janssen; Lilly; Novartis; Pfizer; UCB
9- AbbVie ; BMS ; Celgene ; Johnson & Johnson ; MSD ; Novartis ; Pfizer ; UCB

Dennis McGonagle
The Gut Enthesis Axis Coming into Focus with the Description of Enriched Enthesal Resident Mucosal Associated Invariant T-cells (MAITs) Capable of IL17A and TNF Production
Disclosure:
2- Abbvie; Celgene; Janssen; Lilly; Novartis; Pfizer
8- Abbvie; Celgene; Janssen; Lilly; Novartis; Pfizer; UCB
9- AbbVie ; BMS ; Celgene ; Johnson & Johnson ; MSD ; Novartis ; Pfizer ; UCB

Dawn McGuire
Intra-Articular TPX-100 Significantly Delays Pathological Bone Shape Change at 6 and 12 Months in Moderate to Severe Tibiofemoral OA

Disclosure:
3- OrthoTrophix; OrthoTrophix, Inc
4- OrthoTrophix; OrthoTrophix, Inc

Dawn McGuire
Stabilization of Patellar Bone-Shape Correlates Significantly with Reduced Knee Pain Frequency After IA TPX-100 in Subjects with Bilateral Patellofemoral OA

Disclosure:
3- OrthoTrophix; OrthoTrophix, Inc
4- OrthoTrophix; OrthoTrophix, Inc

Neil McHugh
Learning the Relationships Between Psoriatic Arthritis and a Patient’s History of Musculoskeletal Symptoms from Electronic Health Records Using Bayesian Networks
Nothing to Disclose

Neil McHugh
Tumour Necrosis Factor Inhibitor Monotherapy versus Combination Therapy with Conventional Synthetic Disease-modifying Anti-rheumatic Drugs for the Treatment of Psoriatic Arthritis: A Combined Analysis of European Biologics Databases

Disclosure:
2- Pfizer; Celgene; Eli Lilly
5- AbbVie

Iain B McInnes
Effect of Long-Term Treatment with Secukinumab on Cardio-Metabolic Profile in Patients with Active Ankylosing Spondylitis and Psoriatic Arthritis: Pooled 3 Year Analysis

Disclosure:
2- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB
5- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB
8- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB

Molecular Analysis of the Mode of Action of Upadacitinib in Rheumatoid Arthritis Patients: Whole Blood RNA Expression Data from the SELECT-NEXT Study

Disclosure:
2- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB
5- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB
8- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer; UCB

Philip Mease
Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-naive Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results Through Week 52 from a Phase-3 Study

Disclosure:
2- Janssen Research & Development, LLC

Philip J. Mease
Comparison of Men and Women with Axial Spondyloarthritis in the US-Based Corrona Psoriatic Arthritis/Spondyloarthritits (PsA/SpA) Registry

Disclosure:
2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB
5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; Sun; UCB; Boehringer Ingelheim
8- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Genentech; Janssen; Novartis; Pfizer Inc; UCB

Philip J. Mease
Effect of Secukinumab on Radiographic Progression Through 2 Years in Patients with Active Psoriatic Arthritis: End-of-study Results from a Phase III Study

Disclosure:
2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB
Philip J. Mease
Impact of Peripheral Swollen and Tender Joints at Baseline on Response to Treatment with Secukinumab in Ankylosing Spondylitis
Disclosure: 2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB

Aranzazu Mediero
Netrin-1 and Its Receptor Unc5B Mediates Tenofovir Induced Bone Loss and Dipyridamole, an Agent That Blocks Adenosine Transporter, Is Able to Modulate the Signal
Nothing to Disclose

Aranzazu Mediero
Tenofovir Modulates Semaphorin 4D Signaling and Regulates Bone Homeostasis, Which Can Be Counteracted by Dipyridamole and Adenosine A2A Receptor
Nothing to Disclose

Nicolle Medina-Cintrón
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Jay Mehta
A Qualitative Study of Factors That Influence Interest in a Career in Pediatric Rheumatology
Nothing to Disclose

Rakeshchandra R Meka
Targeted Drug Delivery Using a Novel Joint-homing Peptide for Arthritis Therapy
Nothing to Disclose

Karin Melsens
Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review
Nothing to Disclose

Arielle Mendel
Timely Glucocorticoid Tapering in Vasculitis: A Need for Improved Knowledge Translation to Limit Toxicity
Nothing to Disclose

Arielle Mendel
Use of Rituximab for the Treatment of ANCA-Associated Vasculitis in Canada, 2010-2018
Nothing to Disclose

Alan M Mendelsohn
Efficacy and Safety of Tildrakizumab 100 Mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in a Phase 3 Study
Disclosure: 1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.
4- Johnson and Johnson

Alan M Mendelsohn
Impact of Body Weight on Efficacy of Tildrakizumab in Moderate-to-Severe Plaque Psoriasis
Disclosure: 1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.
4- Johnson and Johnson
Alan M Mendelsohn
Limited Changes in Hematological Parameters During Tildrakizumab Treatment: Post Hoc Analysis of Data from the Tildrakizumab Psoriasis Clinical Program
Disclosure:
1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.
4- Johnson and Johnson

Alan M Mendelsohn
Safety of Tildrakizumab in Psoriatic Arthritis: An Interim Analysis from a Randomized, Double-blind, Placebo-controlled Phase 2b Trial
Disclosure:
1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.
4- Johnson and Johnson

Alan M Mendelsohn
Tildrakizumab Efficacy on Psoriasis in Patients with Psoriatic Arthritis—An Analysis from a Phase 2 Study
Disclosure:
1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.

Mario R Mendoza
Disclosure:
3- Centrexion Therapeutics Corp

Claudia Mendoza-Pinto
Endothelial Dysfunction and Arterial Stiffness in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-analysis
Nothing to Disclose

Tao Meng
Association of Glucose Homeostasis and Metabolic Syndrome Measures with Knee Cartilage Defects and Cartilage Volume in Young Adults
Nothing to Disclose

Victoria Menzies
Metabolomic and Symptom Comparison in Women With/without Fibromyalgia: A Pilot Study
Nothing to Disclose

Carolina Merino Argumanez
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Nothing to Disclose

Peter A Merkel
Adaptive Study Design of a Randomized, Multicenter, 2-Part Phase 2 Trial of Replacement of Glucocorticoids by IFX-1, a C5a Inhibitor, in Active Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Disclosure:
2- AstraZeneca; AstraZeneca,; Boeringher-Ingelheim; Bristol-Myers Squibb; Celgene; ChemoCentryx; Genentech/Roche; Genzyme/Sanofi; GlaxoSmithKline; Kypha; TerumoBCT
5- Abbvie; AbbVie; AstraZeneca; AstraZeneca,; Biogen; Boeringher-Ingleheim; Bristol-Myers Squibb; Celgene; Celgene; ChemoCentryx; CSL Behring; Genentech/Roche; Genetech/Roche; Genzyme/Sanofi; GlaxoSmithKline; InflaRx; Insmed; Jannsen; Kiniksa
7- UpToDate

Peter A Merkel
Design of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of 2 Different Dose Regimens of IFX-1, a C5a Inhibitor, as an Add-On Therapy for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Disclosure:
2- AstraZeneca; AstraZeneca,; Boeringher-Ingehelm; Bristol-Myers Squibb; Celgene; ChemoCentryx; Genentech/Roche;
Joseph F Merola
Guselkumab Was More Effective Than Secukinumab in Patients with Plaque Psoriasis and the Subset of Patients with Self-Reported Psoriatic Arthritis in a Randomized, Double-blind, Head-to-head Comparison Study over 1 Year
Disclosure:
2- Janssen Research & Development, LLC

Joseph F Merola
Improvement in the Signs and Symptoms of Psoriatic Arthritis with Ixekizumab Compared to Adalimumab in Patient Subgroups Defined by Baseline Disease Characteristics
Disclosure:
2- AbbVie; Aclaris; Almirall; Biogen; Celgene; Dermavant; Eli Lilly; GSK; Incyte; Janssen; Leo Pharma; Merck Research Laboratories; Novartis; Pfizer; Sanofi Regeneron; Sun Pharma; UCB
5- AbbVie; Aclaris; Almirall; Amgen; Biogen; Celgene; Dermavant; Eli Lilly; GSK; Incyte; Janssen; Leo Pharma; Merck Research Laboratories; Novartis; Pfizer; Regeneron; Sanofi Regeneron; Sun Pharma; UCB

Meron Mezgebe
Emergency Department Encounters in a Large US Payer Database: Tophaceous versus Non-tophaceous Gout Patients
Disclosure:
3- Horizon Therapeutics
9- Horizon Therapeutics (Fellow in the Horizon Therapeutics plc. Medical Affairs Fellowship program)

Lavalley Michael
Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis
Nothing to Disclose

Despina Michailidou
Clinical Symptoms and Associated Vascular Imaging Findings in Takayasu’s Arteritis Compared to Giant Cell Arteritis
Nothing to Disclose
Martin Michaud
Effectiveness and Safety of Off-label Use of Tocilizumab in Refractory Autoimmune Diseases: A Multicenter Study
Nothing to Disclose

Brigitte Michelsen
Secukinumab Effectiveness in 1134 Patients with Psoriatic Arthritis Treated in Routine Clinical Practice in 11 European Countries in the EuroSpA Research Collaboration Network
Disclosure:
2- Novartis
5- Novartis

Alberto Migliore
Cycling of Tumor Necrosis Factor-α (TNF-α) Inhibitors versus Switching to Different Mechanism of Action in Rheumatoid Arthritis Patients with Inadequate Response to TNF-α Inhibitor: A Bayesian Network Meta-analysis
Disclosure:
2- Pfizer; UCBPharma; Merck; Roche; Brystol-Myers Squibb; IBSA; Sanofi-Aventis; Fidia Pharma

Eric S Miller
A Prospective, Unblinded, Non-randomized Pilot Study Examining the Effect of a Musculoskeletal Immersion Curriculum for First Year Internal Medicine Residents
Nothing to Disclose

Brooke Mills
Improving Lactation Knowledge Among Providers Caring for Rheumatology Patients
Nothing to Disclose

Milena Mimica
Factors Associated with Accrual of Damage over Time in Patients with SLE: Results from a Multinational Latin American Cohort
Nothing to Disclose

Hong Ki Min
Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Nothing to Disclose

Maria-Eugenia Miranda-Carus
Treatment with Abatacept but Not with TNF Blockers, Is Associated with a Reduction of Constitutively Elevated Circulating Follicular Helper T Cells in Rheumatoid Arthritis
Disclosure:
2- BMS; Roche Pharma

Dipendra Kumar Mitra
Impact of Interleukin-9 on the Immune Suppressive Functions of Regulatory T Cells in Rheumatoid Arthritis
Nothing to Disclose

Stéphane Mitrovic
Adult-Onset Still’s Disease and Spondyloarthritis: Overlapping Syndrome or Incidental Association? A Series of 5 Cases
Nothing to Disclose

Marisa Mizus
Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Nothing to Disclose

Mitra Moazzami
Validity and Reliability of Patient Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Tests (CAT) in a Canadian Cohort of Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Bahar Moghaddam
Prevalence of Cognitive Impairment in an Inception Lupus Cohort as Assessed by a Comprehensive Neuropsychological Battery
Nothing to Disclose
Aladdin Mohammad
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Nothing to Disclose

Aladdin Mohammad
Healthcare Resources Utilization in Giant Cell Arteritis – a Population-Based Study
Nothing to Disclose

Chi Chiu Mok
Effect of the Metabolic Syndrome on Renal Function Decline in Four Rheumatic Diseases: An 8-year Longitudinal Analysis
Nothing to Disclose

Chi Chiu Mok
Organ Damage Free Survival in Southern Chinese Patients with Active Lupus Nephritis
Nothing to Disclose

Chi Chiu Mok
Prevalence and Risk Factors of Herpes Zoster Reactivation in Patients with Biopsy Proven Lupus Nephritis Undergoing Immunosuppressive Therapies
Nothing to Disclose

Yair Molad
Soluble Triggering Receptor Expressed on Myeloid cells-1 (sTREM-1) Ameliorates Monosodium Urate Crystals (MSUC)-induced Inflammation in a Mouse Air-pouch Model of Gout
Nothing to Disclose

Juan Molina Collada
Doppler in Entheses: A Potential Useful Outcome in Active Spondyloarthritis and Psoriatic Arthritis
Nothing to Disclose

Anna Moltó
Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort
Nothing to Disclose

Marie Moly
Factors Associated with Discordance Between Patient and Rheumatologist Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission
Nothing to Disclose

Marie Moly
In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?
Nothing to Disclose

Kanika Monga
#WomeninRheumatology: Is There a Speaker Gender Gap at ACR Meetings?
Nothing to Disclose

Kanika Monga
Associations of Work-Related Abilities with Disability in Ankylosing Spondylitis
Nothing to Disclose

Luke Monteagudo
The Clinical Characteristics of Patients with Inflammatory Arthritis and a Persistently Low Alkaline Phosphatase Level in a Veteran Affairs Rheumatology Clinic
Nothing to Disclose

Nicholas Mook
Differences in Stepping and Standing Based on Self-reported Exercise Identity in Persons Following Total Knee Replacement
Nothing to Disclose

Priyanka Moolchandani
Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation
Nothing to Disclose

Erica Moore
Characterizing the Brain T Cell Receptor Repertoire in Neuropsychiatric Lupus
Nothing to Disclose

Robyn Moran
Screening for Hepatitis B Surface Antigen and Core Antibody Prior to Administration of Rituximab in Rheumatology Patients
Nothing to Disclose

Eric F Morand
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Disclosure:
2- AstraZeneca; Bristol Myers Squibb; Eli Lilly; Janssen; Merck Serono
5- AstraZeneca; Eli Lilly; Janssen; Merck Serono; UCB; GSK; CSL Inc; Neovacs; Wolf Biotherapeutics; AbbVie; Amgen

Emilia Moreira
Functional Exercise for Adults with Chronic Nonspecific Low Back Pain
Nothing to Disclose

Esi Morgan
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Nothing to Disclose

caroline Morizot
To Evaluate Spine Ankylosis, Vertebral Fractures and Bone Fragility on a Single Imaging Exam in Patients with Ankylosing Spondylitis: Myth or Reality?
Nothing to Disclose

Rosa Morlà
High MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/Routine Assessment of Patient Index Data) Scores in RA Patients Who Have Depression According to a Screening Questionnaire
Nothing to Disclose

Rosa Morlà
Multidimensional Health Assessment Questionnaire (MDHAQ) as an Effective Screening Tool to Identify Concomitant Depression in Patients with Rheumatoid Arthritis and Spondyloarthritis in Routine Care
Nothing to Disclose

Rosa Morlà
Multidimensional Health Assessment Questionnaire (MDHAQ) Scores in Spain vs USA: Similar Scores for Clinical Status and Self-report of Depression in Rheumatoid Arthritis (RA) but Poorer Scores for Both in Spondyloarthropathies (SpA) in Spain
Nothing to Disclose

Esther Mossel
Clinical Phenotyping of Patients with Primary Sjögren's Syndrome Using Salivary Gland Ultrasonography
Nothing to Disclose

Anita N Moudgal
The Prevalence and Patterns of Celiac Disease Associated Arthropathy and Coexistence of Celiac Disease with Rheumatic Disorders in a Single Tertiary Medical Center
Nothing to Disclose

Gaël Mouterde
Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in Rheumatoid Arthritis: Multicenter and Cross-sectional Study
Nothing to Disclose

Mohammad Movahedi
Time to Discontinuation of Tofacitinib in Rheumatoid Arthritis Patients with and Without Methotrexate: Results from a Rheumatoid Arthritis Cohort
Nothing to Disclose

Evgenia Movshovich
Differences in Correlation Between Objective Disease Measurements and Patient’s/physician’s Global Assessment in the Large Non-interventional Study SUSTAIN
Nothing to Disclose

Veronica M Mruk
Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases
Nothing to Disclose

Rong Mu
Create an Algorithm of Outcome Forecasting and Decision Making for RA Treatment: Data Mining and Machine Learning via the Smart System of Disease Management (SSDM)
Nothing to Disclose

Carolina Muñoz-Grajales
Neutrophils Are an Important Source of Microparticles in Lupus and Asymptomatic ANA+ Individuals
Nothing to Disclose

Tony M Muchamuel
Selective Inhibition of the Immunoproteasome with KZR-616 Blocks Multiple Cell Signaling Pathways, Plasma Cell Signatures and Myeloid Cell Associated Damage in the NZB/W Lupus Nephritis Model
Disclosure:
1- Kezar Life Sciences
3- Kezar Life Sciences

Alisa A Mueller
CD4+ T Helper Cell Populations with High PD-1 Expression Are Expanded in Systemic Sclerosis
Nothing to Disclose

Hafis Muhammed
Cardiovascular Risk Factors in Rheumatoid Arthritis: Prevalence, Comparison of Risk Calculators and Subclinical Atherosclerosis in Indian Patients
Nothing to Disclose

Hafis Muhammed
Targeted 1H NMR Based Metabolomics Analysis Revealed Significantly Higher Synovial Phe/Tyr Ratio in Reactive Arthritis and Undifferentiated Spondyloarthropathy
Nothing to Disclose

Michelle Mulder
Implementing the Psoriatic Arthritis Disease Activity Score (PASDAS) in Routine Clinical Practice: (im)possible?
Nothing to Disclose

Lama Mulki
High Expression of CD38 on CD8 T Cells Predicts Increased Burden of Infections in Patients with SLE
Nothing to Disclose

Takumi Muramatsu
The Effects of Anti-glutamate Receptor Subunit Antiantibodies on Systemic Lupus Erythematosus Without Neuropsychiatric Involvement
Nothing to Disclose

Okinori Murata
Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Nothing to Disclose

Francesco Muratore
Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy: A Retrospective, Single Center Experience over a 21 Years’ Period
Nothing to Disclose

Francesco Muratore
Comparison of Biopsy Proven Giant Cell Arteritis in North America and South Europe: A Population-Based Study
Nothing to Disclose

Goh Murayama
Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Nothing to Disclose

Louise B Murphy
When It Just Won’t Stop: Chronic Pain and High Impact Chronic Pain Among U.S. Adults with Arthritis
Nothing to Disclose

Mark Murphy
Cenerimod, a Potent, Selective and Orally Active Sphingosine 1-phosphate Receptor 1 Modulator, Reduced Blood Antibody-secreting Cells in Patients with SLE Disclosure:
1- Idorsia Pharmaceuticals Ltd
3- Idorsia Pharmaceuticals Ltd
4- Idorsia Pharmaceuticals Ltd

Kieran Murray
A Quality Improvement Intervention to Improve Influenza and Pneumococcal Vaccination Rates in Immunosuppressed Inflammatory Arthritis Outpatients
Nothing to Disclose

William Murray-Brown
Expanded Peripheral T Helper Cells Characterize the Early Rheumatoid Arthritis Synovium
Nothing to Disclose

McKayla Muse
Assessment of Anti-Cyclic Citrullinated Protein and Connective Tissue Disease Screening Questionnaire in Healthy Adults from the Oklahoma Immune Cohort
Nothing to Disclose

ILHAM A MUSLIMOV
Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments
Nothing to Disclose

Cristina Musselli
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BII059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunteers Disclosure:
1- Biogen
3- Biogen
4- Biogen

Elena Myasoedova
Criterion Validity of the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) Questionnaire and FLARE-RA Cut-offs for Clinical Decision Making: International Collaboration
Nothing to Disclose

Elena Myasoedova
Is the Epidemiology of Rheumatoid Arthritis (RA) Changing? Results from a Population-based Incidence Cohort of RA Patients, 2005-2014
Nothing to Disclose

Elena Myasoedova
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Nothing to Disclose

Elena Myasoedova
Nothing to Disclose

Elena Myasoedova
Statin Use Is Associated with Increased Risk of RA in US Population: Results from a Large Nationwide Study
Nothing to Disclose
Elena Myasoedova
What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis
Nothing to Disclose

Vivek Nagaraja
Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
Nothing to Disclose

Sunil Nagpal
Bruton’s Tyrosine Kinase (BTK) Pathway Is Active in Synovium at Various Stages of Rheumatoid Arthritis Disease Progression
Disclosure: 1- Janssen Research, Johnson & Johnson; 3- Janssen Research & Development; 4- Janssen Research, Johnson & Johnson

Anand Ramachandran Nair
Knee Morphology Associates with Tibio-Femoral and Patello-Femoral Osteoarthritis: A Case-Control Study
Nothing to Disclose

Aurelie Najm
EULAR Points to Consider for the Development, Evaluation and Implementation of Mobile Health Applications for Self-management in Patients with Rheumatic and Musculoskeletal Diseases
Nothing to Disclose

Akihiro Nakamura
Macrophage Migration Inhibitory Factor Is a Critical Regulator in a Mouse Model of Spondyloarthritis
Nothing to Disclose

Bone Mineral Density of the Spine, Hip, and Distal Radius in Patients with Postmenopausal Osteoporosis
Nothing to Disclose

Yoichi Nakayama
Risk Factors for Pulmonary Nontuberculous Mycobacterial Disease in Rheumatoid Arthritis Patients
Nothing to Disclose

Francois Nantel
Long-Term Effectiveness and Safety of Infliximab and Golimumab in Ankylosing Spondylitis Patients from a Prospective Observational Registry
Disclosure: 1- Janssen Inc. 3- Janssen Inc.

Francois Nantel
Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Prospective Observational Registry
Disclosure: 1- Janssen Inc. 3- Janssen Inc.

Francois Nantel
Predictors of Response, Adverse Events and Treatment Retention in Ankylosing Spondylitis Patients Treated with Golimumab in a Prospective, Observational Registry
Disclosure: 1- Janssen Inc. 3- Janssen Inc.

Francois Nantel
Predictors of Response, Adverse Events and Treatment Retention in RA Patients Treated with Either Subcutaneous- or Intravenous-Golimumab in a Prospective, Observational Registry
Disclosure:
1- Janssen Inc.
3- Janssen Inc.

Ruth Napier
A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice
Nothing to Disclose

Sonali Narain
Utility of Anti-SSA/SSB Assay and Anti-Ro 52 Antibody Assay in Routine Clinical Practice for Risk Assessment of Patients with Idiopathic Inflammatory Myositis
Disclosure:
2- Exagen

Ravi K Narang
Do Serum Urate-Associated Genetic Variants Influence Gout Risk in People on Diuretics?
Analysis of the UK Biobank
Nothing to Disclose

Peter Nash
Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
Disclosure:
2- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi; UCB
5- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi
8- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi

Peter Nash
The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis
Disclosure:
2- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi
5- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi
8- AbbVie; BMS; Celgene; Eli Lilly; Gilead; Janssen; MSD; Novartis; Pfizer Inc; Roche; Sanofi

Mazen N Nasrallah
Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood
Nothing to Disclose

Mazen N Nasrallah
Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events
Nothing to Disclose

Champa Nataraja
Lyn-Deficient Murine Lupus Is Exacerbated by Glucocorticoid-Induced Leucine Zipper (GILZ) Deficiency
Nothing to Disclose

Iris Navarro-Millan
Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Nothing to Disclose

Adéla Navrátilová
S100A11 (calgizzarin) Is Released During Neutrophil Extracellular Traps (NETs) Formation in Rheumatoid Arthritis (RA)
Nothing to Disclose

Takashi Nawata
Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Nothing to Disclose

Ahmed A Negm
Fibromyalgia and Multiple Switching of Biologics in Spondylarthritis
Nothing to Disclose

Nasha Nensey
Evaluating the Performance of a Single-site Musculoskeletal Ultrasound Clinic Associated with an Academic Rheumatology Practice: Diagnostic and Therapeutic Impact on Patient Care and Survey of Patient and Physician Satisfaction
Nothing to Disclose

Tuhina Neogi
Relation of Intra-Articular Knee Mineralization on CT to Knee Pain in People with or at Risk of Knee Osteoarthritis
Disclosure:
5- MerckSerono; Novartis

Agna Neto
Pregnancy in Antiphospholipid Syndrome: Outcomes and Risk Factors – Data from a Portuguese Multidisclinary Unit
Nothing to Disclose

Agna Neto
Sarcopenia, Segmental Muscle Strength and Body Composition in Young Axial Spondylarthritis Patients: Results from MyoSpA Study
Nothing to Disclose

Wilson Ngai
Efficacy and Safety of Hylan G-F 20 versus Intra-Articular Corticosteroids in Patients with Knee Osteoarthritis: A Systematic Literature Review, Meta-Analysis, and Network Meta-analysis
Disclosure:
1- Sanofi; Sanofi US
3- Sanofi; Sanofi US

Wilson Ngai
High Molecular Weight Intraarticular Hyaluronic Acid for the Treatment of Knee Osteoarthritis: A Network Meta-Analysis
Disclosure:
1- Sanofi; Sanofi US
3- Sanofi; Sanofi US

Cuong Nguyen
Genetic Ablation of γδTCR Inhibits IL-23-induced Neutrophilia and Attenuates Epidermal Hyperplasia, Synovitis, Onycholysis and Enthesitis Associated with Psoriatic Arthritis
Nothing to Disclose

Thao Nguyen
Antirheumatic Therapy Is Associated with Reduced Complement Activation in Rheumatoid Arthritis
Nothing to Disclose

Thao Nguyen
Antirheumatic Therapy Is Not Associated with Changes in Circulating N-terminal Pro-brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis
Nothing to Disclose

Tien Nguyen
A Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Secukinumab in US Biologic-Naïve Patients with Active Psoriatic Arthritis and Psoriatic Skin Lesions
Disclosure:
2- AbbVie; Amgen; Bristol-Myers Squibb; Biogen Idec; Lilly; GSK; Merck; Novartis; Pfizer; Sanofi Regeneron
5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Lilly; Corrona; Janssen; Novartis; Pfizer; Sanofi Regeneron; UCB
8- AbbVie; Amgen; Allmiral; Celgene; Lilly; Novartis; Pfizer; Sanofi Regeneron; Sun Pharma

Peiyun Ni
Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review
Nothing to Disclose

Pieter H Nienhuis
Visual and Quantitative Assessment of Cranial Arteries on FDG-PET/CT Can Reliably Diagnose Cranial Giant Cell Arteritis
Nothing to Disclose

Svetlana I Nihtyanova
Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis
Disclosure: 3- Daiichi Sankyo

Martin Nikolov
Dual Femur Bone Density Measurements with Novel Sonographic Approach - Radiofrequency Echographic Multi Spectrometry
Nothing to Disclose

Takahiro Nishino
The Influence of Gender on Composite Disease Activity Indices for Rheumatoid Arthritis
Nothing to Disclose

Susumu Nishiyama
Location and Size of Affected Joints Are Useful to Predict Prognosis of Patients with Rheumatoid Arthritis
Nothing to Disclose

Ravyn Njagu
Effect of Race and Lupus Nephritis on Pregnancy Outcomes in Systemic Lupus Erythematosus: An Individual Participant Meta-analysis
Nothing to Disclose

Ravyn Njagu
Impact of the Healthy Outcomes in Pregnancy with SLE Through Education of Providers (HOP-STEP) Program: A Mixed Methods Approach
Nothing to Disclose

Gaetane Nocturne
In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature
Nothing to Disclose

Kentaro Noda
Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory
Nothing to Disclose

Uxia Nogueira-Recale
Fibrates as Drugs with Senolytic and Autophagic Activity for Osteoarthritis Treatment
Nothing to Disclose

Atsushi Nomura
Unique Primed Status of Microglia Under the Systemic Autoimmune Condition of Lupus-Prone Mice
Nothing to Disclose

Vibeke Norvang
Achievement of Remission in Two Early Rheumatoid Arthritis Cohorts Implementing Different Treat-To-Target Strategies
Nothing to Disclose

Vibeke Norvang
Evaluation of Methods to Account for Differential Follow-up When Comparing Clinical Trial Data to Observational Data
Nothing to Disclose

Antonella Notarnicola
Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features
Nothing to Disclose

W. Benjamin Nowell
Patient Beliefs and Perceptions of Methotrexate for the Treatment of Rheumatoid Arthritis and Psoriatic Arthritis
Disclosure:
1- AbbVie; Allergan; Biogen; BMS; CVS; Eli Lilly; GSK; Merck; Pfizer; Stryker
3- Global Healthy Living Foundation

W. Benjamin Nowell
Understanding Which Patient-Reported Outcomes Are Important to Rheumatology Patients: Findings from ArthritisPower
Disclosure:
1- AbbVie; Allergan; Biogen; BMS; CVS; Eli Lilly; GSK; Merck; Pfizer; Stryker
3- Global Healthy Living Foundation

Carol A Oatis
Descriptive Analysis of Patient-Reported Home Exercise and Physical Activity and Their Associations with Patient Baseline Characteristics Following Total Knee Replacement
Nothing to Disclose

Anthony J Ocon
In Rheumatoid Arthritis, New-onset Prednisone Use Is Associated with a Daily Dose, Cumulative Dose, and Duration-dependent Risk for Cardiovascular Events at 6 Months and 1 Year of Use
Nothing to Disclose

Yoshikazu Ogawa
Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis
Nothing to Disclose

Alexis Ogdie
Burden of Disease at Treatment Initiation Among Biologic-Naïve Patients with Oligoarticular versus Polyarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry Disclosure:
2- Amgen; Amgen to Forward National Databank; Novartis; Novartis to UPenn; Novartis, Pfizer; Pfizer; Pfizer Inc; Pfizer to UPenn
4- Amgen; Celgene

Alexis Ogdie
Characteristics of Patients with Seropositive or Seronegative Rheumatoid Arthritis, Psoriatic Arthritis, or Axial Spondyloarthritis: Data from the US-Based Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Disclosure:
2- Amgen; National Psoriasis Foundation; NIH/NIAMS; Novartis; Pfizer; Rheumatology Research Foundation
5- AbbVie; Amgen; BMS; Celgene; Corrona, LLC; Lilly; Novartis; Pfizer; Takeda
7- Novartis
8- AbbVie; Amgen; Celgene

Alexis Ogdie
Clinical Characteristics and Treatment Profiles of Patients with Ankylosing Spondylitis Who Initiated Secukinumab and Other Biologics: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry Disclosure:
2- Amgen; National Psoriasis Foundation; NIH/NIAMS; Novartis; Pfizer; Rheumatology Research Foundation
5- AbbVie; Amgen; BMS; Celgene; Corrona, LLC; Lilly; Novartis; Pfizer; Takeda
7- Novartis
8- AbbVie; Amgen; Celgene

Alexis Ogdie
Impact of Multidomain Disease Presentations on Overall Disease Burden Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry Disclosure:
2- Amgen; National Psoriasis Foundation; NIH/NIAMS; Novartis; Pfizer; Rheumatology Research Foundation
Alexis Ogdie
Multi-Symptom Impact on the EQ5D Index in Bio-naïve Active Psoriatic Arthritis Patients: An Analysis Through Week 24 of the GO-VIBRANT Study
Disclosure:
5- Novartis; Pfizer; Abbvie; Amgen; BMS; Celgene; Corrona, LLC; Lilly; Novartis; Pfizer; Takeda
7- Novartis
8- AbbVie; Amgen; Celgene

Alexis Ogdie
Pain Perception and Opiate Use Among Patients with Inflammatory Arthritis
Disclosure:
2- Amgen; Novartis; Pfizer
5- Abbvie; Amgen; BMS; Celgene; Corrona; Lilly; Novartis; Pfizer
7- Novartis
8- Abbvie; Amgen; Celgene; Novartis

Alexis Ogdie
Prevalence of Disease Domain Presentations Among Patients with Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Disclosure:
2- Amgen; National Psoriasis Foundation; NIH/NIAMS; Novartis; Pfizer; Rheumatology Research Foundation
5- AbbVie; Amgen; BMS; Celgene; Corrona, LLC; Lilly; Novartis; Pfizer; Takeda
7- Novartis
8- AbbVie; Amgen; Celgene

Alexis Ogdie
Real-World Use of Apremilast in Combination with Biologic Therapy in Patients with Psoriatic Arthritis: Findings from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Disclosure:
2- Amgen; Amgen to Forward National Databank; Novartis; Novartis to UPenn; Novartis, Pfizer; Pfizer Inc; Pfizer to UPenn
4- Amgen; Celgene
5- AbbVie; Abbvie; AbbVie, BMS, Eli Lilly, Novartis, Pfizer, Takeda; Amgen; BMS; Bristol-Myers Squibb; Celgene; Corrona; CORRONA; Lilly; Lily; Novartis; Pfizer; Pfizer Inc
7- From Novartis to husband; Novartis
8- AbbVie; Abbvie; Amgen; Celgene

Alexis Ogdie
Side Effects of Methotrexate and TNFi: Differences in Tolerability Among Patients with PsA and RA
Disclosure:
2- Novartis; Pfizer
5- Abbvie; Amgen; BMS; Celgene; Corrona; Lilly; Novartis; Pfizer
7- Novartis
8- Abbvie; Amgen; Celgene

Yuka Oikawa
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Nothing to Disclose

Yukinori Okada
A Metagenome-wide Association Study of Gut Microbiome Revealed Novel Etiology of Rheumatoid Arthritis in the Japanese Population
Nothing to Disclose

Yuko Okamoto
Mass Cytometry Identifies Enhanced Histone H3 Citrullination and TNFα Production by CD14 Monocytes in Subjects At-Risk for Future Development of Rheumatoid Arthritis
Nothing to Disclose

Ghazala D O'Keefe
Health Literacy, Adherence, and Quality of Life of Uveitis Patients
Nothing to Disclose
Ikumi Okumura
Roles of Histone Acetyltransferases CBP/p300 and Transcriptional Factor RORα/REV-ERBα Against TNFα-induced CCL2 Expression in RA-FLS
Nothing to Disclose

MIKHAIL OLFE RIEV
Gene-Expression Analysis of Male and Female SLE Patients Reveals Candidate Pathogenic Pathways
Nothing to Disclose

Patricia Oliveira
Role of Sialic Acid in the Aggressive Phenotype of RA FLS
Nothing to Disclose

Kevin L Ong
Severe Acute Localized Reactions Following Intra-Articular Hyaluronic Acid Injections in Knee Osteoarthritis
Disclosure:
9- Sanofi US (I am an employee and shareholder of Exponent, a scientific and engineering consulting firm. Exponent has been paid fees for my consulting services on behalf of such companies and suppliers); Medtronic (I am an employee and shareholder of Expone

Voon H Ong
Aberrant Expression Levels of Soluble Co-inhibitory Receptors Linked to Disease Activity in Systemic Sclerosis
Nothing to Disclose

Voon H Ong
Dysregulated IL-6 Dependent Dermal Adenosine Signaling via Adenosine A2A Receptor May Drive Fibrosis in Systemic Sclerosis
Nothing to Disclose

Akira Onishi
The Effects of Erythrocytes and Platelets on Disease Activity in Patients with RA - ANSWER Longitudinal Cohort Study -
Nothing to Disclose

Yuko Ono
RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells
Nothing to Disclose

Win Min Oo
Construct Validity of OMERACT Ultrasound Knee Scores with Pain, Other Symptoms, Radiographic and MRI Findings
Nothing to Disclose

Ana-Maria Orbai
Impact of Enthesitis on Patient Reported Outcomes and Physician Satisfaction with Treatment: Data from a Multinational Patient and Physician Survey Disclosure:
2- AbbVie; Celgene; Eli Lilly and Company; Novartis; Pfizer
5- Eli Lilly and Company; Novartis; Pfizer; UCB

Ana-Maria Orbai
PROMIS Profile29 Differentiates Active Disease from Treat-to-Target State in Psoriatic Arthritis Disclosure:
2- AbbVie; Celgene; Eli Lilly; Horizon; Janssen; Lilly; Novartis
5- Eli Lilly; Janssen; Lilly; Novartis; Pfizer; UCB

Ana-Maria Orbai
Static and Longitudinal Construct Validity of PROMIS CAT and Profile29 for Assessing Pain Interference, Physical Function and Fatigue in Psoriatic Arthritis Disclosure:
2- AbbVie; Celgene; Eli Lilly; Horizon; Janssen; Lilly; Novartis
5- Eli Lilly; Janssen; Lilly; Novartis; Pfizer; UCB

Natividad Oreiro
Erosive Hand Osteoarthritis, Metabolic Syndrome and Knee Osteoarthritis: A Cross-sectional Study Using Data from the PROCOAC Cohort
Nothing to Disclose

Sabina Oreska
Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism
Nothing to Disclose

Michelle Ormseth
Gut Dysbiosis Is Associated with Measures of Early Vascular Dysfunction in Patients with Rheumatoid Arthritis
Nothing to Disclose

Michelle Ormseth
The Endogenous Plasma Small RNAome of Rheumatoid Arthritis
Nothing to Disclose

Jaka Ostrovrsnik
Can We Predict Early Relapses in Adult IgA Vasculitis?
Nothing to Disclose

Yuko Ota
PI3K-Akt Pathway Plays a Crucial Role in Production of Collagen in Fli1 Deficient Condition and Its Inhibitor Has the Therapeutic Potential in Treating Fibrosis
Nothing to Disclose

Rebecca S Overbury
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Nothing to Disclose

Rebecca S Overbury
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Nothing to Disclose

Christopher Overton
Effect of Vitamin D Supplementation on Calcium Levels in Patients with Sarcoidosis: A Retrospective Analysis
Nothing to Disclose

Takayoshi Owada
Continuous Decrease in Serum RF Titer During Anti-TNF Therapy Was Associated with Suppression in Progression of RA Joint Damage
Nothing to Disclose

Claire E Owen
A Novel Diagnostic Algorithm for Polymyalgia Rheumatica Using Three Musculoskeletal Sites on Whole Body PET/CT
Nothing to Disclose

Claire E Owen
A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica
Nothing to Disclose

Katherine Owen
The Integration of Genetic Data, Molecular Pathway Analysis and Differential Expression to Delineate the Impact of Ancestral Differences on Lupus
Nothing to Disclose

Hiroki Ozawa
Effect of a Clinical Decision Support System on a Quality Indicator of Glucocorticoid-induced Osteoporosis and Trends of Drug Treatment in a Japanese Hospital
Nothing to Disclose

Gulsen Ozen
Risk of Subsequent Atherosclerotic Cardiovascular Disease After the First Unprovoked Venous Thromboembolism in Patients with Rheumatoid Arthritis
Nothing to Disclose

Seza Ozen
Recommendation on Colchicine Dosing and Definition of Colchicine Resistance/Intolerance in the Management of Familial Mediterranean Fever Disclosure:
8- Enzyvant
Mert Oztas
Retroperitoneal Fibrosis - a Single Center Experience
Nothing to Disclose

Ahmad P. Tafti
Deep Learning Social Media Analysis
Demonstrated Gender-Specific Disparity in Side Effects from Rheumatoid Medications
Nothing to Disclose

Clara E Pérez-Velásquez
Multidisciplinary Unit of Psoriatic Arthritis: Clinical Results
Nothing to Disclose

Lauren M Pachman
Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells
Disclosure:
2- Reveragen
9- SBIR grant Eric P. Hofffman, PhD RevaraGen, unrelated.,

Christian Pagnoux
Efficacy of Leflunomide for Treatment of Vasculitis
Disclosure:
2- Hoffman-La Roche; Hoffman-LaRoche
5- ChemoCentryx; ChemoCentryx;
Genetech/Roche; Genzyme/Sanoﬁ;
GlaxoSmithKline; Hoffman-La Roche; Hoffman-LaRoche; Sanoﬁ
8- Hoffman-La Roche; Hoffman-LaRoche

Ananta Paine
The Mechanism of DC-STAMP-Mediated Signaling in Cell-Cell Fusion and Osteoclast Maturation
Nothing to Disclose

Natalia Palmou-Fontana
Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Arthritis

Penelope E Palominos
Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries
Nothing to Disclose

Orestis Papasouliotis
Population Pharmacokinetics of Atacicept in Systemic Lupus Erythematosus (SLE) – an Analysis of Three Clinical Trials Disclosure:
3- Merck Institute for Pharmacometrics (an affiliate of Merck KGaA, Darmstadt, Germany)

Matthias Papo
Does PR3-ANCA+ Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) Really Exist?
Nothing to Disclose

Matthias Papo
Giant-Cell Arteritis Associated with Myeloproliferative Neoplasms: A Retrospective Case-Control Study
Nothing to Disclose

Dimitrios A Pappas
Comparative Effectiveness of Tocilizumab in Combination with Methotrexate versus Tumor Necrosis Factor Inhibitors (TNFis) in Combination with Methotrexate in Patients with Rheumatoid Arthritis with Prior Exposure to TNFis Disclosure:
1- Corrona, LLC
3- Corrona, LLC
5- AbbVie; Novartis; Roche; Roche Hellas

Dimitrios A Pappas
Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry Disclosure:
1- Corrona, LLC
3- Corrona, LLC
5- AbbVie; Novartis; Roche; Roche Hellas
Dimitrios A Pappas  
Persistence of Tocilizumab Therapy Among Patients with Rheumatoid Arthritis: Data from the US-Based Corrona Rheumatoid Arthritis Registry  
Disclosure:  
1- Corrona, LLC  
3- Corrona, LLC  
5- AbbVie; Novartis; Roche; Roche Hellas

Eun Hye Park  
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren's Syndrome  
Nothing to Disclose

Eun Hye Park  
The Comparative Risk of Osteoporotic Fractures Among Patients with Rheumatoid Arthritis Receiving TNF Inhibitors versus Other Biologics: A Nation-wide Cohort Study in Korea  
Nothing to Disclose

Jinsu Park  
Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database  
Nothing to Disclose

Sunyoung Park  
KINE-101, a Novel Synthetic Peptide with Potent Regulatory T Cells Activation to Treat Rheumatoid Arthritis  
Nothing to Disclose

Yong-Wook Park  
Altered Distribution and Enhanced Osteoclastogenesis of Mucosal-associated Invariant T Cells in Gouty Arthritis  
Nothing to Disclose

Youngjae Park  
Distinct Clinical Characteristics of Anti-Ro/SSA Negative Primary Sjögren’s Syndrome: Data from a Cohort for Sjögren’s Syndrome in Korea  
Nothing to Disclose

Youngjae Park  
The Positivity for Anti-centromere Antibody Makes Distinct Clinical Features in Primary Sjögren’s Syndrome: Data from a Prospective Korean Nation-wide Cohort  
Nothing to Disclose

Joanna E Parkes  
The Beneficial Effects of Rituximab Treatment in Myositis May Be Due to the Binding of a Non B-Cell Protein, SMPDL3B, in Skeletal Muscle  
Nothing to Disclose

Christine Parks  
Systemic Lupus Erythematosus and Sjögren’s Syndrome in the Agricultural Health Study: Lower Risk Associated with Childhood Farm Residence and Raising Livestock  
Nothing to Disclose

Manpreet Parmar  
Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease  
Nothing to Disclose

Ioannis Parodis  
Antimalarial Agents Improve Physical Functioning in Patients with Systemic Lupus Erythematosus  
Nothing to Disclose

Ioannis Parodis  
Cytokine and Autoantibody Profiles During Treatment with Belimumab in Patients with Systemic Lupus Erythematosus  
Nothing to Disclose

Simon Parreau  
Adventitial Fibroblast, an Important Actor in Giant Cell Arteritis  
Nothing to Disclose

Virginia Pascual-Ramos  
Nail Abnormalities in a Cohort of Rheumatoid Arthritis Patients: Repetitive Trauma-Related Findings in Toenails Are Associated with Radiographic Damage  
Nothing to Disclose
Virginia Pascual-Ramos
Validation of a Risk Perception Questionnaire Developed for Patients with Rheumatoid Arthritis
Nothing to Disclose

Laura Passalent
Axial Spondyloarthritis: Knowledge, Screening and Referral Practices Amongst Primary Care Providers
Disclosure:
5- Abbvie; Novartis; Janssen; UCB
8- Abbvie; Novartis; Janssen

Akshay Patel
Inactivation of Transaldolase and HRES-1/Rab4 Predisposes to Hepatitis in a Mouse Model of Systemic Lupus Erythematosus
Nothing to Disclose

Pankaj A Patel
Early Treatment Failure with Apremilast Among Biologic-naïve Patients with Psoriatic Arthritis
Disclosure:
3- AbbVie
4- AbbVie

Sneha Patel
The Time Lag – the Race in Diagnosis and Management of Hemophagocytic Lymphohistiocytosis
Nothing to Disclose

Veena Patel
Comparison of Healthcare Resource Utilization (HCRU) and Costs of Type 2 Diabetes Mellitus (T2DM)-Related Complications in Medicare Beneficiaries with Rheumatoid Arthritis (RA) and T2DM Who Initiated Treatment with Abatacept versus Other Targeted Disease-Modifyi Disclosure:
3- Bristol-Myers Squibb

Sarit Sekhar Pattanaik
Causes of Death in SLE: Analysis of Inpatient Deaths from 2000-2018 in a Tertiary Care Hospital in India
Nothing to Disclose

Sofia Pazmino
Including Pain, Fatigue and Functionality Regularly in the Assessment of Patients with Early Rheumatoid Arthritis Separately Adds to the Evaluation of Disease Status
Alexander Peck
Prevalence of Anxiety and Depression in a Cohort of Patients with Rheumatic Diseases on Biological Infusions
Nothing to Disclose

Alexander Peck
Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Nothing to Disclose

Sofia Pedro
Co-morbidities in Patients with OA and RA: Results from a Large US Rheumatic Disease Registry
Disclosure:
3- FORWARD, the National Data Bank for Rheumatic Disease; FORWARD, The National Data Bank for Rheumatic Diseases

Sofia Pedro
Two Decades of Changes in RA Treatment and Disease Outcomes from the United States
Disclosure:
3- FORWARD, the National Data Bank for Rheumatic Disease; FORWARD, The National Data Bank for Rheumatic Diseases

Christine A Pellegrini
Early Start of Outpatient Physical Therapy After Knee Replacement Is Associated with More Objectively-measured Steps and Time Spent Upright
Nothing to Disclose

Jean-Pierre Pelletier
In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Effective as Celecoxib in Reducing Pain and Disease Symptoms
Disclosure:
1- ArthroLab Inc.
5- TRB Chemedica

Rosa Pereira
Searching the Calcinosis Signature: A Case Control Study Analyzing Limited Systemic Sclerosis Female Patients with and Without Calcinosis, Paired by Disease Duration, Age and Body Mass Index
Nothing to Disclose

Carlos Perez-Sanchez
Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus
Nothing to Disclose

Harris Perlman
A Novel Subclass of Intravascular Non-classical, Tissue Resident Synovial Monocyte Is Critical for Rheumatoid Arthritis Pathogenesis
Nothing to Disclose

Rebecca Persson
Rates of Myocardial Infarction, Stroke, and Revascularization Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Disclosure:
2- Celgene Corporation

Cory Perugino
CD8+ Cytotoxic T Lymphocytes Are Clonally-expanded in IgG4-related Disease and Home to Affected Tissues
Disclosure:
2- UCB
5- BMS

Cory Perugino
Clonally Expanded CD4+ Cytotoxic T Cells, Endothelial Cell Apoptosis and the Pathogenesis of Early Systemic Sclerosis
Disclosure:
2- UCB
5- BMS

Charles Peterfy
Inhibition of Structural Joint Damage with Upadacitinib as Monotherapy or in Combination
with Methotrexate in Patients with Rheumatoid Arthritis
Disclosure:
1- Spire Sciences, Inc.
3- Spire Sciences, Inc.
4- Spire Sciences, Inc.
5- AbbVie; Acerta; Amgen; AstraZeneca; Bristol-Myers Squibb; Centrexion; Crescendo Bioscience; Daiichi Sankyo; Daiichi Sankyu; EMD Serono; Five Prime; Five Prime Therapeutics; Flexion Therapeutics; Genentech; Genescence; Gilead; GlaxoSmithKline; Hoffmann-La Roche; Janssen; Lilly; MedImmune; Merck; Modern Bioscience; Novartis; Pfizer; Plexikon; Plexxikon; Regeneron; Salix-Santarus; Samsung; Sanofi; SetPoint; Sorrento 8- Amgen; Bristol-Myers Squibb

Michelle Petri
African-American Risk of Proteinuria After SLE Diagnosis Increases Throughout Thirty Years of Followup
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
Effect of Treatment on Antiphospholipid Antibodies in SLE
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
Hydroxychloroquine Increases Low C3 in SLE
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
Low Vitamin D Is Associated with Miscarriage and Preterm Birth in SLE with a U-shaped Relationship
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
Persistency in Platelet C4d and Thrombosis Risk Score Associate with Thrombosis in Systemic Lupus Erythematosus
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
Stroke Clusters in SLE by Lupus Autoantibodies
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michelle Petri
The Systemic Lupus Erythematosus Cardiovascular Risk Equation
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Michael Pham
Anti-Phosphatidylserine Prothrombin Antibodies as a Predictor of the LAC in an All-Comer Population
Nothing to Disclose

Michael Pham
Is There Clinically Relevant Plasma Interference with ELISA Detection of APS Antibodies? Reproducibility of Serum and Plasma Testing in a Real-World Clinical Setting
Nothing to Disclose

Thao Pham
Rheumatoid Arthritis Activity Assessment with Cellphone Thermal Camera Imaging Compared to Clinical and Ultrasound Assessments
Disclosure:
8- Abbvie; Amgen; Biogen; BMS; Celgene; Fresenius-Kabi; Janssen; Lilly; Medac; MSD;
Nordic; Novartis; Pfizer; Roche-Chugai; Sandoz; Sanofi; UCB

Silvia Piantoni
CXCL13 Serum Levels and Circulating Follicular Helper T-Cells Decrease After Co-stimulation Blockade with Abatacept in Rheumatoid Arthritis
Nothing to Disclose

Silvia Piantoni
Prediction of Clinical Response to Abatacept in Rheumatoid Arthritis Patients Through the Determination of Anti-Carbamylated Proteins Antibodies Levels
Nothing to Disclose

Sonsoles Piera-Velazquez
Induction of a Profibrotic Phenotype in Normal Dermal Fibroblasts by Expression of PIM1 Kinase and Demonstration of Antifibrotic Effects of Inhibition of PIM Kinases in Systemic Sclerosis Dermal Fibroblasts
Nothing to Disclose

Florencia S Pierini
Effect of Tocilizumab on HDL and LDL Characteristics in Patients with Rheumatoid Arthritis: Preliminary Results
Nothing to Disclose

Anjani Pillarisetty
Experience with Biologic Agents for the Treatment of Cardiac Sarcoidosis in a U.S. Academic Medical Center
Nothing to Disclose

Victor Pimentel-Quiroz
Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
Nothing to Disclose

Fernando Pimentel-Santos
Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Nothing to Disclose

Fernando Pimentel-Santos
Muscle Physical Properties in Young Adult Axial Spondyloarthritis Patients, the MyoSpA Study
Nothing to Disclose

Iago Pinal-Fernandez
Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy
Nothing to Disclose

Theodore Pincus
A Fibromyalgia Assessment Screening Tool on a Multidimensional Health Assessment Questionnaire (MDHAQ) Which Does Not Include a Self-Report RADI Painful Joint Count (RADI), FAST3nJC, Recognizes Fibromyalgia Similarly to Other FAST3 Indices Which Include Disclosure:
6- Medical History Services LLC; Medical history services LLC
7- Helath Services; Medical History Services LLC; Medical history services LLC
9- Medical History Services LLC

Theodore Pincus
Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Disclosure:
6- Medical History Services LLC; Medical history services LLC
7- Helath Services; Medical History Services LLC; Medical history services LLC
9- Medical History Services LLC

Theodore Pincus
DMARD-naïve Rheumatoid Arthritis (RA) Patients Have Greater RAPID3 Improvement over 6 Months After 1st Visit Than Patients Who Were Treated Previously Treated with DMARDs, Although Baseline RAPID3 Was Similar: The Importance of Early Treatment Disclosure:
6- Medical History Services LLC; Medical history services LLC
Theodore Pincus
Patient Preference for an Electronic MDHAQ/RAPID3 (Multidimensional Health Assessment Questionnaire/ Routine Assessment of Patient Index Data), Which Gives Similar Results Compared to a Paper Version
Disclosure:
6- Medical History Services LLC; Medical history services LLC
7- Helath Services; Medical History Services LLC; Medical history services LLC
9- Medical History Services LLC

Theodore Pincus
Quantitative Physician Global Assessment of Damage And/or Distress, in Addition to Inflammation, at Routine Rheumatology Care: Documenting the Complexity of Rheumatology Patient Encounters as a Rationale for Possible Higher Reimbursement?
Disclosure:
6- Medical History Services LLC; Medical history services LLC
7- Helath Services; Medical History Services LLC; Medical history services LLC
9- Medical History Services LLC

Carlos Pineda
Is Fibromyalgia Associated with Structural or Functional Abnormalities in Skeletal Muscle?
Nothing to Disclose

Rita A Pineda-Sic
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Nothing to Disclose

Salvatore Pirri
The #Worldlupusday 2019 Across Twitter: An Explorative Analysis of Spreading Concepts and Sentiment Perceptions on Social Media
Nothing to Disclose

Chamaida Plasencia
Infliximab Serum Trough Levels Predict Non-clinical Response in Patients with Axial Spondyloarthritis
Nothing to Disclose

Catherine Poholek
The Transcription Factor STAT3 Regulates Pathogenic Th17 Responses in Autoimmune Disease via Noncanonical Roles
Nothing to Disclose

Mohammad Ryadh Pokeerbux
Anti-MDA5 Dermatomyositis: A Case Series, Systematic Review and Meta-analysis of the Literature
Nothing to Disclose

Ari Polachek
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia – Interim Analysis
Nothing to Disclose

Ari Polachek
Ultrasound and Magnetic Resonance Imaging Evaluation of the Fingers’ Joints of Psoriatic Arthritis Patients – Interim Analysis
Nothing to Disclose

Kristen Polinski
Associations Between Circulating Cytokines and Incident Inflammatory Arthritis in an Anti-citrullinated Protein Antibody Positive Population
Disclosure:
2- Pfizer

Remy A Pollock
Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Nothing to Disclose

Giovanni Pomponio
Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies
Nothing to Disclose

Nantakarn Pongtarakulpanit
Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study
Nothing to Disclose

Janet Pope
A Systemic Review of Factors Associated with Systemic Sclerosis-associated Pulmonary Arterial Hypertension (SSc-PAH)
Disclosure:
2- Amgen; AstraZeneca; Astra-Zeneca; Bayer; BMS; Merck; Pfizer; Roche; Seattle Genetics; UCB
5- AbbVie; Abbvie; Actelion; Actellion; Amgen; Bayer; BMS; Eicos Sciences; Eli Lilly & Company; Eli Lilly and Company; EMERALD; Emerald; Genzyme; Janssen; Lilly; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB
8- UCB

Janet Pope
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Disclosure:
2- Amgen; AstraZeneca; Astra-Zeneca; Bayer; BMS; Merck; Pfizer; Roche; Seattle Genetics; UCB
5- AbbVie; Abbvie; Actelion; Actellion; Amgen; Bayer; BMS; Eicos Sciences; Eli Lilly & Company; Eli Lilly and Company; EMERALD; Emerald; Genzyme; Janssen; Lilly; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB
8- UCB

Janet Pope
Does Improvement in Patient Pain and Fatigue Lag Behind Clinical Remission in Rheumatoid Arthritis Patients? Data from a Rheumatoid Arthritis Registry
Disclosure:

2- Amgen; AstraZeneca; Astra-Zeneca; Bayer; BMS; Merck; Pfizer; Roche; Seattle Genetics; UCB
5- AbbVie; Abbvie; Actelion; Actellion; Amgen; Bayer; BMS; Eicos Sciences; Eli Lilly & Company; Eli Lilly and Company; EMERALD; Emerald; Genzyme; Janssen; Lilly; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB
8- UCB

Dillon Popovich
Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses
Nothing to Disclose

Maria Powell
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Nothing to Disclose

Klára Prajzlerová
The Dysregulation of NK Cells and Non-Conventional NK-T and γδ-T Cells in Individuals at Risk of Developing Rheumatoid Arthritis
Nothing to Disclose

Smriti Prasad
Further Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis of Morphea in Adults and Children
Nothing to Disclose

Smriti Prasad
Principal Components Analysis as a Tool to Identify Lesional Skin Patterns in Cutaneous Lupus Erythematosus
Nothing to Disclose

Andrew D Price
The Effects of Apremilast Therapy on Deployability in Active Duty U.S. Army Soldiers with Plaque Psoriasis and Psoriatic Arthritis
Nothing to Disclose
Lynn Price
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits Nothing to Disclose

Lynn Price
Pre-Biologic Use of Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis in the United States Nothing to Disclose

DIANA PRIETO- PENA
Application of Different Sets of Classification/diagnostic Criteria for Polymyalgia Rheumatica: Single Center Study of 100 Patients Nothing to Disclose

DIANA PRIETO- PENA
Biological Therapy in Non Ischaemic Optic Neuritis Associated to Immune-mediated Inflammatory Diseases: Multicenter Study Nothing to Disclose

DIANA PRIETO- PENA
Certolizumab Therapy in Patients with Uveitis During Pregnancy: Multicenter Study Nothing to Disclose

DIANA PRIETO- PENA
Influence of Steroid Treatment on 18F-FDG PET/CT Accuracy to Detect Vascular and Musculoeskeletal Involvement in Patients with Polymyalgia Reumatica Nothing to Disclose

DIANA PRIETO- PENA
Long-term Survival in Lung Transplantation and Allograft Rejection in Patients with Interstitial Lung Disease Related with Rheumatoid Arthritis: Study from a Single Referral Center Nothing to Disclose

DIANA PRIETO- PENA
Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement Nothing to Disclose

Fabian Proft
Development of an Optimized Online Self-Referral Tool for Early Recognition of Patients with Axial Spondyloarthritis - Data from the OptiRef Study Disclosure:
2- Novartis Pharma
5- Abbvie; Novartis; Pfizer; UCB
8- Abbvie; BMS; MSD; Novartis; Pfizer; Roche; UCB

Fabian Proft
Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER) Disclosure:
2- Novartis Pharma
5- Abbvie; Novartis; Pfizer; UCB
8- Abbvie; BMS; MSD; Novartis; Pfizer; Roche; UCB

Fabian Proft
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial Disclosure:
2- Novartis Pharma
5- Abbvie; Novartis; Pfizer; UCB
8- Abbvie; BMS; MSD; Novartis; Pfizer; Roche; UCB

Mikhail Protopopov
Association of Clinical and Radiographic Phenotype of Axial Spondyloarthritis and Skin Psoriasis: Results from the German Spondyloarthritis Inception Cohort Disclosure: 5- Novartis 8- MSD; Novartis; Pfizer

Mikhail Protopopov
Peripheral Involvement Is Associated with Less Radiographic Spinal Progression in Patients with Early Axial Spondyloarthritis: Results from the German Spondyloarthritis Inception Cohort Disclosure: 5- Novartis 8- MSD; Novartis; Pfizer

Susanna Proudman
Modifiable Factors Associated with Response to Treatment in Early Rheumatoid Arthritis Disclosure: 2- Actelion; Boehringer-Ingelheim; Bayer; Corbus 6- Boehringer-Ingelheim 9- Melrose Health

Katherine Pryor
Reproductive Health Intention Screening in Women with Systemic Rheumatic Diseases: Low Uptake and Gender-Specific Provider Patterns Following a Standardized Intervention Nothing to Disclose

Jerod L Ptacin
THOR-809: An IL-2 Engineered from an Expanded Genetic Alphabet for the Potential Treatment of Autoimmune Disorders Disclosure: 3- Synthorx

Antonia Puchner
Important Role of CD11c+ Cells in Inflammatory Arthritis Nothing to Disclose

Maria Pueyo
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Japanese

Subjects of the ADAMTS-5 Inhibitor S201086/GLPG1972, a Potential New Treatment in OA Disclosure: 3- Institut de Recherches Internationales Servier

Alisson Pugliesi
Pulmonary Cysts: Very Common Finding on Computed Tomography of the Chest of Asymptomatic Patients with Primary Sjögren’s Syndrome Nothing to Disclose

Grégory Pugnet
Increased Risk of Acute Coronary Artery Disease and Ischemic Stroke in Patients with Eosinophilic Granulomatosis with Polyangiitis Nothing to Disclose

Silva Pukšić
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial Nothing to Disclose

Veronica Pulito-Cueto
Endothelial Progenitor Cells in the Pathophysiology of Interstitial Lung Disease Associated with Rheumatoid Arthritis Nothing to Disclose

Amrutesh S Puranik
Interferon Pathway Activation in T Follicular Helper (Tfh) Cell Subsets in Human Myositis Nothing to Disclose

Amrutesh S Puranik
Single Cell Transcriptome Analysis of Circulating Plasmacytoid Dendritic Cells and Switched Memory B-cells in SLE Patients Reveals
Transcriptional Subsets Within the Classical Cell Lineages
Nothing to Disclose

Michael Putman
Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis
Nothing to Disclose

Yan Qin
Combined Detection of Cytokines and Biomarkers Improve the Diagnostic Performance of Bacteria Infection in Rheumatoid Arthritis
Nothing to Disclose

Rubén Queiro
Is There Any Relationship Between Cardiovascular Comorbidity and a Patient-Acceptable Symptom State in Psoriatic Arthritis?
Nothing to Disclose

Rubén Queiro
Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis
Nothing to Disclose

Kaitlin Quinn
Initial Clinical Presentation Is Associated with Outcome in Takayasu’s Arteritis
Nothing to Disclose

Alexis Régent
Management of Severe Renal Disease in Anti-Neutrophil-Cytoplasmic-Antibodies Associated Vasculitis: Role of Rituximab and Plasma Exchange?
Nothing to Disclose

Mislav Radic
Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillaroscopy for Microvascular Assessment in Systemic Sclerosis
Nothing to Disclose

Mislav Radic
Does Digital Thermal Monitoring Correlate to Specific Nailfold Videocapillaroscopy Abnormalities?
Nothing to Disclose

Massimo Radin
A Multicentre Study of 244 Pregnancies in Women with Undifferentiated Connective Tissue Disease: Foetal/Perinatal and Maternal Outcomes and Disease Evolution Towards a Definite Connective Tissue Disease
Nothing to Disclose

Yasser A Radwan
Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases
Nothing to Disclose

Yasser A Radwan
Significance of Abnormal Nailfold Videocapillaroscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Nothing to Disclose

Francisco Ramírez-Valle
A Novel MK2 Inhibitor for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases Disclosure:
3- Celgene Corporation
9- Celgene Corporation (May or may not own equity)

Paula S Ramos
Classical Monocytes from African Ancestry Patients with Systemic Sclerosis Show Transcription and Energy Regulation Gene Expression Signatures
Nothing to Disclose
Rosalind Ramsey-Goldman
Complement Activation in Probable Systemic Lupus Erythematosus (pSLE) May Predict Progression to SLE Defined by Fulfillment of ACR Classification Criteria
Disclosure: 2- Exagen

Siba P Raychaudhuri
Drug-induced IgA Vasculitis: Data from the French Pharmacovigilance Network and the WHO VigiBase
Nothing to Disclose

Siba P Raychaudhuri
JAK-STAT Signaling System in Pannus Formation of Psoriatic Arthritis: A Therapeutic Target
Disclosure: 2- AbbVie; Janssen; Novartis; Pfizer; Pfizer Inc; Sun Pharma
5- Amgen; Janssen; Lilly; Novartis; Pfizer

Solbritt Rantapää-Dahlqvist
Protein Profiling and Network Enrichment Analysis in Individuals Before and After the Onset of Rheumatoid Arthritis
Nothing to Disclose

Cristina Reátegui-Sokolova
Predictors of Renal Damage in Systemic Lupus Erythematosus Patients from Latin America
Nothing to Disclose

Sangita Rastogi
Intraarticular and Circulatory Cytokine Responses to Chlamydia Trachomatis: A Clinical Study in Reactive Arthritis/ Undifferentiated Spondyloarthropathy Patients
Nothing to Disclose

Jürgen Rech
Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Disclosure: 5- BMS; Celgene; Chugai; Novartis; Roche

Siba P Raychaudhuri
Regulatory Role of IL-23 and Its Receptor System in Spondyloarthritis and Its Therapeutic Relevance in anti-IL-17 Failure Patients
Disclosure: 2- AbbVie; Janssen; Novartis; Pfizer; Pfizer Inc; Sun Pharma
5- Amgen; Janssen; Lilly; Novartis; Pfizer

Jürgen Rech
Psoriatic Arthritis - Epidemiology, Incidence Rate in Psoriasis Patients, Comorbidity Profiles and Risk Factor Analysis
Disclosure: 5- BMS; Celgene; Chugai; Novartis; Roche
8- AbbVie; Biogen; BMS; Celgene; MSD; Novartis

Smitha Reddy
Pilot, Randomized, Double-Blinded, Placebo Controlled Efficacy AndSafety Study of a Transdermal Alkalinizing and Pain Relieving Treatment ForAcute Gout Flare
Nothing to Disclose

Imke Redeker
Association of Comorbidities with Disease Activity and Functional Impairment in Axial Spondyloarthritis: Results from a Nationwide Population-Based Study
Nothing to Disclose

Imke Redeker
Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis?
Nothing to Disclose

Tyler Reese
Heart Rate Visit-to-Visit Variability in Patients with Systemic Lupus Erythematosus Is Associated with Increased Mortality
Nothing to Disclose

Anthony Reginato
PANLAR Ultrasound Study Group
Recommendations for the Use of Imaging in the Management of Patients with Gout
Disclosure: 5- Eli Lilly and Company; Novartis; Horizon

Tatiana Reitblat
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Nothing to Disclose

Kimberly J Reiter
Rheumatologists’ Opinions and Use of Telemedicine in the Southwestern U.S
Nothing to Disclose

Rosanne Reitsema
Elevated Proliferative Capacity of CD8+ T Cells in Giant Cell Arteritis
Nothing to Disclose

Elaine F Remmers
Genetic Evidence for Recent Positive Selection of the HLA-B*51:01 Allele in the Turkish Population, a Population with a High Prevalence of HLA-B*51-Associated Behçet’s Disease
Nothing to Disclose

Iván Dario Remolina Rincón
Sarcopenia in Systemic Sclerosis
Nothing to Disclose

Claire Rempenault
Risk of Diverticulitis and Gastro-Intestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab and Abatacept: A Prospective Propensity-matched Cohort Study
Nothing to Disclose

Sara Remuzgo-Martinez
The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3-Year-Prospective Study from a Referral Center of Lung Transplantation
Nothing to Disclose

Jacinta Renaldi
Improving Patient-Centered Care by Utilizing Lupus Wellness Program
Nothing to Disclose

Thomas Renson
High Prevalence of Sacroiliac Bone Marrow Edema on MRI in Post Partum Women: A Temporary Phenomenon
Nothing to Disclose

Soledad Retamozo
Systemic Manifestations of Primary Sjögren Syndrome out of the ESSDAI Classification: Prevalence and Clinical Relevance in a Large International, Multi-ethnic Cohort of Patients
Nothing to Disclose

Soledad Retamozo
The Prevalence of 78 Autoimmune Diseases in Catalonia (MASCAT-PADRIS Big Data Project)
Nothing to Disclose

Miriam Retuerto
Polyarthritis Rheumatica: New Therapeutic Strategy Based on Low Dose Metrotexate Plus Local Infiltration with Corticosteroids
Nothing to Disclose

John D Reveille
Effects of Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody, on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 1-Year Results of a Phase III Trial Disclosure:
2- Abbvie; Eli Lilly; Janssen; Janssen Research & Development, LLC; Pfizer
5- CB; Eli Lilly; Novartis; Pfizer; UCB
8- Eli Lilly

Richard Reynolds
Whole Blood RNA Sequencing Study of Gout Cases and Controls Demonstrates Transcriptomic Differences with Relevance to Inflammatory Cell Activation
Nothing to Disclose

Ileana Cecilia Reynosa-Silva
Are Rheumatologists Correctly Identifying and Controlling Traditional Cardiovascular Risk Factors?
Nothing to Disclose

Leyre Riancho-Zarrabeitia
Antiphospholipid Syndrome (APS) in Systemic Lupus Erythematosus (SLE) Leads to a More Severe Disease Disclosure:
8- Abbvie

Do All Antiphospholipid Antibodies Confer the Same Risk for Major Organ Involvement in Systemic Lupus Erythematosus Patients? Disclosure:
8- Abbvie

Ana Ribeiro
Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort
Nothing to Disclose

Antonella Riccardi
Undifferentiated Connective Tissue Disease at Risk for SSc: Potential Role of Circulating CXCL-10, CXCL-11 and IL-33 in Predicting Disease Evolution
Nothing to Disclose

Christophe Richez
Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis Disclosure:
5- astrazeneca; BMS; Glenmark; Janssen; Lilly; Pfizer; Roche; UCB
8- astrazeneca; BMS; Glenmark; Janssen; Lilly; Pfizer; Roche; UCB

Jutta Richter
Mobile Responsive App – Useful Additional Tool for Data Collection in the German Pregnancy Register Rhekiss?
Nothing to Disclose

Michael D Richter
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Nothing to Disclose

Edd Ricker
B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
Nothing to Disclose

Casey A. Rimland
Outcome Measures in Large-Vessel Vasculitis: Relationships Between Patient, Physician, Imaging, and Laboratory-Based Domains
Nothing to Disclose

Ariana Ringer
Screening and Follow-up of Patients with Rheumatic Diseases and Rheumatological Treatments Infected with Trypanosoma Cruzi (American Trypanosomiasis or Chagas' Disease). Is It Possible a Reactivation?
Nothing to Disclose

Garth Ringheim
Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Disease: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures
Nothing to Disclose

Sarah Ringsted
Idiopathic Granulomatous Mastitis: The Role of Rheumatologists in Treating This Rare Cause of Breast Pain
Nothing to Disclose

Christopher T Ritchlin
Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
Disclosure:
2- AbbVie; Amgen; Janssen Research & Development, LLC; Pfizer; UCB
5- AbbVie; Amgen; BMS; Janssen; Lilly; Novartis; Pfizer Inc; UCB
9- AbbVie

Elodie Rivière
An ex-vivo Assay to Evaluate the Efficacy of Different Treatments for Inhibiting B Lymphocytes Activation by Salivary Gland Epithelial Cells in Sjögren’s Syndrome
Nothing to Disclose

Janet Roberts
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Nothing to Disclose

Philip C Robinson
Colchicine Prophylaxis of Gout Flares When Commencing Allopurinol Is Very Cost Effective: A Health Economic Analysis
Nothing to Disclose

Beatriz Rocha
Identification of Distinct Lipidomic Profiles in Synovial Membranes from Inflammatory Arthritis by Mass Spectrometry Imaging
Nothing to Disclose

Laurindo Rocha Jr
Association of Sexual Dysfunction and Depression in Rheumatoid Arthritis Female Patients
Nothing to Disclose

Laurindo Rocha Jr
Biological Therapy Is Associated with Faster Recovery and Lower Frequency of Switch Treatment in Patients with Chikungunya Fever
Nothing to Disclose

Damien Roche
Systematic Literature Review and Network Meta-Analysis Comparing Incidence of Uveitis and IBD in Axial Spondyloarthritis Patients Treated with Anti-TNF versus Anti-IL17A in Placebo Controlled Randomized Trials
Nothing to Disclose

Edward Roddy
“If It Was Unicorn Dust I’d Have It Again.” Patient Experiences of Hip Osteoarthritis and Treatments in the Hip Injection Trial
Nothing to Disclose

Luis Rodríguez-Rodríguez
Outpatient Readmission in Rheumatology: A Machine Learning Predictive Model of Patient’s Return to the Clinic
Nothing to Disclose

Luis Rodriguez-Rodriguez
Predictors of Health-Related Quality of Life in Patients with Musculoskeletal Diseases: A Longitudinal Analysis from an Electronic Health Record Database
Nothing to Disclose

Santiago Rodrigues-Manica
Effectiveness of Switching Between TNF Inhibitors in Patients with Axial Spondyloarthritis: Is the Reason to Switch Relevant?
Nothing to Disclose

MARIA FLORENCIA Rodriguez
Primary Sjögren’s Syndrome and Development of Another Connective Tissue Disease During Follow-up
Nothing to Disclose

Martin A Rodriguez
Arthritis, Physical Function, and Disability Among Older Mexican Americans over 20-Years of Follow-up
Nothing to Disclose

Martin A Rodriguez
Arthritis, Upper-Lower Extremity Functional Limitations, and Disability in American Older Adults: Findings from the National Health and Aging Trends Study (NHATS)
Nothing to Disclose

Sebastian C Rodriguez-Garcia
Exposure to Avian and Fungal Antigens in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease: Something to Keep in Mind
Nothing to Disclose

Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Nothing to Disclose

Alicia Rodriguez-Pla
Geographic Disparities in Mortality Rates of Vasculitis in the United States: 1999 to 2017
Nothing to Disclose

Alicia Rodriguez-Pla
Giant Cell Arteritis Diagnostic Workup Among Medicare Beneficiaries
Nothing to Disclose

Jennifer L Rogers
Disability Among Subtypes of SLE
Nothing to Disclose

Cleo Rogier
Is Shoulder Involvement an Early Feature of Rheumatoid Arthritis in Clinically Suspect Arthralgia? A Longitudinal Ultrasound Study
Nothing to Disclose

Juanita Romero-Diaz
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-Calcification and Its Progression in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

David Roofeh
Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions
Nothing to Disclose

Zulema Rosales Rosado
Discontinuation of Disease Modifying Drugs Due to Inefficacy in Patients with Incident Rheumatoid Arthritis
Nothing to Disclose

Rebecca Ross
BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent
IFN Activation and Tissue Fibrosis in vitro and in vivo
Nothing to Disclose

Yael Ross
Affect of Obesity on Multi-Biomarker Disease Activity (MBDA) Measurements in Rheumatoid Arthritis (RA) Patients
Nothing to Disclose

Hannah M Rowe
In Vitro Human Enthesitis Model with Induced IL-17A and TNFα from CD4+ and CD8+ T Cells and Effect of Pharmacological Antagonism with Janus Kinase and Retinoic Acid Receptor-related Orphan Receptor γ Inhibition
Nothing to Disclose

Barbara Ruaro
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
Nothing to Disclose

Andrea Rubbert-Roth
Development and Outcome of Aortic Complications During Tocilizumab (TCZ) Treatment of GCA and Histopathologic Evidence of Residual Inflammation
Nothing to Disclose

Esteban Rubio
Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Disclosure: 2- Gebro

Michal Rudnik
Altered Inflammatory Response of Macrophages in the Fosl-2 Transgenic Mouse Model of Systemic Sclerosis
Nothing to Disclose

Linda Russell
Readmissions After Staged vs Simultaneous Bilateral Total Knee Replacements (TKR)
Disclosure:
6- Arthritis Foundation

Tobias Russell
IL-17A Induces Distinct Functional Differences Between Two Novel Mesenchymal Stem Cell Populations Identified at the Human Enthesis
Nothing to Disclose

Philipp Rustler
Seasonal Clustering of Acute Sarcoidosis in South-West Germany and Associations with Particulate Matter Air Pollution
Nothing to Disclose

Carlos Sánchez-Piedra
Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
Nothing to Disclose

Alain Sánchez-Rodríguez
Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management
Nothing to Disclose

Alain Sánchez-Rodríguez
Rheumatic Immune-related Adverse Effects from Checkpoint Inhibitor Immunotherapy in Patients with Solid Tumors in a Latin American Population
Nothing to Disclose

Kenneth Saag
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Disclosure:
2- Amgen; Ampel; Horizon; Ironwood/AstraZeneca; Mereo; Radius Health; SOBI; Sobi; Takeda
5- Abbvie; AbbVie; Amgen; Bayer; Gilead; Horizon; Ironwood/AstraZeneca; Kowa; kowa;
Kenneth Saag
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry Disclosure:
2- Amgen; Ampel; Horizon; Ironwood/AstraZeneca; Mereo; Radius Health; SOBI; Sobi; Takeda
5- Abbvie; AbbVie; Amgen; Bayer; Gilead; Horizon; Ironwood/AstraZeneca; Kowa; kowa; Radius; Radius Health; Roche/Genentech; SOBI; Sobi; Takeda; Teijin; Tejin
Silvana Saavedra
Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis
Nothing to Disclose
Sara Sabbagh
Anti-mitochondrial Autoantibodies in Idiopathic Inflammatory Myopathies
Nothing to Disclose
Sara Sabbagh
Features of Pneumocystis Jirovecii Pneumonia in Juvenile Idiopathic Inflammatory Myopathy
Nothing to Disclose
Lena Sabih
The Impact of Race on Birth Outcomes Among Women with Autoimmune Rheumatic Diseases
Nothing to Disclose
Mohammed J Saeed
National Estimates of Pain Medication Use in Patients with Osteoarthritis
Nothing to Disclose
Stephanie A Saeli
Associations of Disease-Modifying Anti-Rheumatic Drug (DMARD) Adherence with Time to First Biologic and Cycle Time on DMARDs, and Healthcare Utilization/Cost in a New RA Patient Cohort
Nothing to Disclose
Victoria Saferding
The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis
Nothing to Disclose
Koji Sakurabas
Metabolic Changes Induced by Anti-Malondialdehyde Antibodies Promote Osteoclast Development
Nothing to Disclose
Maria Salgado Guerrero
Clinical and Serological Lupus Activity Before and After Developing End Stage Renal Disease
Nothing to Disclose
Maria Salgado Guerrero
Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease
Nothing to Disclose
Elizabeth Salt
A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis Disclosure:
2- Pfizer; Pfizer and IHI
Alexandra P Saltman
Bioethics for the Rheumatologist: A Needs Assessment, Curriculum Development, and Knowledge Assessment of Bioethical Topics for Rheumatology Trainees
Nothing to Disclose
Carlo Salvarani
Adult Primary Central Nervous System Vasculitis Treatment and Course: A Long-term Follow-up Study
Nothing to Disclose
Carlo Salvarani
Flares and Long-term Remission in Large-vessel Giant Cell Arteritis in Northern Italy:
Characteristics and Predictors in a Long-term Follow-up Study
Nothing to Disclose

Anthony Sammel
PET/CT Vascular Findings at Baseline and Six Months in Patients with Newly Diagnosed Giant Cell Arteritis
Nothing to Disclose

Einer Sanchez Prado
Rheumachek - Spondyloarthritis: Comprehensive Fast-track Diagnosis Program. What Benefits Does It Offer in a Developing Country?
Nothing to Disclose

Catalina Sanchez-Alvarez
Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Nothing to Disclose

Lara Sanchez-Bilbao
Comparative Study of Renal Transplantation Due to Rapidly Progressive Glomerulonephritis (RPGN): Study of 42 Patients from a Single Tertiary Centre
Nothing to Disclose

Lara Sanchez-Bilbao
Ocular Scleral Pathology and Relationship with Autoimmune Diseases: Study of 101 Patients from a Single Universitary Centre
Nothing to Disclose

Lara Sanchez-Bilbao
Systemic and Ocular Sarcoidosis Study of 381 Patients from a Single Universitary Centre in the Last 20 Years
Nothing to Disclose

Virinderjit Sandhu
An Observational Analysis of the Co-existence of Brugada Syndrome in Patients with Spondyloarthritis; A Potentially Important Link
Nothing to Disclose

Vaneet K Sandhu, MBBS

Bone Health in Lupus: Findings from the Southern California Lupus Registry
Nothing to Disclose

Sabina Sandigursky
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Nothing to Disclose

Maria Graciela Sandoval-Flores
Factors Influencing the ESSPRI Index in Primary Sjögren’s Syndrome
Nothing to Disclose

Sébastien Sanges
Teaching Rare Diseases Through Role Play: Results of an Experimental Workshop About Raynaud Phenomenon
Nothing to Disclose

Liliana Santos Ribeiro
The Expression of the Interferon Inducible Gene SERPING1 Is Reduced by Rituximab and Correlates with Clinical Response in Systemic Lupus Erythematosus
Nothing to Disclose

Tsuneo Sasai
Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?
Nothing to Disclose

Sho Sasaki
Comparison of the Efficacy and Safety of Abatacept in Rheumatoid Arthritis Patients with and Without Interstitial Lung Disease
Nothing to Disclose

Sho Sasaki
New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody
Nothing to Disclose

Hani Manfred Sauermilch
Adipocytokines and Obesity in the Context of Rheumatoid and Osteoarthritis Mouse Models

38
Tetsuji Sawada
Importance of Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) as a Novel Disease Activity Biomarker of Systemic Lupus Erythematosus
Nothing to Disclose

Sujata Sawhney
Factors Impacting Referral of Juvenile Idiopathic Arthritis Patients to a Tertiary Level Pediatric Rheumatology Center in North India
Nothing to Disclose

Amit Saxena
Evaluation of Factors Associated with Bone Structure in an SLE Cohort Measured by Clinical 3T MRI and DEXA
Disclosure:
2- Exagen

Didem Saygin
Musculoskeletal Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy: Single Center Experience
Nothing to Disclose

Santiago Scarafia
Diagnostic Delay in Spondyloarthritis
Nothing to Disclose

Martin Schaefer
Which Factors Influence Achievement of Treatment Satisfaction in Rheumatoid Arthritis?
Nothing to Disclose

Valentin Schaefer
Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study
Nothing to Disclose

Jennifer R Schenfeld
Impact of Formulary Change on TNFi Treatment Patterns and Healthcare Utilization Costs in RA Patients
Disclosure:
3- Amgen, Inc
4- Amgen, Inc

Georg Schett
Anti-citrullinated Vimentin Antibodies Are Associated to Early Deterioration of Cortical Bone and Volumetric Bone Mineral Density in Finger Joints in RA-at-risk Patients
Disclosure:
2- BMS, Celgene, GSK, Lilly, Novartis
5- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB
8- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer

Georg Schett
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Disclosure:
2- BMS, Celgene, GSK, Lilly, Novartis
5- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB
8- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer

Orit Schieir
Real-World Remission Outcomes in the First Year Following RA Diagnosis Vary Considerably with the Disease Activity Index Used and a Sizable Proportion Have Persistent Active Disease Across All Measures: Results from the Canadian Early Arthritis Cohort (CA
Nothing to Disclose

Naomi Schlesinger
Development of a Multivariable Improvement Measure for Gout
Disclosure:
2- amgen; Astra Zeneca; pfizer
5- Horizon; horizon; IFM Therapeutics; Mallinckrodt Pharmaceuticals; Novartis; olatec; selecta

Naomi Schlesinger
Improvement in Hepatic Fibrosis Estimated by Fibrosis-4 (FIB-4) Index in Subjects with Chronic Refractory Gout Treated with Pegloticase
Disclosure:
2- amgen; Astra Zeneca; pfizer
5- Horizon; horizon; IFM Therapeutics;
Mallinckrodt Pharmaceuticals; Novartis; olatec; selecta

Naomi M Schlesinger
Increased Physical Activity in Gout Patients Correlates with Better Prognosis, Decreased Pain, and Suppressed C-Reactive Protein Levels
Disclosure:
2- amgen; pfizer
5- horizon pharma; IFM Therapeutics;
Mallinckrodt Pharmaceuticals; Novartis; olatec; Selecta Biosciences

Naomi Schlesinger
Rheumatologist Care Is Associated with Fewer Emergency Room Visits by Persons with Gout
Disclosure:
2- amgen; Astra Zeneca; pfizer
5- Horizon; horizon; IFM Therapeutics;
Mallinckrodt Pharmaceuticals; Novartis; olatec; selecta

Maria Schletzbaum
Healthcare Factors More Predictive of Smoking Cessation in Patients with Rheumatoid Arthritis Than Patient Characteristics
Nothing to Disclose

Gabriela Schmajuk
Patterns of Medication Use for Patients with Sarcoidosis: Data from the ACR’s RISE Registry
Nothing to Disclose

Gabriela Schmajuk
Pre-treatment Screening for Hepatitis B and C Among Users of Biologics or New Synthetic Disease Modifying Drugs: An Analysis Using RISE Data
Nothing to Disclose

Marc Schmalzing
Etanercept Biosimilar GP 2015 (Erelzi®) in Rheumatic Diseases: Interim Analysis of Real-World Data from COMPACT: A Multicentric, Prospective, Observational Cohort Study

Disclosure:
2- AbbVie, Actelion, BMS, Celgene, Chugai/Roche, Genzyme, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Shire (Baxalta), UCB
5- AbbVie, Actelion, BMS, Celgene, Chugai/Roche, Genzyme, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Shire (Baxalta), UCB
7- AbbVie, Actelion, BMS, Celgene, Chugai/Roche, Genzyme, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Shire (Baxalta), UCB
8- AbbVie, Actelion, BMS, Celgene, Chugai/Roche, Genzyme, Hexal/Sandoz, Janssen-Cilag, MSD, Novartis, Pfizer, Sanofi Pasteur, Shire (Baxalta), UCB

Nimisha Schneider
Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics
Disclosure:
3- PatientsLikeMe, Inc.; PatientsLikeMe, Inc.

Thomas J Schnitzer
What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatologists, Orthopaedic Surgeons, and Primary Care Physicians?
Disclosure:
2- AbbVie; Eli Lilly and Company; Flexion; Galapagos; Grunenthal; Kolon TissueGene; Pfizer; Regeneron
5- Eli Lilly and Company; Pfizer

Katherine Schultz
Addressing the Pediatric Rheumatology Physician Shortage: Does Early Exposure Matter?
Nothing to Disclose

Katherine Schultz
We Can Do Better: Evaluating Inpatient Pediatric Rheumatology Inpatient/Consult Service Performance
Alexandra Schwab
Sleep Quality Among Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Noa Schwartz
Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model
Nothing to Disclose

Sergio Schwartzman
Inflammatory Bowel Disease and Anterior Uveitis in Patients Treated with Ixekizumab for Radiographic Axial Spondyloarthritis: Results from Two Phase 3 Studies Through 52 Weeks Disclosure:
2- Janssen Research & Development, LLC
4- Amgen; Boston Scientific; Gilead Sciences; Medtronic; Pfizer
5- AbbVie; Crescendo Bioscience; Dermtech; Eli Lilly and Company; Gilead Sciences; Janssen Pharmaceutica; Myriad Genetics; Novartis; Regeneron; Samsung; Sanofi; UCB
6- National Psoriasis Foundation
8- AbbVie; Eli Lilly and Company; Genentech; Janssen Pharmaceutica; Novartis; Pfizer; Regeneron; Sanofi; UCB
9- Myriad Genetics

Sergio Schwartzman
United States Rheumatology Practice-Based Real-World Evidence of Infusion Reactions in Rheumatoid Arthritis Patients Treated with Intravenous Golimumab or Infliximab: Impact of Prior Biologic Exposure and Methotrexate Utilization Disclosure:
2- Janssen Research & Development, LLC
4- Amgen; Boston Scientific; Gilead Sciences; Medtronic; Pfizer
5- AbbVie; Crescendo Bioscience; Dermtech; Eli Lilly and Company; Gilead Sciences; Janssen Pharmaceutica; Myriad Genetics; Novartis; Regeneron; Samsung; Sanofi; UCB
6- National Psoriasis Foundation

Savo Sciascia
Added Clinical Utility of Testing for Extra-Criteria Antibodies Specificities Beyond Sapporo and Sydney Criteria Recommendations Nothing to Disclose

Savo Sciascia
Identifying Phenotypes of Patients with Antiphospholipid Antibodies: Results from a Cluster Analysis in a Large Cohort of Patients Nothing to Disclose

Robert H Scofield
Anti-ovarian Antibodies Are Not Associated with Premature Menopause in SLE Treated with Cyclophosphamide
Nothing to Disclose

Robert H Scofield
Association of Rheumatic Autoimmune Disease, Including Rheumatoid Arthritis, with Post-Traumatic Stress Disorder but Not Traumatic Brain Injury in Veterans
Nothing to Disclose

Marco Sebastiani
Therapeutic Strategies and Survival in Patients with Interstitial Pneumonia with Autoimmune Features
Nothing to Disclose

Dale Seguin
Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE
Nothing to Disclose

Luciana Seguro
Bone Metabolism Impairment in Heart Transplant: Results from a Prospective Cohort Study
Nothing to Disclose

Sonya Selvaraj
Targeted Education Improves Awareness of Reproductive Health Issues Among Women with Rheumatologic Diseases
Nothing to Disclose

Luca Semerano
Serum Long-chain n-3 and -6 Fatty Acids Are Associated with Disease Feature at Onset and with 6-month Disease Activity in Early RA: Results from the ESPOIR Cohort
Nothing to Disclose

Mitali Sen
Pregnancy in Patients with Systemic Lupus Erythematosus After Cyclophosphamide Therapy
Nothing to Disclose

Rouhin Sen

Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Nothing to Disclose

Mi Ryoung Seo
Clinical Relevance According to Staining Patterns and Titers of Antinuclear Antibody
Nothing to Disclose

Loqmane Seridi
Baseline Cytotoxic Gene Expression Associates with Ustekinumab Response in Systemic Lupus Erythematosus
Disclosure:

Raphaèle Seror
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Disclosure:

Eliana R Serrano
Performance of the “Do You Know What I Mean” Questionnaire in the Assessment of Disease Knowledge in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Rosa Maria Serrano
Comparison of the Physicians’ Clinical Diagnosis and the EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a Multiethnic Cohort
Nothing to Disclose

Juan Sevillano
Tolerance, Survival, and Adherence to Methotrexate Treatment in Patients with Rheumatoid Arthritis
Nothing to Disclose

Ecem Sevim
Mouse SLE Studies Do Not Describe Human SLE
Nothing to Disclose

Ecem Sevim
The Clinical and Laboratory Characteristics of Antiphospholipid Antibody Positive Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")
Nothing to Disclose

Philipp Sewerin
Delayed Gadolinium-enhanced MR Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX versus Placebo Plus MTX on Cartilage in Early RA Patients (CAR-ERA-Study)
Disclosure:
2- AbbVie; Celgene; Chugai; Janssen-Cilag; Lilly; Novartis; Pfizer; UCB
5- AbbVie; Biogen; BMS; Celgene; Chugai; Hexal; Janssen-Cilag; Lilly; Novartis; Pfizer; Roche; Sanofi-Genzyme; Swedish Orphan Biovitrum; UCB
8- AbbVie; Biogen; BMS; Celgene; Chugai; Hexal; Janssen-Cilag; Lilly; Novartis; Pfizer; Roche; Sanofi-Genzyme; Swedish Orphan Biovitrum; UCB

Andrew Shaffer
Longitudinal Variation in Repeat Serum Urate Levels: Relationship with Hyperuricemia Classification
Nothing to Disclose

Ankoor Shah
Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry Disclosure:
2- Boehringer-Ingelheim; Bristol-Myers Squibb; Reata

Bhakti Shah
Revising the SLEDAI-2K to Include Additional Constitutional Symptoms to More Accurately Assess Lupus Disease Activity
Nothing to Disclose

Charmi Shah
Extracellular Adenosine Increases IL-6 Production by Aging Tenocytes and May Contribute to the Age-related Pattern of Polymyalgia Rheumatica
Nothing to Disclose

Victoria Shanmugam
Asymptomatic Scleroderma Antibody Positivity and Progression to Systemic Sclerosis Disclosure:
2- AbbVie

Victoria Shanmugam
Impact of Smoking Status on Remission in Hidradenitis Suppurativa Disclosure:
2- AbbVie

Victoria Shanmugam
The Collaborative National Quality and Efficacy Registry for Scleroderma: Data Completion Outcomes from a Multicenter United States Cohort Using Guideline-Based Registry Practices Disclosure:
2- AbbVie

Chanakya Sharma
Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Nothing to Disclose

Shefali k sharma
A Comparison of Risk of Ovarian Failure Following Intravenous Cyclophosphamide Therapy in Juvenile versus Adult Systemic Lupus Erythematosus
Nothing to Disclose

Shefali k sharma
Prognostic Role of Measurement of Renal Resistive Index in Systemic Sclerosis
Nothing to Disclose

Taran S Sharma
Factors Associated with Clinical Disease Activity Index Adoption at an Academic Rheumatology Practice
Nothing to Disclose

Rupal Shastri
Duloxetine for Chronic Pain Management in a Tertiary Care Rheumatology Practice: How Patients Are Doing in the Real World
Nothing to Disclose

Anna Sheahan
Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting
Disclosure:
1- UCB Pharma
3- UCB Pharma

Anna Sheahan
Inadequate Response Within a Year of Biologic and Oral Synthetic DMARD Treatment Initiation Among Psoriatic Arthritis Patients in the USA Real-World Setting
Disclosure:
1- UCB Pharma
3- UCB Pharma

Anna Sheahan
Opioid Use Surrounding Diagnosis of Inflammatory Arthritis
Disclosure:
1- UCB Pharma
3- UCB Pharma

Miriam A Shelef
Autoantibodies in Rheumatoid Arthritis Target Citrulline-Containing and Native Epitopes from Conformationally Disordered Regions of Proteins
Nothing to Disclose

Fang Shen
Blockade of Antigen-specific T Cell Activation by a Non-Depleting Anti-HLA-DR Monoclonal Antibody with a Unique Binding Epitope
Disclosure:
1- Janssen Research, Johnson&Johnson
3- Janssen Research, Johnson&Johnson
4- Janssen Research, Johnson&Johnson

Jun Shen
Exposure–Response Modeling of an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, BMS-986165, for Pain Visual Analog Scale Score, in Patients with Psoriasis and Musculoskeletal Symptoms
Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb

Min Shen
Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Nothing to Disclose

Yawen SHEN
Seasonal Variation in Idiopathic Inflammatory Myopathies Incidence and Presentation: A Retrospective Study in Beijing and Hong Kong
Nothing to Disclose

Hui Shi
Elevated Levels of the Neutrophil Extracellular Trap-binding Protein LILRA3 in Primary Antiphospholipid Syndrome
Nothing to Disclose

Jing Shi
Aberrant M1 Polarization of Macrophages in Behcet’s Disease
Nothing to Disclose

Sheue-Fang Shih
Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis
Disclosure:
1- Taiwan Liposome Company, Ltd.
3- Taiwan Liposome Company, Ltd.

Yenju Shih
Association Between Ambient Air Pollutant Exposures and Childhood-Onset Systemic Lupus Erythematosus: A 12-Year Population-Based Cohort Study in Taiwan
Nothing to Disclose

Seung-Cheol Shim
Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model
Nothing to Disclose

Hiromi Shimada
The Titer of Anti-Double Stranded DNA Antibody Could Affect the Apgar Score of Newborns, Which Is Considered as the Predictive Clinical Index for Neurological or Physical Development
Nothing to Disclose

Jieun Shin
CKD-506, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, Regulates Inflammatory Responses Through NF-kB and AP-1 Signaling
Nothing to Disclose

Kichul Shin
Detrimental Factors Affecting the First-year Clinical Response in Korean Patients with Polymyalgia Rheumatica
Nothing to Disclose

Kichul Shin
The Interaction Between Human Leukocyte Antigen Class II Alleles and Seroprotection to Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A post-hoc Analysis
Nothing to Disclose

Yong Dae Shin
Discovery of DW212525, a Potent JAK3 and BTK Dual Target Inhibitor for the Treatment of Autoimmune Diseases
Nothing to Disclose

Shunichi Shiozawa
Systemic Lupus Erythematosus (SLE) Is Caused by Expanded DOCK8-Positive Autoantibody-Inducing CD4 T (aiCD4 T) Cell
Nothing to Disclose

Yuichiro Shirai
Risk Assessment in Connective Tissue Disease Associated Pulmonary Arterial Hypertension
Disclosure:
8- Actelion; Bayer; Boehringer-Ingelheim; Mochida Pharma; Nippon Shinyaku; Pfizer

Yuichiro Shirai
Vonoprazan, a Novel Potassium-competitive Acid Blocker, for Treatment of Proton Pump Inhibitor-resistant Reflux Esophagitis in Patients with Systemic Sclerosis
Disclosure:
8- Actelion; Bayer; Boehringer-Ingelheim; Mochida Pharma; Nippon Shinyaku; Pfizer

Takeshi Shoda
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Nothing to Disclose

Kimberly F Showalter
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
Nothing to Disclose

Kimberly F Showalter
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Nothing to Disclose

Kimberly F Showalter
Reproductive Counseling Documentation Practices for Women Receiving Teratogenic Medications in an Academic Rheumatology Clinic Serving a Medicaid/Medicare Patient Population
Nothing to Disclose

Justine Shum
Type I Interferon Levels Vary with Regional Ancestry in European-derived SLE Cohorts
Nothing to Disclose

Marian M Sidor
Ultrasound Measurement of the Nail Bed Matrix Thickness as a Useful Marker for Scleroderma-Related Interstitial Lung Disease
Nothing to Disclose

Stefan Siebert
Concomitant Treatment with Methotrexate Does Not Increase the Efficacy of Ustekinumab or TNF Inhibitors in Psoriatic Arthritis: Results from a Real-world, Multicenter Study
Disclosure: 2- Abbvie; AbbVie; BMS; Boehringer Ingelheim; Celgene; Janssen; Novartis; Pfizer; UCB
5- Abbvie; AbbVie; Boehringer Ingelheim; Celgene; Janssen; Novartis; Pfizer; UCB
8- Abbvie; Boehringer Ingelheim; Celgene; Janssen; Novartis; Pfizer; UCB

Ruby J Siegel
A Novel Role for Extracellular Sulfatase-2 in Mediating IL-6-induced Adhesion and Migration Molecules in Human Rheumatoid Arthritis
Synovial Fibroblasts
Nothing to Disclose

Daniela Sieghart
Diagnostic Performance of Anti-cyclic Citrullinated Peptide (CCP) 2 and CCP3.1 Assays in Early Rheumatoid Arthritis
Nothing to Disclose

Johanna Sigaux
Women with Rheumatoid Arthritis Have Higher Lifetime Occupational and Non-occupational Exposure to Silica Dust Compared to French General Population
Nothing to Disclose

Viola Signorini
Early Vascular Ageing as a Predictor of Future Cardiovascular Events and Mortality in Systemic Lupus Erythematosus Patients: A Prospective Cohort Study
Nothing to Disclose

Maite Silva-Díaz
Prevalence of Symptomatic Axial Osteoarthritis and Poliarticular Phenotypes in Spain: EPISER 2016 Study
Nothing to Disclose

Joana Silva-Dinis
Patterns and Clinico-Radiological Correlates of Symptomatic Atlantoaxial Joint Involvement in Patients with Calcium Pyrophosphate Deposition Disease
Nothing to Disclose

Thomas Simon
Stimulation of Splenic Neurovascular Bundle Protects Mice from Developing Collagen-induced Arthritis
Nothing to Disclose

Anil Singh
Interleukin-6 Promotes Osteoclast-like Phenotype in Human Rheumatoid Arthritis Synovial Fibroblasts
Nothing to Disclose

Ankita Singh
Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients
Nothing to Disclose

Gurkirpal Singh
Gout in the US: Significant Association with Cardiovascular and Renal Disease Hospitalizations - A Nationwide Study
Disclosure: 2- Horizon Pharma
5- Horizon Pharma

Jasvinder Singh
Alcohol Use Hospitalizations in People with Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain Are Increasing: A Time-trends Study Using the U.S. National Data
Disclosure:
1- Amarin pharmaceuticals; Viking therapeutics
4- Amarin pharmaceuticals; Viking therapeutics
5- Clearview healthcare partners; Clearview healthcare partners; Clinical Care options;
Horizon; Medisys; Putnam associates; Spherix; the American College of Rheumatology; The
American College of Rheumatology; The National Institutes of Health; the National
Institutes of Health; WebMD
6- OMERACT

Jasvinder Singh
Pop a Pill or Give Myself a Shot? Patient Perspectives of Disease-modifying Anti-rheumatic Drug (DMARD) Choice for Rheumatoid Arthritis (RA)
Disclosure:
1- Amarin pharmaceuticals; Viking therapeutics
4- Amarin pharmaceuticals; Viking therapeutics
5- Clearview healthcare partners; Clearview healthcare partners; Clinical Care options;
Horizon; Medisys; Putnam associates; Spherix; the American College of Rheumatology; The
American College of Rheumatology; The National Institutes of Health; the National
Institutes of Health; WebMD
6- OMERACT

Jasvinder Singh
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Disclosure:
1- Amarin pharmaceuticals; Viking therapeutics
4- Amarin pharmaceuticals; Viking therapeutics
5- Clearview healthcare partners; Clearview healthcare partners; Clinical Care options;
Horizon; Medisys; Putnam associates; Spherix; the American College of Rheumatology; The
American College of Rheumatology; The National Institutes of Health; the National
Institutes of Health; WebMD
6- OMERACT

Namrata Singh

Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases
Nothing to Disclose

Paramjit Singh
Assessing Long-term Poor Outcomes in Systemic Lupus Erythematosus Patients with Acute Coronary Syndromes
Nothing to Disclose

Ram Raj Singh
Men and Black Persons Die at Younger Ages from Systemic Sclerosis: A Nationwide Population-based Study
Nothing to Disclose

Sukhraj Singh
Evaluation of Opioid Analgesia in Hospitalized Patients with Acute Crystal Induced Arthritis
Nothing to Disclose

Pamela S Sinicrope
‘It Felt Like I Was Walking on Rocks” Patients Share First Symptoms of RA
Nothing to Disclose

Natalie Sippl
Large Joint Arthritis in Systemic Lupus Erythematosus Is Characterized by TH17 Cells Rather Than B Cell Accumulation
Nothing to Disclose

Sirisha Sirobhushanan
Staphylococcus Aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by Interferon-Mediated Barrier Disruption
Nothing to Disclose

Jagan Sivakumaran
Assessment of the QRISK2, QRISK3, SLE Cardiovascular Risk Equation, Framingham and Modified Framingham Risk Calculators as Predictors of Cardiovascular Disease Events in Systemic Lupus Erythematosus
Nothing to Disclose
Sladjana Skopolja-Gardner
UV Light Stimulates a Systemic Neutrophil Response Associated with Transient Kidney Injury
Nothing to Disclose

Tara Skorupa
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Nothing to Disclose

Anastasia Slobodnick
Allopurinol Use and Type 2 Diabetes Incidence Among Patients with Gout: A VA Cohort Study
Nothing to Disclose

Sarah Smilow
Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative
Nothing to Disclose

Isabel Smith
Depression of Vitamin D Levels After Adult Primary Posterior Spinal Fusion: Are We Adding Insult to Injury?
Nothing to Disclose

Jacquelyn A Smith
Associations Between Baseline and Longitudinal Quantitative Joint Space Width and Incident Hip Osteoarthritis: The Johnston County Osteoarthritis Project
Nothing to Disclose

Josef S Smolen
A Pooled Analysis of 1-year Clinical Outcomes Among 6-month Responders and Non-responders from Three Randomized Controlled Studies of TNF Inhibitor Biosimilars in Patients with Rheumatoid Arthritis
Disclosure:
2- AbbVie; Eli Lilly, Janssen, MSD, Pfizer, Roche
5- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi
8- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi

Josef S Smolen
Comparative Effectiveness of Ustekinumab and TNF Inhibitors in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study
Disclosure:
2- AbbVie; AstraZeneca; Eli Lilly and Company
5- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi
8- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi

Josef S Smolen
Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 Weeks
Disclosure:
2- AbbVie; AstraZeneca; Eli Lilly and Company
5- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi
8- AbbVie; AstraZeneca; Celgene; Celltrion; Chugai; Gilead; ILTOO; Janssen; Novartis-Sandoz; Pfizer; Samsung; Sanofi; Kabi

Vincent Sobanski
Myositis-specific and -associated Antibodies in Systemic Sclerosis: Prevalence and Clinical Associations
Disclosure:
8- Actelion; Grifols; GSK; octapharma; Pfizer; Shire

Cristina Sobrino
B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
Nothing to Disclose

Cristina Sobrino
Diagnosis of Systemic Sclerosis: How and When Nothing to Disclose

Yasumori Sobue
Inhibition of CD44 Intracellular Domain Production Suppresses Bovine Articular Chondrocyte De-differentiation Induced by Excessive Mechanical Stress Loading Nothing to Disclose

Yutaro Soejima Identification of a Distinct Intestinal Behçet’s Disease Cluster in Japan: A Nationwide Retrospective Observational Study Nothing to Disclose

Bret Sohn Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis Nothing to Disclose

Lilian SOLE Autologous Conditioned Serum and Plasma Rich in Growth Factors Show Stronger Evidence of Efficacy Than Other Kinds of Platelet-Rich Plasma Nothing to Disclose

Andrea Soliman Practice Based Education Program to Increase Vaccination Rate in Patients on Immunotherapeutic Agents Nothing to Disclose

Daniel H Solomon Methotrexate Liver Toxicity in a Large Randomized Controlled Trial Disclosure: 2- AbbVie; Abbvie; Amgen; AstraZeneca; Corrona; Genentech; Janssen; Lilly; Pfizer

Olivia Solomon DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients Nothing to Disclose

Emily C Somers Prescription Opioid Use and Osteoporotic Fractures in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort Nothing to Disclose

Jung-Soo Song The Role of a ‘Treat-to-Target’ Approach on Long-term Renal Outcomes in Patients with Gout Nothing to Disclose

Paula Song Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis Nothing to Disclose

Dipekka Soni Anti–MDA5 Antibody Positive Dermatomyositis Is Not Always Associated with Recalcitrant Lung Disease or Mortality Nothing to Disclose

Thierry Sornasse Treatment with Upadacitinib Results in the Normalization of Key Pathobiologic Pathways in Patients with Rheumatoid Arthritis Disclosure: 3- AbbVie 4- AbbVie

Cameron Speyer Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls Nothing to Disclose

Robert Spiera Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis Disclosure: 2- BIP; Chemocentryx; Corbus Pharmaceuticals; Cytori; Formation Biologics; Genentech/Roche; Glaxosmithkline; Sanofi 5- Chemocentryx; Genentech/Roche; Glaxosmithkline; Janssen; Sanofi
Jason M Springer
Clinical Characteristics of a Cohort of Patients with a Self-Reported Diagnosis of Granulomatosis with Polyangiitis or Microscopic Polyangiitis
Disclosure:
9- InflaRx (Site investigator for Clinical Trial sponsored by company.)

Andrew Stahly
Metabolomics Screening in Axial Spondyloarthritis: Identifying Potential Biomarkers
Nothing to Disclose

Rosalinde A Stal
Facet Joint Ankylosis on Whole Spine Low-Dose CT in Radiographic Axial Spondyloarthritis
Nothing to Disclose

Rosalinde A Stal
Spinal Bone Formation as Assessed by Low-Dose CT Scan in Patients with Radiographic Axial Spondyloarthritis – Comparison of the Progression Observed in Vertebrae and Facet Joints
Nothing to Disclose

Pavlos Stamatis
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
Nothing to Disclose

Lisa Stamp
Relationship Between Adalimumab Concentrations, Plasma Cytokines, Anti-drug Antibodies and Disease Activity in Rheumatoid Arthritis
Nothing to Disclose

Lisa Stamp
Relationships Between Allopurinol Dose, Oxypurinol Levels and Serum Urate – in Search of an Oxypurinol Therapeutic Concentration
Nothing to Disclose

Elizabeth E Stanley
Lifetime Direct Medical and Indirect Cost of Knee Osteoarthritis: Impact of Pain and Structural Severity
Nothing to Disclose

Patrick Stauffer
The Use of Microbial Flow Cytometry to Analyze the Intestinal and Oral Microbiota
Nothing to Disclose

Joshua Stefanik
Relation of MRI-detected Structural Damage in the Knee to Anterior Knee Pain: The MOST Study
Nothing to Disclose

Mara Stellato
Myocardial Involvement in SSc: Key Role of Ling-gp38+ Stromal Cells in the Onset of Fibrosis and Defects of the Conduction System
Nothing to Disclose

Oleg Stens
The US Prevalence of Inflammatory Bowel Disease and Associated Axial Pain: Data from the National Health & Nutrition Examination Survey (NHANES)
Nothing to Disclose

Sarah Stewart
Adverse Events During Colchicine Use: A Systematic Review and Meta-Analysis of Randomized Controlled Trial Events
Nothing to Disclose

Sarah Stewart
How Are Flares Reported in Long-term Gout Clinical Trials? A Content Analysis of Randomized Controlled Trials
Nothing to Disclose

Sarah Stewart
Presentation Order Bias in Rheumatology Journals: A Content Analysis
Nothing to Disclose

Blanka Stibunkova
Identification and Characterization of a Novel Dysfunction Variant p.I24T in ABCG2 Transporter in a Family with Early-onset Hyperuricamia and Gout
Nothing to Disclose

William Stohl
Combined First-Trimester Serum BAFF and sFlt-1 Levels as an Early Biomarker of Spontaneous Abortion
Disclosure:
2- GlaxoSmithKline
5- Janssen R&D; Janssen Research & Development

George Stojan
Body Mass Index at Time of Diagnosis Is Predictive of Future Disease Activity in SLE
Nothing to Disclose

George Stojan
Cachexia in Systemic Lupus Erythematosus
Nothing to Disclose

George Stojan
Environmental and Atmospheric Factors in Systemic Lupus Erythematosus: A Regression Analysis
Nothing to Disclose

George Stojan
High Risk Low Attenuation Non-Calcified Coronary Plaque in Lupus vs. Controls
Nothing to Disclose

John H Stone
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
Disclosure:
2- Genentech; Roche; Xencor
5- Genentech; Roche; Xencor

Hana Storkanova
Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis
Nothing to Disclose

Hana Storkanova
Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies
Nothing to Disclose

Rachael Stovall
Relation of Therapies for Ankylosing Spondylitis to Risk of Total Hip and Knee Arthroplasty
Nothing to Disclose

Adrienne Strait
Clinical Trials in Rheumatoid Arthritis Have Inadequate Racial/Ethnic, Gender and Age Diversity: A Systematic Review
Nothing to Disclose

Vibeke Strand
An Examination of Patient-Reported Outcomes Data from a Randomized Trial Examining Etanercept and Methotrexate as Monotherapy or in Combination in Patients with Psoriatic Arthritis
Disclosure:
5- Abbvie; AbbVie; Amgen; Amgen, Abbvie, Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Celgene; Celltrion; CORRONA; Crescendo; Crescendo Bioscience; Eli Lilly; EMD Serono; Genentech; GlaxoSmithKline; GSK; Horizon; Inmedix; Janssen; Kezar; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche; Samsung; Sandoz; Sanofi; Servier; Setpoint; UCB
7- Up to Date
8- AURA; Cleveland Clinic; NACCME; Purdue; RA Forum; RAN; SLRA; Washington University; WIR; WRA

Vibeke Strand
High Baseline Serum IL-6 Predicts Increased Sarilumab Treatment Response for Patient
Reported Symptoms and Health-Related Quality of Life Among Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate Disclosure: 5- Abbvie; Amgen, Abbvie; Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Celgene; Celltrion; CORRONA; Crescendo; Crescendo Bioscience; Eli Lilly; EMD Serono; Genentech; GlaxoSmithKline; GSK; Horizon; Inmedix; Janssen; Kezar; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche; Samsung; Sandoz; Sanofi; Servier; Setpoint; UCB
7- Up to Date
8- AURA; Cleveland Clinic; NACCME; Purdue; RA Forum; RAN; SLRA; Washington University; WIR; WRA

Vibeke Strand
Impact of 24- or 26-Week Upadacitinib Monotherapy on Patient-Reported Outcomes in Patients with Moderately to Severely Active Rheumatoid Arthritis and No Prior Use of or an Inadequate Response to Methotrexate: Results from Two Phase 3 Trials Disclosure: 5- Abbvie; Amgen, Abbvie; Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Celgene; Celltrion; CORRONA; Crescendo; Crescendo Bioscience; Eli Lilly; EMD Serono; Genentech; GlaxoSmithKline; GSK; Horizon; Inmedix; Janssen; Kezar; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche; Samsung; Sandoz; Sanofi; Servier; Setpoint; UCB
7- Up to Date
8- AURA; Cleveland Clinic; NACCME; Purdue; RA Forum; RAN; SLRA; Washington University; WIR; WRA

Vibeke Strand
MTX Withdrawal in Patients with RA Who Achieve Low Disease Activity with Tofacitinib Modified-Release 11 Mg Once Daily + MTX: An Assessment of the Impact on the Short Form-36 Patient-Reported Outcome Disclosure: 5- Abbvie; Amgen, Abbvie; Bayer, BMS, Boehringer Ingelheim, Celltrion, Janssen, Lilly, Merck, Novartis, Pfizer, Regeneron, Samsung, Sandoz, Sanofi, UCB; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Celgene; Celltrion; CORRONA; Crescendo; Crescendo Bioscience; Eli Lilly; EMD Serono; Genentech; GlaxoSmithKline; GSK; Horizon; Inmedix; Janssen; Kezar; Lilly; Merck; Novartis; Pfizer; Regeneron; Roche; Samsung; Sandoz; Sanofi; Servier; Setpoint; UCB
7- Up to Date
8- AURA; Cleveland Clinic; NACCME; Purdue; RA Forum; RAN; SLRA; Washington University; WIR; WRA

Anja Strangfeld
No Confirmation of Increased Risk of Idiopathic Facial Nerve Palsy Under Tocilizumab Disclosure: 8- Abbvie, BMS, MSD, Pfizer, Roche, Takeda and UCB

Anja Strangfeld
No Difference in Treatment Continuation of Different Biologics in Elderly Patients > 70 Years Compared to Younger Patients ≤ 65 Years Disclosure: 8- Abbvie, BMS, MSD, Pfizer, Roche, Takeda and UCB

Ingrid Strusberg
Multicenter, Evaluator-blinded, Randomized, Non-inferiority Study, to Assess the Efficacy, Safety and Immunogenicity of Etanercept Biosimilar (EtaBS) vs. Reference Etanercept (EtaRef) in Combination with Methotrexate for the Treatment of Patients with Rhe Disclosure:
5- SANOFI; genzime
8- BRISTOL MYERS SQUIBB ARGENTINA; GEMA BIOTECH SAU
9- Janssen (Educational activities support); Pfizer (Educational activities support); Abbvie (Educational activities support)

Kaihong Su
Antibodies to Malondialdehyde-acetaldehyde (MAA) Protein Adduct as a Biomarker for Cardiovascular Manifestations in Systemic Lupus Erythematosus
Nothing to Disclose

Rui Su
Imbalance Between Th17 and Regulatory T Cells in Patients with Systemic Lupus Erythematosus
Combined EBV/CMV Viremia
Nothing to Disclose

Yossra A Suliman
Energy Levels: An Overlooked Element in Patient Assessment in Scleroderma
Nothing to Disclose

Alberto Sulli
Assessment of Bone Quality by Trabecular Bone Score (TBS) in Systemic Lupus Erythematosus Patients
Nothing to Disclose

Alberto Sulli
Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns
Nothing to Disclose

Alberto Sulli
Body Composition and Nailfold Videocapillaroscopy Patterns in a Cohort of Systemic Sclerosis Patients

Nothing to Disclose

Alberto Sulli
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Nothing to Disclose

Kathleen E Sullivan
HER2 as a Biomarker of Proliferative Lupus Nephritis in Children
Nothing to Disclose

Kai Sun
Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study
Nothing to Disclose

Kai Sun
Racial Disparities in Factors Associated with SLICC Damage Score Among Patients with SLE
Nothing to Disclose

Kai Sun
Racial Disparities in Lupus Medication Adherence
Nothing to Disclose

Lingyun Sun
Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation
Nothing to Disclose

Meng Sun
Monoclonal ACPA Promote Synovial Fibroblasts Migration Through a Peptidylarginine Deiminases (PAD) Dependent Pathway
Nothing to Disclose

Ying Sun
Interleukin-6 May Predict Disease Relapse During Long-term Follow-up in Takayasu’s Arteritis in a Han Chinese Population
Nothing to Disclose

Ulf Sundin
Ultrasound versus Conventional Treat-To-Target Strategies in Early Rheumatoid Arthritis: Magnetic Resonance Imaging Outcome Data from a 2-year Randomized Controlled Strategy Trial
Nothing to Disclose

Mochihito Suzuki
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Disclosure: 8- Bristol-Myers Squibb

Takeshi Suzuki
Low-grade Total Rheumatoid Arthritis MRI Scoring System Can Predict Successful Half-dose Reduction of MTX in Patients with RA in Clinical Remission
Nothing to Disclose

Thein Swe
Compliance with Hydroxychloroquine Dosage According to 2016 American Academy of Ophthalmology (AAO) Guidelines: A Study with 6591 Patients
Nothing to Disclose

Farhan Syed
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Nothing to Disclose

Hazaefah Syed
Practice Patterns in Bone Health and Vitamin D Management in Sarcoidosis: A Survey of Physicians Who Manage Sarcoidosis
Nothing to Disclose

Ashit Syngle
Impact of Smartphone Application Based Management in Rheumatoid Arthritis: SMART-RA Study
Disclosure:

Teresa Szlachetka
Determinants of Cognitive Function in Rheumatoid Arthritis (RA) Patients
Nothing to Disclose

Masahiro Tada
Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device
Nothing to Disclose

Hideto Takada
Oxidized Human Serum Albumin Is Increased in Systemic Lupus Erythematosus, but Not in Rheumatoid Arthritis
Nothing to Disclose

Hiroyuki Takahashi
Oxytocin Attenuates Tactile Allodynia in Experimental Fibromyalgia Rats
Nothing to Disclose

Nobunori Takahashi
Improvement in Matrix metalloproteinase-3 Levels at 12 Weeks Independently Predicts Achievement of Low Disease Activity at 52 Weeks in Bio-switch Patients with Rheumatoid Arthritis Treated with Abatacept
Disclosure: 8- Abbvie; Astellas Pharma; Bristol-Myers Squibb; Chugai Pharmaceutical; Eisai; Janssen Pharmaceutical; Pfizer; Takeda Pharma; Tanabe Mitsubishi Pharma; UCB

Yuta Takamura
KL-6 Is a Useful Marker to Monitor the Progression of RA-ILD, but Not to Diagnose or Predict the Development of ILD
Nothing to Disclose

Nozomi Takasugi
Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Nothing to Disclose

Sayaka Takenaka
Clinical Features of Elderly-onset Adult Still's Disease
Nothing to Disclose

Mitsuhiro Takeno
Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study
Disclosure:
5- Celgene Corporation
8- Mitsubishi-Tanabe

Tsutomu Takeuchi
Adverse Events of Special Interest in Patients with Rheumatoid Arthritis Treated with Peficitinib in Asian Population: Pooled Safety Findings
Disclosure:
2- AbbVie; AbbVie GK; Asahi Kasei; Asahikasei; Asahikasei Pharma Corp.; Astellas; Astellas Pharma Inc; Astellas Pharma, Inc.; Astra Zeneca; AYUMI; AYUMI Pharmaceutical Corporation; BMS; Bristol-Myers; Chugai; Chugai Pharmaceutical Co, Ltd.; Daiichi Sankyo; Daiichi Sankyo Co., Ltd.; Eisai; Eisai Co., Ltd.; Eli Lilly; Janssen; Mitsubishi Tanabe; Mitsubishi Tanabe Pharma Co.; Mitsubishi-Tanabe Pharma Corp; Nippon Kayaku; Nipponkayaku; Nipponkayaku Co.Ltd.; Novartis; Novartis Pharma K.K; Novartis Pharma K.K.; Pfizer; Pfizer Japan; Pfizer Japan Inc.; Shionogi & Co.; Shionogi & Co., LTD.; Taisho; Taisho Toyama; Takahashi Industrial and Economic Research Foundation; Takeda; Takeda Pharmaceutical Co., Ltd.; Teijin
5- AbbVie; Astellas Pharma, Inc.; Eisai
8- AbbVie; Astellas; Astellas Pharma, Inc.; AstraZeneca; BMS; Bristol-Myers Squibb; Chugai; Daiichi Sankyo; Eisai; Eli Lilly; GSK; Janssen; Mitsubishi-Tanabe Pharma Corp; Novartis; Pfizer; Sanofi; Taisho; Taisho Toyama; Takeda; Teijin; UCB
9- AbbVie GK; Astellas; Astellas Pharma, Inc.; AYUMI; Boehringer-Ingelheim; Bristol–Myers K.K. ; Chugai; Daiichi Sankyo ; Eisai ; Eli Lilly Japan ; Gilead Sciences, Inc.; GlaxoSmithKline K.K ; Janssen Pharmaceutical K.K ; Mitsubishi Tanabe ; Mitsubishi

Tsutomu Takeuchi
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy Disclosure:
2- Mitsubishi Tanabe Pharma Co.; Mitsubishi Tanabe Pharma Corporation
5- Mitsubishi Tanabe Pharma Corporation
8- Mitsubishi Tanabe Pharma Co.; Mitsubishi Tanabe Pharma Corporation

Tsutomu Takeuchi
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Disclosure:
2- AbbVie; AbbVie GK; Asahi Kasei; Asahikasei; Asahikasei Pharma Corp.; Astellas; Astellas Pharma Inc; Astellas Pharma, Inc.; Astra Zeneca; AYUMI; AYUMI Pharmaceutical Corporation; BMS; Bristol-Myers; Chugai; Chugai Pharmaceutical Co, Ltd.; Daiichi Sankyo; Daiichi Sankyo Co., Ltd.; Eisai; Eisai Co., Ltd.; Eli Lilly; Janssen; Mitsubishi Tanabe; Mitsubishi Tanabe Pharma Co.; Mitsubishi-Tanabe Pharma Corp; Nippon Kayaku; Nipponkayaku; Nipponkayaku Co.Ltd.; Novartis; Novartis Pharma K.K; Novartis Pharma K.K.; Pfizer; Pfizer Japan; Pfizer Japan Inc.; Shionogi & Co.; Shionogi & Co., LTD.; Taiho; Taisho; Taisho Toyama; Takahashi Industrial and Economic Research Foundation; Takeda; Takeda Pharmaceutical Co., Ltd.; Teijin
5- AbbVie; Astellas Pharma, Inc.; Eisai
8- AbbVie; Astellas; Astellas Pharma, Inc.; AstraZeneca; BMS; Bristol-Myers Squibb; Chugai; Daiichi Sankyo; Eisai; Eli Lilly; GSK; Janssen; Mitsubishi-Tanabe Pharma Corp; Novartis; Pfizer; Sanofi; Taisho; Taisho Toyama; Takeda; Teijin; UCB
9- AbbVie GK; Astellas; Astellas Pharma, Inc.; AYUMI; Boehringer-Ingelheim; Bristol–Myers K.K. ; Chugai; Daiichi Sankyo ; Eisai ; Eli Lilly Japan ; Gilead Sciences, Inc.; GlaxoSmithKline
K.K; Janssen Pharmaceutical K.K; Mitsubishi Tanabe; Mitsubishi Tsutomu Takeuchi

Longer Term Safety and Efficacy of Peficitinib in Patients with Rheumatoid Arthritis After 22.7 Months Mean Treatment Exposure: Interim Data from a Long-Term, Open-Label Extension Study in Japan, Korea and Taiwan

Disclosure:
2- AbbVie; AbbVie GK; Asahi Kasei; Asahikasei; Asahikasei Pharma Corp.; Astellas; Astellas Pharma Inc; Astellas Pharma, Inc.; Astra Zeneca; AYUMI; AYUMI Pharmaceutical Corporation; BMS; Bristol-Myers; Chugai; Chugai Pharmaceutical Co, Ltd.; Daiichi Sankyo; Daiichi Sankyo Co., Ltd.; Eisai; Eisai Co., Ltd.; Eli Lilly; Janssen; Mitsubishi Tanabe; Mitsubishi Tanabe Pharma Co.; Mitsubishi-Tanabe Pharma Corp; Nippon Kayaku; Nippon Kayaku Co.Ltd.; Novartis; Novartis Pharma K.K; Novartis Pharma K.K.; Pfizer; Pfizer Japan; Pfizer Japan Inc.; Shionogi & Co.; Shionogi & Co., LTD.; Taiho; Taisho Toyama; Takahashi Industrial and Economic Research Foundation; Takeda; Takeda Pharmaceutical Co., Ltd.; Teijin
5- AbbVie; Astellas Pharma, Inc.; Eisai
8- AbbVie; Astellas; Astellas Pharma, Inc.; AstraZeneca; BMS; Bristol-Myers Squibb; Chugai; Daiichi Sankyo; Eisai; Eli Lilly; GSK; Janssen; Mitsubishi-Tanabe Pharma Corp; Novartis; Pfizer; Sanofi; Taiho; Taisho Toyama; Takeda; Teijin; UCB
9- AbbVie GK ; Astellas ; Astellas Pharma, Inc. ; AYUMI ; Boehringer-ingelheim ; Bristol–Myers K.K. ; Chugai ; Daiichi Sankyo ; Eisai ; Eli Lilly Japan ; Gilead Sciences, Inc. ; GlaxoSmithKline K.K ; Janssen Pharmaceutical K.K ; Mitsubishi Tanabe ; Mitsubishi

Mehret B Talabi
Perspectives of Female Patients with Rheumatic Diseases Regarding Pregnancy Planning with Rheumatologists
Nothing to Disclose

Ayantika Talukdar
Sec16A Abnormalities Affect the Intracellular Trafficking of HLA-B27 in the Pathogenesis of Axial Spondyloarthritis
Nothing to Disclose

Angela Tam
Identification of Distinct Pro-Fibrotic Monocyte and Macrophage Subsets in Systemic Sclerosis
Nothing to Disclose

Jeyanesh Tambiah
Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
Disclosure:
1- Samumed, LLC
3- Samumed, LLC

Wenfeng Tan
Conditional Deletion of MKL1 Inhibits Osteoclast Formation and Bone Erosions in Collagen Induced Arthritis Mice
Nothing to Disclose

York Kiat Tan
Thermal Imaging in Rheumatoid Arthritis: A Comparative Analysis with Ultrasonography and Clinical Joint Assessment
Nothing to Disclose

Ikuko Tanaka
Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study
Nothing to Disclose

Ikuko Tanaka
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Nothing to Disclose

Yoshiya Tanaka
A Phase 2 Study of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients with...
Rheumatoid Arthritis Inadequately Responding to Biologics

Disclosure:
2- Asahi-kasei; Asahi-Kasei; Asahi-kasei, BMS, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Takeda, UCB; Astellas Pharma, Inc.; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Eisai; Mitsubishi-Tanabe; Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, Taisho-Toyama.; Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, Eisai; Ono; Sanofi; Takeda; UCB
3- Astellas Pharma, Inc.
5- AbbVie; Astellas Pharma, Inc.; BMS; Eli Lilly; Genzyme; Pfizer; Roche
8- AbbVie; AbbVie; Astellas; Astellas Pharma, Inc.; Astellas, BMS, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe, Pfizer, Sanofi, UCB, YL Biologics; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers; Eisai; Eli Lilly; Eli Lilly and Company; Glaxo-Smithline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi-kasei; Janssen; Mitsubishi-Tanabe; Novartis; Pfizer; Pfizer Inc; Takeda; Teijin; YL Biologics
9- Astellas Pharma ; Astellas Pharma, Inc.

Thai-Son Tang
Genetics of Longitudinal Kidney Function in Children and Adults with Systemic Lupus Erythematosus
Nothing to Disclose

Yan Ki Tang
Comparison of Single and Dual Latent Tuberculosis Screening Strategies Before the Initiation of Biologic and Targeted Therapy in Rheumatological Patients in Hong Kong
Nothing to Disclose

Yundi Tang
LILRA3 Promotes Lupus-like Chronic Graft-versus-Host Disease by Expansion of Follicular Helper T Cells and Anti-dsDNA Autoantibodies
Nothing to Disclose

Tamara Tanner
Seasonality of Cutaneous and Systemic Flares in Adults and Children in the Einstein Lupus Cohort
Nothing to Disclose

Madiha Tariq
Understanding the Mystery of Sarcoidosis: An Academic Rheumatology Center Experience
Nothing to Disclose

Oshrat Tayer-Shifman
Can the Montreal Cognitive Assessment (MoCA) Improve the Automated Neuropsychological Assessment Metrics (ANAM) Performance in Screening for Cognitive Impairment in Lupus Patients?
Nothing to Disclose

Oshrat Tayer-shifman
Persistent Cognitive Impairment in Lupus Patients over 1 Year and Associated Factors
Nothing to Disclose

Oshrat Tayer-Shifman
Validity Evidence Supports the Use of Automated Neuropsychological Assessment Metrics (ANAM) as a Screening Tool for Cognitive Impairment in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Adam Taylor
Patient and Clinical Characteristics Associated with Increased Willingness to Adopt RA Treatment After an Educational Intervention: An Analysis of the Confident Treatment Decisions for Living with Rheumatoid Arthritis (CONTROL-RA) Trial
Nothing to Disclose

Peter C Taylor
A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
Disclosure:
Peter C Taylor
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis Disclosure:
2- Celgene; Eli Lilly and Company; Galapagos; Janssen; Lilly
5- AbbVie; Abbvie; Biogen; Celgene; Eli Lilly and Company; Fresenius; Fresenius SE & Co; Fresnius; Galapagos; Gilead; GlaxoSmithKline; Janssen; Lilly; Nordic Pharma; NORDIC Pharma; Pfizer; Pfizer Inc; Roche; Sanofi; UCB

Steven Taylor
Pre-Rheumatoid Arthritis Diagnosis Prevalence of Commercial CCP Antibody Positivity Increases over Time with Strong Agreement Between Commercial Assays and Positivity Is Predictive of Developing Rheumatoid Arthritis Within 3 Years Nothing to Disclose

Sara K. Tedeschi
Classifying Pseudogout Using Machine Learning Approaches with Electronic Health Record Data Nothing to Disclose

Walcy R Teodoro
Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis Nothing to Disclose

Walcy R Teodoro
Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity Nothing to Disclose

Kenya Terabe
Mechanism of Chondroprotective Effects of 4-Methylumbelliferone and 2-Deoxyglucose Nothing to Disclose

Sima Terebelo
DEXA Does Not Accurately Reflect FRAX Score in Patients with Autoimmune Disease on Corticosteroids Nothing to Disclose

Robert Terkeltaub
Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout Disclosure:
2- Astra-Zeneca
5- Astra-Zeneca; Horizon; Selecta; SOBI; Sobi
Benjamin Terrier
Cardiac Involvement of Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss): Initial Manifestations and Outcomes Based on Data from a Monocenter Patient Cohort Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Dramatic but Suspensive Effect of interleukin-1 Inhibitors on Persistent Urticarial Vasculitis Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Glucocorticoids Plus Rituximab versus Glucocorticoids Plus Placebo in Non-infectious Active Mixed Cryoglobulinemia Vasculitis: Results of a Placebo-Controlled Randomized Trial Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Polyarteritis Nodosa Nothing to Disclose

Benjamin Terrier
Predictors of Relapse in Giant Cell Arteritis: Data from an International Collaboration Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Remission and Low Disease Activity State in Patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Risk of Vasculitis Associated with Inflammatory Bowel Diseases: Evidence for a Role of TNF-α Blockers Disclosure:
8- Grifols; GSK; LFB; Roche

Lene Terslev
Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment - Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD Nothing to Disclose

John Tesser
CDAI Analysis of Dose Escalation in a Trial of Infliximab for Rheumatoid Arthritis Disclosure:
2- Janssen Research & Development, LLC

Aikaterini Thanou
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity Disclosure:
2- BMS; GSK
5- Neovacs SA

Kristina A Theis
Arthritis-Attributable Work Limitation Variation by U.S. County Classifications and Selected Characteristics, 2017 Nothing to Disclose

Kristina A Theis
Too Soon to Say: Promising Results from a Community-Delivered RCT Examining Work-Related Outcomes of the Chronic Disease Self-Management Program Nothing to Disclose

Kristina A Theis
Why so Fast? A Focus on Reasons for an Increase in Arthritis-Attributable Activity Limitation Trends, 2002-2017 Nothing to Disclose

Louise M Thoma
Restricting Activity to Evade Knee Symptoms Is Associated with Worse Physical Function and Radiographic Osteoarthritis
Matthias H Thomas
Golimumab as First, Second or at Least Third Biologic Agent in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Post Hoc Analysis of a Non-Interventional Study in Germany
Disclosure:
3- MSD Shap & Dohme GmbH Germany; MSD Sharp & Dohme GmbH, Germany

Matthias H Thomas
Golimumab Improves Direct Costs of Healthcare Utilization and Indirect Costs Within Patients with RA, PsA, and as - Analysis of a Non-Interventional Study in Germany
Disclosure:
3- MSD Shap & Dohme GmbH Germany; MSD Sharp & Dohme GmbH, Germany

Mohammed Tikly
A Comparison of Convergent Validity and Sensitivity to Change of the Conventional Scoring Method to Alternative Scoring Methods of the Health Assessment Questionnaire in Rheumatoid Arthritis
Nothing to Disclose

Vivekanand Tiwari
Association of Periodontitis with Rheumatological Disorders: NHANES III Analysis
Nothing to Disclose

Vivekanand Tiwari
Prevalence of Burnout in Rheumatology Professionals
Nothing to Disclose

Fergus To
Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice
Nothing to Disclose

Mayra A Tobar Jaramillo
Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study
Nothing to Disclose

René Toes
Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
Nothing to Disclose

Zeynep Toker Dincer
Anakinra Treatment in Recurrent Pericarditis: Single Center Experience
Nothing to Disclose

Gabriella Tom
Hypersensitivity Beyond Pain: Hyperacusis and Hyperalgesia of Patients with Fibromyalgia
Nothing to Disclose

Gunnar Tomasson
Assessments of Quality of Life in Patients with Eosinophilic Granulomatosis with Polyangiitis
Nothing to Disclose

Michal Tomcik
Sexual Health in 39 Female Patients with Idiopathic Inflammatory Myopathies
Nothing to Disclose

Michal Tomcik
Sexual Health in 60 Female Patients with Systemic Sclerosis
Nothing to Disclose

Flora To-Miles
The Health-promoting Potential of Everyday Activities: Preliminary Results from an Exploratory Study of Adults with and Without Inflammatory Arthritis
Nothing to Disclose

Yanli Tong
Intestinal Microbiota Dynamics in the Progression of Rheumatoid Arthritis
Paola Toniati
Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center
Nothing to Disclose

Michael Toprover
Gout and Serum Urate Levels Are Associated with Lumbar Spine Monosodium Urate Deposition and Chronic Low Back Pain: A Dual-Energy CT Study
Nothing to Disclose

William J Torelli
Screening and Treating Hyperlipidemia in Patient's on Tofacitinib, Tocilizumab, Sarilumab, and Baricitinib
Nothing to Disclose

Carolina Tornero
Can We Predict Hypophosphatasia-Mutation Result Based on Alkaline Phosphatase Serum Levels?
Nothing to Disclose

Jesus Tornero
Consensus Statement and Recommendations on Methotrexate Use in Combined Therapy with Biological or Targeted Synthetic Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Nothing to Disclose

Jessica Torres Chichande
EULAR Definition of "Arthralgia Suspicious for Progression to Rheumatoid Arthritis" in a Cohort of Patients Included in a Program for Rapid Diagnosis: Role of Ultrasound and Antibodies
Nothing to Disclose

Julian Torres Vazquez
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Nothing to Disclose

Zahi Touma
Cluster Profiling of Patients in a Real-World Data Set with Systemic Lupus Erythematosus and Their Associated Treatments Disclosure:
2- Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC

Zahi Touma
Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus Disclosure:
2- Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC

Zahi Touma
Performance of Montreal Cognitive Assessment (MoCA) in Screening for Cognitive Impairment in Patients with Lupus Compared to the Neuropsychological Battery Disclosure:
2- Janssen Research & Development, LLC; Janssen Scientific Affairs, LLC

Anne TOURNADRE
Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
Nothing to Disclose

Eric Toussirot
Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Nothing to Disclose

Eric Toussirot
Increased High Molecular Weight Adiponectin and Lean Mass During Tocilizumab Treatment in Patients with Rheumatoid Arthritis: A 12 Month Multicenter Study
Nothing to Disclose
Francisco Treviño-Tello
T-cell Exhaustion in Prolonged Remission SLE Patients
Nothing to Disclose

Elisa Trujillo
Assisted Reproductive Technology in Patients with Inflammatory and Autoimmune Rheumatic Disease
Nothing to Disclose

Elisa Trujillo
Frailty and Sarcopenia in Inflammatory Rheumatic Disease
Nothing to Disclose

Linh Truong
The Role of Immunosuppressive Therapy in the Development of Atherosclerotic Cardiovascular Disease in Patients with Psoriatic Arthritis
Nothing to Disclose

Konstantinos Tselios
Antimalarial-Induced Cardiomyopathy: Outcome in 10 Patients
Nothing to Disclose

Konstantinos Tselios
Do All Patients Who Achieve Lupus Low Disease Activity State Have Similar Outcomes?
Nothing to Disclose

Konstantinos Tselios
Factors Implicated in the Development of Early Osteonecrosis in Systemic Lupus Erythematosus
Nothing to Disclose

Konstantinos Tselios
The Impact of the New American College of Cardiology/American Heart Association Definition of Hypertension on Cardiovascular Events in Systemic Lupus Erythematosus
Nothing to Disclose

Pei-Suen Tsou
Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma
Nothing to Disclose

Pei-Suen Tsou
Inhibition of Histone Readers Bromodomain and Extraterminal Domain Proteins Alleviates Scleroderma Fibrosis
Nothing to Disclose

Naomi Tsuchida
Novel Nonsense Variant and Entire Deletion of TNFAIP3 Cause Haploinsufficiency of A2O Clinically Distinct from Behçet's Disease
Nothing to Disclose

Naonori Tsuda
Analysis of Adverse Events of Methotrexate (MTX), bDMARDs and Tofacitinib (TOFA) Reported to Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Nothing to Disclose

Ana Tucker*
The Relationship Between Gastrointestinal Symptoms and Severity and Whole Gut Transit in Patients with Systemic Sclerosis
Nothing to Disclose

Sevket E Tunc
The Association Between Metabolic Syndrome and Radiographic Damage in Psoriatic Arthritis
Nothing to Disclose

Carl Turesson
Smoking, Alcohol Intake and Body Mass Index in Prediction of Disease Activity over Time in Early Axial Spondyloarthritis - Results from the SPondyloArthritis Caught Early (SPACE) Cohort
Nothing to Disclose

Carl Turesson
The Course of Disability in Early Rheumatoid Arthritis over 10 Years of Follow-up in Women and Men - Comparison with the General Population
Nothing to Disclose

Carl Turesson
The Course of Disability Related to Function of the Upper Extremities in Early Rheumatoid Arthritis over 10 Years of Follow-up
Nothing to Disclose

Anthony Turkiewicz
Ixekizumab Demonstrates Consistent Improvement up to Week 108 in Psoriatic Arthritis Across Individual ACR Components for Patients Naïve to Biologic DMARDs or with Previous Inadequate Response to TNF Inhibitors
Disclosure:
2- AbbVie; GeneTech; Janssen; Eli Lilly and Company; Novartis; Pfizer; Regeneron; Sanofi
5- AbbVie; GeneTech; Janssen; Eli Lilly and Company; Novartis; Pfizer; Regeneron; Sanofi
8- AbbVie; GeneTech; Janssen; Eli Lilly and Company; Novartis; Pfizer; Regeneron; Sanofi

Jessica L Turnier
BATF2 Contributes to Interferon Dysregulation in SLE Keratinocytes
Nothing to Disclose

Eishi Uechi
Comparison of the Management and Prognosis of Pneumonia in Patients with and Those Without Rheumatoid Arthritis Using the Japanese Diagnosis Procedure Combination Database
Nothing to Disclose

Manuel F Ugarte-Gil
Correlation Between the Lupus Foundation of America - Rapid Evaluation of Activity in Lupus (LFA-REAL) Patient Reported Outcome (PRO) and Health-Related Quality of Life (HRQoL) and Other PROs in a Primarily Mestizo Population
Nothing to Disclose

Manuel F Ugarte-Gil
Evaluation of the Lupus Foundation of America - Rapid Evaluation of Activity in Lupus (LFA-REAL) Clinician Reported Outcome (ClinRO) and
Patient Reported Outcome (PRO) in a Primarily Mestizo Population
Nothing to Disclose

Manuel F Ugarte-Gil
Patients Who Do Not Fulfill the 2018 EULAR/ACR Criteria for Systemic Lupus Erythematosus Accrue Less Damage: Data from a Multicenter, Multiethnic US Cohort
Nothing to Disclose

Serdal Ugurlu
Comparison of FMF Patients with Age of Onset Before 20 versus 40 Years and Over
Nothing to Disclose

Serdal Ugurlu
Is Exon 2 Associated with FMF or a New Disease?
Nothing to Disclose

Till Uhlig
Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study
Nothing to Disclose

Kennedy Ukadikе
High Prevalence and Disease Correlation of Autoantibodies Against p40 Encoded by Long Interspersed Nuclear Elements (LINE-1) in SLE
Nothing to Disclose

Asad Ullah
Improving Compliance with Screening for Osteoporosis in Elderly Women
Nothing to Disclose

Anam Umar
Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital
Nothing to Disclose

Anam Umar
Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?
Kunihiko Umekita
The Role of NFAT5-p65 Complex Enhanceosome in the Inflammatory Responses of Rheumatoid Arthritis Synovial Fibroblasts via TLR4 Signaling
Nothing to Disclose

Brian Ung
Assessing Psoriatic Arthritis Treatment Trends and Patient Journeys Between 2012 and 2018 Disclosure:
3- Celgene Corporation

Patompong Ungprasert
Nothing to Disclose

Patompong Ungprasert
Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States
Nothing to Disclose

Patompong Ungprasert
Inpatient Epidemiology of Granulomatosis with Polyangiitis in the United States
Nothing to Disclose

Patompong Ungprasert
Patients with Rheumatoid Arthritis Have a Higher Risk of Bipolar Disorder: A Systematic Review and Meta-analysis
Nothing to Disclose

Patompong Ungprasert
Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis
Nothing to Disclose

Sebastian H Unizony
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice Disclosure:

Murray B Urowitz
Incidence and Predictors of Atherosclerotic Vascular Events in a Multicentre Inception SLE Cohort Disclosure:
2- Janssen Research & Development, LLC 9- UCB Pharma

Sadettin Uslu
The Efficacy and Safety of Anti-TNFα Treatment in Ankylosing Spondylitis Patients with Late Onset Compared to Those with Adult Onset; The Data from TURKBIO Registry
Nothing to Disclose

Carlos Vaamonde-García
The Synthesis of Hydrogen Sulfide Is Impaired in Osteoarthritic Chondrocytes from Diabetic Patients and in Vitro in Cells Under High Glucose Environment
Nothing to Disclose

Raj V Vachhani
Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Nothing to Disclose

Camille Valdeyron
Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels
Nothing to Disclose

Antonia Valenzuela
Change in Calcinosi over 1 Year Using the SCTC Radiologic Scoring System for Calcinosi of the Hands in Patients with Systemic Sclerosis
Nothing to Disclose

Valeria Valerio
An Intervention Bundle Increases Uptake of Influenza Vaccine by Rheumatoid Arthritis Patients
Nothing to Disclose
Grissell Alejandra Valero-Gaona  
Childhood Takayasu Arteritis: Characteristics and Outcomes of a Mexican Cohort  
Nothing to Disclose  

Ana Valido  
Efficacy, Immunogenicity and Cost Analysis of a Systematic Switch from Originator Infliximab to Biosimilar CT-P13 of All Patients with Inflammatory Arthritis from a Single Center  
Nothing to Disclose  

Ana Valido  
Loss to Follow-up in Registries of Rheumatic Patients Treated with Biologics: A Potentially Valuable Hidden Real-world Data That Is Being Overlooked?  
Nothing to Disclose  

Giancarlo Valiente  
The Role of the Intestinal Microbiota in Lupus Nephritis  
Nothing to Disclose  

Ana Valle  
Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity  
Nothing to Disclose  

Larissa Valor  
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis  
Nothing to Disclose  

Larissa Valor  
Polyautoimmunity and Major Organ Involvement Prevalence in Sjögren’s Syndrome: Thyroid, Liver, Lung and Kidney as Targets. a Single Center Cross Sectional Study  
Nothing to Disclose  

Larissa Valor  
The anti-Ro52 Prevalence in the Sjögren’s Syndrome Picture: A Single Center Cross Sectional Study  
Nothing to Disclose  

Rianne E van Bentum  
Objective Ankylosing Spondylitis Physical Performance Index (ASPI) Is Highly Reliable and Feasible in Chilean Patients  
Nothing to Disclose  

Rianne E van Bentum  
Retina of Ankylosing Spondylitis Patients Shows Early Signs of Atherosclerotic Disease in Comparison with Healthy Controls  
Nothing to Disclose  

Shane V van Breda  
Regulation of Neutrophil Extracellular Traps by Apremilast (phosphodiesterase 4 Inhibition)  
Disclosure:  
2- Celgene  

Laura S van Dam  
ANCA Response upon Rituximab or Cyclophosphamide in ANCA-associated Vasculitis Patients  
Nothing to Disclose  

Laura S van Dam  
Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients  
Nothing to Disclose  

Mart A.F.J. van de Laar  
Contribution of Pain Relief to Function, Fatigue, and Quality of Life When Inflammation Is Controlled in Patients with Rheumatoid Arthritis  
Disclosure:  
2- Abbvie; Eli Lilly and Company; Merck; Pfizer; Grünenthal B.V.; Swedish Orphan Biovitrum AB  
5- Abbvie; Eli Lilly and Company; Merck; Pfizer; Sanofi Genzym  
8- Eli Lilly and Company; Pfizer  

Bastiaan van Dijk
Can a Single Question on Functional Impairments Facilitate the Diagnosis of Early Inflammatory Arthritis? A Cross-Sectional Derivation and Validation Study in Two Early Arthritis Recognition Clinics
Nothing to Disclose

Jordan Van Dyk
Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study
Nothing to Disclose

Nina van Leeuwen
Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis
Nothing to Disclose

Nina van Leeuwen
Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts
Nothing to Disclose

Emma Van Lieshout
Evidence for Substantial Immune Activation in Asymptomatic ANA Positive Individuals
Nothing to Disclose

Miranda van Lunteren
Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort
Nothing to Disclose

Elise van Mulligen
The Patient’s Perspective on a Disease Flare During Tapering of DMARDs in Rheumatoid Arthritis
Nothing to Disclose

Jolien F van Nimwegen
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren’s Syndrome –

Open-label Extension Phase of a Randomized Controlled Phase III Trial
Disclosure:
5- Bristol-Myers Squibb
8- Bristol-Myers Squibb

Jolien F van Nimwegen
Pathogenesis of Vaginal Dryness in Primary Sjögren’s Syndrome: A Histopathological Case-control Study
Disclosure:
5- Bristol-Myers Squibb
8- Bristol-Myers Squibb

Marion van Rossum
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis
Nothing to Disclose

Ronald F van Vollenhoven
The Impact of Upadacitinib versus Methotrexate or Adalimumab on Individual and Composite Disease Measures in Patients with Rheumatoid Arthritis
Disclosure:
2- AbbVie; Arthrogen; BMS; GSK; Lilly; Pfizer; UCB
9- AbbVie ; AstraZeneca ; Biotest ; BMS ; Celgene ; GSK ; Janssen ; Lilly ; medac ; Merck ; Novartis ; Pfizer ; Roche ; UCB

Catherine Vasilakis-Scaramozza
Rates of Treated Depression Among Patients with Psoriatic Arthritis Treated with Apremilast, Biologics, DMARDs, and Corticosteroids in the US MarketScan Database
Disclosure:
2- Celgene Corporation

Dimitrios Vassilopoulos
Real-World Evidence on the Early Effects of Golimumab on Work Productivity and Activity Impairment in Patients with Spondyloarthritis: Interim Results from a Prospective, Observational Study
Nothing to Disclose

Keila Veiga
Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity
Nothing to Disclose

Andrew Vendel
Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis
Disclosure:
1- Eli Lilly and Company
3- Eli Lilly and Company
4- Eli Lilly and Company

Shilpa Venkataraman
Correlation of Urinary Soluble CD163 Levels with Clinicopathological Features in Lupus Nephritis: Its Role as a Potential Biomarker
Nothing to Disclose

Linda G Vergel Orduz
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Nothing to Disclose

Josep Verges
Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review
Nothing to Disclose

Maxime Verhoeven
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies
Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Nothing to Disclose

Devanshu Verma
Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO): A Case Series

Lucia Vernerová
Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies
Nothing to Disclose

Elsa Vieira-Sousa
Gender Differences in Psoriatic Arthritis – Impact on Tumor Necrosis Factor Inhibitors Persistence and Response
Nothing to Disclose

Michel Villatoro-Villar
Head and Neck Involvement of IgA Vasculitis: A Case-Control Study
Nothing to Disclose

Ernest R Vina
Attitudes and Beliefs About Opioid Medications: Determining Treatment Use in Osteoarthritis
Nothing to Disclose

Evelyne Vinet
Risk of Serious Infections in Offspring According to TNFi Subtypes
Nothing to Disclose

DOROTHEE VINSON
Impact of Tapering Targeted Therapies (bDMARDs or Jakinibs) on the Risk of Adverse Events of Special Interest in Patients with Rheumatoid Arthritis or Spondyloarthritis: A Systematic Analysis of the Literature and Meta-analysis
Nothing to Disclose

Belén M Virasoro
Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?
Nothing to Disclose

Belén M Virasoro
Performance of the European League Against Rheumatism/American College of Rheumatology Idiopathic Inflammatory
Myopathies Classification Criteria in a Myositis Cohort from Argentina
Nothing to Disclose

Santosh Vishwakarma
Novel, Selective, Orally Active PAD4 Inhibitors for the Treatment of Autoimmune Disorders
Nothing to Disclose

Yvonne Viteri
Adherence to Biologic Disease-modifying Anti-rheumatic Drugs (DMARDs) — a Comparison of Long-term Adherence Among Patients with Various Inflammatory Conditions by Primary Dispensing Channel
Disclosure:
3- Accredo

Panagiotis Vlachoyiannopoulos
Whole Transcriptome Analysis Maps Proinflammatory and Procoagulant Pathways in aPL Treated HUVECs
Nothing to Disclose

Elizabeth R Volkmann
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
Disclosure:
1- Pfizer
4- Pfizer
5- Boehringer Ingelheim; Boehringer-Ingelheim

Elizabeth R Volkmann
The MUC5B Promoter Variant Does Not Predict Outcomes in Systemic Sclerosis-related Interstitial Lung Disease
Disclosure:
1- Pfizer
4- Pfizer
5- Boehringer Ingelheim; Boehringer-Ingelheim

Johannes von Kempis
Association Between the Soluble Terminal Complement Complex C5b-9 (sC5b-9) and Signs of Active Kidney Disease in a Swiss SLE Cohort

Nothing to Disclose

Nothing to Disclose

Madelon C Vonk
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSICIS Trial by Corticosteroid Use
Disclosure:
2- Actelion; actelion; Actelion Pharmaceuticals; Ferrer; Ferrer International; Ferrier
5- Actelion; actelion; Actelion Pharmaceuticals; Boehringer Ingelheim; Boehringer ingelheim; GSK
6- GSK
8- Actelion; actelion; Actelion Pharmaceuticals; Boehringer Ingelheim; Boehringer ingelheim; Roche

Milena Vukelic
Elevated Serum Interleukin-23 Level in Patients with Systemic Lupus Erythematosus Is Associated with Disease Activity, Clinical and Immunological Markers
Nothing to Disclose

Yoko Wada
Serum Myostatin in Patients with Rheumatoid Arthritis and Its Correlations with Body Compositions and the Disease Activity
Nothing to Disclose

Yoko Wada
Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Nothing to Disclose

Wendy Waegell
Development of a Novel Anti TNF-Steroid Antibody Drug Conjugate That Shows Promising Efficacy at Doses That Avoid Steroid Side Effects in a Mouse Model of Rheumatoid Arthritis
Disclosure:
3- AbbVie; Abbvie

Saadia Waheed
The Effects of Pegloticase on Mean Arterial Blood Pressure: An Age Modulated Relationship?
Nothing to Disclose

Risa Wakiya
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Nothing to Disclose

Beth I Wallace
Evidence to Guide Glucocorticoid Tapering Is Lacking in RA

Zachary Wallace
Increasing Capacity and Reducing Costs of Rituximab Administration
Disclosure:
2- National Institute of Arthritis, Musculoskeletal, and Skin Diseases; Rheumatology Research Foundation

Rachael Wallwork
Early Mortality in IgG4-Related Disease
Nothing to Disclose

Jessica A Walsh
Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity
Disclosure:
2- AbbVie; Amgen; Janssen Research & Development, LLC; Lilly; Novartis; Pfizer; PFIZER, ABBVIE
5- AbbVie; ABBVIE, NOVARTIS, LILLY, AMGEN, UCB; Amgen; Lilly; Novartis; Pfizer; UCB

Jessica A Walsh
Izekizumab Significantly Improves Self-reported Overall Health as Measured by Short-Form-36 in Patients with Active Non-radiographic Axial Spondyloarthritis: 16- and 52-Week Results of a Phase 3 Randomized Trial (COAST-X)

Disclosure:
2- AbbVie; Amgen; Janssen Research & Development, LLC; Lilly; Novartis; Pfizer; PFIZER, ABBVIE
5- AbbVie; ABBVIE, NOVARTIS, LILLY, AMGEN, UCB; Amgen; Lilly; Novartis; Pfizer; UCB

Jessica A Walsh
Real-world Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Biologic Therapies

Disclosure:
2- AbbVie; Amgen; Janssen Research & Development, LLC; Lilly; Novartis; Pfizer; PFIZER, ABBVIE
5- AbbVie; ABBVIE, NOVARTIS, LILLY, AMGEN, UCB; Amgen; Lilly; Novartis; Pfizer; UCB

Hayley B Walter
Impact of Pathogenic and Protective Environmental Exposures on Autoimmune Disease—The Microbiome Effects on Lupus (MEL) Study

Nothing to Disclose

Theresa Walunas
Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities

Disclosure:
5- Pfizer Inc.; Wyeth LLC; Genetics Institute, LLC; Merck KGaA; EMD Serono, Inc

Marilyn Wan
Longitudinal Construct Validity and Responsiveness of MDHAQ and HAQDI in PsA: Can MDHAQ Replace HAQDI?

Nothing to Disclose

Chenchen Wang
Effects of Tai Chi versus Aerobic Exercise on Mindfulness in Fibromyalgia

Nothing to Disclose

Liqin Wang
A Retrospective Cohort Study Using Clinical Notes and Latent Topic Modeling to Characterize the Natural History of ANCA-Associated Vasculitis

Nothing to Disclose

Runci Wang
Mass Cytometry Immunophenotyping of Synovial Fluid from Checkpoint Inhibitor Related Arthritis

Nothing to Disclose

Runsheng Wang
Identification of Patients with Rheumatoid Arthritis Treated with Biologics Using Standardized Vocabularies

Nothing to Disclose

Xuan Wang
The DLEU2/miR-15a/16-1 Cluster Inhibit Foxp3+ Treg Cells in Salivary Glands of pSS via Targeting Foxp3

Nothing to Disclose

Xuan Wang
Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis

Nothing to Disclose

Yanlin Wang
Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis

Nothing to Disclose

Yiting Wang
Prevalence of Diagnosed Systemic Lupus Erythematosus (SLE), Patient Healthcare Utilization and Characteristics by Major Health Insurance Types in the US

Disclosure:
3- Janssen Pharmaceutical R&D, LLC
4- Janssen Pharmaceutical R&D, LLC

Yongfu Wang
Psychological Profile in Patients with Rheumatic Diseases in China: A Study of HADS Self-assessment with Smart System of Disease Management (SSDM)
Nothing to Disclose

Yujiao Wang
Cardiac Involvements Are Related to Poor Prognosis in Patients with Takayasu’s Arteritis in China
Nothing to Disclose

Matthew Warr
GS-4875, a First-in-Class TPL2 Inhibitor Suppresses MEK-ERK Inflammatory Signaling and Proinflammatory Cytokine Production in Primary Human Monocytes
Disclosure:
1- Gilead Sciences, Inc.
2- Gilead Sciences, Inc.
3- Gilead Sciences, Inc.

Caroline Wasén
Inflammation and Neuronal Growth Factors in Rheumatoid Arthritis
Nothing to Disclose

Siegfried Wassenberg
Efficacy of Etanercept on Radiographic Progression in Adult Patients with Rheumatoid Arthritis or Psoriatic Arthritis: Final Results from a German Non-Interventional, Prospective, Multi-Center Study
Disclosure:
5- AbbVie; Chugai; Janssen; MSD; Novartis; Pfizer; Roche; UCB

Haruki Watanabe
Cluster Analysis for Classification of Japanese Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Subgroup Analysis of Nationwide Cohort Studies
Nothing to Disclose

Shinji Watanabe
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Nothing to Disclose

Patrick Webster
Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
Nothing to Disclose

Hua Wei
Improving Healthcare Quality and Reducing Cost via Online Interaction for Chinese Patients with Rheumatic Diseases Based on Smart System of Disease Management (SSDM) Mobile Tool
Nothing to Disclose

James C Wei
Ixekizumab Significantly Improves Patient-reported Overall Health as Measured by SF-36 in Patients with Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Trials
Disclosure:
2- AbbVie; BMS; Celgene; Janssen; Novartis; Pfizer Inc; UCB Pharma; Eli Lilly
5- AbbVie; BMS; Celgene; Chugai; Eisai; Janssen; Novartis; Pfizer Inc; Sanofi-Aventis; UCB Pharma

James C Wei
Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
Disclosure:
2- AbbVie; BMS; Celgene; Janssen; Novartis; Pfizer Inc; UCB Pharma; Eli Lilly
5- AbbVie; BMS; Celgene; Chugai; Eisai; Janssen; Novartis; Pfizer Inc; Sanofi-Aventis; UCB Pharma

Kevin Wei
Multiomics Pipeline for Phase 2 of the Accelerating Medicine Partnership (AMP) – RA Network
Nothing to Disclose

Michael Weinblatt
Clinical Responses in Patients with Inadequate Response to bDMARDs upon Treatment with Upadacitinib
Disclosure:
1- Canfite; Lycera; Scipher
2- Amgen; BMS; Bristol-Myers Squibb; Crescendo Bioscience; Regeneron; Sanofi; Sanofi-Regeneron
4- Can Fite; CanFite; Inmedix; Lycera; Scipher; Vorso
5- AbbVie; Amgen; BMS; Bristol-Myers Squibb; Corrona; CORRONA; Crescendo Bioscience; Gilead; GlaxoSmithKline; GSK; Horizon; Lilly; Lycera; Merck; Novartis; Pfizer; Roche; Samsung; Scipher; Set Point; SetPoint; UCB

Michael Weinblatt
Impact of Baseline Demographics and Disease Activity on Outcomes in Patients with Rheumatoid Arthritis Receiving Upadacitinib
Disclosure:
1- Canfite; Lycero; Scipher
2- Amgen; BMS; Bristol-Myers Squibb; Crescendo Bioscience; Regeneron; Sanofi; Sanofi-Regeneron
4- Can Fite; CanFite; Inmedix; Lycera; Scipher; Vorso
5- AbbVie; Amgen; BMS; Bristol-Myers Squibb; Corrona; CORRONA; Crescendo Bioscience; Gilead; GlaxoSmithKline; GSK; Horizon; Lilly; Lycera; Merck; Novartis; Pfizer; Roche; Samsung; Scipher; Set Point; SetPoint; UCB

Daniel WENDLING
Dactylitis Occurrence in Early Spondyloarthritis: Five Years Data from a French National Prospective Cohort
Nothing to Disclose

Daniel WENDLING
Muscle Involvement Revealed by 18F-PET-CT in Polymyalgia Rheumatica
Nothing to Disclose

Cynthia Matilda A Wendo
Prevalence of Peripheral Neuropathy and Its Electrophysiological Types in Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Peter J Wermuth
TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype
Nothing to Disclose

Rene Westhovens
Efficacy and Safety of a Novel Subcutaneous Formulation of CT-P13 over the 1-year Treatment Period and After Switching from Intravenous CT-P13 in Patients with Active Rheumatoid Arthritis: Results from Part 2 of Phase I/III Randomized Controlled Trial
Disclosure:
2- Celltrion, Inc.; Galapagos/Gilead
5- Celltrion; Celltrion, Inc.; Galapagos; Galapagos NV; Galapagos/Gilead; Gilead Sciences, Inc.
8- Celltrion; Galapagos; Gilead Sciences, Inc.
9- Celltrion ; Galapagos NV ; Gilead Sciences, Inc.

Marie Wetterslev
Development and Validation of a Preliminary MRI Sacroiliac Joint Composite Structural Damage Score in a 5-year Longitudinal Study of Patients with Axial Spondyloarthritis
Nothing to Disclose

Cornelia M Weyand
Loss-of-function of the DNA Repair Nuclease MRE11A Induces Mitochondrial Failure and Tissue Inflammation in Rheumatoid Arthritis
Disclosure:
2- Kiniska Pharmaceuticals

Tamar Wheeler
Identification of Differential Chromatin Accessibility Using ATAC-seq in a Novel 3D Tissue Culture System of Systemic Sclerosis
Nothing to Disclose

Daniel Whibley
The Association Between Non-restorative Sleep and Diurnal Patterns of Cognitive Function and Fatigue in People with Fibromyalgia and Matched Controls
Nothing to Disclose

Raeann Whitney
Pharmacotherapies Targeting Type 2 SLE Symptoms
Nothing to Disclose

Victoria Wickenheisser
Light Mediated Therapeutics in Arthritis
Nothing to Disclose

Erin Wilfong
The Presence of Circulating CD19+CD21lo cells Predicts the Presence of Interstitial Lung Disease in Patients with Systemic Sclerosis
Nothing to Disclose

Brooke A Williams
Utility of a Mobile Phone Based Application to Collect Patient-Reported Outcome Information from People Living with Systemic Lupus Erythematosus
Nothing to Disclose

Rachel Williams
The Relationship Between Pain and Patient Demographics, Clinical Features, and Health Outcomes in a Cohort of Rheumatoid Arthritis Patients Recruited and Studied Using a Mobile Application
Disclosure:

1- GSK
2- GSK
3- GSK
4- GSK

Tyler Williams
Correlation Between Patient Reported Outcomes Measurement Information System (PROMIS) and RAPID3 in Rheumatoid Arthritis Patients Starting a New Biologic DMARD
Nothing to Disclose

Rohan Willis
Comparative Efficacy of Beta-2-Glycoprotein I Domain V Structural Analogue Variants in Preventing Antiphospholipid Antibody-Mediated Endothelial Cell Activation
Nothing to Disclose

Rohan Willis
Inhibition of IκB Kinase-IKK Complex of Canonical NF-κB Pathway in Antiphospholipid Antibody-Mediated Endothelial Cell Activation
Nothing to Disclose

William Willis
Covalent High Molecular Weight HMGB1 Complexes in Muscle Regeneration: Implications in Inflammatory Myopathy
Nothing to Disclose

Thomas Winans
Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice
Nothing to Disclose

Chris Wincup
Disease Activity and Dysregulated Iron Metabolism: A Potentially Overlooked Mechanism for Anaemia in Patients with Systemic Lupus Erythematosus?
Nothing to Disclose

Freke Wink
Prevalence of Radiographic Enthesal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls
Disclosure:
2- Abbvie; Pfizer; UCB
5- Abbvie; Pfizer

Kevin Winthrop
Pooled Safety Analyses from Phase 3 Studies of Filgotinib in Patients with Rheumatoid Arthritis
Disclosure:
2- Bristol-Myers Squibb; Pfizer; UCB Pharma, Pfizer, Bristol-Myers Squibb, Eli Lilly, AbbVie, and Roche.
5- AbbVie; Abbvie; Bristol-Myers Squibb; Eli Lilly; Galapagos; Galapagos NV; Gilead; Gilead Sciences, Inc.; GSK; Lilly; Pfizer; Roche; UCB; UCB Pharma; UCB Pharma, Pfizer, Bristol-Myers Squibb, Eli Lilly, AbbVie, and Roche.

Kristin Wipfler
The Importance of Diagnosis: Clinical Distinctions Between Adult JIA and RA, and a Characterization of Patients with JIA Reclassified as RA in Adulthood
Disclosure:
3- Option Care

Leanna Wise
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Nothing to Disclose

Ruth Wittoek
Natural Disease Progression in Hand Osteoarthritis: Results from a Belgian Ten-years Prospective Cohort Study
Nothing to Disclose

Rachel M Wolfe
Simulated Rheumatology Clinic: Bridging Basic Science and Clinical Application
Nothing to Disclose

VERONICA WOLFF
Myositis Related Antibodies and Interstitial Lung Disease: Variables Associated with Baseline Lung Function and Functional Improvement: Results from a Multicentric Latin-american Cohort
Nothing to Disclose

Lutz Wollin
The Effect of Nintedanib versus Mycophetolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease
Disclosure:
3- Boehringer Ingelheim

Matthew Wright
Investigating the Post-Partum Flare in Rheumatoid Arthritis Using Transcriptome Analysis
Nothing to Disclose

Cheng-Han Wu
Autoantibodies from Sjögren's Syndrome Enhance NLRP3 Inflammasome Activation and IL-18 Production in Human Salivary Gland Cell Line A-253
Nothing to Disclose

Wenbin Wu
CD39 Produced from Human Gingiva-Derived Mesenchymal Stem Cells Regulates the Balance of Osteoclasts and Osteoblasts Through Wnt / β-catenin Pathway in Osteoporosis
Nothing to Disclose

Katherine D Wysham
Differences in Fracture Risk Assessment (FRAX) and Osteoporosis Treatment Cutoffs with and Without Bone Mineral Density Are Greater in Anti-Cyclic Citrullinated Peptide Positive Rheumatoid Arthritis
Nothing to Disclose

Katherine D Wysham
Rheumatoid Arthritis Disease Activity Is Associated with Low Femoral Neck Bone Mineral Density in a Diverse Cohort of Patients
Nothing to Disclose

Fan Xiao
MRI of the Wrist in Early Rheumatoid Arthritis
After 1-year Treat-to-target Strategy
Nothing to Disclose

Xinyue Xiao
Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis
Nothing to Disclose

JIAYE XI
Anti-Polygalacturonic Acid Antibody (PGA-Ab) Induced Bone Destruction in Rheumatoid Arthritis by Promoting Osteoclastogenesis via Integrin Beta 5
Nothing to Disclose

Christine Xu
Sarilumab and Tocilizumab Receptor Occupancy (RO), and Effects on C-Reactive Protein (CRP) Levels, in Patients with Rheumatoid Arthritis (RA)
Disclosure:
1- Sanofi
3- Sanofi

Jing Xue
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up of Ankylosing Spondylitis (AS) Patients with a Rheumatologist-patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Nothing to Disclose

Tomohiro Yamada
Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody
Nothing to Disclose

Kunihiro Yamaoka
The Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis
Disclosure:
8- Pfizer; Chugai Pharmaceutical; Takeda; Astellas; AbbVie; BMS; Mitsubishi-Tanabe

MASAOMI YAMASAKI
Comparison of Sustained Clinical Remission And/or Low Disease Activity Rate Between Rapidly and Gradually De-escalation of Abatacept in Rheumatoid Arthritis
Nothing to Disclose

Yoshioki Yamasaki
The Contribution of Left Heart Disease in Patients with Systemic Sclerosis-associated Pulmonary Hypertension Having Normal Pulmonary Artery Wedge Pressure
Nothing to Disclose

Qingran Yan
Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study
Nothing to Disclose

Rongzi Yan
AR882, a Potent and Selective URAT1 Inhibitor with a Favorable Pharmacological, Pharmacokinetic and Toxicity Profile
Nothing to Disclose

Ailing E Yang
Stakeholder Feedback on Novel Behavioral Intervention Targeting Comorbid Chronic Back Pain and Depression in Older Adults
Nothing to Disclose

Jing Yang
Not All Joints Are Equal: Challenge DAS28 System and Identify Factors Leading to a Mismatch Between T2T and HAQ Among RA Patients Through Data Mining from Smart System of Disease Management (SSDM)
Nothing to Disclose

Liu Yang
pH-Sensitive Nanoformulated Triptolide as a Targeted Therapeutic Strategy for Rheumatoid Arthritis
Nothing to Disclose

Xiang Yang
Citrullinated Antigens with Multiple Citruline Similar Motif Could Be Used for RA Diagnosis
Nothing to Disclose

Yunjiao Yang
The Clinical and Angiographic Features of Chinese Takayasu’s Arteritis Patients: A Cohort Study of 591 Patients in 6 Years
Nothing to Disclose

Qingping Yao
Expanding the Phenotypic and Genotypic Spectrum in Yao Syndrome
Nothing to Disclose

Mark Yates
Assessing Care Quality in Rheumatology Services
Nothing to Disclose

Yusuf Yazici
Safety Profile to Date of the Novel, Intra-articular Agent Lorecivivint (LOR; SM04690), a CLK/DYRK1A Inhibitor That Modulates the Wnt Pathway, in Subjects with Knee Osteoarthritis
Disclosure:
1- Samumed, LLC
3- Samumed, LLC
4- Samumed, LLC
6- Samumed, LLC

Yusuf Yazici
The Novel, Intra-articular CLK/DYRK1A Inhibitor Lorecivivint (LOR; SM04690), Which Modulates the Wnt Pathway, Improved Responder Outcomes in Subjects with Knee Osteoarthritis: A Post Hoc Analysis from a Phase 2b Trial
Disclosure:
1- Samumed, LLC
3- Samumed, LLC
4- Samumed, LLC
6- Samumed, LLC

Liain Yeh
AR882, a Potent and Selective Uric Acid Lowering Agent Acting Through Inhibition of Uric Acid Reuptake, Shows Excellent

Pharmacokinetics and Pharmacodynamics in a Phase 1 Clinical Trial
Nothing to Disclose

Ting-Chun Yeh
US Community Rheumatologists’ Knowledge and Perceptions of Biosimilar Expanded Indication Approval by Extrapolation Disclosure:
3- Cardinal Health

Ai Li Yeo
ANA-lysis: Utility of Repeated Antinuclear Antibody Testing in a Single Center
Nothing to Disclose

Jina Yeo
Effect of Long-term Treatment with TNF-α Inhibitor on Lipid Profile in Spondyloarthritis: Data from Nationwide Korean College of Rheumatology Biologics (KOBIO) Registry
Nothing to Disclose

Nadiya V Yerich
Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort
Nothing to Disclose

Meital Yerushalmi
The Cutaneous Microbiome of Psoriatic Disease Is Influenced by Disease Susceptibility HLA Alleles but Not Clinical Phenotype
Nothing to Disclose

Naoto Yokogawa
Pharmacokinetics of Hydroxychloroquine in Systemic Lupus Erythematosus Patients with Renal Impairment
Nothing to Disclose

Chio Yokose
Frequently Encountered Artifacts in Novel Application of Dual-Energy CT to Vascular Imaging: A Pilot Study
Nothing to Disclose
Chio Yokose
Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population - Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
Nothing to Disclose

Kazuhiro Yokota
Functional Differences Between Osteoclasts and Osteoclast-like Cells Differentiated from Peripheral Blood Mononuclear Cells in Patients with Rheumatoid Arthritis
Nothing to Disclose

Hyun Jung Yoo
The Indole Derivative NecroX Blocks Th17 Cell Differentiation and Fibroblast-like Synoviocytes-mediated Th1/Th17 Responses in Rheumatoid Arthritis
Nothing to Disclose

Wan-Hee Yoo
Inhibition of Endoplasmic Reticulum Stress Using 4-phenylbutyric Acid Ameliorates the Severity of Collagen-induced Arthritis in Mice via Attenuation of Proliferation and Inflammatory Responses of Synovial Fibroblasts
Nothing to Disclose

Kazuki Yoshida
Accrual of Multimorbidity After Incident Rheumatoid Arthritis and Matched Comparators Using a Large Prospective Cohort with 30 Years of Follow-up
Nothing to Disclose

Takeshi Yoshida
Dual Analysis with Nerve Ultrasound and Skin Biopsy in Painful Neuropathy Associated with Sjögren's Syndrome
Nothing to Disclose

Hajime Yoshifuji
Long-term Clinical Course and Outcomes of 2013 Patients with Takayasu Arteritis

8- Chugai Pharmaceutical
Yuji Yoshioka
Treatment for Rheumatoid Arthritis After Methotrexate-associated Lymphoproliferative Disorder Developed
Nothing to Disclose

Hanxiao You
Early Anticoagulation Improves the Long-term Prognosis in Patients with Antiphospholipid Syndrome Associated Portal Vein Thrombosis
Nothing to Disclose

Nicholas Young
RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery
Nothing to Disclose

Jennifer J Young-Glazer
Identifying Jo-1-Specific B Cells in the Primary Immune Repertoire in Idiopathic Inflammatory Myopathies
Nothing to Disclose

Haidy Adel A Youssef
Interstitial Lung Disease in ANCA Associated Vasculitis: A Single Center Retrospective Analysis
Nothing to Disclose

Micah Yu
Outcomes of a Fracture Liaison Service at an Academic Health Center
Nothing to Disclose

Yiwei Yuan
Identification of miRNAs in Systemic Sclerosis Based on Activity and Network Analysis---
Nothing to Disclose

Emily Yuki
Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates
Nothing to Disclose

Huifeng Yun
Identifying Comorbidities and Seropositivity in Rheumatoid Arthritis Patients Using Single-specialty Electronic Health Record Data
Disclosure:
2- BMS; Bristol-Myers Squibb; Pfizer

Jakub Závada
The Epidemiology of Rheumatoid Arthritis in the Czech Republic
Nothing to Disclose

Johana B Zacariz Hereter
Utility of Power Doppler Ultrasound–Detected Synovitis for the Prediction of Flare in Psoriatic Arthritis Patients in Clinical Remission
Nothing to Disclose

Maria del Carmen Zamora Medina
Mortality in a SLE Inception Cohort of Hispanic Patients
Nothing to Disclose

Maria del Carmen Zamora Medina
Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Nothing to Disclose

Richard Zamore
Improving Access in an Academic Rheumatology Department by Reducing the No Show Rate
Nothing to Disclose

Majid Zeidi
Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema
Nothing to Disclose

Sabine Zenz
Diminished Memory B-cells in Systemic Lupus Erythematosus Patients with Low Disease Activity
Nothing to Disclose

Jingchuan Zhang
Long-Term Treatment Patterns of Biologics and Apremilast Among Patients with Moderate-to-Severe Plaque Psoriasis by Psoriatic Arthritis Status
Disclosure:
3- Sun Pharmaceutical Industries

Qing Zhang
Aberrant H3K9me3 Modification in Promoter Region Up-regulates cAMP Response Element Modulator Alpha in Systemic Lupus Erythematosus
Nothing to Disclose

Qing Zhang
Inhibited Expression of Hematopoietic Progenitor Kinase 1 in Tfh Cells Contributes to Autoimmunity in Systemic Lupus Erythematosus
Nothing to Disclose

Qing Zhang
Relationships Among Cognitive Emotion Regulation, Body Image, Family and Marital Function and Quality of Life in Chinese Female Patients with Systemic Lupus Erythematosus
Nothing to Disclose

Sheng-xiao Zhang
Diversity Analysis of Intestinal Flora in Patients with Rheumatoid Arthritis
Nothing to Disclose

Sheng-xiao Zhang
Diversity Analysis of Intestinal Flora in Patients with Sjogren’s Syndrome
Nothing to Disclose

Sheng-xiao Zhang
Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2
Nothing to Disclose

Ximei Zhang
Difference of Induced CD4+ and Natural Regulatory T Cells in Targeting Inflamed Synovial Tissues in Autoimmune Arthritis
Nothing to Disclose

Ximei Zhang
Gingival-Derived Mesenchymal Stem Cells Alleviate Cartilage Damage in Collagen-Induced Arthritis via Suppressing Activities of Inflamed Synovial Fibroblast
Nothing to Disclose

Yujuan Zhang
Acupuncture for Chronic Musculoskeletal Pain: A Review of Randomized Controlled Trials
Nothing to Disclose

Yan Zhao
Develop Risk Prediction Model and Drug Withdrawal Road Map Through Pattern Extraction and Data Mining: Create a Master Algorithm from the Smart System of Disease Management (SSDM)
Nothing to Disclose

Boyang Zheng
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
Nothing to Disclose

Song Guo Zheng
Human Gingiva-derived Mesenchymal Stem Cells Are Therapeutic in Lupus Nephritis Through Targeting of CD39-CD73 Signaling Pathway
Nothing to Disclose

Yufei Zheng
The Socioeconomic, Gender, Urban-rural, and Regional Disparities in the Risk of Acute Myocardial Infarction Among RA Patients
Nothing to Disclose

Minlin Zhou
An Updated Meta-Analysis of the Efficacy and Safety of Mycophenolate Mofetil in the Induction Treatment of Chinese Patients with Lupus Nephritis
Nothing to Disclose

Lisa Zhu
Assessing the Validity of QRISK3 at Predicting Cardiovascular Events in Systemic Lupus Erythematosus Patients
Nothing to Disclose

Joe Zhuo
Health Care Resource Utilization and Costs in Patients with Juvenile Idiopathic Arthritis Treated with Abatacept and Other Targeted Disease Modifying Anti-rheumatic Drugs
Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb

Joe Zhuo
Interstitial Lung Disease Associated Health Care Resource Utilization and Cost in Rheumatoid Arthritis Patients in an Insured Population
Disclosure:
1- Bristol-Myers Squibb
3- Bristol-Myers Squibb

Nelly Ziade
Concordance Between Physician and Patient Assessment of Disease Activity in Rheumatoid Arthritis Using Disease Activity Score: Phase II Results
Nothing to Disclose

Michael Ziegelasch
Ultrasound Is More Sensitive Compared to Conventional Radiography to Detect Joint Erosions in ACPA-positive Patients with Musculoskeletal Pain
Disclosure:
5- AbbVie; MSD; Pfizer; BK Medical

Devy Zisman
Increased Prevalence of Systemic Lupus Erythematosus Co-morbidity in Patients with Psoriatic Arthritis: A Population-Based Case-Controlled Study
Disclosure:
Hanyan Zou
Distinct Characteristics of the Gut Microbiome of Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth
Nothing to Disclose

Katie E Zuech
Patients of African Descent Score Higher on Quality of Life Indices Despite Their Known Disease Severity
Nothing to Disclose

Yu Zuo
Metabolomics Analysis Identifies Biomarkers for APS and Suggests a Potential New Pathway Related to APS Pathogenesis
Nothing to Disclose

Rizi Ai
Differential Methylation of Peripheral Blood Adaptive Immune Cells in Individuals at High Risk for RA and with Early RA Compared with Controls Identifies Pathways Important in Transition to Arthritis
Nothing to Disclose

Mitsuhiro Akiyama
Neutrophil Extracellular Traps Induce Tissue-Invasive Macrophages in Granulomatosis with Polyangitis Dominated by Ear, Nose and Throat Manifestations
Nothing to Disclose

Michail K Alevizos
High Lung Attenuation Measured with Quantitative Densitometry as a Surrogate Marker for Interstitial Lung Disease in RA: Association with Anti-CCP, Smoking, and Absence of Shared Epitope
Nothing to Disclose

Ramadan A Ali
Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation
Nothing to Disclose

Fatma Alibaz-Oner
Assessment of Femoral Vein Wall Thickness with Doppler Ultrasound Can Be a Diagnostic Tool for Behçet’s Disease
Nothing to Disclose

Stefano Alivernini
Semi-quantitative Assessment of Synovial Inflammation on US-Guided Synovial Membrane Biopsy Is Contingent to Disease Phase, Autoimmune Profile and Treatment Response in Rheumatoid Arthritis: Large Single Center Experience (SYNGem Cohort)
Nothing to Disclose

Matt Allsion
Assessing the Impact of Digital Health Coaching on Quality Adjusted Life Years, Symptom Severity and Disease Activity in Patients with Rheumatoid Arthritis
Nothing to Disclose

M A Amin
The Role of Bradykinin Receptor B1 and Its New Ligand Soluble CD13 in Rheumatoid Arthritis and Inflammatory Arthritis Mouse Model
Nothing to Disclose

Adel T Andemeskel
The Association Between Omega-3 Supplementation and Disease Activity in a Rheumatoid Arthritis (RA) Observational Cohort
Nothing to Disclose

Céline Anquetil
Rheumatic Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Retrospective, Pharmacovigilance Study
Nothing to Disclose

Marco Antivalle
Diagnosis of Fibromyalgia: Comparison of AAPT and ACR Criteria
Nothing to Disclose

Cristina Arriens
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Disclosure: 2- BMS; Exagen; GSK
5- AstraZeneca; BMS; GSK
Fawad Aslam
Tenosynovial Aspiration by Ultrasound Guidance: Correlation and Diagnostic Implications of Tenosynovial Analysis and Ultrasound Doppler Signal
Nothing to Disclose
Shervin Assassi
Serum Interferon Chemokine Score Predicts Better Response to Immunosuppression in Systemic Sclerosis Related Interstitial Lung Disease
Disclosure: 2- Bayer; Boehringer Ingelheim; Momenta
5- Boehringer Ingelheim
8- Boehringer Ingelheim; Integrity Continuing Education; Medscape
9- Integrity Continuing Education; Medscape
Yemil Atisha Fregoso
Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity
Nothing to Disclose
Jerome Avouac
Semaphorins: From Angiogenesis to Inflammation in Rheumatoid Arthritis
Disclosure: 2- Pfizer
8- Pfizer
KATHRYN L BACON
Does Cartilage Loss Cause Pain in Osteoarthritis?
Nothing to Disclose
Sangmee Bae
Paraoxonase 1 Activity Is Abnormal in Patients with Idiopathic Inflammatory Myopathies and Associates with Poor Disease Control
Nothing to Disclose
Joshua F Baker
Disease Activity, Cytokine Profiles, and the Risk of Incident Diabetes in Rheumatoid Arthritis
Disclosure: 2- Myriad RBM
5- Bristol-Myers Squib; Burns-White LLC
Sufia Bakshi
MyD88 S209R Enhances Inflammation in Mouse Models of Arthritis
Nothing to Disclose
Raveendhara R Bannuru
Is There Any Role for Opioids in the Management of OA?
Nothing to Disclose
Xenofon Baraliakos
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Disclosure: 2- AbbVie; Biocad; Bristol-Myers Squibb; Celgene; Chugai; Eli Lilly; Galapagos; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; UCB
4- AbbVie; Bristol-Myers Squibb
5- AbbVie; Biocad; Bristol-Myers Squibb; Celgene; Chugai; Eli Lilly; Galapagos; Janssen; Lilly; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; Bristol-Myers Squibb; Celgene; Galapagos; Janssen; Lilly; Novartis; Pfizer; UCB
Xenofon Baraliakos
Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with
Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging

Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Merc; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB

Xenofon Baraliakos
Which Magnetic Resonance Imaging Lesions of the Sacroiliac Joints Are of Diagnostic Value for Axial Spondyloarthritis?
Disclosure:
2- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
5- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Merc; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
8- AbbVie; Abbvie; BMS; Bristol-Myers Squibb; Celgene; Chugai; Janssen; Lilly; Merck; MSD; Novartis; Novatis; Pfizer; UCB; UCB Pharma; Werfen
9- BMS ; Celgene ; Chugai ; Janssen ; Lilly ; MSD ; Novartis ; Pfizer ; UCB

Fatima Barbar-Smiley
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Nothing to Disclose

Medha Barbhaiya
Mortality Rates After Coronary Revascularization Procedures Among Systemic Lupus Erythematosus Compared to Diabetes Mellitus and General Population Medicaid Patients
Nothing to Disclose

April Barnado
Systemic Lupus Erythematosus Risk Alleles Drive Autoimmune Features in a Population Without Diagnosed Autoimmune Diseases
Nothing to Disclose

Christie Bartels
Implementing the BP Connect Systems-Based Blood Pressure Follow-Up Protocol with Community Rheumatology Clinic Teams
Disclosure:
2- Pfizer; Pfizer Independent Grants for Learning and Change

Anne R Bass
Racial Disparities in Septic and Aseptic Total Knee Replacement Revision Risk: A Study Using Four State-wide Inpatient Databases
Nothing to Disclose

Edward Behrens
Monomethyl Fumarate as a Novel Therapy for Macrophage Activation Syndrome: Mechanism of Action in an Animal Model
Nothing to Disclose

Silvia Bellando-Randone
Predictors to Develop Definite Systemic Sclerosis (SSc): Results from an International Multicentre Study on Very Early Diagnosis of Systemic Sclerosis (VEDOSS)
Nothing to Disclose

Louise A Bennett
Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis
Nothing to Disclose

Lorenzo Beretta
An Integrated Gut Microbiomic and Plasma Metabolomic Analysis in Patients with Four Systemic Autoimmune Diseases
Nothing to Disclose
Sasha Bernatsky
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Nothing to Disclose

Sasha Bernatsky
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Nothing to Disclose

Rohit Bhan
Assessing Commercial Titers of anti-Ro60 and Ro52 Antibodies to Risk Stratify Surveillance of Anti-Ro/SSA Antibody Positive Pregnancies
Nothing to Disclose

Megan Bielawski
Use of a Novel Electronic Auto-notification Process to Manage Transitions of Care in Rheumatic Patients on DMARD Therapy
Nothing to Disclose

Jonathan J Bjerre-Bastos
Co-morbidities Associated with Discordance Between Structural Severity and Pain in Osteoarthritis: Implications for Clinical Trial Design in OA — a Post-Hoc Analysis of Data from Two Randomized Controlled Trials
Disclosure: 3- Nordic Bioscience Clinical Development

Aron H Bjornsson
Antimicrobial Use Is High in Patients with Rheumatoid Arthritis, and Further Increases with First-Line TNFi Therapy — Nationwide Results from Iceland
Nothing to Disclose

Sarah A Blackstone
Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
Nothing to Disclose

Irene Blanco
Needs Assessment of Rheumatology Fellowship Program Directors on the Need for a Health Disparities Curriculum for Our Fellowship Programs
Nothing to Disclose

Alexandra Bocharnikov
The Transcription Factor MAF Controls the Ability of T Peripheral Helper (Tph) Cells to Help B Cells
Nothing to Disclose

Marco Boeri
Patient Preferences for Attributes of Treatments for Chronic Pain Associated with Osteoarthritis Pain and Chronic Low Back Pain That Differentiate Nerve-Growth Factor Inhibitors, Nonsteroidal Anti-inflammatory Drugs, and Opioids in the United States: A Disclosure: 3- RTI Health Solutions

Gilles Boire
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Disclosure: 2- Bristol-Myers Squibb Canada 5- Bristol-Myers Squibb Canada

Maria I Bokarewa
Interferon-gamma Supports Transcriptional Activity of BIRC5 in CD4+ T Cells in Established Rheumatoid Arthritis
Nothing to Disclose

Tawnie Braaten
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
Nothing to Disclose

Jacques P Brown
Romosozumab Improves Lumbar Spine Bone Mineral Density and Bone Strength Greater Than Alendronate as Assessed by Quantitative Computed Tomography and Finite Element Analysis in the ARCH Trial
Hermine I Brunner
Disability and Health-Related Quality of Life Outcomes in Patients with Systemic or Polyarticular Juvenile Idiopathic Arthritis Treated with Tocilizumab in Randomized Controlled Phase 3 Trials
Disclosure:
2- Bristol-Myers Squibb; Genentech; Pfizer
5- AbbVie; AstraZeneca; Bayer; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Janssen; Lilly; Novartis; Pfizer; R-Pharm; Sanofi; UCB
8- Genentech; Novartis

Lisa Buckley
Psoriasis Associated with Anti-Tumor Necrosis Factor-Alpha Therapies in Children with Inflammatory Bowel Disease, Juvenile Idiopathic Arthritis, and Chronic Noninfectious Osteomyelitis
Nothing to Disclose

William Bush
A Path Model Analysis of the Cognitive Determinants of Physical Activity Among Patients with Fibromyalgia (FM)
Nothing to Disclose

Frank Buttgerait
Impact of Glucocorticoid Tapering on Markers of Bone Metabolism in Patients with Rheumatoid Arthritis Who Achieved Low Disease Activity or Remission on Tocilizumab: Exploratory Analysis from a Randomized Controlled Trial
Disclosure:
2- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme
5- Medac; Pfizer; Roche; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme
8- Medac; Pfizer; Roche/Chugai; Roche-Chugai; Sanofi-Genzyme

Tianrun Cai
Improving the Efficiency of Clinical Trial Recruitment Using Electronic Health Record Data, Natural Language Processing, and Machine Learning
Nothing to Disclose

Veronica T Campbell
A First-in-class Selective and Potent IRAK4 Degrader Demonstrates Robust In Vitro and in Vivo Inhibition of TLR/IL-1R Activation and Inflammation
Disclosure:
1- Kymera Therapeutics
3- Kymera Therapeutics

Scott Canna
Multiplex Serum Analysis Identifies Potential Biomarkers of Systemic Juvenile Idiopathic Arthritis, Macrophage Activation Syndrome, and Associated Pulmonary Alveolar Proteinosis: Evidence for Independently-regulated Hyperinflammatory and Eosinophilic Infl
Disclosure:
5- AB2 Bio Ltd; Novartis
8- AB2Bio, Ltd; Novartis

Lisa Carlesso
The Relation of Pain Sensitization and Conditioned Pain Modulation to Pain Patterns in Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Nothing to Disclose

Francine Castillo
Deriving Accurate Prednisone Dosing from Electronic Health Records: Analysis of a Natural
Language Processing Tool for Complex Prescription Instructions
Nothing to Disclose

francesca cedola
Clinical and Biological Changes in Rheumatoid Arthritis Patients Exposed to an Anti-inflammatory Diet
Nothing to Disclose

Matteo Cesaroni
Biomarker Profiling Reveals Novel Mechanistic Insights into Ustekinumab Therapeutic Responses in Systemic Lupus Erythematosus
Disclosure:
3- Janssen Research & Development, LLC

Gaëlle Chédeville
Parent-Reported Medication Side-Effects and Their Impact on Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Nothing to Disclose

Unnikrishnan M Chandrasekharan
Myosin Regulation of TNF Receptor 2 Signaling May Contribute to Anti-TNF Therapy Response
Nothing to Disclose

Joyce C Chang
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Nothing to Disclose

Joyce C Chang
Patterns of Ambulatory Health Care Utilization and Medication Adherence Among Transition-Age Youth with Systemic Lupus Erythematosus
Nothing to Disclose

Miao Chang
Linking Toll-Like Receptor Signaling and Type I Interferons to Inflammation and Fibrosis in a Macrophage/Fibroblast Model of Congenital Heart Block
Nothing to Disclose

Kristen L Chen
Myeloid Dendritic Cells (mDCs) Are Major Producers of Interferon-β in Dermatomyositis and Higher Numbers of mDCs Are Found in Hydroxychloroquine Nonresponders
Nothing to Disclose

Shang-Yang Chen
Single Cell RNA-sequencing Reveals Distinct Macrophage Subsets in the Joint with Differing Ontogenies During Steady-state and Arthritis
Nothing to Disclose

Ann Chodara
Rate of Thirty-Day Readmissions in Systemic Lupus Erythematosus Rivals Congestive Heart Failure and Exceeds the General Medicare Population
Nothing to Disclose

Ernest Choy
MACE and VTE Across Multiple Upadacitinib Studies in Rheumatoid Arthritis: Integrated Analysis from the SELECT Phase 3 Clinical Program
Disclosure:
2- Amgen; Bio-Cancer; Bio-Cancer, Biogen, Novartis, Sanofi, Roche, Pfizer and UCB; Biogen; Chugai Pharma; Ferring Pharmaceuticals; Novartis; Novimmune; Pfizer; Roche; Sanofi; Union Chimique Belge
5- AbbVie; Abbvie, Roche, Chugai, Amgen, Eli Lilly, Janssen, Novartis, Regeneron, R-Pharm and Sanofi; Amgen; AstraZeneca; Biogen; BMS; Boehringer Ingelheim; Celgene; Chugai Pharma; Eli Lilly; Ferring Pharmaceuticals; GSK; Hospira; Janssen; Jazz Pharmaceuticals; Merck Sharp & Dohme; Merrimack Pharmaceutical; Napp; Novartis; Novimmune; ObsEva; Pfizer; Regeneron; Roche; R-Pharm; Sanofi; SynAct Pharma; Tonix; Union Chimique Belge
8- Amgen; Amgen, Roche, Chugai, Bristol-Myers Squibb, Eli-Lilly Janssen, Pfizer, Regeneron, Sanofi and UCB.; BMS; Boehringer Ingelheim; Eli Lilly; Hospira; Merck Sharp & Dohme; Novartis; Pfizer; Regeneron; Roche; Sanofi; Union Chimique Belge

85
Sara Nysom Christiansen  
Assessing the Sensitivity to Change of the OMERACT Ultrasound Structural Gout Lesions During Urate-Lowering Therapy  
Nothing to Disclose

Sara Nysom Christiansen  
Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout  
Nothing to Disclose

Rebecca J Cleveland  
Associations of Socioeconomic Status with Rheumatoid Arthritis (RA) Progression in African Americans with Early Disease  
Nothing to Disclose

Laura C Coates  
Continuing versus Withdrawing Ixekizumab in Patients with Psoriatic Arthritis Who Achieved Sustained Minimal Disease Activity: Results from the SPIRIT-P3 Study  
Disclosure:  
2- AbbVie; Celgene; Novartis; Pfizer; Eli Lilly and Company  
5- AbbVie; Celgene; Novartis; Pfizer; Eli Lilly and Company; Amgen; Galapagos NV; Gilead Sciences; Janssen Pharmaceuticals; UCB  
8- AbbVie; Novartis; Pfizer; Eli Lilly and Company; Amgen; UCB

Stanley Cohen  
Efficacy and Safety of Fenebrutinib, a BTK Inhibitor, Compared to Placebo in Rheumatoid Arthritis Patients with Active Disease Despite TNF Inhibitor Treatment: Randomized, Double Blind, Phase 2 Study  
Disclosure:  
2- AbbVie; Amgen Inc.; AstraZeneca; Biogen-IDEC; Bristol-Myers Squibb; Genentech; Janssen; Lilly; Merck; Novartis; Pfizer; Roche  
5- AbbVie; Abbvie; Amgen; Amgen Inc.; AstraZeneca; Biogen-IDEC; Bristol Meyer Squibb; Genentech; Janssen; Lilly; Merck; Novartis; Pfizer; Roche

Chloé COMARMOND  
TLR9 Signaling in HCV-Associated Atypical Memory B Cells Triggers Th1 and Rheumatoid Factor Autoantibody Responses  
Nothing to Disclose

Denis Comte  
Signaling Lymphocytic Activation Molecule Family (SLAMF) Receptors Deregulation Is Implicated in the Altered Function of NK Cells in Systemic Lupus Erythematosus  
Nothing to Disclose

Alessandro Consolaro  
Discriminant and Predictive Ability of the Parent Version of the Juvenile Arthritis Disease Activity Score in Two Large Multination Cohorts of Patients with Juvenile Idiopathic Arthritis  
Disclosure:  
2- Abbvie; Pfizer

Alice Courties  
Critical Role of the Cholinergic System Involvement in Osteoarthritis  
Nothing to Disclose

Pierre Cunin  
Neutrophil Passage Through the Megakaryocyte Cytoplasm via Emperipolesis Modulates Neutrophil Migration  
Nothing to Disclose

Jeffrey R Curtis  
Exploring Heterogeneity in Rheumatoid Arthritis: Outcomes up to 4 Years of Follow-Up in Patient Clusters Identified by Data-driven Analysis of the BRASS Registry  
Disclosure:  
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen Research & Development, LLC; Lilly; Myriad; Patient Centered Outcomes Research Institute (PCORI); Pfizer; Regeneron; Roche; UCB  
3- Roche
Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients

Disclosure:
2- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB

9- Jeffrey R Curtis

Results from a Randomized Controlled Trial of the Safety of the Live Varicella Vaccine in TNF-Treated Patients

Disclosure:

5- AbbVie; Abbvie; AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Lilly, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB; Amgen; Amgen Inc.; BMS; Bristol-Myers Squibb; Corrona; Crescendo; Eli Lilly; Eli Lilly and Company; Genentech; Janssen; Janssen; Lilly; Myriad; Pfizer; Regeneron; Roche; Roche/Genentech; UCB

9- Radius Health, Inc.

Maria-Antonietta D'Agostino

Cluster-based Spondyloarthritis Phenotypes Defined at Baseline Are Predictive of Different Severity Outcomes at 5-Year in the DESIR Cohort

Nothing to Disclose

Spencer I Danto

Efficacy and Safety of the Selective Interleukin-1 Receptor Associated Kinase 4 Inhibitor, PF-06650833, in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

Disclosure:
1- Pfizer Inc
3- Pfizer Inc

Cecilie L Daugaard

Perfusion in Bone Marrow Lesions Assessed on Dynamic Contrast-enhanced MRI and Its Association with Pain in Knee Osteoarthritis: A Cross-sectional Study

Nothing to Disclose

Anne Davidson

Reversible Dysregulation of Renal Circadian Rhythm in Lupus Nephritis

Nothing to Disclose

Anne Davidson

Single Cell Analysis of Renal Myeloid Cells from NZB/WF1 Mice with Lupus Nephritis Reveals Multiple Subsets with Altered Functions

Nothing to Disclose
Aileen Davis
Exploring Possible Predictors of Physical Activity in Knee Replacement Patients
Nothing to Disclose

Hubert de Boysson
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis Disclosure:
2- Roche Chugai
5- Chugai Pharma France; Roche Chugai

Ann-Sophie De Craemer
Ileal but Not Colonic Inflammation Is Linked to Fatty Lesions on MRI of the Sacroiliac Joints in Spondyloarthritis Patients
Nothing to Disclose

Manouk de Hooge
AxSpA Patients with Symptom Onset < 30 Years Have More Structural Lesions on MRI of the Sacroiliac Joints When Fulfilling the Modified New York Criteria
Nothing to Disclose

Adriana de Jesus
Interferon Signature and Cytokine Patterns Define Novel Autoinflammatory Diseases
Nothing to Disclose

Adriana A de Jesus
Small Vessel Vasculitis Syndrome with Autoinflammation Caused by De Novo Mutations in LYN Kinase
Nothing to Disclose

Guilherme R De Jesus
sFlt-1, PI GF and VEGF in the Differential Diagnosis Between Active SLE Nephritis During Pregnancy and Preeclampsia
Nothing to Disclose

Karina de Leeuw
The Presence of Extractable Nuclear Antigens (ENA) Antibodies in a Large Population-based Cohort from the Netherlands and Their Association with Known Risk Factors for Systemic Lupus Erythematosus and Primary Sjögren Syndrome
Nothing to Disclose

Emma C de Moel
Serum Calprotectin Is a Prognostic Marker for Drug-Free Remission in RA
Nothing to Disclose

Francesco Del Galdo
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSC (CRISS) Disclosure:
2- Capella Biosciences; Chemomab
5- AstraZeneca; GSK; Boehringer-Ingelheim; Actelion; Capella Biosciences; Chemomab
8- AstraZeneca; GSK; Boehringer-Ingelheim; Actelion

M. Kristen Demoruelle
Lung-Related Factors Are Associated with Transitions from Systemic Anti-CCP Antibody Positivity to Classified RA Disclosure:
2- Pfizer

Christopher P Denton
Evaluation of the Highly Selective Endothelin a Receptor Antagonist Zibotentan in Systemic Sclerosis Associated Chronic Kidney Disease Disclosure:
2- CSL Behring; GlaxoSmithKline; Inventiva; Leadiant Biosciences
5- Actelion; Actelion Pharmaceuticals; Actelion, GlaxoSmithKline, Bayer, Sanofi, Inventiva, Boehringer Ingelheim, Roche, Bristol Myers Squibb, CSL Behring, UCB, Leadiant Biosciences; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Bristol-Myers Squibb; Corbus Pharmaceuticals; CSL Behring; GlaxoSmithKline; Inventiva; Leadiant Biosciences; Inventiva; Pfizer; Roche; Sanofi; UCB

Thierry Dervieux
Antibody Systems Targeting Citrullinated, Carbamylated, and Peptidyl Arginine Deaminase Autoantigens Distinguish Rheumatoid Arthritis in Combination with Rheumatoid Factors
Disclosure:
1- Exagen
3- Exagen
4- Exagen
6- Exagen

Umesh S Deshmukh
Activation of the STING Pathway Is a Shared Feature of Salivary Gland and Lung Inflammation in Sjogren's Syndrome
Nothing to Disclose

Vishal Deshmukh
Lorecivivint (SM04690), a Potential Disease-Modifying Osteoarthritis Drug, Inhibits CLK2 and DYRK1A, Novel Molecular Regulators of Wnt Signaling, Chondrogenesis, and Inflammation
Disclosure:
1- Samumed, LLC
3- Samumed, LLC

Brian L Dizon
Prevalence of Atopic Features in Classic Autoinflammatory Diseases
Nothing to Disclose

Robyn Domsic
The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud Phenomenon in Early Diffuse Scleroderma: Results of the "Tamer" Study
Disclosure:
5- Boehringer Ingelheim; Boehringer-Ingelheim; Eicos; EICOS Sciences Inc

Robin Dore
Treatment Patterns and Persistency Following the First Biologic DMARD in Patients with Rheumatoid Arthritis: Real-World Analysis of 2012–2016 US Medicare Data
Disclosure:
2- AbbVie; Abbvie, Inc.; Amgen; Biogen; Gilead Science; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB
5- AbbVie; AbbVie, Inc.; Amgen; Biogen; Gilead Sciences, Inc.; Lilly; Novartis; Pfizer; UCB

Irena Doubelt
Clinical Manifestations of Patients with Eosinophilic Granulomatosis with Polyangiitis in a Large North American Cohort
Nothing to Disclose

Charmayne M Dunlop-Thomas
Predictors of Mortality Among Black Women with Systemic Lupus Erythematosus: The Black Women’s Experiences Living with Lupus (BeWELL) Study
Nothing to Disclose

Pierre-Marie Duret
BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years
Nothing to Disclose

Bhargavi Duvvuri
Mechanisms Contributing to Formation of Neutrophil Extracellular Traps in Tissue and Peripheral Blood in Juvenile Dermatomyositis
Nothing to Disclose

Lihi Eder
The Pattern of Musculoskeletal Complaints in Patients with Suspected Psoriatic Arthritis and Their Correlation with Physical Examination and Ultrasound
Disclosure:
2- Abbvie; Lily; Novartis; Pfizer; UCB
5- Abbvie; Celgene; Janssen; Lily; Novartis
8- Abbvie; Pfizer

Bugra Han Egeli
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
Nothing to Disclose

Noha M Elemam
Natural Killer Cells Gene Expression Can Differentiate Rheumatoid Arthritis Patients from Healthy Controls
Nothing to Disclose

Whitney Elg-Salsman
A Quarter of Patients Treated with Checkpoint Inhibitors Develop Immune-Related Adverse Events: A University Center Experience
Nothing to Disclose

Muriel Elhai
The Long Non-coding RNA HOTAIR Regulates BMP2 and Wnt Pathways in Synovial Fibroblasts
Nothing to Disclose

Ori Elkayam
Safety and Humoral Immunogenicity to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis (interim Analysis)
Disclosure:
2- Pfizer
5- Pfizer
8- Pfizer

Bryant R England
Trajectory of Multimorbidity in Rheumatoid Arthritis in a U.S. Commercial Insurance Claims Database from 2006-2015
Nothing to Disclose

Martin Englund
Does Early Anterior Cruciate Ligament Reconstruction Prevent Further Meniscal Damage? Secondary Analysis of a Randomized Controlled Trial
Nothing to Disclose

Erik F Eriksen
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Disclosure:
2- Amgen; Takeda
5- Amgen; Takeda; Ascendis; Lilly; Merck
8- Takeda; Lilly; Merck; Mylan

Nnenna Ezeh
Baseline Clinical and Serological Findings in Pediatric-Onset Discoid Lupus Erythematosus: Analysis of a Multicenter Retrospective Cohort Study
Nothing to Disclose

Robert Fairchild
Development and Preliminary Validation of a Novel Lung Ultrasound Interpretation Criteria for the Detection of Interstitial Lung Disease in Patients with Systemic Sclerosis
Nothing to Disclose

Niamh Fanning
A Burden of Missense Genetic Variants in Urate Secretory Genes Is Associated with Inadequate Response to Allopurinol in People with Gout
Nothing to Disclose

Andrea Fava
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Nothing to Disclose

Candace H Feldman
Avoidable Acute Care Use for Vaccine-Preventable Illnesses Among Medicaid Beneficiaries with Lupus: Demographic and Healthcare Utilization Differences
Nothing to Disclose

Benoit Flachaire
Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of 556 Spondyloarthritis
Disclosure:
9- UCB pharma, BMS, Novartis
(Accommodation, lunch)

Roy Fleischmann
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response

Disclosure:
2- AbbVie; Acea; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Centrexion; Eli Lilly; Eli Lilly and Company; EMD Merck-Serono; EMD Serono; EMD-Serano; EMD-Serono; Genentech; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Merck; Nektar; Novartis; Pfizer; Pfizer Inc; Regeneron; Resolve; Roche; Sanofi Genzyme; Sanofi-Aventis; Sanofi-Aventis; Sanofi-Genzyme; Selecta; UCB; Boehringer Ingelheim; Gilead; Aventis; Samumed
5- AbbVie; Acea; Akros; Amgen; AstraZeneca; BMS; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Celtrion; Celtrion; Eli Lilly; Eli Lilly and Company; EMD Merck-Serono; Genentech; GlaxoSmithKline; GSK; Janssen; Lilly; Novartis; Pfizer; Pfizer Inc; Samsung; Sandoz; Sanofi-Aventis; Sanofi-Aventis; Taiho; Taiho; UCB; Galvani

Achilleas Floudas
Hypoxia Resistant Pathogenic B Cells Accumulate in the RA Synovial Tissue in a CXCR3 Dependent Manner
Nothing to Disclose

Charlene M Foley
Arthropathy of down Syndrome: An Under-diagnosed Inflammatory Joint Disease That Warrants a Name Change
Nothing to Disclose

Liana Fraenkel
Stopping NSAIDs for Arthritis Pain (SNAP): A Randomized Withdrawal Trial Comparing NSAIDs to Cognitive Behavioral Therapy
Nothing to Disclose

Michael Fralick
Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study

Nothing to Disclose

Sarah French
Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
Nothing to Disclose

Benjamin Friedman
Adenosine A2A Receptor Signaling Activates FoxO1 and FoxO3 and Promotes Cartilage Autophagy
Nothing to Disclose

Koji Fukuda
Expression Profiling of Genes in Rheumatoid Fibroblast-like Synoviocytes Regulated by Fas Ligand Using cDNA Microarray Analysis
Nothing to Disclose

Richard A Furie
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obinutuzumab or Placebo in Combination with Mycophenolate Mofetil in Patients with Active Class III or IV Lupus Nephritis
Disclosure:
2- GlaxoSmithKline; UCB Pharma
5- Biogen; GlaxoSmithKline; UCB Pharma; Genentech, Inc.

Richard A Furie
Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
Disclosure:
2- GlaxoSmithKline; UCB Pharma
5- Biogen; GlaxoSmithKline; UCB Pharma; Genentech, Inc.

Richard A Furie
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
Disclosure:
2- GlaxoSmithKline; UCB Pharma
Angelo L Gaffo
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Disclosure:
2- Amgen

Barry Garchow
HIF-1α and miR-210 Differential and Lineage-specific Expression in Systemic Lupus Erythematosus
Nothing to Disclose

Rodrigo Garcia Salinas
Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina
Disclosure:
9- Genentech, Inc. (Study Investigator)

Shivani Garg
Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk
Nothing to Disclose

Norman B Gaylis
Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator
Disclosure:
2- SetPoint Medical; BMS; AbbVie; GSK; Janssen; Amgen; Pfizer; Regeneron; UCB; Sanofi; ImmunPharma; Astra Zeneca; Sandoz; Novartis; Gilead
5- electroCore

Lin-Yu Geng
A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model
Nothing to Disclose

Mark Genovese
Effects of Filgotinib on Anemia, Thrombocytopenia and Leukopenia: Results from a Phase 3 Study in Patients with Active Rheumatoid Arthritis and Prior Inadequate Response or Intolerance to Biological DMARDs
Disclosure:
4- UNITY

Mark Genovese
Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 7 Years: An Updated Integrated Safety Analysis
Disclosure:
4- UNITY

Michael D George
Association Between Rheumatoid Arthritis Treatment and the Risk of Death or Readmission After Major Surgery
Disclosure:
2- Bristol Myers Squibb; Bristol-Myers Squibb
5- AbbVie

Michael D George
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Disclosure:
2- Bristol Myers Squibb; Bristol-Myers Squibb
5- AbbVie

Michael D George
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Disclosure:
2- Bristol Myers Squibb; Bristol-Myers Squibb
5- AbbVie

Gabriella Giancane
Long-term Outcome of Juvenile Idiopathic Arthritis: From the Methotrexate to the Biologic Era
Nothing to Disclose

Jon T Giles
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to
Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Nothing to Disclose

Tejpal Gill
Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis
Nothing to Disclose

Elena Gkrouzman
Antiphospholipid Antibody Profile Stability over Time: Prospective Results from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository ("Registry")
Nothing to Disclose

Vera Golder
Prospective Demonstration That Attainment of the Lupus Low Disease Activity State Is Associated with Improved Health Related Quality of Life
Nothing to Disclose

Yvonne M Golightly
High Intensity Interval Training for Knee Osteoarthritis: A Pilot Study
Nothing to Disclose

Yvonne M Golightly
Knee Injury and Transitions Among States of Knee Osteoarthritis in the Johnston County Osteoarthritis Project: A Multi-State Time-To-Event Modeling Approach
Nothing to Disclose

Takahisa Gono
Predictive Factors for Mortality in Anti-melanoma-associated Gene 5 Antibody-associated Interstitial Lung Disease
Disclosure:
8- Astellas; Astellas Pharma; Boehringer-ingelheim Pharma; Chugai; Janssen; MBL; MEDICAL & BIOLOGICAL LABORATORIES CO., LTD; Ono; Ono Pharma; Tanabe-Mitsubishi; UCB Japan

Adam P Goode
Predictors of Incident and Worsening Lumbar Spine Degeneration: The Johnston County Osteoarthritis Project
Nothing to Disclose

Jacques-Eric Gottenberg
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell CXCL13 and Disease-Relevant Immune Cell CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Disclosure:
2- BMS; Pfizer
5- BMS; Lilly; Pfizer; Sanofi-Genzyme; UCB
8- Abbvie; Lilly; Roche; Sanofi-Genzyme; UCB

Jacques-Eric Gottenberg
IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Disclosure:
2- BMS; Pfizer
5- BMS; Lilly; Pfizer; Sanofi-Genzyme; UCB
8- Abbvie; Lilly; Roche; Sanofi-Genzyme; UCB

Jacques-Eric Gottenberg
Systems Biology in 874 Patients with Primary Sjögren's Syndrome Indicates the Predominant Role of Interferon Alpha Compared to Interferon Gamma, Its Association with Systemic Complications, and a New Aspect of the Genetic Contribution of HLA
Disclosure:
2- BMS; Pfizer
5- BMS; Lilly; Pfizer; Sanofi-Genzyme; UCB
8- Abbvie; Lilly; Roche; Sanofi-Genzyme; UCB

K Bates Gribbons
Clinical Subsets in Giant Cell Arteritis
Nothing to Disclose

K Bates Gribbons
Comparison of Arterial Patterns of Disease in Takayasu’s Arteritis and Giant Cell Arteritis
Nothing to Disclose
Ricardo Grieshaber-Bouyer
Single-Cell RNA Sequencing of Murine Neutrophils Identifies a Transcriptional Continuum (“Neutrotime”) Across Biological Compartments
Nothing to Disclose

Hans Guehring
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial Disclosure:
3- Merck KGaA, Darmstadt, Germany

Latika Gupta
NMR-Based Serum, Urine and Muscle Metabolomics in Inflammatory Myositis for Diagnosis and Activity Assessment: Serum Metabolomics Can Differentiate Active from Inactive Myositis
Nothing to Disclose
2- APLAR

Emma Haley
Cytokine Dependence of Enthesis-resident Lymphocytes in Murine Spondyloarthritis
Nothing to Disclose

Hilde B Hammer
Ultrasound Demonstrates Rapid Reduction of Crystal Depositions During a Treat-to-target Approach in Gout Patients: Two-year Results from a Longitudinal, Observational Study (NORGOUT)
Nothing to Disclose

Edward R Hammond
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systemic Lupus Erythematosus: A Real-World Cohort Study, United States, 2004–2015 Disclosure:
3- AstraZeneca

Jennifer S Hanberg
Epidemiology and Presentation of Sarcoidosis with and Without HIV Infection
Nothing to Disclose

Johannes Hartl
Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis
Nothing to Disclose

Sarfaraz Hasni
A Phase 1b/2a Trial of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus
Nothing to Disclose

Gulen Hatemi
Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study Disclosure:
2- BMS, Celgene Corporation, Silk Road Therapeutics; Silk Road Therapeutics 5- Bayer, Eli Lilly 8- Abbvie, Mustafa Nevzet, UCB

Andrew C Heisler
Association of Pain Centralization with DMARD Response in Active RA Nothing to Disclose

Viktoria Hermann
First Use of Cenerimod, a Selective sphingosine-1-phosphate 1 (S1P1) Receptor Modulator, for the Treatment of Systemic Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase II, Proof-of-Concept Study Disclosure:
1- Idorsia 3- Idorsia

Borja Hernández-Breijo
Changes in B Cell Profile as a Marker of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Nothing to Disclose

Kristin B Highland

Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial Disclosure:
2- Actelion Pharmaceuticals; Boehringer Ingelheim; Eiger Pharmaceuticals; Genentech; Reata Pharmaceuticals; United Therapeutics
5- Boehringer Ingelheim
8- Actelion Pharmaceuticals; Bayer; Bayer Healthcare; Boehringer Ingelheim; Genentech; Gilead Sciences; United Therapeutics
9- Actelion Pharmaceuticals ; Boehringer Ingelheim

Shunsei Hirohata
Enhanced Expression of mRNA for TAK1 in CD34+ Cells of the Bone Marrow in Rheumatoid Arthritis
Nothing to Disclose

Carol A Hitchon
The Impact of Psychiatric Comorbidity on Health Care Utilization and Preventive Health Care in Rheumatoid Arthritis: A Population Based Study Disclosure:
2- Pfizer; UCB Canada

Marc C. Hochberg
Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study Disclosure:
3- Rheumcon, Inc
4- BriOri Biotech; Theralogix LLC
5- Bioiberica SA; Bone Therapeutics; Bristol Myers Squibb; Eli Lilly; EMD Serono; EMD Serono Research and Development Institute, Inc.; Galapagos; IBSA Biotechniq SA; Novartis Pharma AG; Pfizer; Pfizer Inc; Plexxikon; Regenosine, Samumed LLC, Symic Bio Inc., Theralogix LLC, TissueGene Inc., TLC Biopharmaceuticals, Inc., and Zynerba; Samumed LLC; Theralogix LLC; TissueGene Inc
7- Elsevier; UpToDateTM
9- Galapagos, IQVIA and Hoffman LaRoche

Asako Ichihara
Dimethyl Fumarate Ameliorates the GATA6 Deficiency-Induced Pulmonary Hypertension by Normalizing Oxidative and ER Stress
Nothing to Disclose

Naira Ikram
Breastfeeding in Women with Rheumatic Diseases
Nothing to Disclose

Priyanka Iyer
Wellness and Resiliency Among Recent Rheumatology Fellowship Graduates: A Qualitative Study
Nothing to Disclose

Ruchi Jain
Identifying Educational Themes and Knowledge Gaps Through Analysis of Electronic Consultation (eConsult) Communication Between Primary Care Physicians and Rheumatologists
Nothing to Disclose

Eddie A James
Differences in the Phenotypic Landscape and Antigen Specificity of CD4+ T Cells Are Present in CCP+ Subjects Before the Onset of Rheumatoid Arthritis Disclosure:
2- Pfizer; Janssen

Tim L Jansen
The First Phase 2a Proof-of-Concept Study of a Selective NLRP3 Inflammasome Inhibitor, Dapansutrile™ (OLT1177™), in Acute Gout Disclosure:
2- Olatec, Grunenthal
5- AbbVie, Celgene Corporation
8- Grunenthal, Sobi

Sungsin Jo
Enthesal CD90+ SOX9+ Cartilage-like Cells
Initiate Spinal Ankylosis in Ankylosing Spondylitis
Nothing to Disclose

Tate Johnson
Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Nothing to Disclose

Anna Helena Jonsson
An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium
Nothing to Disclose

April Jorge
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Nothing to Disclose

Vijay Joshua
Citrulline Reactive B Cells Are Present in the Lungs of Early Untreated RA
Nothing to Disclose

Hanna Källmark
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy - A Swedish Nationwide Register Study
Nothing to Disclose

Merlijn Kaaij
Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Nothing to Disclose

Umut Kalyoncu
Mortality Ratio and Risk Factors in CT Confirmed Rheumatoid Arthritis Related Lung Disease: UIP, Pleural Effusion and the Time of Diagnosis of Rheumatoid Arthritis - Lung Disease
Nothing to Disclose

Rie Karasawa
Clinical Correlations of Autoantibodies Against Heat Shock Cognate 71 kDa Protein in Patients with Juvenile Dermatomyositis
Nothing to Disclose

George A Karpouzas
Beta-2-Glycoprotein-I IgA Antibodies Predict Coronary Plaque Burden, Progression and Moderate the Effect of Inflammation on Atherosclerosis in Rheumatoid Arthritis
Disclosure:
2- Pfizer
5- Sanofi
8- Bristol Meyer Squibb; Bristol-Meyer-Squibb; Sanofi
9- Pfizer

George A Karpouzas
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
Disclosure:
2- Pfizer
5- Sanofi
8- Bristol Meyer Squibb; Bristol-Meyer-Squibb; Sanofi
9- Pfizer

George A Karpouzas
Highly-sensitive Cardiac Troponin-I and Beta-2-Glycoprotein-I IgA Antibodies Inform the Utility of Screening and Follow-up Non-invasive Coronary Atherosclerosis Evaluation and Optimize Cardiovascular Risk Assessment in Rheumatoid Arthritis
Disclosure:
2- Pfizer
5- Sanofi
George A Karpouzas
Medication Necessity and Concerns Beliefs Are Distinct, Interactive Predictors of Treatment Adherence in Rheumatoid Arthritis
Disclosure:
2- Pfizer
5- Sanofi
8- Bristol Meyer Squibb; bristol Meyer Squibb; Bristol-Meyer-Squibb; Sanofi
9- Pfizer

George A Karpouzas
Statin Exposure Moderates the Effects of Chronic Inflammation on Coronary Atherosclerosis Progression and Cardiovascular Events in Rheumatoid Arthritis
Disclosure:
2- Pfizer
5- Sanofi
8- Bristol Meyer Squibb; bristol Meyer Squibb; Bristol-Meyer-Squibb; Sanofi
9- Pfizer

Shanthini Kasturi
Implementing Patient-Reported Outcome Measures in Clinical Care: Rheumatologist Perspectives on Opportunities and Challenges
Nothing to Disclose

Jonathan Kay
Earlier Treatment of Non-Radiographic Axial Spondyloarthritis with Certolizumab Pegol Results in Improved Clinical and Patient-Reported Outcomes
Disclosure:
2- Gilead; Gilead Sciences, Inc; Gilead Sciences, Inc.; Gilead Sciences, Inc., Novartis AG, Pfizer, UCB Pharma; Novartis AG; Pfizer; Pfizer Inc; Pfizer Inc.; UCB; UCB Pharma; UCB, Inc.
5- AbbVie; Abbvie; Abbvie, Boehringer Ingelheim, Celltrion, Horizon Therapeutics, Merck, MorphoSys AG, Novartis AG, Pfizer, Samsung Bioepis, Sandoz Inc., UCB Pharma;

AAbbVie, Inc.; Boehringer Ingelheim GmbH; Boehringer-Ingelheim; Boehringer-Ingelheim GmbH; Celltrion Healthcare; Celltrion Healthcare Co. Ltd; Celltrion Healthcare Co. Ltd.; Gilead Sciences; Horizon Therapeutics; Horizon Therapeutics PLC; Merck Sharp & Dohme; Merck Sharp & Dohme Corp; Merck Sharp & Dohme Corp.; MorphoSys AG; Novartis AG; Novartis Pharmaceuticals; Pfizer; Pfizer Inc; Pfizer Inc.; Samsung Bioepis; Samsung Bioepis Co., Ltd.; Sandoz; Sandoz Inc; UCB; UCB Pharma; UCB, Inc.

Nikolas H Kazmers
Identification of Genetic Variants Associated with Erosive Hand Osteoarthritis Using Pedigrees from a State-Wide Population-Based Cohort
Nothing to Disclose

Joanna Kedra
Radiographic Progression During a 10-Year Follow-Up: Results from the French Cohort ESPOIR
Nothing to Disclose

Joanna Kedra
Towards the Lowest Efficacious Dose (ToLEDo): Results of a Multicenter Non-Inferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis Patients in Remission
Nothing to Disclose

David Kendler
Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
Disclosure:
2- Amgen Inc.; Eli Lilly
5- Amgen Inc.; Eli Lilly; Pfizer
8- Amgen Inc.; Eli Lilly

Marianne Kerski
Perioperative Anti-rheumatic Medications Are Not Associated with 30-day Odds of Infection in Rheumatoid Arthritis Patients Undergoing Surgery: A Retrospective Cohort Study
Nothing to Disclose

Dinesh Khanna
Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis— Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial
Disclosure:
2- Bayer; BMS; Horizon; Pfizer
4- Eicos, Inc
5- Acceleron; Actelion; Bayer; Blade Therapeutics; BMS; Boehringer Ingelheim; Celgene; ChemomAB; Corubus; CSL Behring; Curzion; Cytori; Genentech; GSK; Mitsubishi Tanabe Pharma Development America; Sanofi-Aventis; UCB

Urmila Khanna
Utility of Repeat Latent Tuberculosis Testing in Patients Taking Biologics
Nothing to Disclose

Uta Kiltz
Clinically Relevant Deficits in Performance Tests in Patients with Axial Spondyloarthritis(axSpA) – Collecting Questionnaires Is Insufficient
Disclosure:
2- AbbVie; ABBVIE, NOVARTIS, PFIZER,BIOGEN; Biocad; Biogen; Chugai; Eli Lilly; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
5- AbbVie; ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB; Biocad; Biogen; Chugai; Eli Lilly; Eli Lilly and Company; Grünenthal; Janssen; MSD; Novartis; Pfizer; Roche; UCB
8- AbbVie; ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB; Chugai; Grünenthal; Janssen; MSD; Novartis; Roche; UCB

Seoyoung C. Kim
Risk of Serious Infections in Tofacitinib versus Other Biologic Drug Initiators in Patients with Rheumatoid Arthritis: A Multi-database Cohort Study
Disclosure:
2- AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics; Roche; Roche/Genentech

Seoyoung C. Kim
Trajectories of Opioid Filling Patterns After Total Knee Replacement
Disclosure:
2- AbbVie; AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics; Roche; Roche/Genentech

Yoo Jung Kim
A Double-Blind, Placebo-Controlled, Phase 2 Trial of a Novel Toll-Like Receptor 7/8/9 Antagonist (IMO-8400) in Dermatomyositis
Nothing to Disclose

Kathryn M Kingsmore
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
Nothing to Disclose

Andrew J Kinloch
Serum Anti-Vimentin Autoantibodies May Uniquely Predict Response to Therapy in Lupus Nephritis
Nothing to Disclose

Signe S Knudsen
Rheumatoid Arthritis in Pregnancy and Offspring School Performance. a Danish Nationwide Register-Based Study
Nothing to Disclose

Maximilian Konig
Hydroxychloroquine Blood Levels and Risk of Thrombotic Events in Systemic Lupus Erythematosus
Nothing to Disclose

Bon San Koo
Tumor Necrosis Factor Inhibitors Slow Radiologic Progression in Patients with Ankylosing Spondylitis: 18-year Longitudinal Cohort Study
Nothing to Disclose

Marie Kostine
Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors
Nothing to Disclose

Joel M Kremer
Comparison of Malignancy and Mortality Rates Between Tofacitinib and Biologic DMARDs in Clinical Practice: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Disclosure:
1- Corrona
2- AbbVie; Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
5- AbbVie; Amgen; Bristol-Myers Squibb; Genentech; Gilead; Lilly; Pfizer; Regeneron; Sanofi

Jasmin Kuemmerle-Deschner
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
Disclosure:
2- SOBI; Novartis
8- SOBI; Novartis

Deepak Kumar
Physical Therapy and Opioid Use in Knee Osteoarthritis
Nothing to Disclose

Burak Kundakci
The Efficacy of Non-Pharmacological Interventions for Fibromyalgia: A Systematic Review with Meta-Analysis
Nothing to Disclose

Izumi Kurata
Potential Involvement of OX40 Expressing Tfh Cells on Regulation of Autoantibody Sialylation in Experimental and Rheumatoid Arthritis
Nothing to Disclose

Tadeja Kuret
The Long Noncoding RNA HOTTIP Regulates Cell Cycle and Inflammatory Response in Hand Synovial Fibroblasts
Disclosure:
2- EULAR Scientific Bursary; IUBMB Wood-Whelan Fellowship; Swiss-European Mobility Programme (SEMP) Scholarship; Slovenian Research Agency

Alysia Kwiatkowski
Education of Rheumatology Faculty: Evaluation of an Interactive Team Based Approach versus Traditional Didactic Teaching
Nothing to Disclose

Alysia Kwiatkowski
Time to Bridge the Gap in Rheumatology Education: Interactive Team Based Learning Is Most Effective in Increasing Internal Medicine Residents' Knowledge
Nothing to Disclose

Diane Lacaille
Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study
Nothing to Disclose

Ryan Laird
TNF Inhibitor Treatment and Dramatic Stroke Risk Reduction in Patients with Deficiency of Adenosine Deaminase 2
Nothing to Disclose

W. Blaine Lapin
School Nurse Education for Juvenile Idiopathic Arthritis
Nothing to Disclose

Pui Lee
Adenosine Deaminase 2 as a Circulating Biomarker of Macrophage Activation Syndrome
Nothing to Disclose

Yvonne C Lee
Effect of a Mobile App to Monitor Patient Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial
Disclosure:
1- Cigna Corp
2- Eli Lilly; Eli Lilly and Company; Pfizer
3- Express Scripts
4- Eli Lilly

David Leverenz
Rheumatology Mechanism Madness: A Pilot Collaborative Learning Activity for Rheumatology Trainees
Nothing to Disclose

Daniel Li
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Nothing to Disclose

Linda C Li
Efficacy of a 3-Month Wearable-enabled Physical Activity Counselling Program for People with Knee Osteoarthritis
Nothing to Disclose

Lingyi Li
Risk of Cardiovascular Disease Associated with the Use of Glucocorticoids in Patients with Incident Systemic Lupus Erytematosus: A Population-based Study
Nothing to Disclose

Lingyi Li
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Initiating Biologic and Non-biologic DMARDs, a Population-based Study
Nothing to Disclose

Lingyi Li
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Nothing to Disclose

Lily SH Lim
Delineating Early Response Trajectories to Biologics in Polyarticular Course Juvenile Idiopathic Arthritis
Nothing to Disclose

S Sam Lim
The Association of Discrimination and Stress on Cardiovascular Disease in a Population-Based Cohort with Systemic Lupus Erythematosus
Nothing to Disclose

Peter E Lipsky
Development of a Multi-Modality Imaging Approach to Evaluate Lupus Nephritis
Disclosure:
2- Janssen Research & Development, LLC
5- Horizon

Lucy Liu
Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Nothing to Disclose

Xiao-qing Liu
Low-Dose IL-2 Effectively Restored Decreased Regulatory T Cells in Patients with Behcet’s Disease
Nothing to Disclose

Polly Livermore
Assessing Psychosocial Needs in Juvenile Dermatomyositis Patients Across the United Kingdom
Disclosure:
9- National Institute of Health Research (I am on a PhD fellowship)

Christian Lood
Clinical Implications of Neutrophil Extracellular Traps in Systemic Lupus Erythematosus
Nothing to Disclose

Chary Lopez-Pedrera
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
Nothing to Disclose

Gary J Macfarlane
Maintaining Musculoskeletal Health: A Randomized Controlled Prevention Trial Amongst People at High Risk of Developing Chronic Widespread Pain
Disclosure: 2- Celgene

Lindsey A MacFarlane
The Effects of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older U.S. Adults
Disclosure: 5- Flexion

Rohan Machhar
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Nothing to Disclose

Olivier Malaise
Mesenchymal Stem Cell Senescence Alleviates Their Chondrogenic and Seno-Suppressive Properties, Contributing to Osteoarthritis Development
Nothing to Disclose

Fardina Malik
Magnetic Resonance Enterography as a Screening Tool to Detect Sacroiliitis in Crohn’s Disease: Association with Clinical and Endoscopic Markers of Crohn’s Disease Activity Disclosure: 5- Pfizer

Hiral Master
Does the Degree of Decline in Walking Speed Predict Mortality Risk Beyond the Present Level of Walking Speed in Knee Osteoarthritis?
Nothing to Disclose

Hiral Master
Optimal Threshold of Walking Speed Predictive of Mortality Risk over 9 Years in Knee Osteoarthritis: Data from Osteoarthritis Initiative
Nothing to Disclose

Elke G Mathijssen
Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
Nothing to Disclose

Kotaro Matsumoto
Platelet Mediates Neutrophil Extracellular Traps Formation via TLR Signaling in ANCA-associated Vasculitis
Nothing to Disclose

Xanthe ME Matthijssen
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Nothing to Disclose

Xanthe ME Matthijssen
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Nothing to Disclose

Mark Matza
Ustekinumab for the Treatment of Giant Cell Arteritis
Nothing to Disclose

Daniele Mauro
The Deubiquitinase TRABID Is a Potential Therapeutic Target in Spondyloarthritis
Nothing to Disclose

Natalie McCormick
From a Potential Solution to Part of the Problem: Analysis of Spending and Price Trends for Brand-Name and Generic Colchicine and Other Gout Medications
Nothing to Disclose

Greg McDermott
Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis
Nothing to Disclose

Joseph McDonald
Major Salivary Gland Ultrasound: Pilot Study of Findings and Feasibility in Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Nothing to Disclose

Kevin McElhanon
Auto-antibodies Targeting Components of Sarcolemma Repair: A Pathogenic Mechanism in Human Inflammatory Myopathies
Nothing to Disclose

Jenna McGoldrick
An Evaluation of Burnout Among U.S. Rheumatology Fellows: A National Survey
Nothing to Disclose

Iain B McInnes
Clinically Relevant Patient Clusters Identified by Machine Learning Tools in a Large Database from the Secukinumab Psoriatic Arthritis Clinical Development Program
Disclosure:
2- AbbVie; Amgen; BMS; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB
5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; Sun; UCB; Boehringer Ingelheim
8- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Genentech; Janssen; Novartis; Pfizer Inc; UCB

Philip J. Mease
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Disclosure:
2- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Janssen; Novartis; Pfizer Inc; Sun; UCB
5- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Gilead; Janssen; Novartis; Pfizer Inc; Sun; UCB; Boehringer Ingelheim
8- AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Eli Lilly; Genentech; Janssen; Novartis; Pfizer Inc; UCB

Bella Mehta
Community-level Deprivation Index: Impact on Discharge Destination After Elective Hip Replacement
Nothing to Disclose

Jacob Meindertsma
What Disease Do You Have? – Assessment and Predictors of Accurate Illness Naming in Rheumatology
Nothing to Disclose

Philip J. Mease
Alan M Mendelsohn
Tildrakizumab Efficacy for Psoriatic Arthritis: 24-week Analysis of Swollen and Tender Joint Counts and Pain
Disclosure:
1- Johnson and Johnson
3- Sun Pharmaceutical Industries, Inc; Sun Pharmaceutical Industries, Inc.
4- Johnson and Johnson

Peter A Merkel
Predictors of Renal Involvement in ANCA-Associated Vasculitis
Disclosure:
2- AstraZeneca; AstraZeneca,; Boeringher-Ingehelm; Bristol-Myers Squibb; Celgene; Celgene; ChemoCentryx; Genentech/Roche; Genentech/Roche; Genzyme/Sanofi; GlaxoSmithKline; Kypha; TerumoBCT
5- Abbvie; AbbVie; AstraZeneca; AstraZeneca,;
Biogen; Boeringher-Ingehelm; Bristol-Myers Squibb; Celgene; Celgene; ChemoCentryx; CSL Behring; Genentech/Roche; Genentech/Roche; Genzyme/Sanofi; GlaxoSmithKline; InflaRx; Insmed; Jannsen; Kiniksa
7- UpToDate

Christopher Mesa
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
Nothing to Disclose

Stephen P Messier
Is Long-term High-intensity Strength Training Beneficial or Harmful for Knee Osteoarthritis Patients? The Strength Training and Arthritis Trial (START)
Nothing to Disclose

Brigitte Michelsen
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Disclosure:
2- Novartis
5- Novartis

Brigitte Michelsen
High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients - Data from the EuroSpA Research Collaboration Network
Disclosure:
2- Novartis
5- Novartis

Ted R Mikuls
Autoantibodies to Malondialdehyde-acetaldehyde Preceding the Diagnosis of Rheumatoid Arthritis
Disclosure:
2- BMS; Horizon

Hong Ki Min
Alcohol Consumption as a Predictor of the Progression of Spinal Structural Damage in Axial Spondyloarthritis: Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Nothing to Disclose

Amir minerbi
Dietary Intake Does Not Explain Microbiome Alterations or Symptom Severity in Fibromyalgia
Nothing to Disclose

Deeba Minhas
Cost-related Prescription Non-adherence Is Associated with Patient-reported Outcomes of Systemic Lupus Erythematosus Activity and Damage: The Michigan Lupus Epidemiology & Surveillance (MILES) Cohort
Nothing to Disclose

Francesca Minoia
Development and Initial Validation of the MS Score for Diagnosis of Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Devyani Misra
The Association of Serum Magnesium with Chondrocalcinosis and Osteoarthritis
Nothing to Disclose

Mitra Moazzami
Combined Trajectories of Fatigue and Disease Activity in an Inception Cohort of Lupus Patients over 10 Years
Nothing to Disclose

Burkhard Moeller
Drug Retention of Biological DMARDs Targeting IL-12/IL-23 or IL-17 versus TNF Inhibitors, After a First Line TNF Inhibitor, in Patients with Psoriatic Arthritis – an Analysis in the Swiss SCQM Register
Disclosure:
2- AbbVie; Eli Lilly; Janssen; Merck; Novartis; Pfizer; UCB
8- AbbVie; Eli Lilly; Janssen; Merck; Novartis; Pfizer
9- UCB

Mosaab Mohameden
Wikipedia as a Source of Health Information for the Public: Systematic Analysis of Quality and Readability of 8 Common Rheumatic Diseases Articles
Nothing to Disclose

Chi Chiu Mok

Long-term Outcome of a Randomized Controlled Trial Comparing Tacrolimus with Mycophenolate Mofetil as Induction Therapy of Severe Lupus Nephritis
Nothing to Disclose

Anna Moltó
5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Nothing to Disclose

Anna Moltó
Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort
Nothing to Disclose

Sara Monti
Treatment Response Criteria for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-vasculitis: Results of a Scoping Review
Nothing to Disclose

Erica Moore
The Pathogenic Potential of Choroid Plexus T Cells in Neuropsychiatric Lupus
Nothing to Disclose

Richard Moore
Anti-Mitochondrial Antibodies Predict Severe Erosive Disease in Rheumatoid Arthritis
Nothing to Disclose

Eric F Morand
The Glucocorticoid-Induced Protein GILZ Represent a Checkpoint in the IFN Program in SLE
Disclosure:
2- AstraZeneca; Bristol Myers Squibb; Eli Lilly; Janssen; Merck Serono
5- AstraZeneca; Eli Lilly; Janssen; Merck Serono; UCB; GSK; CSL Inc; Neovacs; Wolf Biotherapeutics; AbbVie; Amgen

Erika Mosor
“When You Read This, You Really Feel Old!” Perspectives of Young People with
Inflammatory Arthritis on Patient Reported Outcome Measures from a European Qualitative Study
Nothing to Disclose

John D Mountz
Lower IL-4R in IgD+ Naïve B Cells Is a Pre-disposing Factor for Development of T-bet+ DN2 B Cells in Systemic Lupus Erythematosus
Nothing to Disclose
2- VA Merit Review grant (I01BX004049); Lupus Research Alliance Distinguished Innovator Award; NIH R01-AI-071110, R01 AI134023, P30-AR-048311

Michelle Mulder
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Nothing to Disclose

Yoon Y Mun
Anti-CCP Antibody and Pain Sensitization in Rheumatoid Arthritis
Nothing to Disclose

Melissa E. Munroe
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Disclosure:
2- Progentec Diagnostics, Inc.

Melissa E. Munroe
Alterations in Inflammatory, TNF-Superfamily, and IFN-Associated Chemokines Precede Clinical Changes in SLEDAI After Methylprednisolone Treatment of SLE Patients
Disclosure:
2- Progentec Diagnostics, Inc.

Francesco Muratore
Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study

Nothing to Disclose

Goh Murayama
Mucosal-associated Invariant T Cells Can Be Therapeutically Targeted in Lupus
Nothing to Disclose

Tomoyuki Mutoh
Endothelial Protein C Receptor and Scavenger Receptor Class B Type 1 Negatively Regulate Vascular Inflammation and Are Major Autoantigens in Takayasu Arteritis
Nothing to Disclose

Elena Myasoedova
Improved Incidence of Cardiovascular Disease in Patients with Incident Rheumatoid Arthritis in 2000s: A Population-Based Cohort Study
Nothing to Disclose

Navraj S Nagra
Antibiotic Use and the Development of Rheumatoid Arthritis (RA) and Risk of RA Flares: Case-Control and Self-Controlled Case Series Studies in Two National Electronic Patient Databases (SIDIAP and CPRD)
Nothing to Disclose

Benjamin S Naovarat
Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis
Nothing to Disclose

Ruth Napier
The Card9-Neutrophil Signaling Axis Is Critical to Induction of Th17-Mediated Arthritis in SKG Mice
Nothing to Disclose

Sonali Narain
Cell-bound Complement Activation Products in Combination with Low Complement C3 or C4 Have Superior Diagnostic Performance in Systemic Lupus Erythematosus
Disclosure:
2- Exagen

Iris Navarro-Millan
The Preparation and Recovery Experience from Total Knee Replacement of Patients with Osteoarthritis: A Qualitative Study
Nothing to Disclose

Fatemeh Navid
Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements
Nothing to Disclose

Renuka Nayak
Perturbation of the Human Gut Microbiome by Methotrexate Contributes to the Resolution of Inflammation and Autoimmune Disease
Nothing to Disclose

Jessica Neely
Gene Expression Meta-Analyses Reveals Commonalities in Gene Activation and Enrichment of Immune Pathways and Cell Types in Dermatomyositis Target Tissues
Nothing to Disclose

Eric Newman
Treat to Target Opportunities – Design, Testing, and Adoption of a Novel EHR-Integrated Electronic System to Engage Rheumatologists and Capture Decision Making
Nothing to Disclose

Cuong Nguyen
CLEC5A/MDL-1 Is Critical for Inflammatory Arthritis and Skin Inflammation
Nothing to Disclose

MaiLan Nguyen
Myositis-Specific Antibodies and Muscle Histopathology in Juvenile Dermatomyositis: New Insights into the Mechanism of Injury
Nothing to Disclose

Yann Nguyen
Bone Manifestations in Gaucher Disease: A Monocentric Study of 128 Patients
Nothing to Disclose

Mark Nicolls
Safety and Efficacy of B-cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension in a Multi-center NIH Clinical Trial
Nothing to Disclose

Svetlana I Nihtyanova
Frequency and Predictors of Meaningful Decline in Forced Vital Capacity During Follow up of a Large Cohort of Systemic Sclerosis Associated Pulmonary Fibrosis Patients
Disclosure:
3- Daiichi Sankyo

Elena Nikiphorou
Do Smoking and Socio-economic Factors Independently Influence Imaging Outcomes in Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Disclosure:
5- Celltrion; Gilead; Sanofi
6- Celltrion; Gilead
8- AbbVie; Eli Lilly; Eli Lilly and Company; Pfizer; Sanofi

Antonio Nino
Efficacy and Safety of Intravenous Belimumab in Children with Systemic Lupus Erythematosus: An Across-Trial Comparison with the Adult Belimumab Studies
Disclosure:
1- GlaxoSmithKline
3- GlaxoSmithKline

Jill Norris
Progression to Inflammatory Arthritis After Screening Autoantibody Positive in a Non-Clinical Setting
Disclosure:
2- Janssen R&D; Pfizer
5- BMS; Celgene

Matthew D O’Dell
Increased Expression of Extracellular Matrix Proteins in Human Fibroblast Synoviocytes and Lung Epithelial Cells Following
Malondialdehyde-Acetaldehyde Adduct (MAA)/Citrullinated Protein Stimulation
Nothing to Disclose

Alexis Ogdie
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Disclosure:
2- Abbvie; Novartis; Pfizer
5- Abbvie; Amgen; BMS; Celgene; Corrona; Lilly; Novartis; Pfizer
7- Novartis
8- Abbvie; Amgen; Celgene; Novartis

Thomas Olenginski
Geisinger HiROC Performance 2017-2018: Continuing to Narrow the Post-Fracture Treatment Gap
Disclosure:
8- Amgen; Radius

Stephen Oliver
Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Iналумаб (VAY736)
Disclosure:
1- Novartis Pharma AG
3- Novartis Pharma AG

Kelly D O'Neill
Importance of Discussing RA Treatment Goals: Patients Report Providers Seldom Discuss Treatment Goals and Outcomes Improve When Goals Are Discussed
Nothing to Disclose

Sabina Oreska
Body Composition in Myositis Patients Is Negatively Changed Compared to Healthy Controls and the Changes Are Associated with Disease Activity and Duration, Skeletal Muscle Involvement and Physical Activity and Nutritional Status
Nothing to Disclose

Charles Oshinsky
Tubulo-interstitial Inflammation Predicts Outcomes in Lupus Nephritis
Nothing to Disclose

Gulsen Ozen
First Cardiovascular Event in Rheumatoid Arthritis: Do Patients with Venous Thromboembolism Have a Different Risk Profile Than Patients with Atherosclerotic Cardiovascular Disease?
Nothing to Disclose

Sandra Pérez-Baos
Cholesterol Sequestration in Macrophages Contributes to the Lipid Paradox in Chronic Arthritis
Nothing to Disclose

Elena Pachera
Cracking a Novel Profibrotic Molecular Mechanism: IncRNA H19X and DDIT4L Crosstalk
Nothing to Disclose

John F Paolini
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
Disclosure:
3- Kiniksa Pharmaceuticals

Kim A Papp
Safety and Efficacy Results from the Open Label Extension of a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor in Patients with Active Psoriatic Arthritis
Disclosure:
5- AbbVie; Akros; Allergan; Amgen; Anacor; Kyowa Hakko Kirin; Arcutis; Astellas; AstraZeneca; Baxalta; Baxter; BMS; Boehringer Ingelheim; CanFite; Celgene; Coherus; Demira; Dow Pharma; Eli Lilly; Forward Pharma; Galderma; Genentech; Gilead; GSK; InflaRx GmbH; Janssen; Leo; MedImmune; Meiji Seika Pharma; Merck Sharp & Dohme; Merck-Serono; Mitsubishi Pharma; Moberg Pharma; Novartis; Pfizer; PRCL Research; Regeneron; Roche; Sanofi-Aventis/Genzyme; Takeda; UCB; Valeant/Bausch Health
Vardhaman Patel
Comparison of Infection-Related Hospitalization Risk and Cost in TNFi-Experienced Medicare Beneficiaries with Rheumatoid Arthritis Treated with Abatacept or Other Targeted Disease-Modifying Anti-Rheumatic Drugs
Disclosure:
3- Bristol-Myers Squibb

Sarah Patterson
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Nothing to Disclose

Tim Pelle
Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial
Nothing to Disclose

Cory Perugino
Clonal Expansion of a Specific Subset of Cytotoxic CD4+T Cells and Tissue Apoptosis in Patients with IgG4-related Disease
Disclosure:
2- UCB
5- BMS

Michelle Petri
Comparison of the Thrombosis Risk Score with Triple Positivity in SLE Thrombosis
Disclosure:
2- Exagen
5- Eli Lilly and Company; Exagen

Costantino Pitzalis
A Randomised, Open Labelled Clinical Trial to Investigate Synovial Mechanisms Determining Response - Resistance to Rituximab versus Tocilizumab in Rheumatoid Arthritis Patients Failing TNF Inhibitor Therapy
Nothing to Disclose

Remy A Pollock
Characterizing the Epigenomic Landscape of Psoriasis Patients Destined to Develop Psoriatic Arthritis
Nothing to Disclose

Janet Pope
Baricitinib 4 Mg and 2 Mg Once Daily Reduced Pain in Both Patients Who Were Opioid Users and Non-users in Active Rheumatoid Arthritis: A Post-hoc Analysis of Phase 3 Trials
Disclosure:
2- Amgen; AstraZeneca; Astra-Zeneca; Bayer; BMS; Merck; Pfizer; Roche; Seattle Genetics; UCB
5- AbbVie; Abbvie; Actelion; Actellion; Amgen; Bayer; BMS; Eicos Sciences; Eli Lilly & Company; Eli Lilly and Company; EMERALD; Emerald; Genzyme; Janssen; Lilly; Merck; Novartis; Pfizer; Roche; Sandoz; Sanofi; UCB
8- UCB

Ali Porter
Evaluation of Marijuana and Cannabidiol Use in the Rheumatologic Population from a Patient and Clinician Perspective: A Survey-Based Study
Nothing to Disclose

Ginto Pottackal
Application of Bayesian Statistics to Support Approval of Intravenous Belimumab in Children with Systemic Lupus Erythematosus in the United States
Nothing to Disclose

Xavier Puéchal for the French Vasculitis Study Group
Granulomatosis with Polyangiitis Sustained Remission Off-Therapy: Data from the French Vasculitis Study Group Registry Disclosure:
2- LFB; Pfizer, Roche

Amy Puenpatom
Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors Disclosure:
1- Merck & Co., Inc.
4- Merck & Co., Inc.

Chaim Putterman
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity Disclosure:
2- Equillium, Inc; Exagen
5- Equillium; Equillium, Inc

Kaitlin A Quinn
Imaging Acquisition Technique Influences Interpretation of Positron Emission Tomography Vascular Activity in Large-Vessel Vasculitis Nothing to Disclose

Alexis Régent
High Resolution 3D Fast Spin-Echo T1 Black-Blood Imaging for the Diagnosis of Giant Cell Arteritis Nothing to Disclose

Yasser A Radwan
Reliability of Traditional Cardiovascular Risk Calculators in Predicting Risk of Cardiovascular Disease in Systemic Sclerosis Nothing to Disclose

Julio Ramirez
Biomarkers of Clinical Relapse and Radiological Progression in Patients with Rheumatoid Arthritis in Remission: Observational Study of 5 Years of Follow-up Nothing to Disclose

Anne-Christine Rat
Patients and Relatives Coping with Inflammatory Arthritis: Impact of Communication, Social Support and Relatives Burden on Patients Perceived Health Nothing to Disclose

Alan Rathbun
Depression as a Moderator of Analgesic Effectiveness in Knee Osteoarthritis Nothing to Disclose

Soledad Retamozo
Musculoskeletal Sarcoidosis: Characterization and Clinical Expression of 129 Patients with Granulomatous Infiltration of Bones And/or Muscles Nothing to Disclose

Soledad Retamozo
Sarcoidosis as a Systemic Disease. Clinical and Epidemiological Characterization of Systemic Phenotype in 1521 Patients Nothing to Disclose

Soledad Retamozo
Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR) Nothing to Disclose

Rennie L Rhee
Longitudinal Changes in the Nasal Microbiome and Disease Activity in Patients with Granulomatosis with Polyangiitis Nothing to Disclose

Valentin Ritschl
The Need for Personalized, Non-Pharmacological Intervention Programmes in Autoimmune Connective Tissue Disorders: Results of a EULAR-Funded Scoping Review with a Nested, Descriptive Meta-Analysis
Nothing to Disclose
Felice Rivellese
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Nothing to Disclose
George Robinson
Sex Differences in Autoimmunity and Cardiovascular Risk Could Be Associated with Altered Treg Phenotype and Lipoprotein Metabolism
Nothing to Disclose
Edward Roddy
Clinical Effectiveness of Ultrasound-guided Intra-articular Corticosteroid and Local Anaesthetic Injections for Hip Osteoarthritis: A Randomised Controlled Trial (HIT)
Nothing to Disclose
Santiago Rodrigues-Manica
Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort
Nothing to Disclose
Sebastian C Rodriguez-Garcia
Quantifying the Placebo Effect After Intra-Articular Injections: Implications for Trials and Practice
Nothing to Disclose
Alicia Rodriguez-Pla
Geographic Disparities in Systemic Sclerosis Mortality in the United States: 1999 to 2017
Nothing to Disclose
Mia Rodziewicz
The Epidemiology of the Antiphospholipid Syndrome in the UK, 1990 – 2016
Nothing to Disclose
9- Pfizer (British Society of Rheumatology Conference fees paid)
Renata F Rosa
Cognitive Dysfunction (CD) and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Primary Antiphospholipid Syndrome (PAPS)
Nothing to Disclose
Michal Rudnik
Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis
Nothing to Disclose
Nicolino Ruperto
Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials Disclosure:
2- Eli Lilly; Janssen; Novartis; Sobi; BMS; Roche; Pfizer Inc; GSK
5- AbbVie; Ablynx; AstraZeneca-MedImmune; Biogen; Boehringer Ingelheim; Eli Lilly; EMD Serono; Janssen; Merck; Novartis; R-Pharma; Sinergie; Sobi; Takeda; BMS; Roche; Pfizer Inc; GSK; Sanofi; Servier
8- AbbVie; Ablynx; AstraZeneca-MedImmune; Biogen; Boehringer Ingelheim; Eli Lilly; EMD Serono; Janssen; Merck; Novartis; R-Pharma; Sinergie; Sobi; Takeda; BMS; Roche; Pfizer Inc; GSK; Sanofi; Servier
Violeta Rus
Response Gene to Complement -32 Exerts Proinflammatory and Profibrotic Effects in Immune Complex Gediated Glomerulonephritis
Nothing to Disclose
Kenneth Saag
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids Disclosure:
Sarah Sacks
The Ankylosing Spondylitis Disease Activity Score Reflects and Predicts Response to Biologic Treatment in Axial Spondyloarthritis Patients with Coexistent Fibromyalgia Compared to the Bath Ankylosing Spondylitis Disease Activity Index
Nothing to Disclose

Sarah A Safran
Ancestry-Specific Classical HLA Alleles Define Phenotypic Subsets in the African American Scleroderma Population
Nothing to Disclose

Elizabeth Salt
Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives
Disclosure:
2- Pfizer; Pfizer and IHI

Gabriela Sandoval-Plata
Asymptomatic Monosodium Urate Crystal Deposition Associates with Increased Expression of Pro-Inflammatory Genes
Nothing to Disclose

Sebastian E. Sattui
Incidence of Dementia and Association with Cardiovascular Disease and Risk Factors in Rheumatoid Arthritis – Analysis of a National Claims Database
Nothing to Disclose

Sebastian E. Sattui
Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database
Nothing to Disclose

Amr Sawalha
Takayasu Arteritis Associated Risk Locus in IL6 Represses the Anti-inflammatory Gene GPNMB Through Chromatin Looping and Recruiting MEF2-HDAC Complex
Nothing to Disclose

Amit Saxena
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Disclosure:
2- Exagen

Didem Saygin
Reliability, Validity and Responsiveness of PROMIS PF-20 in Patients with Inflammatory Myopathy
Nothing to Disclose

Jose U Scher
The Pre-Treatment Gut Microbiome Predicts Early Response to Methotrexate in Rheumatoid Arthritis
Disclosure:
5- Janssen; Novartis; UCB, Inc; Pfizer

Marc SCHERLINGER
A New Role for Selectins in Systemic Lupus Erythematosus
Nothing to Disclose

Georg Schett
Individually Tailored Predictions of Flare Probability for Rheumatoid Arthritis Patients on Biologic DMARDs Based on Machine Learning Stacking Meta-Classifier
Disclosure:
2- BMS, Celgene, GSK, Lilly, Novartis
5- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, UCB
8- AbbVie, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer

Elena Schiopu
Pain Patterns in Idiopathic Inflammatory Myopathy (IIM): Associations with Disease Activity Measures (Muscle Enzymes, Manual Muscle Testing 8), Patient-Reported Quality of Life (HAQ) and Pain Scales (Widespread Pain Index (WPI), Symptom Severity Index (SS)
Nothing to Disclose
Gabriela Schmajuk
Gaps in Care for Patients with SLE: Data from the ACR’s RISE Registry
Nothing to Disclose

Grant S Schulert
Monocyte and Macrophage Transcriptional Phenotypes in Systemic Juvenile Idiopathic Arthritis Reveal TRIM8 as a Mediator of IFNγ Hyperresponsiveness and Risk for Macrophage Activation Syndrome
Disclosure:
5- Novartis
8- Novartis

Grant S Schulert
Systemic Juvenile Idiopathic Arthritis-Lung Disease: Characterization and Risk Factors
Disclosure:
5- Novartis
8- Novartis

Morena Scotece
Mitochondrial DNA Impact on Joint Degeneration Process Using DMM OA and Spontaneous Aging Conplastic Mice Models
Nothing to Disclose

Alexandre Sepriano
Higher Disease Activity Is Associated with More Spinal Radiographic Progression in Patients with Axial Spondyloarthritis Independently of Prior Exposure to TNF Inhibitors
Nothing to Disclose

Alexandre Sepriano
Safety of Synthetic and Biological DMARDs: A Systematic Literature Review Informing the 2019 Update of the EULAR Recommendations for Management of Rheumatoid Arthritis
Nothing to Disclose

Alexandre Sepriano
TNF Inhibitors Reduce Spinal Radiographic Progression in Axial Spondyloarthritis by Mechanisms Associated with but Also Independent of Disease Activity

Alexandre Sepriano
What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Nothing to Disclose

Raphaèle Seror
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Disclosure:
5- bms; BMS; gsk; pfizer; PFIZER; ROCHE; roche

Sengül Seven
The Utility of Fat Lesions in Close Relation to Other Structural MRI Lesions in the Sacroiliac Joints for Diagnosing Patients with Axial Spondyloarthritis
Nothing to Disclose

Philipp Sewerin
High-resolution MRI Assessment of Flexor Tendon Pulleys in Psoriatic Arthritis for Disease Monitoring and Differentiation from Rheumatoid Arthritis Using a 16-channel Hand Coil
Disclosure:
2- AbbVie; Celgene; Chugai; Janssen-Cilag; Lilly; Novartis; Pfizer; UCB
5- AbbVie; Biogen; BMS; Celgene; Chugai; Hexal; Janssen-Cilag; Lilly; Novartis; Pfizer; Roche; Sanofi-Genzyme; Swedish Orphan Biovitrum; UCB
8- AbbVie; Biogen; BMS; Celgene; Chugai; Hexal; Janssen-Cilag; Lilly; Novartis; Pfizer; Roche; Sanofi-Genzyme; Swedish Orphan Biovitrum; UCB

Julia Shalen
Access to Care and Diagnostic Delays in Juvenile Dermatomyositis
Nothing to Disclose

Saira Z Sheikh
Adverse Events of Special Interest, SLE Medication Utilization, Hospitalizations, and Organ Damage: Results from a Phase 4, Randomized, Double-Blind, Placebo-Controlled, 52-week Study of Belimumab in Adults with Active, Autoantibody-Positive SLE Nothing to Disclose 5- GSK

Jeffrey W. Sherman Teprotumumab, a Novel Biologic for Active Thyroid Eye Disease Disclosure: 3- Horizon 4- Horizon 6- Horizon

Heena Sheth Improving Pneumococcal Vaccination Rates in High Risk Rheumatology Patients Nothing to Disclose

Jun Shimizu A Third of Relapsing Polychondritis Patients with Ear Involvement at Presentation Had Airway Involvement at the Last Follow-up with a High Mortality Rate Nothing to Disclose

Kimberly F Showalter Change in Scleroderma Skin Histology Correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in Patients with Early, Diffuse Cutaneous Systemic Sclerosis Nothing to Disclose

Swastina Shrestha Five Year Structural Changes in Patients with Meniscal Tear and Osteoarthritis from an RCT of Arthroscopic Partial Meniscectomy vs. Physical Therapy Disclosure: 2- Roche/Genentech

Genevieve S Silva Long-term Clinical and Economic Benefits of a Short-term Physical Activity Intervention Among

Inactive Knee Osteoarthritis Patients in US: A Model-based Evaluation Nothing to Disclose

Gregg J Silverman Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis Nothing to Disclose 2- NIH-NIAMS

Teresa A Simon Cannabis Use Among Patients in a Large US Rheumatic Disease Registry Disclosure: 3- Bristol-Myers Squibb

Namrata Singh Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis Nothing to Disclose

Vidya Sivaraman Improvement in Hepatitis B Screening Prior to Initiation of Biologic Therapy in the Pediatric Rheumatology Clinic Nothing to Disclose

Christopher Sjöwall Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis Nothing to Disclose

Sladjana Skopelja-Gardner Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury Nothing to Disclose

Daniel H Solomon Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial: Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Disclosure:
2- AbbVie; Abbvie; Amgen; AstraZeneca; Corrona; Genentech; Janssen; Lilly; Pfizer

Emily C Somers
Prevalence of Systemic Lupus Erythematosus in the United States: Preliminary Estimates from a Meta-Analysis of the Centers for Disease Control and Prevention Lupus Registries
Nothing to Disclose

Jeffrey A Sparks
Depression and Subsequent Risk for Incident Seronegative Rheumatoid Arthritis Among Women
Nothing to Disclose

Robert Spiera
Clinical Outcomes of Patients with Giant Cell Arteritis with Polymyalgia Symptoms Only vs Cranial Symptoms Only Treated with Tocilizumab or Placebo in a Randomized Clinical Trial
Disclosure:
2- BMS; Boehringer Ingelheim; Bristol-Myers Squibb; ChemoCentryx; Chemocentryx; Corbus; Cytori; Formation Biologics; Genentech, Inc.; Genzyme/Sanofi; GlaxoSmithKline; GSK; Hoffman-La Roche Ltd; Roche; Roche Genetech; Roche/Genetech; Roche-Genentech; Roche-Genentech; Roche-Genetech
5- ChemoCentryx; CSL Behring; Genzyme/Sanofi; GlaxoSmithKline; GSK; Janssen; Mitsubishi; Roche Genetech; Roche/Genetech; Roche-Genentech; Roche-Genentech; Sanofi; Sanofi-Aventis

Robert Spiera
Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Disclosure:
2- BIPI; Chemocentryx; Corbus Pharmaceuticals; Cytori; Formation Biologics; Genentech/Roche; Glaxosmithkline; Sanofi
5- Chemocentryx; Genentech/Roche; Glaxosmithkline; Janssen; Sanofi

Rosalinde A Stal
Two-Year Progression of Facet Joint Ankylosis on Whole Spine Low-Dose CT in Patients with Radiographic Axial Spondyloarthritis
Nothing to Disclose

Lisa Stamp
Lack of Effect of Tart Cherry Concentrate Dose on Serum Urate in People with Gout
Nothing to Disclose

Lisa Stamp
Nortriptyline in Knee Arthritis (Nortika): A Randomised Controlled Double Blind Trial of Nortriptyline for Pain in Knee Osteoarthritis
Nothing to Disclose

Lisa Stamp
Rheumatoid Arthritis Patients’ Perspectives on Tapering of Biologics: A Qualitative Study
Nothing to Disclose

Emma Stevens
Safety of the Zoster Vaccine Recombinant, Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center’s Experience with 400 Patients
Nothing to Disclose

George Stojan
A Spatial-temporal Analysis of Organ-specific Lupus Flares in Relation to Fine Particulate Matter Pollution and Temperature
Nothing to Disclose

Matthew Stoll
Microbiome in Offspring of Ankylosing Spondylitis Patients
Nothing to Disclose

John H Stone
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
Disclosure:
2- Genentech; Roche; Xencor
Paul Studenic  
Testing Different Thresholds for Patient Global Assessment in Defining ACR-EULAR Boolean Remission Criteria for RA  
Nothing to Disclose

Gautam Sule  
Inhibition of Neutrophil Elastase Reduces Autoantibody Levels and Renal Inflammation in Murine Lupus  
Nothing to Disclose

Gautam Sule  
The IRE1α Pathway Mediates Neutrophil Stress and NETosis in Lupus  
Nothing to Disclose

Gregory Sullivan  
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Bedtime Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia (FM): Evidence for a Broad Spectrum of Activity on the FM Syndrome  
Disclosure:  
1- Tonix Pharmaceuticals Inc  
3- Tonix Pharmaceuticals Inc  
4- Tonix Pharmaceuticals Inc  
6- Tonix Pharmaceuticals Inc

James K Sullivan  
Cost-effectiveness of Duloxetine for Knee OA Patients Whose Pain Can’t Be Controlled by NSAIDs  
Nothing to Disclose

Nicholas Sumpter  
Association of a Gout Polygenic Risk Score with Disease Severity Phenotypes Amongst Caucasian Gout Patients in Three Independent Cohorts  
Nothing to Disclose

Julia Sun  
Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD  
Nothing to Disclose

Lingyun Sun  
Mesenchymal Stem Cell Therapy Induces FLT3L and CD1c+ Dendritic Cells in Systemic Lupus Erythematosus Patients  
Nothing to Disclose

Nina P Sundlisater  
Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients  
Nothing to Disclose

Nina P Sundlisater  
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations  
Nothing to Disclose

Hemant Suryawanshi  
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis  
Nothing to Disclose

Subhashisa Swain  
Trends in Incidence and Prevalence of Osteoarthritis in the United Kingdom: Findings from the Clinical Practice Research Datalink (CPRD)  
Nothing to Disclose

Mika M Tabata  
Skin Disease Activity and Autoantibody Phenotype Are Major Determinants of Blood Interferon Signatures in Dermatomyositis  
Nothing to Disclose

Maxime Taghavi  
Descriptive Analysis of Biopsy-proven Antiphospholipid Antibody-associated Nephropathy Patients Included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)  
Nothing to Disclose

Julia Sun  
Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD  
Nothing to Disclose
Vicky Tai
Do Serum Urate-associated Genetic Variants Differentially Contribute to Gout Risk According to Body Mass Index? Analysis of the UK Biobank
Nothing to Disclose

Yoshiya Tanaka
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in MTX-IR Patients with Rheumatoid Arthritis
Disclosure:
2- Asahi-kasei; Asahi-Kasei; Asahi-kasei, BMS, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi-Tanabe, Ono, Pfizer, Sanofi, Takeda, UCB; Astellas Pharma, Inc.; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Eisai; Mitsubishi-Tanabe; Mitsubishi-Tanabe, Bristol-Myers, Eisai, Chugai, Takeda, Abbvie, Astellas, Daiichi-Sankyo, Ono, MSD, Taiho-Toyama.; Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers, MSD, Astellas, Abbvie, Eisai; Ono; Sanofi; Takeda; UCB
3- Astellas Pharma, Inc.
5- AbbVie; Astellas Pharma, Inc.; BMS; Eli Lilly; Genzyme; Pfizer; Roche
8- Abbvie; AbbVie; Astellas; Astellas Pharma, Inc.; Astellas, BMS, Chugai, Daiichi-Sankyo, Eli Lilly, Janssen, Mitsubishi-Tanabe, Pfizer, Sanofi, UCB, YL Biologics; BMS; Bristol-Myers; Bristol-Myers Squibb; Chugai; Daiichi-Sankyo; Daiichi-Sankyo, Astellas, Eli Lilly, Chugai, Sanofi, Abbvie, Pfizer, YL Biologics, Bristol-Myers; Eisai; Eli Lilly; Eli Lilly and Company; Glaxo-Smithkline, UCB, Mitsubishi-Tanabe, Novartis, Eisai, Takeda, Janssen, Asahi-kasei; Janssen; Mitsubishi-Tanabe; Novartis; Pfizer; Pfizer Inc; Takeda; Teijin; YL Biologics
9- Astellas Pharma ; Astellas Pharma, Inc.

Mark Tatangelo
The Effect of Rheumatoid Arthritis and Biologics on the Acquisition of Subsequent Diseases and Adverse Events: A Matched Longitudinal Population Study
Nothing to Disclose

Oshrat Tayer-Shifman
Nothing to Disclose

Sara K. Tedeschi
Sensitivity of Dual-Energy CT, Ultrasound, and X-Ray for Pseudogout: A Pilot Study
Nothing to Disclose

Benjamin Terrier
Off-Label Use of Biotherapies to Treat Relapsing And/or Refractory Eosinophilic Granulomatosis with Polyangitis (Churg–Strauss)
Disclosure:
8- Grifols; GSK; LFB; Roche

Benjamin Terrier
Renal Histopathological Classifications Predict the Renal Outcomes of Plasma Exchange-Treated ANCA-Associated Vasculitides with Renal Failure
Disclosure:
8- Grifols; GSK; LFB; Roche

Uma Thanarajasingam
Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy: A Distinct Clinical Entity and Immunologic Phenotype
Nothing to Disclose

Mohamed Tharwat Hegazy
Relapsing Cryoglobulinemic Vasculitis Following Successful HCV Eradication by Interferon-Free Direct Acting Antivirals, an International Multicenter Study
Nothing to Disclose

Ranjeny Thomas
A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Disclosure:
2- Janssen; Merck
6- Dendright
8- Janssen; Abbvie

Jessica Tibaldi
Development and Initial Validation of the Systemic JADAS, a New Composite Disease Activity Score for Systemic Juvenile Idiopathic Arthritis
Nothing to Disclose

Jeremy Tilstra
B Cell-specific MyD88 Regulates Pathology After Disease Onset in Murine Lupus
Nothing to Disclose

Eleni Tiniakou
Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis
Nothing to Disclose

Priscilla Toral
A National Needs Assessment of Males with SLE: Assessing Medical, Psychosocial, Support & Coping Needs
Nothing to Disclose

Jeanette Trickey
Very Low Prevalence of Ultrasound Determined Tendon Abnormalities in Healthy Subjects Throughout the Age Range: An Outcome Measures in Rheumatology (OMERACT) Ultrasound Minimal Disease Study
Nothing to Disclose

Anne Troldborg
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis

Laura Trupin
Physical Inactivity Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus
Nothing to Disclose

Betty P Tsao
Does Loss-of-function Variants in SAT1 Cause X-linked Pediatric Lupus?
Nothing to Disclose

Konstantinos Tselios
Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis
Nothing to Disclose

Sadiq Umar
CCL25, a Novel Fibroblast and Macrophage Chemoattractant That Potentiates RA Bone Erosion
Nothing to Disclose

Sebastian H Unizony
Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
Disclosure:
2- Genentech, Inc.

Jaymin Upadhyay
Elucidating Pain Mechanisms in Polyarticular Juvenile Idiopathic Arthritis Patients
Nothing to Disclose

Martín Valdez-López
Sexual Function and Health-related Quality of Life in Male Patients with Systemic Lupus Erythematosus, the Untold Story
Nothing to Disclose

Roberto A Valdovinos
Adverse Childhood Experiences Are Associated with Systemic Lupus Erythematosus in a Clinical Population from Bronx, New York
Nothing to Disclose

Celine J van de Laar
Model-based Cost-Effectiveness Analyses Comparing Combinations of Urate Lowering Therapy and Anti-Inflammatory Treatment in Newly Diagnosed Gout Patients
Nothing to Disclose

Filip Van den Bosch
Patient-Reported Outcomes from a Randomised, Open-Label, Parallel-Group Study Evaluating Ixekizumab versus Adalimumab in Patients with PsA Who Are Biologic DMARD Naïve: 24-Week Results
Disclosure: 2- Bristol-Myers Squibb 5- AbbVie; Abbvie; AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB; ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Janssen; Merck; Novartis; Pfizer; Sanofi; UCB 8- AbbVie; Abbvie; AbbVie, Bristol-Myers Squibb, Celgene, Galapagos, Janssen, Lilly, MSD, Novartis, Pfizer, Sanofi and UCB; ABBVIE, CELGENE, ELI LILLY, GALAPAGOS, MERCK, NOVARTIS, PFIZER, VCB; Bristol-Myers Squibb; Celgene; Eli Lilly; Galapagos; Janssen; Merck; Novartis; Pfizer; Sanofi; UCB

Désirée van der Heijde
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Disclosure: 4- Rheumatology bv 5- AbbVie; Abbvie, Amgen, Astellas, AstraZeneca, BMS; Amgen; Astellas; Astellas Pharma; AstraZeneca; BMS; Boehringer Ingelheim; Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB; Boehringer-Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi; Daiichi Sankyo; Eli Lilly; Eli Lilly and Company; Eli-Lilly; Galapagos; Gilead; Gilead Sciences, Inc.; GlaxoSmithKline; Glaxo-Smith-Kline; GSK; Janssen; Janssen Pharmaceutica; Merck; Novartis; Pfizer; Pfizer Inc; Regeneron; Roche; Sanofi; Takeda; Takeda Pharmaceutical Company; UCB; UCB Pharma 6- Director of Imaging Rheumatology 8- GSK; Janssen; Merck; Novartis; Pfizer; Regeneron; Roche; Sanofi; Takeda; UCB 9- Astellas ; Daiichi ; Director of Imaging Rheumatology bv ; Imaging Rheumatology bv ; Imaging Rheumatology bv. ; Rheumatology bv

Irene van der Horst-Bruinsma
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis Following 1 Year of Treatment with Certolizumab Pegol: 48-Week Interim Results from a 96-Week Open-Label Study
Disclosure: 2- AbbVie; Bristol Myers-Squibb; MSD; Novartis; Pfizer; UCB Pharma 5- AbbVie; Bristol Myers-Squibb; MSD; Novartis; Pfizer; UCB Pharma 8- AbbVie; Bristol Myers-Squibb; MSD; Novartis; Pfizer; UCB Pharma

Elise van Mulligen
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
Nothing to Disclose

Ronald van Vollenhoven
Monotherapy with Upadacitinib in MTX-naïve Patients with Rheumatoid Arthritis: Results at 48 Weeks
Disclosure: 2- AbbVie; AbbVie, Arthrogen, Bristol-Myers Squibb, GlaxoSmithKline (GSK), Lilly, Pfizer, and UCB; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Research & Development, LLC; Pfizer; Roche; UCB
Iazsmin Ventura
Comparative Analysis Between ANCA-associated Interstitial Lung Disease and Interstitial Pneumonitis with Autoimmune Features
Nothing to Disclose

Lise M Verhoef
Ultra-Low Doses of Rituximab for Retreatment of RA: A Randomized Controlled Non-Inferiority Trial
Nothing to Disclose

Elsa Vieira-Sousa
Go-Dact: A Phase 3b Randomized Double-Blind Placebo-Controlled Proof-Of-Concept Trial, of Golimumab Plus Methotrexate (MTX) versus MTX Monotherapy, in Improving Dactylitis, in MTX Na"ive Psoriatic Arthritis Patients
Nothing to Disclose

Evelyne Vinet
Serious Infections in Offspring Exposed in Utero to Non-TNFi Biologics and Tofacitinib
Nothing to Disclose

Dana Voinier
The Effects of Leisure Time Sitting and Sitting at Work on Worsening Radiographic Knee Osteoarthritis over Two Years: Data from the Osteoarthritis Initiative
Nothing to Disclose

Elizabeth R Volkmann
Short- and Long-term Morbidity and Mortality Outcomes of African American Patients with Systemic Sclerosis-Related Interstitial Lung Disease
Disclosure:
1- Pfizer
4- Pfizer
5- Boehringer Ingelheim; Boehringer-Ingelheim

Madelon C Vonk
Predictive Factors for Treatment Related Mortality and Event-Free Survival After Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long Term Follow-up Multi-centre Study Disclosure:
2- Actelion; actelion; Actelion Pharmaceuticals; Ferrer; Ferrer International; Ferrier
5- Actelion; actelion; Actelion Pharmaceuticals; Boehringer Ingelheim; Boehringer ingelheim; GSK
6- GSK
8- Actelion; actelion; Actelion Pharmaceuticals; Boehringer Ingelheim; Boehringer ingelheim; Roche

Sheetal S Vora
Cracks in Your Referral Process? Find Your Sustainable Solution Here
Nothing to Disclose

Milena Vukelic
Calcium/ Calmodulin - Dependent Protein Kinase IV Associates with Phosphofructokinase to Promote Glycolysis and Limit IL-2 Production
Nothing to Disclose

Stefanie D Wade
Comparison of Rituximab-Associated Hypogammaglobulinemia Rates in Patients with Systemic Rheumatologic Conditions
Nothing to Disclose

Daniel J Wallace
A Randomized Prospective Trial to Assess the Clinical Utility of Multianalyte Assay with Complement Activation Products in Diagnosing Systemic Lupus Erythematosus
Disclosure:
2- Exagen
Zachary Wallace
ANCA-Associated Vasculitis Management in the United States: Data from the RISE Registry
Disclosure:
2- National Institute of Arthritis, Musculoskeletal, and Skin Diseases; Rheumatology Research Foundation

Zachary Wallace
Treatment Delays Associated with Prior Authorization for Infusible Medications: A Cohort Study
Disclosure:
2- National Institute of Arthritis, Musculoskeletal, and Skin Diseases; Rheumatology Research Foundation

Chrong-Reen Wang
Experimental Rheumatoid Joint Ameliorated by CRISPR Interference Targeting Long Non-coding RNA H19 Through Wnt Signaling Inactivation
Nothing to Disclose

Tim Warneke
A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)
Disclosure:
3- Vizuri Health Sciences, LLC
4- Vizuri Health Sciences, LLC

Christopher Wasson
Long Non-coding RNA HOTAIR Induces Myofibroblast Activation in Systemic Sclerosis Through EZH2 Dependent De-repression of NOTCH Signalling Pathway Activation
Nothing to Disclose

Alexandra Watts
The Contribution of Disease Activity, Depression, and Anxiety to Health-Related and Non-Health-Related Quality of Life in US and Filipino Patients with SLE
Nothing to Disclose

Ulrich Weber
MRI of the Sacroiliac Joints in Athletes: Do Semi-axial Slices Added to Standard Semi-coronal Scans Facilitate Recognition of Non-specific Bone Marrow Edema?
Nothing to Disclose

Victoria P Werth
Cutaneous Lupus Erythematosus Disease Area & Severity Index (CLASI) Demonstrates Thresholds for Detection of Treatment Response in a Phase-2, Placebo-Controlled Trial of Ustekinumab in SLE
Disclosure:
2- Janssen Research & Development, LLC

Victoria P Werth
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
Disclosure:
2- Biogen; Corbus Pharmaceuticals
5- Biogen
9- Corbus Pharmaceuticals; University of Pennsylvania

Victoria P Werth
Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
Disclosure:
2- Biogen; Corbus Pharmaceuticals
5- Biogen
9- Corbus Pharmaceuticals; University of Pennsylvania

Rene Westhovens
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Disclosure:
2- Celltrion, Inc.; Galapagos/Gilead
5- Celltrion; Celltrion, Inc.; Galapagos; Galapagos NV; Galapagos/Gilead; Gilead Sciences, Inc.
8- Celltrion; Galapagos; Gilead Sciences, Inc.
Cornelia M Weyand
GM-CSF Is a Pro-Inflammatory Cytokine in Experimental Vasculitis of Medium and Large Arteries
Disclosure: 2- Kiniska Pharmaceuticals

Cornelia M Weyand
Lysosomal Placement of the Energy Sensors AMPK and mTORC1 Controls Tissue Inflammation in Rheumatoid Arthritis
Disclosure: 2- Kiniska Pharmaceuticals

Michael Whitfield
Machine-learning Classification Identifies a Subset of Patients That Improve on Abatacept via Modulation of a CD28-Related Pathway
Disclosure: 2- Celdara Medical LLC
5- BMS; Boehringer Ingelheim; Corbus Pharmaceuticals; Third Rock Ventures; Celdara Medical LLC
7- Celdara Medical LLC
9- Celdara Medical LLC (Scientific Founder)

Jessica Williams
Racial Differences in Highly Effective Contraceptive Use Among Medicaid Beneficiaries with SLE
Nothing to Disclose

Joan E Wither
Interferon-Alpha Disrupts Multiple B Cell Tolerance Mechanisms in 3H9 Mice
Nothing to Disclose

Matthew Woodruff
Diseased Lupus Nephritis Kidneys Serve as a Primary Site of Systemic Autoimmune Development
Nothing to Disclose

Dongze WU
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Nothing to Disclose

Meifang Wu
Immune-Mediated Inflammatory Diseases (IMID) Collectively Rank Among the Leading Causes of Death
Nothing to Disclose

Chang Xu
Dietary Patterns and Symptomatic Progression of Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Nothing to Disclose

Arisa Yaekura
Chronotherapy Using Baricitinib Attenuates Collagen-induced Arthritis in Mice
Nothing to Disclose

Qingran Yan
Iguratimod Treated Scleroderma with Interrupted Egr1/TGF-β Loop
Nothing to Disclose

Shima Yasin
Free Interlukin-18: A New Promising Biomarker for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
Nothing to Disclose

Ali Yazdanyar
Risk of 30-day Readmission and Adverse Events After Primary Hip or Knee Arthroplasty: A Comparison of Patients with Rheumatoid Arthritis versus Osteoarthritis Using the Nationwide Readmission Database
Nothing to Disclose

Juliette A Yedimenko
Are PROMIS Measures Associated with Minimal Disease Activity in Psoriatic Arthritis?  
Nothing to Disclose

Eric Yen  
Systemic Sclerosis Deaths at Younger Ages Have Decreased over the past Five Decades  
Nothing to Disclose

Kevin Yip  
Avascular Necrosis Is Associated with APOL1 Variants in African Americans with Systemic Lupus Erythematosus  
Nothing to Disclose

Chio Yokose  
The Effects of a Low-Fat, Mediterranean, or Low-Carbohydrate Diet on Serum Urate  
Nothing to Disclose

Chio Yokose  
Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study  
Nothing to Disclose

Alessandra Zaccardelli  
Elevation of Anti-Citrullinated Protein Antibodies Prior to Rheumatoid Arthritis Onset and Risks for Developing Chronic Obstructive Pulmonary Disease or Asthma  
Nothing to Disclose

Hanna Zembrzuska  
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol  
Nothing to Disclose

Fan Zhang  
Integration of Single Cells from Inflammatory Disease Tissues Reveals Common and Unique Pathogenic Cell States  
Nothing to Disclose

Mingzeng Zhang  
Methionine Commits Immunometabolism and Epigenetic Regulation of BACH2 Loci in B Cells, Resulting in Biases Toward Plasmablast Differentiation in the Pathogenesis of SLE  
Nothing to Disclose

Panpan Zhang  
Comparison of Clinical Manifestations in IgG4 Related Disease Patients with/without Aortitis/Periaortitis and Periarteritis: A Prospective Cohort Study of 587 Patients with IgG4-RD Disease  
Nothing to Disclose

Sheng-xiao Zhang  
Efficacy and Safety of Low-dose IL-2 in Rebuilding Immunity Re-equilibrium of Psoriatic Arthritis Patients  
Nothing to Disclose

Ting Zhang  
Urine CD163 Significantly Discriminates Active Lupus Nephritis and Strongly Correlates with Proliferative Glomerulonephritis  
Nothing to Disclose

Yu Zuo  
Anti-neutrophil Extracellular Trap (NET) Autoantibodies in Primary Antiphospholipid Syndrome  
Nothing to Disclose

Chisa Nosamiefan  
From Diagnosis to the Establishment of the Labalaba Foundation: My Journey from Surviving to Thriving  
Nothing to Disclose

Marie-Claude Beaulieu  
Living and Adjusting to a Diagnosis of Rheumatoid Arthritis (RA) with an Interdisciplinary Team  
Nothing to Disclose

Carlene Harrison  
Bridging the Gap: Leveraging Social Media to Improve Patient Support; Build a Path to Collaborative Medicine  
Aurinia Pharmaceuticals Inc, 5
Christele Felix
*Reclaiming Medical Autonomy Through Healthcare Advocacy*
Aurinia Pharmaceuticals Inc, 5

Nancy Linn
*Race for Relapsing Polychondritis Drives Awareness, Accelerates Research, and Improves the Quality of My Life: How Motorsports Help Me Overcome the Hopelessness of an Incurable, Rare Disease*
Nothing to Disclose

Jennifer Walker
*Art for Arthritis: A New Approach*
Nothing to Disclose

Debbie Schwartz
*Coming to Terms with Lupus: How Learning to Listen to My Body and Letting it Tell Me What to Do Improved My Quality of Life*
Nothing to Disclose

Ida Hakkari
*Framework for Enhancing Patient-Physician Communication in the Context of Rare Disease*
Nothing to Disclose

Dalilah Kalla
*Journeying Towards Hope: Making a Difference in The Lives of Lupus Patients in Mauritius*
Nothing to Disclose

Shannan O'Hara-Levi
*The Practice of Reiki and Meditation in Maintaining Medical Compliance and Decreased Anxiety in an Adult with Juvenile Rheumatoid Arthritis*
Nothing to Disclose